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Relationships between peripheral proteins and membrane-forming lipids are 
essential to proper cellular function and signalling. Particular lipids and lipid arrangements 
are known to recruit proteins to biomembrane surfaces to initiate conformational changes 
and enable proximity-promoted interactions with other proteins. However, globally 
identifying all unique protein-lipid interactions (PLI) and characterizing how they vary 
under changing circumstances is difficult to accomplish with traditional analytical 
methods, especially in vivo. In this work, we aim to solve this problem by synthesizing 
probe molecules that mimic specific classes of lipids, such as diacylglycerol (DAG), 
phosphatidic acid (PA), or phosphatidylserine (PS), and feature a photoaffinity tag for 
crosslinking of associated proteins and a bioconjugation handle to aid in characterization. 
We present the syntheses of clickable lipid photoaffinity probes that exhibit reduced 
synthetic modification from native lipid structures compared to past designs, and we 
demonstrate their efficacy in labeling proteins in cell lysates and in live cells as analyzed 
by SDS-PAGE and proteomic LC-MS. 
 Additionally, we present metabolic probes for infiltrating and labeling lipid 
biosynthetic products in yeast. Metabolic labeling methods related to this aim explore 
novel ways to incorporate synthetic bioconjugation handles onto biomolecules using the 
cell's own enzymatic machinery. Labeled compounds can then be derivitized with a 
fluorescent dye or other group to aid analysis, and then visualized by whole-cell 
microscopy and characterized by extract thin-layer chromatography or mass 
spectrometry. Here, we introduce a collection of glycerol-based fatty monoester and 
monoether probes modified with an azide tag for labeling lipids in yeast.  
vi 
TABLE OF CONTENTS 
1 INTRODUCTION TO SYNTHETIC LIPID PROBES AND METHODS FOR 
CHARACTERIZING PROTEIN-LIPID INTERACTIONS .................................................. 1 
1.1 Chemical Tools for Probing Biological Systems .................................................... 1 
1.2 Overview of Lipids and Biological Membranes ...................................................... 2 
1.3 Structures and Properties of Different Membrane Lipid Types ............................ 7 
1.4 Overview of Lipid Metabolism ................................................................................. 11 
1.5 Overview of Protein-Lipid Interactions .................................................................. 15 
1.6 Lipid Signalling and Dysregulation in Disease ..................................................... 18 
1.7 Past Solutions for identifying PLI ........................................................................... 20 
1.8 Lipid Probes and Proteomic Techniques for Discovering PLI ............................ 22 
2 CLICKABLE BIOMIMETIC LIPID PHOTOAFFINITY PROBES BEARING A 
LYSINE LINKER MODULE FOR STUDYING PROTEIN ASSOCIATIONS OF DAG, PA, 
AND PS ............................................................................................................................ 32 
2.1 Bifunctional Lipid Probes for Labeling Proteins to Elucidate PLI ................ 32 
2.2 Synthesis of DAG, PA, and PS Probes that Include a Lysine Linker ........... 34 
2.3 General Experimental ......................................................................................... 50 
2.4 Detailed Syntheses ............................................................................................. 51 
2.5 List of Mass Spectra ........................................................................................... 96 
3 CLICKABLE LIPID PHOTOAFFINITY PROBES WITH MORE CONSERVATIVE 
STRUCTURAL MODIFICATIONS ................................................................................. 100 
3.1 Minimizing the Presence of Synthetic Structural Modifications on Probes
 100 
3.2 Syntheses of Conservatively Modified DAG and PA Probes ...................... 105 
3.3 Labeling Experiments with Lipid Photoaffinity Probes ............................... 118 
3.4 MudPIT-SEQUEST Proteomic MS Analysis of HEK Cell Labeling .............. 126 
3.5 General Experimental ....................................................................................... 151 
3.6 Detailed Syntheses ........................................................................................... 152 
3.7 List of Mass Spectra for Final Compounds ................................................... 202 
3.8 Protocol for Labeling of HEK Cell Proteins ................................................... 210 
4 AZIDE-BEARING GLYCEROL AND ACYLGLYCEROL ANALOGS FOR 
METABOLIC INFILTRATION OF THE YEAST LIPIDOME ......................................... 216 
4.1 Metabolic Labeling of Lipids ........................................................................... 216 
4.2 Glycerol-based Lipid Metabolic Probes in this Work ................................... 217 
4.3 Known roles of 1- and 2-MAG ......................................................................... 220 
4.4 Synthesis of Glycerol Azide and Acylated Derivatives ................................ 225 
4.5 Metabolic Labeling Experiments in Yeast ..................................................... 234 
4.6 General Synthetic Experimental ..................................................................... 246 
4.7 Detailed Syntheses ........................................................................................... 246 
4.8 List of Mass Spectra for Final Compounds Used in Studies ...................... 296 
4.9 General Experimental for Yeast Labeling Experiments ............................... 318 
4.10 Labeling of Yeast with Azide Glycerol-Based Probes .................................. 320 
4.11 Lipid Extraction, Click, and TLC Procedure .................................................. 320 
vii 
5 CONTRIBUTIONS TOWARD SYNTHESIS OF A CALCIUM-CHELATING INDO-1 
LIPID ............................................................................................................................... 322 
5.1 Calcium-Binding Lipid Concept ...................................................................... 322 
5.2 Synthetic work towards an Indo-1 Lipid ........................................................ 323 
5.3 General Experimental ....................................................................................... 326 
5.4 Detailed Syntheses ........................................................................................... 327 
6 MISCELLANEOUS PROJECT CONTRIBUTIONS ............................................... 337 
6.1 Synthesis of Generic Lipid Photoprobes ....................................................... 337 
6.2 Synthesis and Characterization of a Uniblue-conjugated PE Lipid ........... 338 
6.3 General Experimental ....................................................................................... 339 
6.4 Detailed Syntheses ........................................................................................... 341 
6.5 List of Mass Spectra ......................................................................................... 348 
LIST OF REFERENCES ................................................................................................ 351 
APPENDIX: NMR SPECTRA ........................................................................................ 374 
VITA ................................................................................................................................ 507 
  
viii 
LIST OF TABLES 
Table 1.1: List of fatty acids appearing in mammalian and yeast biological systems 
that are relevant to this work. Unsaturated lipids are assumed to be all-cis. .......... 9 
Table 1.2: Summary of phospholipid classes, characterized by phosphate-linked 
headgroup. ...................................................................................................................... 12 
Table 3.1: Proteomic hits (2-5x) for headless generic diazirine N3-tailed probe 3.3.
 ........................................................................................................................................ 126 
Table 3.2: Proteomic hits (>5x) for headless generic diazirine N3-tailed probe 3.3.
 ........................................................................................................................................ 127 
Table 3.3: Proteomic hits (2-5x) for DAG-diazirine N3-tailed probe 3.4. ............... 128 
Table 3.4: Proteomic hits (>5x) for DAG-diazirine N3-tailed probe 3.4. ................ 130 
Table 3.5: Proteomic hits (2-5x) for DAG-diazirine alkyne probe 3.7. ................... 131 
Table 3.6: Proteomic hits (>5x) for DAG-diazirine alkyne probe 3.7...................... 133 
Table 3.7: Proteomic hits (2-5x) for amide-linked benzophenone-DAG N3-tailed 
probe 3.1. ....................................................................................................................... 134 
Table 3.8: Proteomic hits (>5x) for amide-linked benzophenone-DAG N3-tailed 
probe 3.1. ....................................................................................................................... 146 
Table 4.1: List of ester and ether chains used to make MAG-N3 and MEG-N3 
metabolic probes. ......................................................................................................... 219 
  
ix 
LIST OF FIGURES 
Figure 1.1 General amphiphilic structure of a lipid (blue structure, left), which can 
have intrinsic curvatures (IC) of > 0, roughly 0, and < 0, respectively (red structures, 
right). .................................................................................................................................. 3 
Figure 1.2 Aqueous self-assembly properties of lipids. Lipids with positive IC (red 
structures) form micelles while those with near-neutral IC (yellow structures) favor 
bilayer and vesicular assemblies such as liposomes. ................................................ 4 
Figure 1.3 Conceptual representation of a complex biological membrane 
environment.  The cellular plasma membrane, shown here for example, features 
lipids with signaling roles. .............................................................................................. 6 
Figure 1.4 Oleic acid, an example structure of a fatty acid (FA), including its salt 
form with a biologically prevelant sodium (Na+) countercation. ............................... 8 
Figure 1.5 Core structures of glycerolipids (acylglycerols MAG, DAG and TAG; x, 
y, and z indicate variable carbon chain lengths and degrees of unsaturation). ...... 9 
Figure 1.6 Core structure of glycerolipids (GL) and phospholipids (PL), including a 
polar headgroup (red), fatty hydrocarbon tails (green), and a glycerol backbone 
(blue, with sn-1, sn-2, and sn-3 positions labeled). ................................................... 10 
Figure 1.7 General structures of phospholipid classes. (*PIPn lipids can be 
phosphorylated at every permutation of the 3, 4, and 5 positions on the inositol 
ring, and PGP has an sn-1 phosphate on the headgroup glycerol). ....................... 11 
Figure 1.8 Mammalian glycerolipid and phospholipid biosynthesis pathways, 
focusing on relevant pathways for lipids of interest. Lipid abbreviations are 
summarized in Table 1.2 above, and green boxes represent targeted lipids for 
photoaffinity probe synthesis. ...................................................................................... 13 
Figure 1.9 Lipid metabolism influences protein recruitment and signalling at the 
membrane surface. In this example, a bulk lipid (PC) is cleaved to a signaling lipid 
(PA), which triggers recruitment of a protein. ............................................................ 16 
Figure 1.10 Illustration of general types of protein-lipid interactions in 
biomembranes. ............................................................................................................... 17 
Figure 1.11 General concepts of biomimetic synthetic probes for lipid photoaffinity 
(yellow structures) and metabolic (red structures) labeling. ................................... 23 
Figure 1.12 Examples of covalent protein photocrosslinking by probes bearing 
benzophenone (blue), Pfp-azide (gray), and alkyl diazirine (green) photoaffinity 
tags. .................................................................................................................................. 24 
Figure 1.13 General function of the Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) to form a triazole ring between azide and alkyne components. .............. 25 
Figure 1.14 Example of a strain-promoted azide-alkyne cycloaddition (SPAAC) for 
tagging labeled protein-probe complexes. ................................................................. 26 
Figure 1.15 Example of labeling experiment using biotin pulldown. This allows 
enrichment (purification) of labeled complexes from irrelevant cell lysate debris.
 .......................................................................................................................................... 27 
Figure 1.16: Workflow for original ABPP, featuring covalent enzyme labeling based 
on activity for the probe headgroup, and analysis based on fluorescence SDS-
PAGE or avidin enrichment followed by MudPIT LC-MS to identify and quantify 
protein targets................................................................................................................. 28 
x 
Figure 1.17: Early examples of lipid probes featuring photoaffinity tags. ............. 29 
Figure 1.18: Examples of bifunctional lipid probes bearing click conjugation 
handles. ........................................................................................................................... 30 
Figure 1.19: Examples of photoaffinity probes designed to label peripheral 
proteins. ........................................................................................................................... 31 
Figure 2.1 Biomimetic DAG, PA, and PS lipid photoaffinity probes targeted for 
synthesis. *Syntheses of 2.4 and 2.5 were not finished............................................ 33 
Figure 2.2 Design of experiments for labeling proteins with lipid photoaffinity 
probes. ............................................................................................................................. 34 
Figure 3.1: SKOV3 lysate labeling by lysine scaffold methyl ester 2.17. Generic 
probe 6.2, which bears triazole linkage to the same scaffold, included for 
comparison. .................................................................................................................. 101 
Figure 3.2: SKOV3 lysate labeling by lysine scaffold carboxylic acid 2.20. Generic 
probe 6.2, which bears a triazole linkage the same scaffold, included for 
comparison. .................................................................................................................. 102 
Figure 3.3: Structure of generic probe 6.2 used to compare proteomic labeling by 
lysine-benzophenone-alkyne scaffolds 2.17 and 2.20. ............................................ 103 
Figure 3.4: Structures of novel DAG lipid probes (3.1 and 3.2) that eliminate need 
for a lysine linker, and DAG (3.4 and 3.7) and PA (3.5 and 3.8) diazirine photoaffinity 
probes along with their “headless” generic probe counterparts (3.3 and 3.6). ... 104 
Figure 3.5: 10 M probe labeling using whole HEK cell lysates in 1X PBS. ......... 119 
Figure 3.6: 10 M probe labeling using live HEK cells in FCS-free media. .......... 121 
Figure 3.7: 100 M probe labeling in live HEK cells in 10% FCS media. ............... 122 
Figure 3.8: Labeling in live HEK cells using 50 M probes complexed with delivery 
agents: -methylcyclodextrin (-MCD) or polyethylenimide (PEI). ........................ 125 
Figure 4.1: Structures of glycerol-based metabolic labeling probes, defining probe 
backbone positions as sn-3’, sn-2’, and sn-1’ with respect to native glycerol sn-3, 
sn-2, and sn-1 positions. ............................................................................................. 218 
Figure 4.2: General workflow for lipid metabolic labeling using azide-tagged 
probes. ........................................................................................................................... 220 
Figure 4.3: Overview of yeast lipid metabolism,48 highlighting lipids of interest for 
detection of metabolic labeling (yellow). .................................................................. 221 
Figure 4.4: 100 M labeling experiment, screening or optimal TLC plate loading. 
Cy3 alkyne used as fluorescent dye. ......................................................................... 235 
Figure 4.5: Metabolic labeling for different probe (4.1) concentrations. Click with 
Cy3 alkyne. .................................................................................................................... 236 
Figure 4.6: Standard TLC plate, giving Rf values for 4.1, and for PC, PA, PE, PG, 
DAG. And PS. ................................................................................................................ 237 
Figure 4.7: 2 mM incubation of probe 4.1 for 8 h. .................................................... 238 
Figure 4.8: 2 mM incubation of probe 4.1 for 2 or 8 h. ............................................ 239 
Figure 4.9: TLC results for labeling with acetate esters of 4.1, comparing uptake of 
acylated glycerol-N3 derivatives (4.23, 4.25, 4.20) to the original glycerol-N3 probe 
(4.1). ................................................................................................................................ 240 
Figure 4.10: TLC results from 3.5 mM screening experiment exploring lipid labeling 
using 3’-monoacylated glycerol-N3 probes (4.26, 4.2, and 4.4). ............................. 241 
xi 
Figure 4.11: TLC results for 0-2000 M incubation with probe 4.2 for 2.5 or 5.5 h.
 ........................................................................................................................................ 242 
Figure 4.12: Growth chart for concentration and time-dependent labeling with 
probe 4.2. ....................................................................................................................... 242 
Figure 4.13: TLC results of 50, 250, or 1000 M labeling with 3’-MAG-N3 probes 4.2 
– 4.7 in 2% galactose media. ....................................................................................... 243 
Figure 4.14: Growth charts for labeling experiments in galactose media with 3’-
MAG-N3 probes. ............................................................................................................ 244 
Figure 4.15: TLC results 50, 250, or 1000 M incubation of 3’-MAG-N3 probes 4.2 – 
4.7, in 2% glycerol media. ............................................................................................ 245 
Figure 4.16: Growth charts for labeling experiments in glycreol media with 3’-MAG-
N3 probes. ...................................................................................................................... 245 
Figure 5.1: Structures of Ca++-binding synthetic target lipid 5.1, and Indo-1 (5.2), a 
Ca++-indicating probe that fluoresces upon metal chelation to the tetracarboxylate 
array. .............................................................................................................................. 323 
Figure 6.1: Representative image of a preparative thin-layer chromatography plate 
to isolate LysoUB probe 6.9. ....................................................................................... 340 
  
xii 
LIST OF SCHEMES 
Scheme 2.1: Syntheses of PMB-protected ether lipid azide 2.13 and amine 2.14. 36 
Scheme 2.2: Synthesis of bifunctional lysine benzophenone alkyne scaffold 2.20.
 .......................................................................................................................................... 37 
Scheme 2.3:  Synthesis of DAG probe 2.1, with amide linkage to bifunctional lysine 
scaffold. ........................................................................................................................... 38 
Scheme 2.4: Synthesis of dihydroquinoline coupling reagent BBDQ (2.23). ........ 39 
Scheme 2.5:  Synthesis of DAG probe 2.2, with triazole linkage to bifunctional lysine 
scaffold. ........................................................................................................................... 40 
Scheme 2.6: Synthesis of di-protected phosphoramidite 2.29. ............................... 41 
Scheme 2.7 Synthesis of PA probe 2.3 ....................................................................... 42 
Scheme 2.8: Synthesis of protected L-serine phosphoramidite 2.36. .................... 43 
Scheme 2.9: Attempted synthesis of triazole-linked PS probe 2.4. ......................... 43 
Scheme 2.10: Synthesis of DAG probe 2.6, taking advantage of late stage diversity-
creating steps. ................................................................................................................ 44 
Scheme 2.11: Synthesis of pentafluorophenyl azide photoaffinity tag 2.44. ......... 45 
Scheme 2.12: Attempted synthesis of fluoromethyl chlorphosphonate ethyl ester 
2.49. .................................................................................................................................. 46 
Scheme 2.13: Attempted synthesis of phosphatase-resistant PA probe 2.5. ........ 47 
Scheme 2.14: : Synthesis of fluoromethyl phosphonate dimethyl ester intermediate 
2.55. .................................................................................................................................. 48 
Scheme 2.15: Alternate attempted synthesis of phosphatase-resistant PA probe 
2.5. .................................................................................................................................... 49 
Scheme 2.16: Synthetic progress towards proposed enzyme-resistant fluorine-
DAG probe 2.64. .............................................................................................................. 50 
Scheme 3.1: Synthesis of common diazirine linker 3.11. ....................................... 105 
Scheme 3.2: Synthesis of intermediates 3.13 and 3.15, bearing ketone precursor for 
later installation of diazirine photoaffinity tag.......................................................... 106 
Scheme 3.3: Synthesis of azide tail unit 3.19. .......................................................... 107 
Scheme 3.4: Synthesis of benzophenone DAG probe 3.1, eliminating the lysine 
linker by moving azide click tags to the ends of the lipid tails. ............................. 108 
Scheme 3.5: Attempted synthesis of a tetrafluorophenylazide DAG probe, but failed 
to obtain PMB-protected lipid intermediate 3.31. ..................................................... 109 
Scheme 3.6: Initial model/generic probe pathway for installing diazirine onto 
glycerol backbone via Weinreb amide lipid 3.36. ..................................................... 112 
Scheme 3.7: Endgame to obtaining generic diazirine azide lipid 3.3, drawing upon 
single-tailed byproduct isomers from preceding Scheme 3.6. .............................. 113 
Scheme 3.8: Early synthetic route to specific diazirine probes, attempting to 
postpone Grignard addition until after installation of azide tails. ......................... 114 
Scheme 3.9: Synthesis of diazirine azide tail DAG probe 3.4................................. 115 
Scheme 3.10: Synthesis of diazirine alkyne DAG probe 3.7................................... 116 
Scheme 3.11: Attempted synthesis of diazirine alkyne generic probe 3.6. .......... 117 
Scheme 3.12: Synthesis of diazirine azide PA probes 3.5 and 3.8 and their 2Na+ 
salts 3.62 and 3.64, obtained from their respective DAG probe precursors. ....... 117 
xiii 
Scheme 4.1: Synthesis of glycerol azide probe 4.1, and acylated derivatives 4.20, 
4.23, and 4.25. ............................................................................................................... 226 
Scheme 4.2: Systems explored for obtaining glycerol azide monoester probes 
bearing fatty acids on the primary (sn-3’) alcohol. .................................................. 228 
Scheme 4.3: Completed syntheses of 3’-monoacylglycerol azide probes 4.2 
through 4.7, featuring a diversity-creating step from intermediate 4.32. ............. 229 
Scheme 4.4: Systems explored for obtaining glycerol azide monoether probes 
bearing hydrocarbon chains on individual secondary alcohols. .......................... 230 
Scheme 4.5: Current route to obtaining 1’-MEG-N3 (4.14-4.19) and 2’-MEG-N3 (4.8-
4.13) glycerol azide monoethers. ............................................................................... 233 
Scheme 4.6: Synthesis of lipid labeling detection aids for mass spectrometry (4.66) 
and fluorescence TLC (4.70). ...................................................................................... 234 
Scheme 5.1: Early synthetic route in pursuit of Ca++-chelating lipid 5.1, leading to 
synthetic dead end in form of benzoxazine 5.6. ....................................................... 324 
Scheme 5.2: Summary of attempted solutions connecting two units of lipid 5.5 
without benzoxazine cyclization. ............................................................................... 325 
Scheme 5.3:  Installation of the ethane bridge, leading to tetraethyl ester-protected 
lipid 5.17......................................................................................................................... 326 
Scheme 6.1: Synthesis of generic probes with ether (6.1) and ester (6.2) lipid tails, 
with lipid scaffolds provided by Stuart Whitehead. ................................................. 338 
Scheme 6.2: Synthesis of Uniblue A lyso-PE probe 6.9.......................................... 339 
  
xiv 
LIST OF ABBREVIATIONS 
(CH2O)n paraformaldehyde 
(COCl)2 oxalyl chloride 
2,4-DNP 2,4-dinitrophenylhydrazine 
4,5-DCI 4,5-dicyanoimidazole 
ABPP Activity-based protein profiling 
AcOH acetic acid 
AF Alexafluor-alkyne 
BBDQ benzyl 2-(benzyloxy)quinoline-1(2H)-carboxylate 
BCG bromocresol green 
BnOH benzyl alcohol 
Boc tert-butyl carbamate 
BSA bovine serum albumin 
BSTFA N,O-bis(trimethylsilyl) trifluoroacetamide 
C. albicans Candida albicans 
CBz carboxybenzyl 
CDP-DAG Cytidine diphosphate-diacylglycerol 
CeMo cerium molybdate 
CH2Cl2 methylene Chloride 
CHCl3 chloroform 
CL cardiolipin 
CMC critical micelle concentration 
CMP cytidylmonophosphate 
xv 
CSA ()-10-camphorsulfonic acid 
CuAAC Cu(I) catalyzed azide/alkyne cycloaddition 
Cy3 Cyanine 3 
DAG diacylglycerol 





DIAD diisopropyl azidodicarboxylate 





DMEM Dulbecco’s Modified Eagle Medium 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DPPA diphenylphosphoryl azide 
DPPE 1,2-bis(diphenylphosphino)ethane 
EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EEDQ ethyl 2-(ethyloxy)quinoline-1(2H)-carboxylate 
ESI electrospray ionization 
xvi 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
FA fatty acid 
FCS fetal calf serum 
FRET Förster resonance energy transfer 
GL glycerolipids 
H-bond hydrogen bond 
HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HCl hydrochloric acid 
HEK human embryonic kidney 293T 
HOBt hydroxybenzyltriazole 
HOSA hydroxylamine-O-sulfonic acid 
IC intrinsic curvature 
K2CO3 potassium carbonate 
KMnO4 potassium permanganate 
LC-MS liquid chromatography-mass spectrometry 
LPA lyso-phosphatidic acid 
m meta 
m-CPBA meta-chloroperozybenzoic acid 
MAG monoacylglycerol 






MsCl methanesulfony chloride 
Na2CO3 sodium carbonate 
NaBH3CN sodium cyanoborohydride 
NaClO sodium hypochlorite 
NaClO2 sodium chloride 
NaHCO3 sodium bicarbonate 
NaOH sodium hydroxide 
NHS  N-hydroxysuccinimide 
NMM N-methylmorpholine 
NMR nuclear magnetic resonance 
NsCl 4-nitrobenzenesulfonyl chloride 
o ortho 
O-DA Oleamide-diazirine alkyne 
p para 
PA phosphatidic acid 
PBS phosphate buffered saline 
PC phosphatidylcholine 
PC phosphatidylcholine 





PG  phosphatidylglycerol 
PI phosphatidylinositol 
PIPn phosphatidylinositol polyphosphate 
PKC protein kinase C 
PL phospholipids 
PLC phospholipase C 
PLI protein-lipid interactions 




Rf retention factor 
RSM recovered starting material 
rt room tempterature 
S. cerevisiae Saccharomyces cerevisiae 
SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis 
sn stereospecific numbering 




TBAF tetrabutylammonium fluoride 





TEMPO 2,2,6,6,-tetramethylpiperidinyloxy radical 
Tf2O trifluoromethanesulfonic anhydride 
TFA trifluoroacetic acid 
Tfp tetrafluorophenyl 
THF tetrahydrofuran 









1 INTRODUCTION TO SYNTHETIC LIPID PROBES AND METHODS FOR 
CHARACTERIZING PROTEIN-LIPID INTERACTIONS 
1.1 Chemical Tools for Probing Biological Systems 
Synthetic chemical probes impact biological research by providing tools for 
understanding details of how living systems function at the molecular level.1 For example, 
chemical probes reveal the functions of enzymes2 and elucidate the consequences of 
their malfunction,3 support platforms for discovering new enzyme inhibitors,4 investigate 
how cellular exposure to distinct molecular scaffolds influences phenotype,5-6 and explore 
untested chemical spaces for novel pharmacological properties.7 Our research focuses 
on probes for characterizing protein interactions with lipids and biological membranes,8 
and for metabolically labeling lipids with bio-orthogonal conjugation tags. 
Following the introduction to lipids, protein-lipid interactions, and chemical labeling 
tools in this Chapter 1, we discuss in Chapters 2 to 3 the design and syntheses of 
clickable photoaffinity probes that mimic specific signaling lipids with the aim reducing the 
degree of synthetic modification to the cognate native structures. We demonstrate the 
application of these lipid probes to discover protein-lipid interactions in both whole cell 
lysates and in live cells, and the characterization of labeling profiles by SDS-PAGE and 
proteomic mass spectrometry. Then in Chapter 4, we describe the synthesis of azide-
labeled glycerol, monoacylglyerol (MAG) and monoetherglycerol (MEG) probes designed 
for metabolic lipid labeling, their application in yeast, and the assessment of labeling by 





1.2 Overview of Lipids and Biological Membranes 
General Properties of Lipids and Lipid Assemblies 
Amphiphilic biomolecules known as lipids are the principal components of 
biological membranes. Individual lipid and collective lipid bilayer characteristics influence 
biomembrane properties and behavior, including structure and signaling roles. The 
general composition of a lipid is illustrated in Figure 1.1 and features two distinct regions: 
a polar, hydrophilic headgroup region, and a comparatively nonpolar, hydrophobic region. 
On the molecular level, headgroup regions tend to be dense with heteroatoms and 
participate in dipole-dipole, hydrogen bonding, and ionic interactions with other 
molecules. Tail regions contain mostly hydrocarbon content such as alkane and alkene 
chains and interact with other molecules primarily through van der Waals forces. 
Also illustrated in Figure 1.1 is the geometric property of intrinsic curvature (IC), 
which defines lipid shape and determines how assemblies of lipids interact with eachother 
and organize in 3-dimensional space. Lipids with a neutral or near-zero IC have a 
cylindrical shape, with the radius of space occupied by the headgroup region roughly 
equal to that of the tail region. Lipids with a wider headgroup than tail region have positive 
IC (> 0) and assume a cone shape, while those with a narrower headgroup have negative 
IC (< 0) and an inverse-cone shape.9  
In light of the amphiphilic nature of lipids, hydrophilic regions favor alignment 
towards and interaction with polar solvents such as water, while hydrophobic regions 
repel polar solvent in favor of contacting other nonpolar residues. This behavior drives 
spontaneous aggregation in aqueous solution and in high enough concentration leads to 
self-assembly10 into macrostructures, as illustrated in Figure 1.2.11  
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Figure 1.1 General amphiphilic structure of a lipid (blue structure, left), which can 
have intrinsic curvatures (IC) of > 0, roughly 0, and < 0, respectively (red structures, 
right). 
 
Geometric shape determines how self-assembling lipids pack in three-dimensions 
and dictates the morphologies of resulting macrostructures. Upon reaching the critical 
micelle concentration (CMC), lipids with large positive IC arrange into micelles which are 
essentially spherical monolayers that sequester nonpolar tails within their cores.12-13 
Micelle-forming lipids and detergents can destroy more complex bilayer-based structures, 
discussed below. 
Lipids with a near-neutral IC aggregate into bilayers of two opposing planes with 
nonpolar tails sandwiched within the interior and a sea of hydrophilic headgroups 
interacting with the solvent on both outer faces. Bilayer sheets can enclose into vesicles 
that encapsulate a solvent-filled compartment in the middle, and can have multiple lamella  
(MLVs), or inner layers.12-13  Under the right conditions, bilayer vesicles can form 
unilamellar vesicles (ULVs) of various sizes which are useful for drug delivery and as 
model systems of biomembranes for in vitro experiments.14-16 Bilayer-forming lipids are 
essential to forming stable membranes to encapsulate controlled biological environments 
in cells, and have important individual signaling functions as well.  Lipids with large 
negative curvature do no favor bilayer formation and are not shown in Figure 1.2. Among 
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Figure 1.2 Aqueous self-assembly properties of lipids. Lipids with positive IC (red 
structures) form micelles while those with near-neutral IC (yellow structures) favor 
bilayer and vesicular assemblies such as liposomes. 
 
the mixtures of lipids composing these bilayers in living systems, we are interested in 
characterizing their signaling interactions with proteins at membrane surfaces. 
In contrast to the surrounding aqueous phase, a lipid bilayer is its own phase that 
exhibits movement and mixing of its constituent molecules and solvates other entities 
such as small molecules and proteins.  Fluidity properties can vary with packing behavior 
among domains that exhibit liquid disordered (L), liquid ordered (Lo, or crystalline), or gel 
phase (L) packing behavior, which can occur in phases with well-defined boundaries and 
are listed here in order of increasing rigidity.17 Tail regions influence fluidity through van 
der Waals interactions between adjacent bilayer lipids, with increasing length and 
saturation corresponding to higher phase viscosity in a temperature-dependent fashion.18 
These properties control the solubility, mobility, and shape of molecules within the bilayer 
as well, particularly for proteins or protein residues that insert into biomembranes.19-20 
The bulk properties of fluidity, curvature, and charge, along with the characteristics of 
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individual lipid molecules, influence signaling activity in biomembranes such as 
recruitment and arrangement of soluble proteins at the surface.21-22 
Biological Membranes 
The fundamental properties of lipids and lipid formations discussed above govern 
the basic structure and function of membranes in biological systems.  However, as 
illustrated in Figure 1.3, cell membranes are complex environments featuring a variety of 
lipids, proteins, and other molecules and are centers of dense signaling and transport 
traffic.20, 23  In the midst of this activity, cells tightly control lipid populations through 
constant metabolic adjustments to produce and maintain the specific bilayer 
characteristics required for proper function.20, 24 Describing these systems completely has 
been a historically complicated task, and protein-lipid interactions at the membrane  
In 1935, Davson and Danieilli proposed that cellular boundaries are composed of 
thin lipid mixture films in order to explain permeability properties of cells. This model 
assumed that proteins remained adsorbed onto film surfaces, and briefly mentions the 
possibility of membranes composed of lipid-protein mosaic gel mixtures.25 In 1979, Singer 
and Nicholson advanced these ideas further by describing cell membranes as dynamic, 
two-dimensional fluid systems. They proposed that bilayer lipids solvate hydrophobic 
portions of abundant membrane-associated proteins, leaving hydrophilic peptide residues 
hidden within the protein interior or exposed to aqueous solvent beyond one or both 
membrane surfaces.26 This model also recognizes that some lipids may interact in 
specific ways with these surface have been especially difficult events to characterize. 21 
Integral proteins directly to facilitate solvation. Multiple authors in the same decade note 
that the overwhelming variety of natural lipid structures and heterogeneity of their 
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Figure 1.3 Conceptual representation of a complex biological membrane 
environment.  The cellular plasma membrane, shown here for example, features 
lipids with signaling roles. 
 
distribution suggest that lipids have biological roles beyond the demarcation of cellular 
boundaries.11, 27 
In 1997, Simons and Ikonen further elaborated on this model, adding that multiple 
lipid phases exhibiting varying degrees of fluidity exist within membranes for specific 
purposes. In particular, they noted that ordered phases composed of sphingolipids and 
cholesterol separate themselves from the disordered liquid phase of bulk lipids on the 
outer membrane leaflet.28 The authors cite observations from biophysical, lipid 
separation, and detergent solubilization studies as evidence suggesting the existence of 
these lipid rafts, and hypothesize that they form, cluster, and reorganize in response to 
environmental and biochemical inputs, and selectively recruit proteins and transport for 
the purpose of signal transduction.22 In this work, we focus on individual lipid classes and 
their distinguishing functional groups as points of recognition for proteins, rather than 
collective properties of bilayer locales. 
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1.3 Structures and Properties of Different Membrane Lipid Types 
Fatty Acids 
Fatty acids (FA) compose the simplest natural lipid units, featuring a carboxylate 
headgroup directly attached to a hydrocarbon tail that varies in length and degrees of 
unsaturation, as exemplified in Figure 1.4. FAs have a physiologically relevant range of 
roughly but not limited to 10-24 carbons in length at even intervals and up to four degrees 
of unsaturation.29 Table 1.1 contains a list of FA relevant to this work. Among this list, 
palmitate and oleate are the most common saturated and unsaturated FA in mammalian 
lipids,30 while palmitate and oleate or palmitoleate are most common in yeast systems.29  
FAs can exist independently in solution or insert into existing bilayers, but will not 
form bilayers on their own, instead favoring micelles. In vivo, they are subject to addition 
to, removal, from, and transfer between more complex lipid structures where they can 
influence membrane morphology and interactions with proteins.31 Enzymes may also 
adjust them for length and unsaturation, or catabolism for energy as needed.32 They also 
have an impact on health,33 exhibit unique signalling roles of their own,34-35 and are 
subject to their own set of interactions with proteins.36  
More sophisticated lipids that are of interest in this work include glycerolipids (GL), 
which feature a glycerol backbone bearing one, two, or three acyl chains, and 
phospholipids (PL), which have an additional phosphoester-based headgroup added to a 
GL core. Together, these two classes compose up to 65% of mammalian lipid content 
mole-wise.37 The general lipid structure for these molecules is shown in Figure 1.5, 
including sn labels for different backbone positions. Typically in mammalian cells, sn-2 
acyl chains tend to be unsaturated while sn-1 acyl chains are usually saturated. In the 
following sections, features of GL and PL will be examined in more detail. 
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Figure 1.4 Oleic acid, an example structure of a fatty acid (FA), including its salt 
form with a biologically prevelant sodium (Na+) countercation. 
 
Figure 1.6 illustrates different structures of GL, also known as acylglycerols.  
Mooacylglycerols (MAG), which feature a single ester-linked fatty acid tail typically at the 
sn-1 or sn-2 position,38 act as surfactants and emulsifiers, and exhibit micelle forming 
behavior in aqueous media.39 Lipid probes of MAG and their ether analogs are the focus 
of Chapter 4. Diacylglycerols (DAG) have two acyl chains, with 1,2-diacylglycerol being 
one of our target lipids in Chapters 2 and 3 for probe synthesis due to their important 
signalling properties.40 Triacylglycerols are highly nonpolar fully acylated GL associated 
with energy storage, and are not targeted for synthesis in this work, but are possible 
metabolites of probes featured in Chapter 4. 
PL feature one of a variety of phosphate-based headgroups, with examples 
illustrated in Figure 1.7. Several phosphoester-linked headgroups are common in 
mammalian and yeast lipids relevant to cell structure and signalling, summarized in Table 
1.1 to compliment the structures shown in Figure 1.7. PL are typically anionic under 
physiological conditions due to the acidity of phosphate, with the exceptions of PC and 
PE due to their cationic ammonium functional groups. PA and PS are featured lipids 
targeted for imitation using our synthetic probes, and along with DAG will be the focal 
points of this chapter and Chapters 2 and 3. 
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Table 1.1: List of fatty acids appearing in mammalian and yeast biological systems 
that are relevant to this work. Unsaturated lipids are assumed to be all-cis. 
FA Name (Carbon# : Unsaturation#) 
Capric Acid (10:0) 
Lauric Acid (12:0) 
Myristic Acid (14:0) 
Palmitic Acid (16:0) 
Palmitoleic Acid (16:1) 
Steric Acid (18:0) 
Oleic Acid (18:1) 




Figure 1.5 Core structures of glycerolipids (acylglycerols MAG, DAG and TAG; x, 




Figure 1.6 Core structure of glycerolipids (GL) and phospholipids (PL), including a 
polar headgroup (red), fatty hydrocarbon tails (green), and a glycerol backbone 
(blue, with sn-1, sn-2, and sn-3 positions labeled). 
 
Several other lipids that are relevant to membranes and signaling include 
lysolipids, sphingolipids, and cholesterol. Lysolipids differ from PL by the absence of a 
single acyl chain, typically at the sn-2 poition, metabolically important to general GL and 
PL biosynthesis, and have distinct signalling roles in cells.41-42 Due to their large positive 
IC, they are non-bilayer forming and tend to form micelles in aqueous environments.42-43 
Sphingolipids such as sphingosine, ceramide, and sphingomyelins are similar to GL and 
PL, except that they have a nitrogen in place of oxygen at the equivalent sn-2 backbone 
position, and an alkenyl hydrophobic tail stemming from the sn-1 carbon. This lipid class 
has its own complex set of protein interactions and cellular signaling roles44,45 and, along 
with cholesterol, is involved in the formation of stiff, gel phase lipid raft domains.28 
Considering all possible lipid classes, including many outside the scope of this work and 
accounting for acyl chain variations, thousands of unique lipid molecules are known to 




Figure 1.7 General structures of phospholipid classes. (*PIPn lipids can be 
phosphorylated at every permutation of the 3, 4, and 5 positions on the inositol 
ring, and PGP has an sn-1 phosphate on the headgroup glycerol). 
 
1.4 Overview of Lipid Metabolism 
Lipid biosynthesis and interconversion pathways in mammalian cells24, 37 are 
outlined in Figure 1.8, with more details shown for steps proximal to our lipids of interest, 
DAG, PA, and PS. Names and abbreviations of enzymes and relevant cofactors are 
explained in the Figure 1.8 caption. Lipid biosynthesis in yeast is further covered in 
Chapter 4 in which we describe efforts to label biosynthetic products. 
GL and PL are synthesized de novo beginning from glycerol-3-phosphate (Gly-3-
P), which is a product downstream from glycolysis. Successive acyl chain transfers give 
lyso-PA, and then PA, which makes up <1% of phospholipid content but from which 
alllipids are metabolically accessible. PA is concentrated in peroxisomes, the plasma 
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Table 1.2: Summary of phospholipid classes, characterized by phosphate-linked 
headgroup.  
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Figure 1.8 Mammalian glycerolipid and phospholipid biosynthesis pathways, 
focusing on relevant pathways for lipids of interest. Lipid abbreviations are 
summarized in Table 1.2 above, and green boxes represent targeted lipids for 
photoaffinity probe synthesis. 
List of non-lipid molecules: Gly-3-P, glycerol-3-phosphate; FA-CoA, fatty acid coenzyme 
A, CTP, cytidine triphosphate; CDP, cytidine diphosphate; Cho, choline; Ser, serine; Etn, 
ethanolamine; Ins, inositol; PI, phosphatidylinositol. List of enzymes: G3PAT, glycerol-3-
phosphate acyltransferase; LPAAT, lyso-PA acyltransferase; PIS, PI synthase; PLC, 
phospholipase C; PLD, phospholipase D; PAP, PA phosphatase; DGK, DAG kinase; 
DAGL, DAG lipase (phospholipase A1 or A2); MGAT, MAG acyltransferase; DAGAT, 
DAG acyltransferase; CEPT1, choline/ethanolamine phosphotransferase 1; CPT1, 
choline phosphotransferase; PSS1/2, PS synthase 1 or 2; PSD, PS decarboxylase. 
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membrane, ER, Golgi, and to a less extent in mitochondria.47,48,20 PA brings a negative 
charge to the membrane surface, and has slightly negative curvature.49 PA can also be 
biosynthesized by PLD-mediated cleavage of choline from PC and phosphorylation of 
DAG by DGK.50-51 PA serves as a precursor for CDP-DAG, which can then be converted 
to PI and then PIPns, or can feed into the PG→PG-P→CL pathway.  
Phosphate cleavage from PA by PAP gives DAG,52 which is another critical 
metabolic intermediate for several pathways. DAG has negative intrinsic curvature but 
avoids membrane disruption by existing only in small, transient quantities to avoid bilayer 
disruption.24 DAG may also be produced by acyl transfer to MAG by MGAT,53 or PLC 
activity that cleaves PI to leave the free sn-3 hydroxyl headgroup.54 Acyltransferase and 
lipase activity on DAG provide TAG and MAG,53 respectively (1-MAG from DAGL2 and 
2-MAG from DAGL-1). The free hydroxyl group of DAG can be linked to choline by CEPT1 
or CPT1 activity to form PC, the most abundant mammalian membrane lipid. CEPT1 can 
also add ethanolamine to DAG to give PE, which also composes a high percentage of 
mammalian biomembranes.24,55   
PS can be formed from either PC or PE in mammals by base exchange of serine 
for either choline or ethanolamine, catalyzed by PSS1 for conversion from PC, or PSS2 
for conversion from PE. PS composes a small proportion of most biomembranes but 
occurs in relatively higher amounts within the inner leaflet of the plasma membrane. 
Metabolism of PS to PE occurs by decarboxylation catalyzed by PSD.56  
Metabolism of lipids is directly related to cell signalling and function by shifting the 
lipidomic profiles of membranes to influence the bulk membrane properties discussed 
earlier. Related to this project, PA, DAG, and PS may be generated or destoyed at specific 
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times and places in the cell to trigger recruitment and binding of proteins at the membrane 
surface. An example of what this process might look like on the cellular level is illustrated 
in Figure 1.9, which represents a process that we would be interested in characterizing 
using lipid probes. 
In addition to understanding PLI, we are interested in using probe molecules to 
infiltrate lipid metabolic pathways to create novel biomoleucles with bioconjugation 
capacitiy. This aim is covered in greater detail in Chapter 4. 
1.5 Overview of Protein-Lipid Interactions  
Proteins can interact with biomembranes in several ways, exhibiting different 
degrees of immersion in the bilayer and by binding with individual lipid molecules. 
Representations of integral, peripheral, soluble, and lipid-anchored proteins are shown in 
Figure 1.10 to illustrate these types of interactions. 
These interactions are driven by intermolecular interactions between lipids and 
peptides, depending on the polarity of protein residues and on the existence of binding 
domains capable of targeting specific lipids. Integral membrane proteins with chiefly 
nonpolar peptides exist buried within or passing through the hydrophobic bilayer core 
(light red in Figure 1.10, showing a transmembrane protein). Peripheral proteins (blue) 
exhibit broad variation in the extent to which they insert into the bilayer, with either or both 
polar and non-polar forces governing their interactions. Lipid-anchored proteins (red) are 
covalently modified with a nonpolar tail, such as a palmitate ester, that inserts into the 
bilayer. Soluble cytosolic or extracellular proteins (brown) can be recruited to the 
membrane surface where they recognize and interact with moieties on specific lipids (red 
star) at the membrane surface. We are most interested in transient and reversible 
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Figure 1.9 Lipid metabolism influences protein recruitment and signalling at the 
membrane surface. In this example, a bulk lipid (PC) is cleaved to a signaling lipid 
(PA), which triggers recruitment of a protein. 
 
Iipid interactions with recruited cytosolic and peripheral proteins,21 which are difficult to 
discover and characterized in spite of their ubiquity.8 
Attraction of cytosolic proteins to lipids can occur through recognition by a binding 
domain on the protein specific for a lipid class, or by strong intermolecular forces that 
interact with glycerol, phosphate, and headgroup lipid regions. Electrostatic or hydrogen 
bonding is important for PLI,21, 57 with additional influence by the charge and curvature of 
the general membrane environment,58 as well as the constitutional lipid profile.59 
Anionic headgroups in particuar are known to recruit cationic proteins to the 
surface for activation.56 Nonpolar peptide regions, which may be included in or distal from 
binding domains, can instert into the hydrophobic membrane to participate in van der 
Waals interacitions with acyl chains.21 
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Figure 1.10 Illustration of general types of protein-lipid interactions in 
biomembranes. 
 
In general, PA has strong H-bond accepting capacity via its acidic phosphate 
headgroup,60 and can switch to an electrostatic anionic state to pair with cationic peptide 
residues in PA binding domains. PA also has the interesting property of disrupting the 
bilayer with its large positive curvature to create peptide insertion sites.60 The primary 
ammonium group of PS can also donate a hydrogen bond, and also exhibits a well-
characterized intramolecular H-bond that shares a proton between its phosphate and 
serine carboxylate moieties.61 
Over 10 conserved binding domains have been identified that recognize specific 
lipids,62 along with many more that can target multiple lipids.63 Many of them are specific 
for PI and PIPns, but some specifically recognize the lipids that we have targeted for probe 
development in this work. PKC-C1 domains are classic examples of protein regions that 
multivalently recognize DAG and PS64 in addition to membrane anchoring by nonpolar 
residue insertion. Dozens of proteins are now known to contain C1 domains.62 
The anionic headgroups of PA and PS also exhibit important behavior as 
electrostatic moieties, and as chelators of metal cations. Metal cations are abundant 
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among biomembrane surfaces,65 and particularly strong interactions exist between Ca++ 
and PS due to its proximal carboxylate and phosphate functional groups. Ca++ binding 
can influence PLI by bridging acidic lipids to anionic protein residues. This Ca++ bridging 
interaction is well known for recruiting protein kinase C (PKC) to the membrane surface 
through C1 domain targeting.66 PA is known to be targeted by C2 domains, for example 
on PKC, as well thorough this mechanism.63 
Our vision in this project is to synthesize DAG, PS, and PA probes that can imitate 
their native lipid targets and discover protein binding relationships regardless of the 
mechanism of that interaction. 
1.6 Lipid Signalling and Dysregulation in Disease  
Known associations between lipids, proteins and disease have led to a better 
understanding of causes and potential therapies.67 When working properly, cells strictly 
regulate their lipid systems, distributing and metabolizing them to maintain specific 
membrane environments conducive to meeting biological demands.68 However, given 
that thousands of known lipid and protein species exist, it is difficult to isolate PLI among 
a dense, sensitive cell environment, and even harder to follow a lipid’s complete set of 
signalling functions. Due to the centrality of PLI to cell signaling and homeostasis, it is 
important to understand how misregulation of specific lipid profiles can cause a state of 
disease in the cell or organism. 
An often-cited function of DAG is its role in stimulating PKCs to phosphorylate 
serine and threonine targets.69 DAG lipids serve as second messengers, meaning that 
they are generated in the bilayer to transmit a message downstream of a primary signal 
recognition event. In this context, DAG is released into the bilayer by PLC-mediated 
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hydrolysis to release inositol-1,4,5-trisphosphate (IP3) from the headgroup of inositide 
lipid PIP2.69 The end result of malfunction here is the upregulation of pathways involved 
in cell growth whose overactivity can lead to cancer (PKC),70 and insulin management 
that may contribute to diabetes (PKC).71 The sensitivity of the former pathway is 
demonstrated by the ability of carcinogenic phorbol esters to imitate DAG.72-73 In another 
pathway linked to cancer, DAG is required for the guanine nucleotide exchange factor 
RasGRP to interact with proteins of the signaling family Ras.74 DAG also controls 
vesicular protein secretion by the Golgi, and defects in this system adversely affect cell 
growth and function.75 Other experiments demonstrate the ability of DAG to recruit 1-
chimaerin to membrane surfaces, having consequences in neural growth and 
maturation.76 DAG binding to Munc-13 has also been identified as consequential to 
neurotransmitter release.77 DGK phosphorylation of DAG is also suggested to be an 
inhibitory mechanism governing DAG-mediated pathways.78  
Membranes maintain a steady presence of PA as a primary precursor and 
reservoir for DAG in order to meet DAG-related signalling demands. Accordingly, PA 
plays a role in membrane recruitment of cytosolic PAP to carry out this conversion.79-80 
Also related to DAG, PA influences vesicular trafficking of proteins from the Golgi, which 
is essential for proper cell growth and function.47 Genetic defects affecting acyltransferase 
enzymes responsible for PA synthesis are related to growth and developmental 
problems.80 PA dysregulation is linked to cancer as an activator of the mTOR pathway 
through the action of PLD181 via the MAPK/ERK pathway due to the recruitment and 
binding of Raf-1 kinase.82,83 It is also suggested to have a role in membrane morphology 
and cytoskeletal reorganization due to the activity of  PLD184 and PLC2.85 PA is also 
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known to activate NADPH oxidase in neutrophils, leading to oxidative burst.86 Additionally, 
PA is a lipid of interest in investigations of neuropathology,87 and has been linked to the 
infectivity of Plasmodium parasites,88 HIV,89 
PS is well known for its role in presenting an apoptosis signal to extracellular 
proteins by flipping from the inner to outer leaflet of the plasma membrane. This 
knowledge led to an impactful assay for detecting apoptotic cells using annexin A5.90 Like 
PA, PS also binds to Raf-1 kinase, implicating its dysregulation to cancer pathways.82 PS 
is implicated in HIV infectivity by interacting with the C-terminal dimerization domain of 
CA protein.89 It is also important for cell wall integrity in C. albicans both directly and as a 
precursor for PE, and is crucial in this regard for evading recognition by the host immune 
system.91-92 
1.7 Past Solutions for identifying PLI 
Reviews of non-lipid probe methods for characterizing PLI described in this section 
are cited here.93-95 Liposome sedimentation assays measure protein binding affinity for 
lipids formulated into vesicles when mixed together in aqueous buffer. Centrifugation is 
used to separate membrane-bound from unbound protein content, followed by SDS-
PAGE to qualitatively assess binding.93 
Calorimetry experiments measure thermal energy fluctuations that result from 
proteins noncovalently associating lipids. High concentrations of protein are required to 
detect changes that result from equilibration of intermolecular forces when the lipid and 
protein content are mixed. For example, penetration of a nonpolar anchor into a bilayer 
is exothermic and depresses the gel transition temperature of the fluid membrane phase. 
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In similar experiments, supported monolayers and bilayers can be exposed to proteins in 
order to induce variations in surface tension upon binding and insertion. 
Electron spin resonance (ESR) experiments utilize spin-labeled lipids bearing a 
group such as nitroxyl radical. Protein binding can be detected by changes in ESR 
spectra, which reflect movement restriction of a labeled group that encounters steric bulk 
of a nearby protein. Spectroscopic methods such as NMR and IR also detect changes in 
biomolecular structure upon binding, such as changes in protein conformation.96 
Fluoresence experiments detect protein proximity to a labeled lipid by Förster 
resonance energy transfer (FRET), since the amino acid tryptophan can function as a 
FRET donor for a variety of synthetic FRET acceptor labels.83 This technique is usually 
limited to controlled in vitro assays with low interference due to sensitivity issues. 
However, FRET-based fluorescent protein assays have been used to track changes in 
DAG location and concentration in live cells.97 
Immobilized lipid techniques can capture proteins in a high-thorughput fashion 
using lipid monolayers or bilayers that are adsorbed onto nonpolar (monolayer) or polar 
(bilayer) supports structures. Unbound proteins are washed away, and bound proteins 
are measured by surface plasmon resonance (SPR) detection of irregularities in the lipid 
layers where proteins are bound. SPR techniques work to detect recruitment of proteins 
and binding domains to liposomes as well.98 Liposomes and other macrostructures can 
also be immobilized by covalent linkage or biotin-avidin anchoring to a microplate array.99-
100 Detection of bound proteins can be achieved by flouresence tagging of the proteins 
themselves, or by enzyme-linked immunosorbent assatys (ELISA) specific for the target 
protein. 
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Computational apporoaches for investigating PLI utilize model systems built on 
data from previously known interactions.93 These tools have predictive power for 
discovering novel PLI, and binding partners calculated to have a high interaction 
probability can be confirmed in the lab using any of the above methods. 
These techniques are useful for determining thermodynamic and kinetic properties 
of PLI and can be powerful characterization tools when performed in combination. 
However, the main drawback to most of them is the lack of applicability to discovering 
global PLI occurring in live cells, where thousands of functioning lipids and proteins exist 
and operate within a sensitive environment of inimitable complexity. Next, we explore 
existing proteomic methods and previously published lipid probes that are useful for 
characterizing global PLI. 
1.8 Lipid Probes and Proteomic Techniques for Discovering PLI 
Here, we introduce concepts behind lipid probes designed for photoaffinity and 
metabolic labeling studies and discuss the subsystems installed on their structures. Then, 
we cover the analytical methods that enable qualitative and quantitiative characterizations 
of labeling. Finally, we close the chapter with examples of previously published lipid 
photoaffinity probes for characterizing PLI. Examples of probes for metabolic lipid labeling 
will be discussed in Chapter 4. 
 As shown in Figure 1.11, both types of probes have biomimetic qualities that allow 
them to engage biological systems when introduced in vivo as susbstitutes for their 
natural target biomolecules. Key tool groups on bifunctional probes for labeling and 
identifying proteins include a photocrosslinking group for covalently capturing proteins 
and a bioconjugation handle for attaching a fluorophore or biotin analytical group 
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Figure 1.11 General concepts of biomimetic synthetic probes for lipid photoaffinity 
(yellow structures) and metabolic (red structures) labeling. 
 
afterwards. Metabolic lipid probes include only a bioconjugation handle that will be 
introduced into any lipids that tolerate its presence through biosynthesis. 
Photocrosslinking Groups  
Upon photolysis with UV light, photocrosslinking groups ar converted into highly 
reactive radical or carbene groups, which can create covalent linkages with nearby 
protein residues.101 This includes insertion into otherwise unreactive functional groups 
such as hydrocarbon C–H bonds. Mechanisms of photocrosslinking by benzophenone,102 
pentafluorophenyl azide,103-104 and diazirine105 functional groups are illustrated in Figure 
1.12. Photocrosslinking is useful for characterizing PLI because it allows an experimenter 






Figure 1.12 Examples of covalent protein photocrosslinking by probes bearing 




Bio-orthogonal Conjugation Reactions 
Bio-orthogonal conjugation strategies allow the selection and attachment of bulky 
analytical groups to be delayed until after labeling steps by probes, avoiding 
complications that may interfere with bio-mimetic labeling interactions.106 The temporary 
reporter handle on the probe and the chemistry used to attach an analytic group are 
designed to be invisible to biological systems, providing highly selective conjugation on-
demand.106 Here, we rely on the selective cycloaddition between an alkyne and azide  to 
form a 1,2,3-triazole linkage originally described by Huigsen,107 optimized to the copper(I) 
catalyzed azide/alkyne cycloaddition (CuAAC, the “click” reaction)108 by Sharpless and 
Meldal, and described as a useful bio-orthogonal conjugation tool by Kolb.109 Click 
chemistry has since become a mainstream method for chemical biology studies, with an 
example of click conjugation with a photoaffinity probe is shown in Figure 1.13. 
Due to the toxicity of copper ions to living cells, copper-free click methods have 
been developed, with strain-promoted (SPAAC) methods being a common solution.111-112 
This concept is demonstrated in Figure 1.14 in a probe labeling context, using DIBAC113 
as an example of a strained alkyne group. 
 
 
Figure 1.13 General function of the Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) to form a triazole ring between azide and alkyne components. 
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Figure 1.14 Example of a strain-promoted azide-alkyne cycloaddition (SPAAC) for 
tagging labeled protein-probe complexes. 
 
Biotin Tags/Avidin 
In order to selectively isolate labeled probe-protein complexes from a mixture of 
unlabeled biomolecules, biotin is commonly used as an affinity handle, taking advantage 
of its tight and highly specific binding to the protein avidin.114 Avidin can be supported on 
commercially available magnetic beads for easy washing and purification of the desired 
isolates. Biotin can be clicked on after probe labeling to avoid interference with 
biomolecular interactions, but an example of isolation of probe-protein complexes with 
pre-attached biotin is shown in Figure 1.15. 
Activity-Based Protein Profiling  
Activity-based protein profiling (ABPP) is a method that allows characterization of 
global enzyme binding activites for a given substrate from a complex mixture of proteins, 
as illustrated in Figure 1.16.2 ABPP is a critically influential technique to the work 
described in Chapters 2 and 3, demonstrating how a well-designed probe can be used 
to covalently label entire proteomes, and then isolate and identify relevant proteins to 
profile the interactions between biomolecules and substrates.  
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Figure 1.15 Example of labeling experiment using biotin pulldown. This allows 
enrichment (purification) of labeled complexes from irrelevant cell lysate debris. 
 
Original ABPP probes use a suicide substrate to covalently label enzymes that 
have serine hydrolase activity and are prefabricated with a linker bearing a fluorophore 
for visualization by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), or biotin for avidin pulldown and of labeled proteins. Following this enrichment 
step, proteins are lysed with trypsin in preparation for proteomic identification using 
multidimensional protein identification technology (MudPIT),115 which involves peptide 
analysis by liquid chromatography-mass spectrometry (LC-MS), and subsequent protein 
identification from raw data using programs such as SEQUEST.116 ABPP was upgraded 
from its original design with the inclusion of a click conjugation handle to improve bio-
orthogonality,117 and has since been applied as a technique for identifying novel inhibitors 
of target subtrates by observing decreases in protein labeling, reflecting blockage of 
enzyme activity for probes.118-119 Photoaffinity labeling was also incorporated into the 
ABPP workflow to eliminate the need for suicide substrates for enzyme labeling.120 
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Figure 1.16: Workflow for original ABPP, featuring covalent enzyme labeling based 
on activity for the probe headgroup, and analysis based on fluorescence SDS-
PAGE or avidin enrichment followed by MudPIT LC-MS to identify and quantify 
protein targets. 
 
Past Examples Lipid Probes for Labeling Proteins  
Reviews of photoaffinity lipid probes for PLI labeling are cited here.121-122 Early 
examples of lipid photoaffinity probes were introduced specifically as tools for 
investigating PLI in biomembranes. These probes, shown in Figure 1.17, utilize aryl azide 
and aryldiazirine photolabeling groups for photocrosslinking, and are appropriate for 
labeling integral membrane proteins and deep penetrating hydrophobic residues of 
peripheral proteins, given the positions of the phototags on he acyl chains.  PC Probe 1.1 
was synthesized by by Chakrabarti in 1975123 along with several similar analogs. 
Radhakrishnan and Gupta 124-125 improved the syntheses and designs of these probes, 
making PC probes 1.2 and 1.3. These updated analogs feature radiolabeled fatty acids 
for tracing protein labeling after photocrosslinking. These are the first examples of 
bifunctional lipid probes with photocrosslinking and analytical capabilities, and in these 
cases are useful for targeting protein residues buried deep in membranes due to the 
photoaffinity tags being located at the tail ends. 
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Figure 1.17: Early examples of lipid probes featuring photoaffinity tags. 
 
More recent photoaffinity probe designs utilize click chemistry handles for bio-
orthogonal conjugation of any group to aid in analysis, with example structures given in 
Figure 1.18. This makes radiolabeled substrates obsolete, eliminating safety and 
regulatory burdens while providing more options for analysis.30 Lipids targeted for 
imitation have also become diverse, spanning signalling lipids such as DAG (1.4),126 
sphingosine (1.5),127 and PS (1.6).128 The diazirine-alkyne fatty acid attached to DAG 
probe 1.4 has also been used in studies of lipidomic labeling by acyltransferase activity.129 
These examples also demonstrate a bifunctional strategy for crosslinking and analysis, 
installing tool groups in ways that do not interfere with lipid backbone or headgroup 
structures. Probe 1.4 is a special case that has a photocaged hydroxyl headgroup that 
can be unveiled in vivo using a wavelength orthogonal to those that would photolyze with 
the diazirine group.  
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Figure 1.18: Examples of bifunctional lipid probes bearing click conjugation 
handles. 
 
When the aim of photoaffinity lipid labeling is to target peripheral proteins that 
transiently bind lipids and biomembrane surfaces, the phototag must be relocated from 
fatty acid tails to a position more proximal to the lipid headgroup, with examples shown in 
Figure 1.19. The phototag may be placed on the headgroup directly, such as in PC 
probes 1.7, 1.8,130 and 1.9,131 but this comes at the cost of placing an unnatural and 
sterically imposing group in a region likely to influence protein binding. An alternative to 
this approach is to install a phototag on a synthetic sidechain or Y-shaped lysine linker 
off of the glycerol backbone, as shown in DAG probe 1.10132 and PA probe 1.11,98 which 
keeps interacting peripheral and soluble proteins within photocrosslinking range without 
compromising the headgroup.  
Lipid photoaffinity probes 1.10 and 1.11 were synthesized by Matt Smith formerly 
of the Best Research Group. They were shown to retain binding activity characteristic of 
their target natural lipids using liposome recruitment experiments with SPR, attracting to 
the model membranes protein kinase C (PKC) for DAG probe 1.10 and an isolated C2 




Figure 1.19: Examples of photoaffinity probes designed to label peripheral 
proteins. 
 
to the designs of probes made in Chapter 1, along with work performed by Meng Meng 
Rowland. 
The documented successes of lipid probe technology for labeling proteins, recent 
advances in proteomic identification, and established utility of click chemistry methods 
indicate the potential of this approach to globally identify PLI for specific lipids out of 
complex biological samples. Still, there is much room for improvement in the designs and 
syntheses of lipid probes, and in the optimization of protocols to accomplish this task with 
efficiency and accuracy. In the following chapters, we present designs for novel DAG, PA, 
and PS lipid probes, their syntheses, and examples of their application to proteomic 
labeling.  
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2 CLICKABLE BIOMIMETIC LIPID PHOTOAFFINITY PROBES BEARING A 
LYSINE LINKER MODULE FOR STUDYING PROTEIN ASSOCIATIONS OF 
DAG, PA, AND PS 
2.1 Bifunctional Lipid Probes for Labeling Proteins to Elucidate PLI  
Taking into account the past successes of lipid photoaffinity labeling and ABPP, 
we hypothesize that lipomimetic probes equipped with photoaffinity and click tags can be 
made to resemble DAG, PS, and PA lipid classes. The lipid probes we chose to target for 
synthesis, which are illustrated in Figure 2.1, are intended to masquerade as their native 
counterparts when introduced into live cells, lipid vesicle model systems, or cell lysate 
solutions, and ideally would be indistinguishable from the perspective of the cellular 
biomachinery. Their structures are amphiphilic, built from a glycerol-like backbone 
bearing two adjacent hydrocarbons tails at positions resembling the sn-1 and sn--2 
hydroxyl groups, and with headgroups installed at the sn-1 position that match the desired 
lipid class to be imitated. While a four-carbon backbone like the one used for probes 2.1-
2.6 is not natural for lipids, previously published studies have shown that acylglycerol and 
phopsholipid mimics with 1,2,3,4-butanetetrol backbones retain activating properties for 
known protein binding partners.133-135 
Lysine is included in these structures as a modular platform for attaching 
photoaffinity and click tags, enabling a system for synthesizing probe analogs with 
interchangeable tool groups. The lysine scaffolds are attached to the biomimetic lipid 
region by amide (probe 2.1) or triazole (2.2-2.6) linkages, creating structural variation and 
providing different inroads for synthesis. Probes 2.1-2.5 feature benzophenone, and 
probe 2.6 features tetrafluorophenyl (Tfp)-azide for covalent photocrosslinking of 
interacting or proximally-associated proteins. All probes 2.1-2.6 have an alkyne handle 
for bio-orthogonal click conjugation of a reporter group, such as biotin or a fluorescent 
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Figure 2.1 Biomimetic DAG, PA, and PS lipid photoaffinity probes targeted for 
synthesis. *Syntheses of 2.4 and 2.5 were not finished. 
 
dye, in order to aid in analysis as described in Chapter 1. DAG probes 2.1 and 2.2 were 
synthesized by previous Best Research Group member Meng Meng Rowland.136  These 
syntheses were repeated with some modification and described in this work due the 
indespensible influence of the diethyl-L-tartrate building block strategy in the design of all 
lipid probes featured in Chapters 2-4, and since 2.1 and 2.2 are precursors for making 
novel probes with phosphoester headgroups. 
Experimental designs are illustrated in Figure 2.2 for labeling proteins using lipid 
probes synethesized in Chapters 2 and 3. Building from core concepts of ABPP and click 
chemistry approaches described in the previous chapter, we sought to label proteins 
based on their affinities for interacting with each probe independent of enzymatic activity. 
Since headgroups are the only biomimetic variable between our probes, different 
headgroups representing DAG, PA, or PS on the lipid scaffold are expected to attract 
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Figure 2.2 Design of experiments for labeling proteins with lipid photoaffinity 
probes. 
 
populations of proteins in a manner representative of recruitment and binding behavior 
occurring at biomembrane surfaces. Experiments include incubation of probe with cell 
lysates or in whole cells to equilibrate protein-probe binding interactions, followed by 
photocrosslinking to covalently fix those interactions and click conjugation to attach an 
analytical reporter group. Labeled protein-probe complexes are visualized by SDS-PAGE 
with in-gel fluorescence when a fluorophore is attached, or quantitatively characterized 
by liquid chromatography-mass spectrometry (LC-MS) when biotin is attached, enabling 
selective enrichment of labeld complexes by pulldown with avidin beads. 
2.2 Synthesis of DAG, PA, and PS Probes that Include a Lysine Linker 
Several of the molecules and synthetic procedures in this synthesis overlap with 
work completed by past Best Research Group graduates Dr. Matthew Smith137 and Dr. 
Meng Meng Rowland.136 In Dr. Smith’s work, similar DAG and PA probes with these 
modifications were found to retain protein binding properties.98, 132 Bifunctional lysine 
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scaffold 2.20 was previously synthesized by Dr. Rowland, as well as the ether-tail DAG 
probes with amide (2.1) and triazole (2.2) linkages to linker 2.20.  
Following Scheme 2.1, which overlaps with published procedures,132 diethyl-L-
tartrate 2.7 was a readily available four-carbon C2 symmectic building block for 
introducing chirality while avoiding the production of multiple stereoisomers and set up 
for convenient manipulation into a glycerol-like backbone. First, an acetonide acetal was 
put in place to protect the free vicinal diol of 2.7 prior to diester reduction to symmetrical 
primary diol 2.8 using lithium aluminum hydride (LiAlH4).138 Silver-promoted139 reaction 
with p-toluenesulfonyl chloride (TsCl) broke this symmetry to yield monotosylate 2.9, 
which was then subjected to nucleophilic substitution with sodium azide (NaN3) to yield 
azido alcohol 2.10. Formation of a sodium alkoxide salt with the remaining primary alcohol 
prepared this compound as a nucleophile for Williamson ether synthesis to install a 4-
methoxybenzyl (PMB) protecting group, resulting in fully-protected azidobutanetriol 2.11. 
Removal of acetonide under acidic conditions gave vicinal diol 2.12 which was used for 
another Willamson synthesis with tetrabutylammonium iodide (TBAI) catalyst and two 
equivalents of 1-bromohexadecane to generate diether 2.13. This lipid-like scaffold 
bearing a primary azide was used directly in later syntheses, but an additional catalytic 
hydrogenation with palladium on carbon (Pd/C) in the presence of base yielded primary 
amine 2.14 while preserving the PMB protecting group.140 Alternatively, reduction of 2.13 
did not succeed under Staudinger conditions by heating with triphenylphosphine (PPh3) 
in a mixture of THF and H2O, while AcOH and powdered Zn in toluene produced 2.14 
with occasionally high yields but without reliability across several replications. 
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Scheme 2.1: Syntheses of PMB-protected ether lipid azide 2.13 and amine 2.14. 
i) 2,2-dimethoxypropane, p-TsOH, benzene, 85C; ii) LiAlH4, THF, 0C to 20C, 57% (2 
steps); iii) p-TsCl, Ag2O, KI, CH2Cl2; iv) NaN3, DMF, 80C 45% (2 steps); v) NaH, DMF, 
0C; vi) PMBCl, 0C to 20C 58% (2 steps); vii) 1N HCl (aq), THF, 20C, 85%; viii) 1-
bromohexadecane, TBAI, 0C to 20C, 90%; ix) H2, 10% Pd/C, Na2CO3, EtOAc 98%. 
 
Synthesis of the bifunctional photoaffinity tag/click module 2.20 is covered in 
Scheme 2.2, which overlaps with previously reported procedures.141 First, protected L-
lysine 2.15 was stripped of its N-Cbz protecting group by catalytic hydrogenation using 
palladium hydroxide (Pd(OH)2), followed by (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU)-mediated coupling in the presence of 
hyroxybenzotriazole (HOBt) and diisopropylethylamine (DIEA) to generate amide 2.16. 
The side chain N-boc protecting group was then removed with trifluoroacetic acid (TFA), 
and the exposed primary amine was coupled with succinimidyl alkyne linker 2.19 to yield 
methyl ester-protected bifunctional scaffold 2.17. In this case, N,N’-
diisopropylcarbodiimide (DIC) outperformed N,N’-dicyclohexylcarbodiimide (DCC), 
HBTU, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) reagents. Linker 2.19 
was synthesized in one step by nucleophilic acyl ring-opening substitution of succinic 
anhydride 2.18 by propargylamine. Finally, 2.17 was saponified and then re-protonated 
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to yield carboxylic acid 15 ready for coupling to a lipid probe backbone. Characterization 
data for 2.20 matched previous reports by Dr. Rowland.136 
 
 
Scheme 2.2: Synthesis of bifunctional lysine benzophenone alkyne scaffold 2.20. 
i) H2, Pd(OH)2, MeOH; ii) 4-benzoylbenzoic acid, HBTU, HOBt, DIEA, CHCl3, 89% (2 
steps); iii) TFA, CH2Cl2, 89%; iv) 2.19, DIC, HOBt, DIEA, (1:2) DMF/CH2Cl2, 64%; v) 2N 
NaOH, (1:1) MeOH/EtOH, 99%. 
 
Amide bond formation between PMB-protected ether lipid-amine 2.14 and lysine-
benzophenone-alkyne module 2.20, shown in Scheme 3.3 did not succeed with coupling 
reagents DIC, HBTU, or EDCI and various base/solvent combinations, even though a 
nearly identical reaction by Meng Meng Rowland, differing only by the presence of a PMB 
protecting group, worked with EDCI in the presence of N,N-dimethylaminopyridine 
(DMAP), and N-methylmorpholine (NMM).136 Attempts with N-hydroxysuccinimide (NHS) 
ester formation, carbonyldiimidazole (CDI), and samarium diiodide (SmI2) also did not 
38 
work, and pre-activation of the carboxylic acid as a pentafluorophenyl (Pfp)-ester resulted 
in low yields of the target amide linkage (<20% in two steps). Successful coupling to yield 
PMB-protected DAG probe 2.21 was best achieved using dihydroquinoline carbamate 
reagents ethyl 2-(ethyloxy)quinoline-1(2H)-carboxylate (EEDQ) and benzyl 2-
(benzyloxy)quinoline-1(2H)-carboxylate (BBDQ, 2.23) with similar yields, the latter of 
which was synthesized in one step from quinoline 2.22, as shown in Scheme 2.4. 
 
 
Scheme 2.3:  Synthesis of DAG probe 2.1, with amide linkage to bifunctional lysine 
scaffold. 
i) 2.20, EEDQ or 2.23, crushed glass, CH2Cl2, sonication, 30%; ii) DDQ, (1:18) 
H2O/CH2Cl2, 99%. 
 
Since these reagents activate the target carboxylic acid to a carbonate ester 
anhydride for amide coupling, they are vulnerable to byproduct formation if the free amine 
attacks the carbonyl donated from the dihydroquinoline reagent. Reagents bearing bulkier 
esters on the terminal carbonate, commonly an isobutyl group, inhibit this undesirable 
pathway and the availability of benzyl chloroformate rather than its isobutyl analog led to 
the decision to synthesize BBDQ. In the synthesis of 2.21, sonicating all reagents in 
CH2Cl2 with crushed borosilicate marginally outperformed thermal activation.142 Oxidative 
PMB deprotection with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)143 yielded 
DAG probe 2.1, featuring ether-linked hydrocarbon tails and an amide linkage to a lysine-
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Scheme 2.4: Synthesis of dihydroquinoline coupling reagent BBDQ (2.23). 
i) Benzyl chloroformate, BnOH, TEA, THF, -5C to 20C, 30%. 
 
Next, an analog of DAG probe 2.1 featuring a triazole linkage between lipid and 
lysine units was synthesized, as shown in Scheme 5.5, which overlaps with previously 
reported procedures.98 This pathway is close to one presented in Dr. Rownland’s 
dissteration, and delays conjugation handle installation on the lysine side chain since click 
chemistry is used to join the lipid backbone azide to the lysine alkyne. However, this 
rearrangement of steps has the added benefit of keeping options open for choosing a 
conjugation handle until the final step and plays into a greater strategic theme of 
organizing syntheses to facilitate rapid generation of structurally varied probe molecules 
from the fewest possible common intermediates.  
Previously synthesized lysine derivative 2.16 was saponified and then neutralized 
to carboxylic acid 2.24, which was coupled to propargylamine using HBTU, yielding 
alkyne 2.25. A copper(I)-catalyzed azide-alkyne cycloaddition reaction144 coupled alkyne 
2.25 to previously synthesized lipid scaffold azide 2.13 to yield triazole-linked intermediate 
2.26, which could be used to make benzophenone-triazole lipid probes with a variety of 
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conjugation handles. Acid deprotection of the N-Boc side chain on 2.26 also eliminated 
the PMB protecting group, which did not significantly impact subsequent DIC-mediated 
coupling to alkyne linker 2.19 to give finished DAG probe 2.2. This was confirmed by a 
TLC ninhydrin test which indicated the consumption of primary amine. Characterization 
data for 2.2 matched previous reports.136  
 
 
Scheme 2.5:  Synthesis of DAG probe 2.2, with triazole linkage to bifunctional lysine 
scaffold. 
i) 2N NaOH, (3:1) MeOH/EtOH, 94%; ii) Propargylamine, HBTU, HOBt, DIEA, CHCl3, 
77%; iii) 2.13, CuI, 2,6-lutidine, (1:1) MeCN/THF, 76%; iv) TFA, CH2Cl2, 61%; v) 2.19, 
DIC, HOBt, DIEA, CH2Cl2, 0C to 20C, 60%. 
 
With abundant triazole-linked DAG probe 2.2 in hand, we pursued phospholipid 
probes designed to imitate PA (2.3) and PS (2.4). Phosphoramidite coupling, oxidation, 
and deprotection chemistry is mild enough to select for the primary alcohol of 2.2 while 
preserving the phototag and click moieties of the probe structure, providing an opportunity 
to create new probes with varied headgroups divergently from 2.2. To obtain the 
headgroup precursor for synthesizing PA probes, a published protocol was followed,145-
146 as illustrated in Scheme 2.6. Phosphorus trichloride (2.27) was reacted with 
41 
diisopropylamine (DIPA) to form dichloride intermediate 2.28, which was immediately 
reacted with 3-hydroxypropionitrile to make bis--cyanoethyl (-CE)-protected 
phosphoramidite 2.29.  
 
 
Scheme 2.6: Synthesis of di-protected phosphoramidite 2.29. 
i) DIPA, hexane, 0C; ii) 3-hydroxypropionitrile, DIEA, CH2Cl2, 0C, 41% (2 steps).  
 
Next, shown in Scheme 2.7, phosphoramidite 2.29 was coupled in the presence of acid 
catalyst 4,5-dicyanoimidazole (4,5-DCI) to triazole-linked DAG probe 2.2 to produce 
protected PA probe 2.30.146-147 Using tetrazole as the catalyst did not yield any product 
for this reaction system, including attempts with amide-DAG probe 2.1. Silyl-assisted 
deprotection of the bis--CE headgroup with N,O-bis(trimethylsilyl) trifluoroacetamide 
(BSTFA) and  1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) gave neutral triazole-linked PA 
probe 2.3 following methanolysis of the bis-trimethylsilyl (TMS) ester intermediate148 (not 
shown) and citric acid washing to liberate the phosphate from its DBU-H+ salt form.  
A similar pathway employing phosphoramidite chemistry was followed in pursuit of 
triazole-linked PS probe 2.4. Following Scheme 2.8,128, 149 dichloride 2.28 was obtained 
from 2.27 using DIPA in the presence of triethylamine (TEA). Stoichiometric reaction of 
2.28  with 3-hydroxypropionitrile and one equivalent of TEA yielded mono-- CE protected 
monochloride 2.32, which readily reacted with the free alcohol side chain of a Boc-L- 
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Scheme 2.7 Synthesis of PA probe 2.3 
i) 2.29, 4,5-dicyanoimidazole, CH2Cl2; ii) mCPBA, CH2Cl2, -78C to 20C, 77% (2 steps); 
iii) BSTFA, DBU, CH2Cl2, 0C; iv) MeOH, 0C to 20C; then, citric acid (aq), 36% (2 
steps). 
 
serine t-butyl ester to give the previously reported serine phosphoramidite 2.36.128 
Again using 4,5-DCI as a catalyst, 2.36 was coupled to triazole DAG probe 2.2 to 
yield 2.37 as the heavily-protected precursor to our target PS probe, illustrated in Scheme 
2.9.  Attempts to obtain PS probe 2.4 by sequentially removing -CE from phosphate with 
mild TEA, and then both N-Boc and t-butyl ester groups from the serine component under 
acidic conditions did not succeed. Challenges involving moisture sensitivity and small 
scale (~2 mol) of the attempted reaction are believed to have played a role in this failure. 
Moving forward with improving synthetic access to novel lipid probes featuring a 
lysine scaffold, we restarted from triprotected L-lysine 2.15, shown in Scheme 2.10. This 
time, the order of deprotection and coupling of the three functional groups on lysine was 
inverted compared to Scheme 2.2 in order to defer phototag and conjugation handle 
selection to later steps. However, this advantage is traded for the cost of committing to a 
single lipid scaffold, in this case 2.13, which has 16-carbon ether tails. 
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Scheme 2.8: Synthesis of protected L-serine phosphoramidite 2.36. 
i) DIPA, TEA, THF, 0C; ii) 3-hydroxypropionitrile, TEA, THF, 0C; iii) Boc-L-serine t-butyl 
ester, TEA, THF, 0C to 20C, 55% (3 steps). 
 
First, 2.15 was saponified and neutralized to carboxylic acid 2.38, which was 
subjected to HBTU-mediated coupling with propargylamine to yield previously reported 
alkyne amide 2.39,150 reapplying chemistry presented in Scheme 2.5. CuAAC 
conjugation144  of 2.39 to PMB-protected azide lipid 2.13 produced triprotected lipid-lysine 
core 2.40, which could be used in future syntheses as nodal intermediate for creating 
diverse lipid probe structures. In this case we chose to install Tfp-azide carboxylic acid 
2.44. This photoaffinity group was made fresh from a previously published synthesis 
shown in Scheme 2.11,103 which began with nucleophilic aromatic substitution of 
commercially available methyl ester 2.42 using NaN3, followed by saponification and 
reprotonation to carboxylic acid 2.44. Catalytic hydrogenation of N-Cbz on 2.40 to the free 
secondary amine, followed by HBTU-mediated coupling with 2.44 gave intermediate 2.41.  
 
 
Scheme 2.9: Attempted synthesis of triazole-linked PS probe 2.4. 
i) 2.36, 4,5-dicyanoimidazole, THF; ii) m-CPBA, CH2Cl2, -78C to 20C, 32% (2 steps); 
iii) TEA, MeOH; iv) TFA, CH2Cl2. 
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Scheme 2.10: Synthesis of DAG probe 2.6, taking advantage of late stage diversity-
creating steps. 
 i) 2N NaOH, (1:3) MeOH/EtOH, 59%; ii) propargylamine, HBTU, DIEA, CHCl3, 82%; iii) 
2.13, CuI, 2,6-lutidine, DIEA, (1:1) MeCN/THF, 81%; iv) H2, 10% Pd/C, Na2CO3, EtOAc; 
v) 2.44, HBTU, DIEA, CHCl3, 65%; vi) TFA, CH2Cl2; vii) 2.19, DIC, HOBt, DIEA, CH2Cl2, 
42% (2 steps). 
 
Finally, TFA deprotection of N-Boc revealed the side chain primary amine for DIC-
mediated coupling to succinimidyl alkyne 2.19 and removed the PMB protecting group as 
well to yield novel triazole-linked DAG probe 2.6. 
At this point, we had established pathways for enhancing the synthetic 
interchangability of phototag and bioconjugation components on lipid probes bearing a 
lysine linker. Next, we turned our attention to making lipid probes resistant to modification 
by enzymes. Since our lipid probes are designed to be biomimetic, it follows as an ironic 
inconvenience that they are succeptable to processing within lipid metabolic pathways, 
such as those covered in Figure 108. Specifically, we were mindful of lipid kinase, 
phospholipase, and lipase/esterase activity that could phosphorylate the 
hydroxylheadgroup of DAG probes, cleave phosphate headgroups on PA probes, and 
cleave fatty ester chains from all lipid probes, respectively. 
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Scheme 2.11: Synthesis of pentafluorophenyl azide photoaffinity tag 2.44. 
i) NaN3, (1:2) H2O/Acetone, 85C, 21%; ii) NaOH, (1:4) H2O/MeOH; iii) 2N HCl, 0C, 91% 
(2 steps). 
 
Lipid photoaffinity probe metabolism in vivo has been observed by other 
researchers127 for sphingolipid-based systems. One solution to this problem involved 
photocaging of sensitive functional groups that could be unveiled using a compatable 
wavelength of light in vivo just prior to photocrosslinking.126 
We sought to solve the problem of lipase modification by installing fatty 
hydrocarbon tails with ether linkages, which was a feature of past work by Dr. Rowland.136 
This also bypasses the problem of acyl chain migration upon hydroxyl deprotection at the 
end of synthesis.132 We also argue that the probes presented here are suited to discover 
protein interactions with different lipid classes based on the type of headgroup, and we 
leave investigations of acyl chain effects for future studies. It should also be recognized 
that ether lipids are their own class of biomolecule found in peroxisomes and adiposomes, 
and are associated with carcinogenesis.151-152  
Next, we attempted to implement a previously published approach by Prestwich153 
for creating PA lipid probes that resist phosphoester cleavage by phosphatase enzymes. 
This was undertaken by replacing a free phosphate oxygen with a fluoromethyl group with 
similar electronic and steric properties. This synthesis began with diethyl phosphonate 
2.45, as shown in Scheme 2.12, rather than the dimethyl analog used in the original 
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protocol due to lower volatility. Compound 2.45 was subjected to a Pudovik reaction with 
paraformaldehyde (CH2O)n to give -hydroxyphosphonate 2.46, which was then 
converted to triflate 2.47 using trifluoracetic anhydride (Tf2O). Phase transfer-catalyzed 
substitution with potassium fluoride and 18-crown-6 produced -fluorophosphonate 2.48. 
This reaction was interchangeable with substitution using tetrabutylammonium fluoride 
(TBAF) as the nucleophilic source of fluorine. Compound 2.48 was converted to 
phosphonochloridate 2.49 by ester cleavage with t-butylamine (t-BuNH2) to ammonium 
salt 2.50, followed by neutralization to ethyl hydrogen phosphonate 2.51. Re-routing 2.51 
through the ammonium salt intermediate fared better than direct basic hydrolysis, and an 
attempt to convert 2.48 to 2.49 directly using phosphorus pentachloride did not produce 




Scheme 2.12: Attempted synthesis of fluoromethyl chlorphosphonate ethyl ester 
2.49. 
i) (CH2O)n, TEA, 60C, 85%; ii) Tf2O, 2,6-lutidine, THF, -56C to 0C; iii) TBAF3H2O, 
THF, 39% (2 steps from 2.46); iv) KF, 18-crown-6, MeCN, reflux, 26% (2 steps from 
2.46); v) PCl5, CCl4, (trace product) vi) t-butylamine, reflux; vii) CaCO3, then Dowex H+, 
CHCl3 (product confirmed spectroscopically) viii) (COCl)2, DMF, THF, 0C (trace 
product); ix) 10% NaOH (aq), 95C; then, 4N HCl (aq), 0C, 27%. 
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Attempts to form 2.49 in situ for coupling with DAG probe 2.2 also did not succeed 
as summarized in Scheme 2.13. Direct coupling of ethyl hydrogenphosphonate 2.51 to 
2.52 under Mitsunobu conditions also failed. 
 
Scheme 2.13: Attempted synthesis of phosphatase-resistant PA probe 2.5. 
i) 2.2, DIAD, PPh3, THF, 0C to 20C; ii) TMSBr; iii) 2.2, tBuOK, THF. 
 
Redirecting efforts back to the originally published pathway as shown in Scheme 
2.14, a Pudovik reaction with TEA and (CH2O)n was applied to dimethyl phosphonate 
2.52 to yield -hydroxymethylphosphonate 2.53. Since triflic anhydride was temporarily 
unavailable, alternative oxygen activating groups were explored including conversions to 
nosylate 2.54 and mesylate 2.56. However, 2.54 only formed what appeared to be a 
brightly-colored Meisenheimer complex in the presence of nucleophilic fluoride,154 and 
2.56 did not yield to substitution under the conditions tried. Returning from this detour, 
triflation to 2.57 using Tf2O provided access to -fluorophosphonate 2.55 after 
nucleophilic substitution with KF and 18-crown-6.  
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Scheme 2.14: : Synthesis of fluoromethyl phosphonate dimethyl ester intermediate 
2.55. 
i) (CH2O)n, K2CO3, MeOH, 87%; ii) NsCl, TEA, THF, -5C to 20C, 34%; iii) MsCl, Pyridine, 
CH2Cl2, 0C, 55%; iv) Tf2O, 2,6-lutidine, CH2Cl2, -50C to 0C; v) TBAF3H2O, THF, (trace 
product); vi) KF, 18-crown-6, MeCN, reflux, 36% (2 steps from 2.53). 
 
Reapplying previously learned chemistry described in Scheme 2.12, 2.55 was 
cleaved to ammonium salt 2.58 by refluxing in t-butylamine (t-BuNH2) and neutralized 
with a Dowex-H+ to methyl hydrogen phosphonate 2.59, shown in Scheme 2.15. Aiming 
to minimize hydrolysis, phosphonochloridate 2.60 was used immediately without isolation 
after synthesis with (COCl)2. However, coupling to DAG probe 2.2 in the presence of 
potassium t-butoxide (tBuOK) did not yield any detectable amount of product. While a 
separate 31P experiment in anhydrous CDCl3 was performed to confirm that the 




Scheme 2.15: Alternate attempted synthesis of phosphatase-resistant PA probe 
2.5. 
i) t-BuNH2, reflux; ii) Dowex H+, MeOH, 99% (2 steps); iii) (COCl)2, DMF, THF, 0C to 
20C, confirmed spectroscopically; iv) 2.2, tBuOK, CH2Cl2, 0C to 20C. 
 
Finally, we briefly explored a route to installing fluorine in place of a hydroxyl 
headgroup as a possible enzyme-resistant DAG probe, summarized in Scheme 2.16. 
This alteration is designed to avoid phosphorylation by kinases while retaining 
comparable steric and hydrogen bond-accepting properties. X-ray studies indicate that 
while alkyl fluorides are not strong H-bond acceptors, fluorine bonded to sp3 carbon 
exhibits the strongest H-bonding character compared to other carbon-bonded fluorine 
atoms.155 A similar concept was explored by Prestwich in replacing the sn-2 hydroxyl of 
lyso-PA with fluorine.156 From a previously synthesized supply of chiral diol 2.8, mono-
PMB protection following alkoxide formation with one equivalent of sodium hydride (NaH) 
produced primary alcohol 2.61, which was converted to mesylate 2.62 for fluoride 
substitution using TBAF, yielding triprotected fluoride 2.63. While we expect that the same 
chemistry used to attain probe 2.26 is applicable for obtaining a fluorinated DAG probe 
such as 2.64, we did not attempt to synthesize probes from intermediate 2.63. 
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Scheme 2.16: Synthetic progress towards proposed enzyme-resistant fluorine-
DAG probe 2.64. 
i) NaH, DMF, 0C to 20C; ii) PMBCl, 0C to 20C, 72% (2 steps); iii) MsCl, TEA, CH2Cl2, 
-15C to 20C, 95%; iv) TBAF, THF, 55C, 33%. 
 
In spite of the failures to obtain PS probe 2.4 and fluorophosphonate lipid probe 
2.5, potential pathways to these molecules were explored and mapped out in depth. Novel 
PA probe 2.3 was obtained by modifying DAG probe 2.2 previously synthesized by Dr. 
Rowland, demonstrating how PA probes may be obtained in a short number of steps from 
existing DAG probes. DAG probe 2.6 was obtained, demonstrating the interchangability 
of photoaffinity groups in probes with a lysine linker. The synthetic solutions acheived 
were highly influential to the work presented in Chapters 3, 4, and 6, and many of the 
same synthetic tactics were adapted to the construction of molecules presented therein. 
2.3 General Experimental 
Reagents and catalysts were purchased from Fisher Scientific or Sigma Aldrich 
and used as received, or purified according to standard methods as needed.157 Dry 
solvents were obtained from either a Pure Solv delivery system from Innovative 
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Technology, Inc, or distilled according to standard methods158 When required, solvents 
were degassed by repeated cycles of freezing with liquid N2, pumping under high vacuum, 
and thawing before backfilling with Ar. Column chromatography was performed using 230 
to 400 mesh silica gel purchased from Sorbent Technologies, or activated alumina from 
Fisher Scientific. Thin layer chromatography was performed on aluminum or glass-
supported silica plates with UV-254 fluorescent indicator, and visualized using a 254 nm 
lamp, potassium permanganate (KMnO4), cerium molybdate (CeMo), ninhydrin, 
bromocresol green (BCG), 2,4-dinitrophenylhydrazine (2,4-DNP), or Phospray stains. 
NMR spectra were recorded using Mercury 300 MHz and Varian 500 MHz instruments. 
Mass spectra were obtained using JEOL DART-AccuTOF, ABI Voyager DE Pro MALDI, 
ESI-Orbitrap Quadrupole or ESI-QSTAR spectrometers.  
2.4 Detailed Syntheses 
 
 
((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)dimethanol (2.8). A previously 
reported procedure was followed.132, 138 Commercially-available compound 2.7 (6.76 mL, 
39.5 mmol) and p-toluenesulfonic acid (p-TsOH, 128 mg, 0.672 mmol) were added to 200 
mL of benzene in a 200 mL three-necked flask equipped with a Dean and Stark trap and 
stirred under argon. 2,2-Dimethoxypropane (6.03 mL, 48.6 mmol) was added, and the 
solution was heated to 82C for 3.5 h. The clear pale-yellow solution was cooled to rt, 200 
mg of Na2CO3 were added, and the mixture was stirred for 1.5 h before filtering through 
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a glass fritted funnel, rinsing with ethyl acetate. Concentration by rotary evaporation and 
drying under high vacuum left a brown oil, which was dissolved in 20 mL of 
tetrahydrofuran and added to an addition funnel. This mixture was added dropwise over 
30 min to lithium aluminum hydride (LiAlH4, 3.00 g, 79.0 mmol), which was stirring in 70 
mL tetrahydrofuran in a flame-dried 250mL three-necked flask at 0C under argon. After 
stirring for 1 h, the mixture was allowed to warm to rt, stirring for another 1.5 h before 
cooling to 0C, quenching slowly with 3 mL water, 3 mL 10% aqueous sodium hydroxide, 
then 9 mL water. The mixture was stirred vigorously at rt for 20 min, then magnesium 
sulfate was added, stirred for 1.5 h, filtered through a pad of celite, and rinsed with 
tetrahydrofuran. Concetration by rotary evaporation produced a clear yellow oil, which 
was purified on a silica gel column using gradient elution with 60-100% ethyl acetate in 
hexanes, followed by 5% methanol-ethyl acetate to give 2.8 as a white solid (3.688 g, 
57% yield). Rf = 0.49 (10% CH3OH-CH2Cl2, KMnO4). NMR and MS characterization data 




methylbenzenesulfonate (2.9). A previously reported procedure were followed.132 
Another publication is also relevant.139 Compound 2.8 (760 mg, 4.66 mmol), silver(I) oxide 
(Ag2O, 1.627 g, 7.02 mmol), p-toluenesulfonyl chloride (p-TsCl, 984 mg, 5.16 mmol), and 
freshly crushed potassium iodode (KI, 156 mg, 0.94 mmol) were added to a 125 mL flame 
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dried round bottom flask, dissolved in 30 mL methylene chloride under N2, and stirred at 
rt for 3h. The crude mixture was loaded onto a 3 cm plug of silica gel, eluted with ethyl 
acetate, and concentrated by rotary evaporation to yield 1.716 g of crude pale yellow-red 
oil, which was used in the next reaction without further purification.  
 
 
((4S,5S)-5-(azidomethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (2.10). A 
previously reported procedure was followed.132 In a 200 mL round bottom flask, sodium 
azide (NaN3, 909 mg, 13.98 mmol) was added to crude compound 2.9 (theoretical from 
previous step: 1.55 g, 4.66 mmol). 50 mL of N,N-dimethylformamide were added under 
N2, and the mixture was heated to 85C. After 13h, the reaction was allowed to cool to rt 
and then 150 mL of water were added before extracting (x2) with 70 mL of ethyl acetate. 
The combined organic layers were dried over magnesium sulfate, filtered, concentrated 
by rotary evaporation, and dried under high vacuum to produce a pale red oil. The crude 
mixture was purified on a silica gel column using a gradient elution of 20-50% ethyl 
acetate in hexanes to give 2.10 as a clear oil (133 mg, 45% yield over two steps from 2.8) 
Rf = 0.50 (50% EtOAc-Hexanes, CeMo). DART-MS: [M-N2+H]+ for C7H13N3O3 calcd, 





dioxolane (2.11). A previously reported procedure was followed.132 In a 6-dram vial, 
compound 2.10 (100 mg, 0.534 mmol) was vacuum dried, backfilled with argon, and 
dissolved in 2 mL of N,N-dimethylformamide. After cooling the solution to 0C with stirring, 
sodium hydride (NaH, 60% dispersion in mineral oil, 24 mg, 0.588 mmol) was added and 
the mixture was stirred for 10 min before warming to rt, then stirring for another 10 min. 
The pale yellow suspension was cooled again to 0C before adding 4-methoxybenzyl 
chloride (PMBCl, 80 L, 0.588 mmol) and stirred for 10 min before warming to rt and 
stirring overnight. The resulting white suspension was quenched with 0.3 mL methanol, 
poured into 20 mL water, and extracted with (2x) 15 mL methylene chloride. The 
combined organic layers were washed (x4) 6 mL water, and dried over sodium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to produce a 
pale orange oil. The crude mixture was purified on a silica gel column using a gradient 
elution of 10-50% ethyl acetate in hexanes to give 2.11 as a clear oil (85 mg, 52% yield) 
Rf = 0.57 (25% EtOAc-Hexanes, UV and KMnO4). NMR and MS characterization data 





(2S,3S)-1-azido-4-((4-methoxybenzyl)oxy)butane-2,3-diol (2.12). A previously 
published procedure was followed.136 In a 8-dram vial, compound 2.11 (164 mg, 0.534 
mmol) was dissolved in 2.6 mL of tetrahydrofuran. Next, 2.6 mL of 1N hydrochloric acid 
(HCl, aq) was added slowly and the cloudy solution was stirred at rt for 48h. The reaction 
was quenched with 4.5 mL of saturated sodium bicarbonate (NaHCO3, aq) dropwise, and 
then stirred for 30 min. 15 mL of water were added, and the mixture was extracted with 
(2x) 15 mL methylene chloride. The combined organic layers were dried over magnesium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
crude mixture was purified on a silica gel column using a gradient elution of 50-85% ethyl 
acetate in hexanes to give 2.12 as a clear oil (121 mg, 85% yield) Rf = 0.33 (50% EtOAc-




(2.13). A previously published procedure was followed.136 In a flame-dried 10 mL round 
bottom flask, sodium hydride (NaH, 60% dispersion in mineral oil, 89 mg, 2.23 mmol) was 
dissolved in 5 mL N,N-dimethylformamide. Tetrabutylammonium iodide (TBAI, 7 mg, 10% 
w/w of 2.12) was added, and the solution was cooled to 0C. Compound 2.12 was 
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separately dissolved in 3 mL of N,N-dimethylformamide, and added dropwise to  the 
reaction over 15 min. The opaque tan suspension was stirred for another 15 min, warmed 
to rt, and then 1-bromohexadecane (1-BHD, 422 L, 1.38 mmol) was added dropwise 
over 5 min. The pale tan suspension was stirred for 19 h, quenched with 4 mL of 
methanol, diluted with 30 mL ethyl acetate, washed (5x) 9 mL water, then 5 mL organic 
layer was dried over sodium sulfate, filtered, concentrated by rotary evaporation, dried 
under high vacuum, and purified on a silica gel column using a gradient elution of 2-12% 
ethyl acetate in hexanes to give 2.13 as a clear oil (179.mg, 90% yield) Rf = 0.56 (10% 
EtOAc-Hexanes, UV and KMnO4). DART-MS: [M-N2+H]+ for C44H81N3O4 calcd, 688.6238; 
detected, 688.6252. NMR characterization data matches previous reports.136  
 
 
Methyl N2-(4-benzoylbenzoyl)-N6-(tert-butoxycarbonyl)-L-lysinate (2.16). A 
modification of a previously published procedure was followed.141 Commercially available 
N-Cbz-N’-Boc-L-lysine methyl ester 2.15 (1.00 g, 2.54 mmol) and palladium(II) hydroxide 
(Pd(OH)2, 100 mg, 10% w/w of 2.15) were added to a 250 mL round bottom flask, which 
was flushed with N2 before adding 45 mL of methanol. With stirring, the atmosphere was 
replaced with H2, and a full H2 balloon was attached. The reaction was stirred at rt for 16 
h, then filtered through a pad of celite, rinsed with (3x) methanol, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was dissolved in 30 mL of 
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chloroform under N2, then (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU, 1.33 g, 2.54 mmol) and diisopropylethylamine (DIEA, 1.32 
mL, 5.07 mmol) were added. After stirring for 20 min at rt, 4-benzoylbenzoic acid (4-BBA, 
861 mg, 2.54 mmol) was added, and the reaction was stirred for 12 h at rt. The crude 
mixture was concentrated by rotary evaporation, redissolved in 25 mL methylene chloride, 
washed with 20 mL water followed by 5 mL of brine (NaCl (aq)), dried over magnesium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
crude yellow oil was purified on a silica gel column using a gradient elution of 30-60% 
ethyl acetate in hexanes to give 2.16 as a white foam (818 mg, 89% yield) Rf = 0.33 (50% 
EtOAc-Hexanes, UV). NMR and MS characterization data matched previous reports.98 
 
 
Methyl (4-benzoylbenzoyl)-L-lysinate (2.65). A previously published procedure 
was followed.141 Compound 2.16 (50 mg, 0.107 mmol) was dissolved in 2 mL methylene 
chloride in a flame dried 50 mL round bottom flask under N2. 2 mL of trifluoroacetic acid 
was added slowly, and the reaction was stirred at rt for 2 h. The clear pale-pink reaction 
was concentrated by rotary evaporation by azeotropic drying with a 1:1 
benzene:methylene chloride mixture, and dried under high vacuum. The crude oil was 
dissolved in 10 mL chloroform and washed with (x3) 3 mL aqueous ammonia (3% 
NH3(aq)). The organic layer was concentrated by rotary evaporation to give 2.65 as a 
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clear oil (35 mg, 89% yield). TLC spot is purple following ninhydrin stain. DART-MS: 




lysinate (2.17). A previously published procedure was modified for this synthesis.141 In a 
flame dried 1 dram vial, Alkyne linker 2.19 (12 mg, 0.076 mmol) and hydroxybenzotriazole 
(HOBt, 11 mg, 0.083 mmol) were dissolved in 1.5 mL of a 1:2 N,N-
dimethylformamide:methylene chloride mixture under argon. N,N-
diisopropylcarbodiimide (DIC, 13 L, 0.083 mmol) was added, and the mixture was stirred 
at rt. After 20 min, the activated ester solution was transferred dropwise to a separate 6 
dram vial containing compound 2.65 (28 mg, 0.075 mmol) stirring in 1 mL of DMF under 
argon, followed by diisopropylethylamine (DIEA, 38 L, 0.227 mmol). The reaction was 
stirred for 15 h at rt, then concentrated by rotary evaporation. The residue was diluted 
with 30 mL ethyl acetate, washed with (5x) 3 mL water then 3 mL brine, dried over sodium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
oil was purified on a silica gel column using a gradient elution of 40-70% acetone in 
hexanes to give 2.17 as a clear resin (25 mg, 62% yield). Rf = 0.45 (70% EtOAc-Hexanes, 
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UV). DART-MS: [M+H]+ for C28H31N3O6 calcd, 506.2286; detected, 506.2245. NMR 




(2.20). A previously published procedure was followed.141 In a 100 mL round bottom flask, 
compound 2.17 (23 mg, 0.046 mmol) was dissolved in 2 mL (1:3) methanol/ethanol 
mixture, and 1.85 mL of 2N sodium hydroxide (NaOH (aq)) were added. The reaction was 
stirred vigorously for 10 min, cooled to 0C, and neutralized with 3.7 mL of 1N hydrochloric 
acid (HCl (aq)) before diluting with 20 mL 1N HCl. The solution was extracted with 40 mL 
methylene chloride, then (4x) 13 mL of a 1:5 methanol:chloroform mixture. The combined 
organic layers were dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum to give 2.20 as a tan solid (28 mg, >99% yield) 






4-oxo-4-(prop-2-yn-1-ylamino)butanoic acid (2.19). A previously published 
procedure was followed.141 In a 100 mL round bottom flask, propargylamine (200 L, 2.92 
mmol) was dissolved in 20 mL of a 2:1 acetonitrile:N,N-dimethylformamide mixture under 
N2, then cooled to 0C. Succinic anhydride (2.18, 292 mg, 2.92 mmol) was separately 
dissolved in the same solvent, and then added to the reaction mixture. The reaction was 
stirred at rt overnight, concentrated by rotary evaporation, and dried under high vacuum. 
The crude residue was purified on a silica gel column using gradient elution of 15-30% 
methanol in methylene chloride to give 2.19 as a tan solid (438 mg, 97% yield) Rf = 0.75 




(2.14). In a 2 mL test tube, compound 2.13 (17 mg, 0.023 mmol), 10% palladium adsorbed 
on carbon (Pd/C, 3 mg, 20% w/w of 2.13), and crushed sodium carbonate (Na2CO3, 7 
mg, 0.062 mmol) were added, and the tube was flushed with argon. 0.3 mL ethyl acetate 
was added, vigorous stirring begun, and the atmosphere was replaced with H2. After 2.5 
h, the mixture was filtered through celite, concentrated by rotary evaporation, and dried 
under high vacuum. The crude residue was purified on a silica gel column using a gradient 
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elution of 0-7% ammonia-saturated methanol in methylene chloride to give 2.14 as a pale 
yellow resin (16 mg, 98% yield). Rf = 0.40 (50% Acetone-Hexanes, UV, Ninhydrin). 1H 
NMR (500 MHz, CDCl3) δ 7.27 – 7.22 (d, 2H), 6.91 – 6.84 (d, 2H), 4.47 (s, 2H), 3.80 (s, 
3H), 3.64 – 3.42 (m, 10H), 2.93 (dd, J = 71.5, 11.3 Hz, 2H), 1.55 (t, J = 7.1 Hz, 4H), 1.25 
(s, 52H), 0.88 (t, J = 6.9 Hz, 6H).13C NMR (126 MHz, CDCl3) δ 129.35, 113.82, 109.99, 
79.40, 73.17, 71.49, 71.18, 55.23, 31.91, 30.12, 30.09, 29.70, 29.68, 29.65, 29.63, 29.51, 
29.49, 29.35, 26.14, 26.09, 22.68, 14.10. DART-MS: [M+H]+ for C44H83NO4 calcd, 
690.6395; detected, 690.6794 
 
 
Amide-linked PMB-protected DAG-benzophenone-alkyne probe (2.21). 
Compound 2.20 (5.5 mg, 0.011 mmol), N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
(EEDQ, 2.8 mg, 0.011 mmol), and 5 mg of crushed borosilicate glass were combined in 
a flame-dried 1 dram vial under argon. 0.5 mL of methylene chloride were added, and the 
suspension was sonicated at rt for 4 h, gradually turning cloudy. The crude mixture was 
poured into 10 mL of ethyl acetate, washed with 2 mL 10% aqueous citric acid, then 1 mL 
water, then 2 mL 1N sodium bicarbonate (NaHCO3 (aq)), then 1 mL water, then 2 mL 
brine. The organic layer was dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The clear semi-crystalline crude residue was 
loaded onto a silica gel column with methylene chloride, and then purified on a silica gel 
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column with a gradient elution of 30-50% acetone in hexanes to give 2.21 as a clear film 
(3.6 mg, 28% yield) Rf = 0.55 (50% Acetone-Hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 
8.01 – 7.95 (d, 2H), 7.87 – 7.76 (d, 4H), 7.61 (ddt, J = 7.8, 7.0, 1.3 Hz, 1H), 7.53 – 7.46 
(m, 2H), 7.35 (d, J = 7.3 Hz, 1H), 7.27 – 7.19 (m, 2H), 6.89 – 6.83 (m, 2H), 6.55 (t, J = 5.3 
Hz, 1H), 6.20 (t, J = 5.9 Hz, 1H), 4.52 (td, J = 8.0, 5.1 Hz, 1H), 4.48 – 4.42 (m, 2H), 3.98 
(dt, J = 5.3, 2.8 Hz, 2H), 3.79 (s, 3H), 3.71 – 3.42 (m, 8H), 3.31 – 3.21 (m, 3H), 2.53 – 
2.37 (m, 4H), 2.18 (t, J = 2.6 Hz, 1H), 1.96 – 1.72 (m, 2H), 1.59 – 1.35 (m, 6H), 1.24 (dd, 
J = 4.8, 2.1 Hz, 52H), 0.87 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 132.91 , 
130.09 , 129.98 , 129.32 , 128.44 , 127.28 , 113.81 , 95.93 , 71.38 , 55.25 , 38.66 , 31.92 
, 31.55 , 31.54 , 29.75 , 29.71 , 29.69 , 29.68 , 29.65 , 29.35 , 26.13 , 22.68 , 14.10. 
MALDI-MS: [M+Na]+ for C71H110N4O9 calcd, 1185.8165; detected, 1185.7903. 
 
 
Amide-linked DAG-benzophenone-alkyne probe (2.1). A modified literature 
procedure was followed.143 In a 1 dram vial, compound 2.21 (4.8 mg, 0.0041 mmol) was 
dissolved in 0.5 mL of methylene chloride, followed by 28 L of water (18:1 solvent ratio). 
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 2.3 mg, 0.0103 mmol) was added, 
then the purple biphasic reaction was covered in foil and stirred vigorously at rt. After 70 
min, the red-pink heterogenous mixture was washed with (2x) 2 mL saturated sodium 
bicarbonate (NaHCO3 (aq)), and (2x) 2 mL water. The organic later was dried over sodium 
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sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
crude residue was purified on a silica gel column using a gradient elution of 2-10% 
methanol in methylene chloride to give 2.1 as a clear film (4.3 mg, >99% yield) Rf = 0.45 
(50% Acetone-Hexanes, UV). DART-MS: [M+H]+ for C63H102N4O8 calcd, 1043.7771; 
detected, 1043.4021. NMR characterization data  matched previous reports.136 
 
 
N2-(4-benzoylbenzoyl)-N6-(tert-butoxycarbonyl)-L-lysine (2.24). In a 100 mL 
round bottom flask, compound 2.16 (509 mg, 1.087 mmol) was dissolved in 40 mL (1:3) 
methanol/ethanol mixture, and 10 mL of 2N sodium hydroxide (NaOH (aq)) were added. 
The reaction was stirred vigorously for 15 min, then cooled to 0C, diluted with 150 mL of 
2N hydrochloric acid (HCl (aq)) extracted with 300 mL methylene chloride, and then (3x) 
75 mL of a 1:9 methanol:chloroform mixture. The combined organic layers were dried 
over magnesium sulfate, filtered, concentrated by rotary evaporation, and dried under 
high vacuum to give 2.24 as a pale yellow foam (464 mg, 94% yield), which was used in 
the next step without further purification. TLC analysis shows a yellow spot with BCG). 





carbamate (2.25). In a 50 mL round bottom flask, compound 2.24 (110 mg, 0.242 mmol) 
was dissolved in 4 mL chloroform, and 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU, 92 mg, 0.242 mmol) was added, 
followed by diisopropylethylamine (DIEA, 80 L, 0.484 mmol), then propargylamine (16 
L, 0.242 mmol). The reaction was stirred overnight at rt, and then concentrated by rotary 
evaporation. The residue was dissolved in 10 mL methylene chloride, washed with 10 mL 
water, and then 10 mL brine (NaCl (aq)). The organic layer was dried over magnesium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
crude residue was purified on a silica gel column using a gradient elution of 50-80% ethyl 
acetate in hexanes to give 2.25 as a clear oil (92 mg, 77% yield) Rf = 0.49 (50% Acetone-
Hexanes, UV). DART-MS: [M+H]+ for C28H33N3O5 calcd, 492.2493; detected, 492.2735. 
NMR characterization data matched previous reports.98 
 
 
Triazole-linked O-PMB-N-Boc Lysine DAG Probe Precursor (2.26). Reaction 
conditions from a published protocol were adapted for this synthesis.144 In a 50 mL flame 
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dried round bottom flask, compound 2.25 (46 mg, 0.094 mmol), compound 2.13 (65 mg, 
0.094 mmol) and copper(I) iodide (CuI, 2 mg, 0.0094) were dissolved in 4 mL of a freshly 
degassed mixture of 1:1 acetonitrile:tetrahydrofuran under argon. 2,6-Lutidine (22 L, 
0.187 mmol) and diisopropylethylamine (DIEA, 31 L, 0.187 mmol) were added, and the 
resulting clear yellow solution was wrapped in foil and stirred at rt for 2.5 h. The reaction 
was concentrated by rotary evaporation, and the crude residue was dissolved in 30 mL 
ethyl acetate, washed (2x) with 5 mL (9:1) saturated ammonium chloride/30% ammonium 
hydroxide (NH4Cl (aq)/ NH3 (aq)), and then (2x) 4 mL 0.5N hydrochloric acid (HCl (aq)). 
The organic layer was dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was purified on a silica gel 
column using a gradient elution of 20-60% acetone in hexanes to give 2.26 as a yellow 
oil (86 mg, 76% yield) Rf = 0.74 (50% Acetone-Hexanes, UV). 1H NMR (500 MHz, CDCl3) 
δ 7.93 (d, J = 8.2 Hz, 2H), 7.85 (d, J = 8.3 Hz, 2H), 7.79 (d, J = 8.3 Hz, 2H), 7.62 (t, J = 
7.5 Hz, 1H), 7.57 (s, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.29 – 7.22 (m, 2H), 7.00 (s, 1H), 6.87 
(d, J = 8.6 Hz, 2H), 6.70 (s, 1H), 4.69 – 4.48 (m, 3H), 4.46 (s, 2H), 4.31 (dd, J = 14.1, 8.4 
Hz, 1H), 3.87 – 3.81 (m, 1H), 3.80 (s, 3H), 3.68 – 3.55 (m, 3H), 3.50 – 3.42 (m, 1H), 3.42 
– 3.32 (m, 1H), 3.19 – 3.09 (m, 3H), 2.00 – 1.95 (m, 2H), 1.82 – 1.78 (m, 2H), 1.56 (s, 
4H), 1.39 (s, 10H), 1.25 (s, 52H), 0.87 (td, J = 7.1, 1.3 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 132.84 , 132.42 , 130.08 , 130.06 , 129.73 , 129.28 , 128.42 , 128.19 , 127.18 , 
114.41 , 113.79 , 55.87 , 55.23 , 31.91 , 30.09 , 29.69 , 29.65 , 29.51 , 29.44 , 29.34 , 
28.38 , 26.11 , 26.02 , 22.67 , 14.10. DART-MS: [M+H]+ for C72H114N6O9 calcd, 





butanoyl)-L-lysinate (2.66). In a flame dried 1 dram vial, compound 2.20 (15 mg, 0.030 
mmol) was dissolved in 1 mL of N,N-dimethylformamide under argon. Pyridine (3 L, 
0.033 mmol) were added, followed by pentafluorophenyl trifuoroacetate (Pfp-TFA, 6 L, 
0.035 mmol), and the resulting clarified pale yellow solution was stirred at rt. After 1 h, 
Pfp-TFA was added (10 L, 0.058 mmol), and then again (10 L, 0.058 mmol) after 
another hour of stirring. The reaction was stirred overnight at rt, and then was diluted with 
15 mL ethyl acetate, washed with (3x) 2 mL 0.1 N hydrochloric acid (HCl (aq)), (3x) 
saturated sodium bicarbonate (NaHCO3 (aq)), and then with 2mL of brine (NaCl (aq)). 
The organic layer was dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The recovered 16 mg of yellow crude residue 
containing 2.66 was used immediately for coupling to compound 2.14 as an alternate 





Amide-linked PMB-protected DAG-benzophenone-alkyne probe precursor 
(2.21). Compound 2.14 (17 mg, 0.012 mmol) was dissolved in 0.3 mL toluene under argon 
in a flame dried 1 dram vial, and a solution of compound 2.66 (theoretical molar yield from 
last step, 16 mg, 0.012 mmol) in 0.3 mL toluene was added slowly with stirring. After 10 
min, a precipitate formed, 30 L of triethylamine were added, and the solution was stirred 
for 1 h at rt. The cloudy gold suspension was concentrated by rotary evaporation, 
dissolved in 20 mL of methylene chloride, washed with (2x) 3 mL 30% ammonium 
hydroxide (NH3 (aq)), (2x) 3 mL 10% aqueous citric acid,  then 1 mL water, then 2 mL 1N 
sodium bicarbonate (NaHCO3 (aq)), and 3 mL brine. The organic layer was dried over 
sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. The crude residue was loaded onto a silica gel column with methylene chloride, 
and then purified on a silica gel column with a gradient elution of 30-50% acetone in 
hexanes to give 2.21 as a pale yellow oil (2.5 mg, 18% yield over 2 steps from 2.20 via 
2.66) Rf = 0.55 (50% Acetone-Hexanes, UV). NMR and MS characterization data matched 





Triazole-linked DAG-benzophenone-amine probe precursor (2.69). 
Compound 2.26 (50 mg, 0.041 mmol) was dissolved in 2 mL methylene chloride in a 
flame dried 50 mL round bottom flask under argon, and 1.5 mL trifluoroacetic acid (TFA) 
was added slowly with stirring. The reaction was stirred for 75 min at rt, then concentrated 
by rotary evaporation, with azeotropic removal of TFA with (3x) 5 mL of a 1:3 
benzene:methylene chloride mixture. The white oily residue was dissolved in 20 mL of 
methylene chloride, washed with 3 mL 30% ammonium hydroxide (NH3 (aq)), dried over 
magnesium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. Compound 2.69 was left behind as a clear oil and was used for coupling to 2.19 
in the next step without further purification. Rf = 0.40 (50% Acetone-Hexanes, UV, 
ninhydrin: purple). 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 7.94 (d, J = 8.1 Hz, 2H), 
7.81 – 7.72 (m, 4H), 7.70 (s, 1H), 7.67 – 7.55 (m, 1H), 7.47 (t, J = 7.7 Hz, 2H), 4.80 (d, J 
= 7.4 Hz, 1H), 4.66 – 4.45 (m, 2H), 4.45 – 4.30 (m, 1H), 3.83 (s, 1H), 3.73 (ddd, J = 33.3, 
11.7, 4.6 Hz, 2H), 3.60 – 3.40 (m, 2H), 3.38 – 3.32 (m, 1H), 3.23 (q, J = 7.1, 6.6 Hz, 1H), 
3.07 (s, 2H), 1.90 (d, J = 40.2 Hz, 4H), 1.64 – 1.50 (m, 6H), 1.42 (s, 2H), 1.37 – 1.12 (m, 
56H), 0.87 (td, J = 7.0, 1.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 132.87 , 130.06 , 129.94 
, 128.42 , 127.37 , 71.95 , 60.31 , 58.42 , 31.91 , 30.12 , 30.00 , 29.71 , 29.68 , 29.66 , 
29.65 , 29.62 , 29.54 , 29.46 , 29.35 , 26.11 , 26.03 , 22.67 , 14.10. DART-MS: [M+H]+ for 




Triazole-linked DAG-benzophenone-alkyne probe (2.2). Alkyne linker 2.19 (7 
mg, 0.046 mmol) and hydroxybenzotriazole (HOBt, 6mg, 0.046 mmol) were dissolved in 
0.5 mL methylene chloride under argon, and the solution was cooled to 0C with stirring 
before adding N,N-diisopropylcarbodiimide (DIC, 7 L, 0.046 mmol). The mixture clarified 
upon warming to room temperature and was then stirred for 10 min before transferring 
dropwise to a stirring rt solution of compound 2.69 (theoretical amount from previous step, 
0.041 mmol) and diisopropylethylamine (DIEA, 21 L, 0.124 mmol) in 1 mL benzene. The 
reaction was stirred at rt for 1 h, and was then concentrated by rotary evaporation, 
dissolved in 20 mL of methylene chloride, washed with 3 mL water, and then 3 mL brine. 
The organic layer was dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was loaded onto a silica 
gel column with methylene chloride, and then purified first with 50% acetone in hexanes, 
50% acetone in chloroform, and finally a gradient elution of 0.5-10% methanol spiked into 
a 50% solution of acetone in chloroform give 2.2 as a clear film (28 mg, 60%) Rf = 0.34 





N-Benzyloxycarbonyl-2-benzyloxy-1,2-dihydroquinoline (2.23). In a flame 
dried 50 mL round bottom flask, commercially available compound 2.22 (quinoline, 0.60 
mL, 5.02 mmol) was dissolved in 4 mL of tetrahydrofuran and cooled to -5C. With stirring, 
benzyl chloroformate (0.78 mL, 5.52 mmol) was added in portions over 5 min, followed 
by dropwise addition of benzyl alcohol (BnOH, 1.04 mL, 10.04 mmol) mixed with 
triethylamine (TEA, 0.77 mL, 5.52 mmol). The orange suspension was stirred for 1 h at -
5C, then 15 min at rt, and was then filtered through a fritted glass funnel, while rinsing 
with tetrahydrofuran, concentrated by rotary evaporation with gentle heat (<40C), and 
recrystallized from ethanol to produce 2.23 as white crystalline needles (565 mg, 30%) Rf 
= 0.63 (10% MeOH/CH2Cl2, UV). 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.2 Hz, 1H), 
7.37 (s, 3H), 7.42 – 7.31 (m, 2H), 7.28 – 7.19 (m, 5H), 7.18 (dd, J = 6.8, 2.8 Hz, 2H), 7.12 
(td, J = 7.4, 1.1 Hz, 1H), 6.75 (d, J = 9.3 Hz, 1H), 6.24 (d, J = 5.5 Hz, 1H), 6.13 (dd, J = 
9.4, 5.4 Hz, 1H), 5.29 (q, 1H), 4.60 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 154.56, 138.12, 
135.60, 133.55, 128.61, 128.37, 128.25, 128.22, 127.90, 127.73, 127.71, 127.50, 126.79, 
125.79, 124.37, 124.27, 123.58, 78.29, 77.19, 69.03, 68.25. DART-MS: [M+H]+ for 





Bis(2-cyanoethyl) diisopropylphosphoramidite (2.29). In an oven dried 50 mL 
round bottom flask, commercially available phosphorus trichloride 2.27 (PCl3, 262 L, 3.0 
mmol) was dissolved in 8 mL hexane (anh) under argon, and cooled to 0C. 
Diisopropylamine (DIPA, 799 L, 5.7 mmol) was added dropwise as a white precipitate 
formed, and the suspension was allowed to warm to rt and allowed to stir for 1 h. The 
solution was filtered through a plug of celite using argon pressure into an oven dried 50 
mL round bottom flask, rinsing with hexane, then concentrated by rotary evaporation at rt 
and backfilled with argon to yield a clear oil of crude 2.28.  Without further purification, 
this crude was dissolved in 3 mL methylene chloride under argon, and 
diisopropylethylamine (DIEA, 979 L, 6.0 mmol) was added. The solution was cooled to 
0C and brought to vigorous stirring before slowly adding 3-hydroxypropionitrile (410 L, 
0.046 mmol). After warming to rt, the clear pale yellow solution was stirred for 75 min, 
then was concentrated by rotary evaporation, and eluted through a plug of silica gel (SiO2, 
activated at 140C) with 5% triethylamine in benzene to give 2.29 as a clear pale yellow 
oil (331 mg, 41% over two steps from 2.27) Rf = 0.72 (75% Et2O-pentane, KMnO4 (rt)). 
DART-MS: [M+H]+ for C12H22N3O2P calcd, 272.1523; detected, 272.1539. NMR 




Triazole-linked bis(-cyanoethyl)-protected PA-benzophenone-alkyne probe 
precursor (2.30). Reaction conditions from a published procedure were adapted to this 
synthesis.146 In a flame dried 2 mL test tube, compound 2.2 (11 mg, 9.8 mol) and 4,5-
dicyanoimidazole (4,5-DCI, 2.3 mg, 19.6 mol) were dissolved in 0.3 mL methylene 
chloride under argon. To the stirring suspension at rt was added a solution of 
phosphoramidite 2.29 (5.3 mg in methylene chloride, 19.6 mol), and the reaction clarified 
briefly before a gray precipitate began to form. The solution was stirred at rt for 5 h, then 
cooled to -78C before adding a solution dropwise of m-CPBA (2.9 mg in methylene 
chloride, 11.7 mol). The reaction was stirred at rt for 90 min, then was diluted with 12 
mL methylene chloride, washed with 3 mL 10% sodium sulfite (Na2SO3 (aq)), and then 3 
mL brine (NaCl (aq)), dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was loaded onto a silica 
gel column with chloroform and purified with 60% acetone in chloroform as eluant, 
followed by a gradient elution of 0.5-10% methanol spiked into a mixture of 60% acetone 
in chloroform to give 2.30 as a clear oil (10 mg, 77%) Rf = 0.49 (60% acetone-hexanes, 
UV). 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.0 Hz, 2H), 7.84 – 7.75 (m, 4H), 7.71 (s, 
1H), 7.65 (s, 1H), 7.63 – 7.58 (m, 1H), 7.54 (s, 1H), 7.49 (t, J = 7.8 Hz, 2H), 6.89 (s, 1H), 
6.66 (s, 1H), 4.70 – 4.50 (m, 2H), 4.45 – 4.10 (m, 1H), 4.31 (q, J = 6.7 Hz, 5H), 3.99 – 
3.93 (m, 2H), 3.86 (s, 1H), 3.62 (q, J = 7.1 Hz, 1H), 3.47 (dt, J = 33.7, 7.2 Hz, 3H), 3.25 
(dt, J = 35.5, 6.8 Hz, 2H), 2.80 (q, J = 6.1, 4.3 Hz, 4H), 2.49 (s, 4H), 2.20 (t, J = 2.5 Hz, 
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1H), 1.92 (s, 2H), 1.64 – 1.35 (m, 8H), 1.24 (d, J = 6.7 Hz, 56H), 0.87 (td, J = 7.0, 1.0 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 196.01 , 140.32 , 136.90 , 132.93 , 132.14 , 130.09 , 
129.93 , 128.44 , 127.34 , 125.43 , 116.50 , 79.60 , 72.11 , 71.79 , 71.37 , 62.49 (d, J = 
5.9 Hz), 38.56 , 31.90 , 31.30 , 30.06 , 29.92 , 29.69 , 29.66 , 29.64 , 29.62 , 29.52 , 29.45 
, 29.34 , 29.11 , 28.56 , 26.03 (d, J = 6.9 Hz), 22.67 , 19.68 (d, J = 7.4 Hz), 14.09. 31P 
NMR (202 MHz, CDCl3) δ -2.43. MALDI-MS: [M+Na+]+ for C77H112N9O11P calcd, 
1332.8111; detected, 1332.9926. 
 
 
Triazole-linked (2H+)PA-benzophenone-alkyne probe (2.3). A previously 
published procedure was followed.148 In a flame dried 1 dram vial, compound 2.30 (10 
mg, 7.5 mol) was dissolved in 0.5 mL methylene chloride under argon and cooled with 
stirring to 0C before adding N,O-bistrifluoroacetamide (BSTFA, 10 L, 37.4 mol), then 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 5.6 L, 37.4 mol). The clear solution was 
stirred at 0C for 30 min, then 161 L methanol was added and the faint pink solution 
then allowed to warm to rt and stir for 3 h, then concentrated by rotary evaporation under 
gentle heat (<40C). The red solid residue was then loaded onto a silica gel column with 
chloroform and purified with 50% acetone in chloroform, then 10% methanol in 
chloroform, and finally eluted with 65:45:4 chloroform/methanol/water. The obtained 
2(DBUH+) salt form of 2.3 was converted to its protonated form by diluting in 5 mL of a 
1:4 methanol:chloroform mixture, and washing with (2x) 1 mL 10% aqueous citric acid, 1 
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mL water, then 1 mL saturate sodium chloride (NaCl (aq)). The organic layer was dried 
over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum to give 2.3 as a clear oil (3.3 mg, 36%). Rf = 0.49 (20% MeOH-CH2Cl2, UV). 1H 
NMR (500 MHz, (1:1) Methanol-d/ CDCl3) δ 7.98 (d, J = 8.0 Hz, 2H), 7.87 – 7.74 (m, 4H), 
7.73 (s, 1H), 7.65 – 7.57 (m, 1H), 7.50 (t, J = 7.7 Hz, 2H), 4.68 – 4.56 (m, 2H), 4.53 – 
4.36 (m, 2H), 3.92 (d, J = 2.5 Hz, 1H), 3.84 (s, 1H), 3.67 – 3.60 (m, 1H), 3.57 – 3.42 (m, 
5H), 3.40 – 3.36 (m, 1H), 3.25 – 3.09 (m, 3H), 2.72 (s, 1H), 2.43 (s, 4H), 2.29 – 2.22 (m, 
1H), 2.10 – 1.99 (m, 1H), 1.94 – 1.67 (m, 5H), 1.64 – 1.47 (m, 4H), 1.38 (dd, J = 22.2, 7.6 
Hz, 4H), 1.32 – 1.03 (m, 56H), 0.89 – 0.78 (m, 6H). 31P NMR (202 MHz, (1:1) Methanol-




Methyl 4-azido-2,3,5,6-tetrafluorobenzoate (2.43). In a 50 mL round bottom 
flask, sodium azide (NaN3, 11 mg, 0.173 mmol) was dissolved in 3 mL (1:2) 
water/acetone, and then commercially available compound 2.42 (20 L, 0.133 mmol) was 
added. A condenser was equipped, the flask was covered with foil, and the solution was 
heated to reflux for 8 h. The solution was cooled, 7 mL of water were added, and the 
mixture was extracted with (2x) 7 mL diethyl ether. The combined organic layers were 
dried over magnesium sulfate, filtered, concentrated down to ~4 mL by rotary evaporation, 
and left in the dark overnight at rt. The solution was filtered to give 2.43 as white, lacelike 
75 
crystals (7 mg, 21%) Rf = 0.25 (5% EtOAc-hexanes, UV). DART-MS: [M+H]+ for 




4-azido-2,3,5,6-tetrafluorobenzoic acid (2.44). In a 3 mL test tube, compound 
2.43 (7 mg, 0.028 mmol) was dissolved in 0.55 mL methanol and 0.3 mL 95% ethanol, 
and then 0.1 mL of 10% sodium hydroxide (NaOH (aq)) was added, and the cloudy yellow 
solution was stirred at rt in the dark for 20 min. The clarified solution was then cooled to 
0C, quenched with 2.5 mL 2N hydrochloric acid (HCl (aq)), and extracted with (3x) 6 mL 
chloroform. The combined organic layers were dried over magnesium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum to give 2.44 as a white 
solid, which was protected from light during handling and storage (6 mg, 91%). TLC on 
silica gave a yellow spot with BCG stain. 19F NMR (470 MHz, CDCl3) δ -137.24 (d, J = 
23.2 Hz), -150.78 (ddq, J = 14.2, 8.8, 5.3 Hz). DART-MS: [M-H+]- for C7HF4N3O2 calcd, 






3-((Chloro(diisopropylamino)phosphaneyl)oxy)propanenitrile (2.29). In a 
flame dried 125 mL round bottom flask, commercially available phosphorus trichloride 
2.27 (PCl3, 88 L, 1.0 mmol) was dissolved in 2.5 mL tetrahydrofuran under argon, 
followed by triethylamine (TEA, 139 L, 1.0 mmol). The clear solution was cooled to 0C, 
diisopropylamine (DIPA, 175 L, 1.0 mmol) was added dropwise, and the solution was 
stirred at 0C for 45 min. Without isolating intermediate 2.28, a pre-cooled solution of 3-
hydroxypropionitrile (68.3 l, 1.0 mmol), TEA (139 L, 1.0 mmol), and 1 mL 
tetrahydrofuran was added dropwise, and the solution was stirred under argon at 0C for 




phosphaneyl)-L-serinate (2.36). A pre-cooled solution of commercially available N-boc-
L-serine t-butyl ester (174 mg, 0.67 mmol) and triethylamine (TEA, 102 L, 0.80 mmol) in 
1 mL of tetrahydrofuran was transferred dropwise to the crude solution of compound 2.32 
in tetrahydrofuran (theoretical yield from previous step of 236 mg, 1.0 mmol) stirring at 
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0C under argon. The reaction was allowed to warm to rt and stir for 2 h, then was filtered 
through a fritted glass funnel, rinsed with tetrahydrofuran, concentrated by rotary 
evaporation, diluted with 40 mL methylene chloride, washed with (2x) 25 mL saturated 
sodium bicarbonate (NaHCO3 (aq)), dried over sodium sulfate, filtered, concentrated 
under rotary evaporation and dried under high vacuum. The crude clear yellow oil was 
purified on a silica gel column using (65:34:1) hexanes/ethyl acetate/triethylamine to give 
compound 2.36 as a clear oil (170 mg, 55% yield over 3 steps from 2.27). NMR 
characterization data  matches previous reports.128 
 
 
Triazole-linked -cyanoethyl-protected N-Boc-lysine-t-butyl ester PS-
benzophenone-alkyne probe precursor (2.37). A previously published procedure was 
followed.146 In a flame dried 2 mL test tube, compound 2.2 (10.5 mg, 9.3 mol) and 4,5-
dicyanoimidazole (4,5-DCI, 2.2 mg, 18.7 mol) were dissolved in 0.3 mL tetrahydrofuran 
under argon. To the stirring suspension at rt was added 55 L solution of phosphoramidite 
2.36 (9.3 mg in tetrahydrofuran, 20.2 mol), and the reaction clarified to a tan solution. 
The reaction was stirred at rt overnight, then cooled to -78C before adding dropwise a 
0.5 mL solution of m-chloroperoxybenzoic acid (m-CPBA, 2.8 mg in methylene chloride, 
11.2 mol). The reaction was stirred at rt for 2 h, then was diluted with 12 mL methylene 
chloride, washed with 3 mL 10% sodium sulfite (Na2SO3 (aq)), then 3 mL brine (saturated 
sodium chloride (aq)), dried over magnesium sulfate, filtered, concentrated by rotary 
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evaporation, and dried under high vacuum. The crude residue was loaded onto a silica 
gel column with chloroform and purified with 50% acetone in chloroform, followed by a 
gradient elution of 0.5-8% methanol spiked into a mixture of 50% acetone in chloroform 
to give 2.37 as a clear oil (4.4 mg, 32% yield) Rf = 0.16 (50% acetone-hexanes, UV). 1H 
NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 8.4, 4.6 Hz, 2H), 7.80 (q, 4H), 7.65 (s, 1H), 7.61 
(t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 6.84 (d, J = 12.6 Hz, 1H), 6.66 (s, 1H), 5.56 
(s, 1H), 4.63 (d, J = 15.8 Hz, 3H), 4.44 – 4.29 (m, 2H), 4.30 – 4.11 (m, 3H), 3.97 (s, 2H), 
3.86 (s, 1H), 3.83 – 3.68 (m, 1H), 3.65 – 3.39 (m, 5H), 3.24 (s, 4H), 2.76 (q, J = 7.0 Hz, 
1H), 2.50 (s, 4H), 2.22 – 2.18 (m, 1H), 1.97 – 1.79 (m, 2H), 1.64 – 1.49 (m, 4H), 1.48 (t, 
J = 1.4 Hz, 9H), 1.44 (s, 9H), 1.41 – 1.32 (m, 4H), 1.32 – 1.16 (m, 56H), 0.92 – 0.84 (m, 
6H). 13C NMR (126 MHz, CDCl3) δ 195.98 , 136.93 , 136.75 , 132.91 , 130.09 , 129.94 , 
129.92 , 128.43 , 127.33 , 109.99 , 77.18 , 71.26 (d, J = 31.0 Hz), 40.05 , 31.90 , 31.31 
(d, J = 3.6 Hz), 30.04 , 29.69 , 29.66 , 29.64 , 29.60 , 29.52 , 29.49 , 29.46 , 29.41 , 29.34 
, 28.28 , 27.92 , 26.08 (d, J = 6.2 Hz), 25.99 , 22.67 , 14.09. 31P NMR (202 MHz, CDCl3) 
δ -1.88. MALDI-MS: [M+H]+ for C81H130N9O15P calcd, 1499.9497; detected, 1499.9451. 
[M+Na]+ for C81H130N9O15P calcd, 1522.9316; detected, 1522.9231. 
 
 
N-Cbz-N’-Boc-L-lysine (2.38). In a 250 mL round bottom flask, commercially 
available N-Cbz-N’-Boc-L-lysine methyl ester 2.15 (394 mg, 1.0 mmol) was dissolved in 
32 mL of a 3:1 methanol:ethanol mixture. While stirring vigorously at rt, 8 mL 2N sodium 
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hydroxide (NaOH (aq)) was added slowly, and the cloudy mixture clarified while stirring 
for 20 min. The reaction was cooled to 0C, quenched with 16 mL 2N hydrochloric acid 
(HCl (aq)), then diluted with 240 mL methylene chloride and 120 mL 2N HCl(aq). The 
organic layer was separated, and the remaining aqueous layer was extracted with (3x) 
60 mL of a 1:4 methanol:chloroform mixture. The combined organic layers were dried 
over magnesium sulfate, filtered, concentrated by rotary evaporation, and dried under 
high vacuum to give 2.38 as a pale yellow foam (225 mg, 59%) Rf = 0.50 (15% MeOH-
CH2Cl2, UV, BCG: yellow).  DART-MS: [M-H+]- for C19H28N2O6 calcd, 381.2020; detected, 
381.2021. NMR data  matches previous reports.161 
 
 
N-Cbz-N’-Boc-L-lysine propargylamide (2.38). In a 100 mL round bottom flask, 
compound 2.38 (225 mg, 0.591 mmol) was dissolved in 9 mL chloroform.  (2-(1H-
Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 224 mg, 
0.591 mmol) was added, followed by diisopropylethylamine (DIEA, 195 l, 1.182 mmol), 
then propargylamine (38 L, 0.591 mmol). The cloudy white suspension was stirred at rt 
overnight, and the resulting orange suspension was concentrated by rotary evaporation, 
diluted with 20 mL methylene chloride, washed with 20 mL water, then 20 mL brine 
(saturated NaCl(aq)), dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was purified on a silica gel 
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column using a gradient elution of 35-75% acetone-hexanes to give 2.39 as a white 
poweder (203 mg, 82%) Rf = 0.60 (50% acetone-hexanes, KMnO4). DART-MS: [M+H]+ 




Triazole-linked O-PMB-N-Cbz-N’-Boc-protected DAG probe precursor (2.40). 
Reaction conditions from a published protocol were adapted for this synthesis.144 In a 100 
mL flame dried round bottom flask, compound 2.39 (38 mg, 0.090 mmol), compound 2.13 
(62 mg, 0.090 mmol) and copper(I) iodide (CuI, 2 mg, 0.009 mmol) were dissolved in 4 
mL of a freshly degassed mixture of 1:1 acetonitrile:tetrahydrofuran under argon. 2,6-
lutidine (21 L, 0.180 mmol) and diisopropylethylamine (DIEA, 30 L, 0.180 mmol) were 
added, and the resulting clear yellow solution was wrapped in foil and stirred at rt for 45 
min. The reaction was concentrated by rotary evaporation, and the crude residue was 
dissolved in 30 mL ethyl acetate, washed (2x) with 5 mL a 9:1 saturated ammonium 
chloride:30% ammonium hydroxide mixture (NH4Cl (aq):NH3 (aq)), and then (2x) 4 mL 
0.5 N hydrochloric acid (HCl (aq)). The organic layer was dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum. The crude 
residue was purified on a silica gel column using a gradient elution of 20-30% acetone in 
hexanes to give 2.40 as a tan solid (83 mg, 81% yield) Rf = 0.51 (40% Acetone-Hexanes, 
UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.55 (s, 1H), 7.38 – 7.27 (m, 5H), 7.26 – 7.21 
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(m, 2H), 6.90 – 6.84 (m, 2H), 6.68 (s, 1H), 5.43 (s, 1H), 5.08 (s, 2H), 4.59 (dd, J = 13.6, 
3.4 Hz, 2H), 4.51 (dd, J = 19.6, 5.3 Hz, 1H), 4.46 (s, 2H), 4.30 (dd, J = 14.1, 8.5 Hz, 1H), 
4.16 – 4.11 (m, 1H), 3.86 – 3.76 (m, 1H), 3.80 (s, 3H), 3.67 – 3.55 (m, 3H), 3.49 – 3.32 
(m, 3H), 3.15 (dt, J = 9.3, 6.6 Hz, 1H), 3.09 – 3.04 (m, 2H), 1.85 (h, J = 7.7 Hz, 1H), 1.63 
(s, 3H), 1.57 (t, J = 7.0 Hz, 2H), 1.38 (s, 8H), 1.25 (s, 58H), 0.88 (t, J = 6.9 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 129.27 , 128.50 , 128.17 , 128.11 , 123.41 , 113.79 , 78.75 , 
78.16 , 73.15 , 72.06 , 68.21 , 67.10 , 35.05 , 31.91 , 30.09 , 29.93 , 29.70 , 29.68 , 29.66 
, 29.65 , 29.63 , 29.62 , 29.51 , 29.45 , 29.35 , 28.39 , 26.11 , 26.01 , 22.67 , 22.37 , 14.10. 
 
Triazole-linked O-PMB-N-Boc-protected DAG-tetrafluorophenyl azide probe 
precursor (2.41). In a 3 mL test tube under argon, compound 2.40 (20 mg, 17.6 mol), 
10% palladium on carbon (Pd/C, 5 mg, 25% w/w of 2.40) and freshly crushed sodium 
carbonate (Na2CO3, 5 mg, 45.8 mol mmol) were covered with 0.5 mL ethyl acetate. The 
atmosphere was replaced with H2, and the reaction was stirred vigorously at rt for 4 h, 
confirming the disappearance of the 2.40 spot on TLC, and the emergence of the 
intermediate amine by ninhydrin (Rf = 0.3, 50% acetone-hexanes).  The reaction was 
filtered through celite concentrated by rotary evaporation, and dissolved in 1 mL 
chloroform. This amine solution was added to a separate solution of activated ester, 
generated by adding diisopropylethylamine (DIEA, 5.8 L, 35.2 mol) to a solution of 
compound 2.44 (4.1 mg, 17.6 mol) stirring in 1 mL chloroform at rt. After 12 h, the 
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reaction was concentrated by rotary evaporation, dissolved in 8 mL methylene chloride, 
washed with 8 mL water, and then 8 mL brine (saturated sodium chloride (aq)). The 
organic layer was dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum while protected from light. The crude residue 
was purified on a silica gel column using a gradient elution of 20-50% acetone in hexanes 
to give 2.41 as a white solid (14 mg, 65% yield over 2 steps from 2.40) Rf = 0.75 (50% 
Acetone-Hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.57 (s, 1H), 7.28 – 7.21 (m, 2H), 
7.05 (d, J = 6.4 Hz, 1H), 6.90 – 6.84 (m, 2H), 6.78 (t, J = 5.3 Hz, 1H), 4.61 (ddd, J = 13.8, 
9.4, 5.3 Hz, 2H), 4.54 (t, J = 5.5 Hz, 2H), 4.46 (s, 2H), 4.31 (dd, J = 14.0, 8.4 Hz, 1H), 
3.83 (dt, J = 8.3, 4.0 Hz, 1H), 3.80 (s, 3H), 3.68 – 3.55 (m, 3H), 3.49 – 3.33 (m, 3H), 3.15 
(dt, J = 9.2, 6.6 Hz, 1H), 3.07 (dt, J = 13.5, 6.2 Hz, 2H), 2.02 – 1.69 (m, 2H), 1.57 (p, J = 
6.9 Hz, 2H), 1.49 (d, J = 7.1 Hz, 2H), 1.42 (d, J = 7.1 Hz, 1H), 1.38 (s, 9H), 1.25 (s, 56H), 
0.88 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 159.24 , 130.01 , 129.27 , 123.34 
, 113.78 , 78.74 , 78.15 , 73.15 , 72.06 , 71.33 , 68.19 , 55.23 , 53.65 , 51.18 , 35.22 , 
31.91 , 30.08 , 29.93 , 29.70 , 29.68 , 29.66 , 29.65 , 29.63 , 29.62 , 29.56 , 29.51 , 29.44 
, 29.34 , 28.30 , 26.11 , 26.02 , 22.67 , 22.08 , 14.09. 19F NMR (470 MHz, CDCl3) δ -
140.64, -140.64, -140.66, -140.69, -140.70, -140.71, -150.42, -150.44, -150.46, -150.48. 





Triazole-linked DAG-alkyne-tetrafluorophenyl azide probe (2.6). Compound 
2.41 (14 mg, 11.5 mol) was dissolved in 1mL methylene chloride in a 6 dram vial under 
argon, and 0.5 mL trifluoroacetic acid (TFA) was added slowly with stirring. The pale 
yellow solution was stirred for 1 h at rt, then concentrated by rotary evaporation, with 
azeotropic removal of TFA using (3x) 5 mL of a 1:3 benzene:methylene chloride mixture, 
and dried under high vacuum. The resulting crude was used in the next step without 
further purification. However, washing the free amine intermediate with 3% ammonium 
hydroxide may have improved final yield. 
Alkyne linker 2.19 (2.0 mg, 12.7 mol) and hydroxybenzotriazole (HOBt, 1.7 mg, 
12.7 mol) were dissolved in 0.5 mL methylene chloride in a flame dried 1 dram vial under 
argon, and the solution was cooled to 0C with stirring before adding N,N-
diisopropylcarbodiimide (DIC, 7 L, 0.046 mmol). The mixture clarified upon warming to 
room temperature and was then stirred for 10 min before transferring dropwise to a stirring 
rt solution of the free amine product of the previous step and diisopropylethylamine (DIEA, 
21 L, 0.124 mmol) in 1 mL methylene chloride under argon.  The reaction was stirred at 
rt for 30 min, and then an additional 100 L of DIEA was added to achieve basic conditions 
(pH = 9-11). The reaction was stirred for 30 min at rt, and was then concentrated by rotary 
evaporation, dissolved in 12 mL of methylene chloride, washed with 3 mL water, and then 
3 mL brine (saturated sodium chloride (aq)). The organic layer was dried over magnesium 
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sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum. The 
crude residue was loaded onto a silica gel column with chloroform, and then purified first 
with 50% acetone in hexanes, 50% acetone in chloroform, and finally a gradient elution 
of 0.5-4% methanol spiked into a 50% solution of acetone in hexanes to give 2.6 as a 
clear film (5.5 mg, 42%). 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H), 7.47 (d, J = 7.2 Hz, 
1H), 7.35 (d, J = 7.3 Hz, 1H), 6.71 (t, J = 5.4 Hz, 1H), 6.61 (t, J = 6.0 Hz, 1H), 4.63 (ddd, 
J = 18.7, 13.0, 4.4 Hz, 3H), 4.48 (dd, J = 15.2, 5.4 Hz, 1H), 4.38 (dd, J = 14.1, 8.4 Hz, 
1H), 4.06 – 3.95 (m, 2H), 3.91 – 3.84 (m, 1H), 3.77 (ddd, J = 43.4, 11.7, 4.6 Hz, 2H), 3.56 
(tt, J = 6.4, 3.2 Hz, 2H), 3.49 – 3.39 (m, 2H), 3.29 – 3.15 (m, 3H), 2.62 – 2.46 (m, 3H), 
2.22 (t, J = 2.5 Hz, 1H), 1.95 – 1.76 (m, 2H), 1.49 (d, J = 7.2 Hz, 2H), 1.44 (s, 2H), 1.25 
(s, 58H), 0.88 (t, J = 6.9 Hz, 6H). 19F NMR (470 MHz, CDCl3) δ -140.35 – -141.65 (m), -
150.00 – -151.40 (m). MALDI-MS: [M+H]+ for C59H96F4N10O7 calcd, 1133.7473; detected, 
1133.7743.   
 
 
Diethyl (hydroxymethyl)phosphonate (2.46). A published procedure was 
followed.162 Commercially available diethylphosphonate (2.45, 258 L, 2.0 mmol) was 
added to paraformaldehyde ((CH2O)n, 23 mg, 1.19 mmol) in a flame dried 3 mL test tube 
under argon. 200 L triethylamine (TEA) were added, and the solution was heated to 
60C. The white suspension clarified while stirring over 45 min, and the resulting solution 
was concentrated by rotary evaporation (<40C). The clear oily crude was purified on a 
silica gel column using a gradient elution of 0-12% methanol in ethyl acetate, giving 2.46 
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as a clear oil (286 mg, 85% yield). Rf = 0.38 (10% MeOH-CH2Cl2, KMnO4). DART-MS: 




(Diethoxyphosphoryl)methyl trifluoromethanesulfonate (2.47). Published 
procedures were modified for this synthesis.153, 162, 164 In a flame dried 3 mL test tube, 
trifluoromethanesulfonic anhydride (Tf2O, 109 L, 0.649 mmol) was added dropwise to a 
solution of compound 2.46 (91 mg, 0.541 mmol) and 2,6-lutidine (125 L, 1.082 mmol) 
stirring in 2 mL tetrahydrofuran at -56C under argon. The yellow solution was gradually 
warmed over 1 h to 0C, then stirred for 45 min. The resulting orange solution was diluted 
with 15 mL cold diethyl ether and washed with 6mL cold water, 6 mL cold 1N hydrochloric 
acid (HCl (aq)), and 6 mL cold brine (saturated sodium chloride (aq)). The organic layer 
was dried over sodium sulfate, filtered, concentrated by rotary evaporation (<25C), and 
used in the next step (synthesis of 2.48) without further purification. DART-MS: [M+H]+ 
for C6H12F3O6PS calcd, 301.0117; detected, 301.0126. 
 
 
Diethyl (fluoromethyl)phosphonate (2.48). A published procedure was modified 
for this synthesis.153 In a 50 mL round bottom flask, the crude oil of compound 2.47 
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(theoretical yield from previous step of 0.541 mmol) was dissolved in 3 mL 
tetrahydrofuran, and cooled to 0C. TBAF•3H2O (171 mg, 0.541 mmol) was dissolved in 
0.5 mL tetrahydrofuran and added dropwise to the crude solution, and the mixture was 
stirred at 0C for 3.5 h. The resulting clear solution was concentrated by rotary 
evaporation (<25C), diluted in 12 mL methylene chloride, washed with (3x) 3mL water, 
dried over magnesium sulfate, filtered, and concentrated by rotary evaporation (<25C). 
The clear crude oil was purified on a silica gel column using a gradient elution of 40-80% 
ethyl acetate in hexanes to give compound 2.48, which was freed from traces of ethyl 
acetate by (3x) rotary evaporation with 3 mL methylene chloride (<25C) (36 mg, 39% 
over 2 steps from 2.46). DART-MS: [M+H]+ for C5H12FO3P calcd,171.0581; detected, 
171.0597. NMR charactreization data  matched previous reports.164 
 
 
Diethyl (fluoromethyl)phosphonate (2.48). In a flame dried 10 mL round bottom 
flask, potassium fluoride (KF, 47 mg, 0.936 mmol) and 18-crown-6 (18-C-6, 22 mg, 0.085 
mmol) were dissolved in 2 mL tetrahydrofuran under argon. The suspension was stirred 
at rt, and a solution of triflate 2.47 (0.851 mmol theoretical yield from previous step) in 2 
mL tetrahydrofuran were added dropwise, producing a yellow solution. The reaction was 
stirred at rt for 3 h, then concentrated by rotary evaporation. The crude yellow oil was 
purified on a silica gel column using a gradient elution of 0-4% methanol in 
dichloromethane to give 2.48 as a yellow oil (38 mg, 26% yield in 2 steps from 2.46). NMR 
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and MS characterization data matched that obtained by the previously described route to 
2.48 using TBAF.  
 
 
t-Butylammonium ethyl(fluoromethyl)phosphonate (2.50). This procedure 
followed modified a version of a published synthesis.153 In a flame dried 10 mL round 
bottom flask, compound 2.48 (20 mg, 0.118 mmol) was refluxed overnight in 3 mL t-
butylamine (t-BuNH2) under argon. The resulting solution was concentrated by rotary 
evaporation to give crude 2.50 as a light brown oil, which was used in the next step 
(synthesis of compound 2.51) without further purification. 
 
 
Ethyl hydrogen(fluoromethyl)phosphonate (2.51). In a 2 mL test tube, 
compound 2.48 (8 mg, 0.047 mmol) was dissolved in 0.5 mL of 10% sodium hydroxide 
(NaOH (aq)), and heated the mixture was heated to 95C for 80 min. The reaction was 
cooled to 0C, and 0.45 mL 4 N hydrochloric acid (HCl (aq)) was added, then the aqueous 
layer was extracted with (2x) 2 mL chloroform and then concentrated under rotary 
evaporation to give compound 2.51 as a clear oil (1.8 mg, 27%).  DART-MS: [M+H]+ for 




Dimethyl (hydroxymethyl)phosphonate (2.53). This synthesis followed a 
published procedure.153 Commercially available dimethylphosphonate (2.52, 90 L, 0.981 
mmol) was added to a stirring solution of paraformaldehyde ((CH2O)n, 23 mg, 1.19 mmol) 
and freshly crushed potassium carbonate (K2CO3, 7.0 mg, 0.051 mmol)  in 1 mL methanol 
under argon at rt. The white suspension clarified while stirring for 1 h and was then filtered 
through a 0.45 m membrane using a 1 mL syringe, rinsing with methanol. The filtrate 
was concentrated by rotary evaporation and dried under high vacuum to give 2.53 as a 
clear oil (119 mg, 87% yield). Rf = 0.16 (50% Acetone-Hexanes, KMnO4, rt). DART-MS: 




(Dimethoxyphosphoryl)methyl 4-nitrobenzenesulfonate (2.54). In a flame 
dried 3 mL test tube, compound 2.53 (20 mg, 0.143 mmol) and triethylamine (TEA, 21 
L, 0.143 mmol) were dissolved in 1 mL tetrahydrofuran under argon. The solution was 
cooled to -5C, and a solution of 4-nitrobenzenesulfonyl chloride (32 mg, 0.143 mmol) in 
1 mL tetrahydrofuran was added dropwise. After stirring for 10 min, the reaction was 
warmed to rt and stirred for 20 min, then was concentrated by rotary evaporation. The 
oily crude was triturated with 12 mL diethyl ether, and the organic layer was washed with 
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3 mL water, 3 mL 1N hydrochloric acid (HCl (aq)), and 3 mL brine (saturated sodium 
chloride (aq)), and then dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The clear crystalline crude was purified on a 
silica gel column using a gradiaent elution of 20-60% acetone in hexanes to give 2.54 as 
a white crystalline solid (16 mg, 34% yield). Rf = 0.42 (50% Acetone-Hexanes, UV). 1H 
NMR (500 MHz, CDCl3) δ 8.46 – 8.40 (m, 2H), 8.18 – 8.11 (m, 2H), 4.35 (d, J = 9.5 Hz, 
2H), 3.80 (d, J = 10.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 129.51 , 124.55 , 62.13 , 
60.77 , 53.71 (d, J = 6.7 Hz). 31P NMR (202 MHz, CDCl3) δ 16.93. DART-MS: [M+H]+ for 
C9H12NO8PS calcd, 326.0094; detected, 326.0105 
 
 
(Dimethoxyphosphoryl)methyl methanesulfonate (2.56). A modified synthesis 
was followed.166 In a dry 6 dram vial, pyridine (46 L, 0.565 mmol) was added to a solution 
of compound 2.53 (72 mg, 0.514 mmol) stirring in 2 mL methylene chloride at -5C under 
argon. Methanesulfonyl chloride (MsCl, 44 L, 0.565 mmol) was added, and the solution 
was stirred for 1 h, and was then quenched with 5 mL cold water. The organic layer was 
separated, and the remaining aqueous later was extracted with (2x) 10 mL methylene 
chloride. The combined organic layers were dried over sodium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum. The clear semi-
crystalline crude was triturated with (3x) 5 mL diethyl ether, and the combined organic 
layers were evaporated to give 2.56 as a pale yellow oil (52 mg, 46% yield). Rf = 0.75 
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(50% Acetone-Hexanes, KMnO4). DART-MS: [M+H]+ for C4H11O6PS calcd, 219.0087; 
detected, 219.0129. NMR characterization data  matched previous reports.167  
 
 
(Dimethoxyphosphoryl)methyl trifluoromethanesulfonate (2.57). This 
synthesis followed a published procedure.153 In a dry 6 dram vial, trifluoromethanesulfonic 
anhydride (Tf2O, 230 L, 1.37 mmol) was added slowly to a solution of compound 2.53 
(165 mg, 1.18 mmol) and 2,6-lutidine (167 L, 1.45 mmol) stirring in 2 mL methylene 
chloride at -78C under argon. The pale yellow solution was warmed gradually to 0C 
while stirring over 1 h. The resulting cloudy brown suspension was diluted with 15 mL 
diethyl ether and washed with 5mL water, 5 mL 1N hydrochloric acid (HCl (aq)), and 5mL 
brine (saturated sodium chloride (aq)). The organic layer was dried over sodium sulfate 
and decanted into the next reaction (synthesis of 2.55) without further purification. 1H 
NMR (500 MHz, CDCl3) δ 4.65 (d, J = 8.8 Hz, 2H), 3.89 (d, J = 11.0 Hz, 6H). 19F NMR 




Dimethyl (fluoromethyl)phosphonate (2.55). In a flame dried 50 mL round 
bottom flask, potassium fluoride (KF, 71 mg, 1.42 mmol) and 18-crown-6 (18-C-6, 187 
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mg, 0.708 mmol) were dissolved in 2 mL tetrahydrofuran under argon. The suspension 
was cooled to 0C, and a solution of triflate 2.57 (1.18 mmol theoretical yield from previous 
step) in diethyl ether were added slowly, producing a cloudy yellow suspension. The 
reaction was warmed to rt and stirred for 30 min, then concentrated by rotary evaporation. 
The crude yellow oil was purified on a silica gel column using a gradient elution of 50-
100% diethyl ether in hexanes to yield 2.55 (60 mg, 36% yield in 2 steps from 2.53 via 




t-Butylammonium methyl(fluoromethyl)phosphonate (2.58). A previously 
reported procedure was followed.153 In a flame dried 10 mL round bottom flask, compound 
2.55 (60 mg, 0.422 mmol) was refluxed overnight in 5 mL t-butylamine (t-BuNH2) under 
argon. The resulting solution was concentrated by rotary evaporation to give compound 
2.58 as white crystals (69 mg, 81% yield). 1H NMR (300 MHz, CDCl3) δ 8.33 (s, 3H), 4.58 
(ddd, J = 47.4, 4.6, 0.8 Hz, 2H), 3.66 (dd, J = 10.3, 0.8 Hz, 3H), 1.37 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 155.53 , 104.99 , 51.08 , 27.54. 19F NMR (282 MHz, CDCl3) δ -78.55 
, -243.86 (dt, J = 56.9, 47.5 Hz). 31P NMR (121 MHz, CDCl3) δ 12.22 (d, J = 56.9 Hz). 




Methyl hydrogen(fluoromethyl)phosphonate (2.59). A previously reported 
procedure was modified for this synthesis.153 A microcolumn was packed with ~1 g Dowex 
WX8 (100-200 mesh), and activated into its H+ form by eluting 6 mL 1N hydrochloric acid 
(HCl (aq)), and prepared with 3 mL water followed by 3 mL methanol. Crude 2.58 
(theoretical yield of 0.148 mmol from previous step) was loaded onto the column with 
methanol, and eluted with 8 mL methanol, and then 8 ml of a 1:1 methanol:chloroform 
mixture. The organic solution was concentrated by rotary evaporation with gentle heating 
(<50C) to give compound 2.59 as a colorless grainy oil (19 mg, >99% yield). 1H NMR 
(300 MHz, CDCl3) δ 8.24 (d, J = 86.1 Hz, 1H), 4.71 (ddd, J = 46.6, 5.0, 0.7 Hz, 2H), 3.84 
(dd, J = 11.0, 0.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 53.28 (d, J = 5.9 Hz), 30.88. 31P 
NMR (121 MHz, CDCl3) δ 18.66. 19F NMR (470 MHz, CDCl3) δ -251.47 (dt, J = 67.0, 
46.5 Hz).DART-MS: [M+H]+ for C2H6FO3P calcd, 129.0112; detected, 129.0112. 
 
 
Methyl (fluoromethyl)phosphonochloridate (2.60). A published procedure was 
followed for this synthesis.153 In an oven dried 1 dram vial, compound 2.59 (19 mg, 0.148) 
was dissolved in 1.5 mL methylene chloride, followed by N,N-dimethylformamide (0.6 L, 
7 mol). The solution was cooled to 0C, oxalyl chloride ((COCl)2, 20 L, 0.238 mmol) 
was added, and the yellow bubbling solution was stirred while warming to room 
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temperature for 1.5 h. The resulting solution was added directly to the next reaction 
without purification (synthesis of 2.5). 
A separate spectroscopic experiment was performed to observe the formation of 
2.60. Compound 2.59 (4.5 mg, 0.03 mmol) was dissolved in 0.7 mL of deuterated 
chloroform (CDCl3, anh), and transferred to an oven dried NMR tube, under argon. ~0.5 
l of N,N-dimethylformamide (catalytic) were added, and then the vessel was cooled to 
0C before adding 1.1 L oxalyl chloride ((COCl)2, 4.1 L, 0.05 mmol). The NMR tube 
was then removed from ice, briefly allowed to warm before insertion into a Varian 500 
mHz spectrometer, and tube rotation at 20 Hz was initiated prior to recording spectra. 1H, 




methanol (2.61). A previously reported synthesis was followed.137 Sodium hydride (60% 
dispersion NaH in mineral oil, 114 mg, 2.85 mmol) was added to a flame dried 3 neck 
flask under argon, and then dissolved in 15 mL N,N-dimethylformamide. The cloudy 
mixture was cooled to 0C, and then a solution of previously synthesized compound 2.8 
(465 mg, 2.85 mmol) in 15 mL N,N-dimethylformamide was added dropwise. The mixture 
was stirred for 10 min, and then warmed to rt and stirred for 25 min. The resulting gray 
suspension was cooled to 0C, and 4-methoxybenzylchloride (PMBCl, 425L, 3.14 mmol) 
was added slowly. After 5 min of stirring, the reaction was allowed to warm to rt and stir 
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for 7 h. The pale yellow cloudy suspension was quenched with 30 mL water, extracted 
with (2x) 35 mL methylene chloride, dried over magnesium sulfate, filtered, concentrated 
by rotary evaporation, and dried under high vacuum. The crude yellow oil was purified on 
a silica gel column using a gradient elution of 30-50% ethyl acetate in hexanes to give 
compound 2.61 as a clear oil (578 mg, 72%). Rf = 0.38 (50% EtOAc-hexanes, UV). NMR 




yl)methyl methanesulfonate (2.62). In a flame dried 6 dram vial undr argon, compound 
2.61 (99 mg, 0.351 mmol) was dissolved in 2 mL methylene chloride. Triethylamine (TEA, 
55L, 0.369) was added, and the solution was cooled to -15C before adding 
methanesulfonyl chloride slowly (29L, 0.369 mmol). The clear solution was allowed to 
warm to rt and stir for 3.5 h and was then cooled back to 0C and quenched with 2 mL 
water and extracted with (2x) 3 mL methylene chloride. The combined organic layers were 
washed with 2 mL brine (saturated sodium chloride (aq)), dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum. The crude 
yellow oil was purified on a silica gel column using a gradient elution of 10-30% ethyl 
acetate in hexanes to give compound 2.62 as a clear pale yellow oil (120 mg, 95%). Rf = 
0.55 (50% EtOAc-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.28 – 7.22 (m, 2H), 6.91 
– 6.84 (m, 2H), 4.50 (s, 2H), 4.41 (dd, J = 11.2, 3.1 Hz, 1H), 4.25 (dd, J = 11.2, 5.6 Hz, 
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1H), 4.10 (ddd, J = 8.5, 5.5, 3.1 Hz, 1H), 4.02 (ddd, J = 8.1, 5.7, 4.9 Hz, 1H), 3.81 (s, 3H), 
3.65 (dd, J = 9.9, 4.9 Hz, 1H), 3.53 (dd, J = 9.9, 5.7 Hz, 1H), 3.02 (s, 3H), 1.44 – 1.39 (m, 
6H). 13C NMR (126 MHz, CDCl3) δ 159.35 , 129.64 , 129.39 , 113.86 , 110.26 , 76.94 , 
75.73 , 73.34 , 69.69 , 69.06 , 55.26 , 37.63 , 26.96 , 26.83. DART-MS: [M-H:]+ for 




1,3-dioxolane (2.63). In an oven dried 5 mL round bottom flask under argon, compound 
2.62 was dissolved in 2 mL tetrahydrofuran. Tetrabutylammonium fluoride (TBAF, 1M 
THF, 0.6 mL, 0.6 mmol) was added, and the brown solution was heated to 55C. After 6 
h the reaction was concentrated under reduced pressure, and the crude residue was 
triturated with (7x, until product TLC spot gone) 2 mL diethyl ether, and the combined 
organic layers were concentrated by rotary evaporation. The crude pink oil was purified 
on a silica gel column using a gradient elution of 10-30% ethyl acetate in hexanes to give 
compound 2.63 as a clear oil (31 mg, 33%). Rf = 0.69 (50% EtOAc-hexanes, UV). 1H 
NMR (500 MHz, CDCl3) δ 7.27 – 7.21 (m, 2H), 6.92 – 6.85 (m, 2H), 4.56 – 4.45 (m, 3H), 
4.64 – 4.36 (m, 1H), 4.12 – 4.00 (m, 2H), 3.81 (s, 3H), 3.64 (dd, J = 10.0, 5.0 Hz, 1H), 
3.58 – 3.51 (m, 1H), 1.45 – 1.41 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 159.29 , 129.80 
, 129.30 , 113.81 , 110.03 , 83.25 , 81.87 , 77.73 (d, J = 19.5 Hz), 75.26 (d, J = 6.7 Hz), 
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73.28 , 70.01 , 55.25 , 27.00 , 26.70. 19F NMR (470 MHz, CDCl3) δ -229.23 (td, J = 47.4, 
20.3 Hz). DART-MS: [M-H:]+ for C15H21FO4 calcd,283.1351; detected, 283.1350. 
2.5 List of Mass Spectra 
 
 
Spectrum 2.1. MALDI-TOF mass spectrum of amide-linked PMB-protected DAG-
benzophenone-alkyne probe precursor 2.21. 
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Spectrum 2.2. QSTAR-ESI mass spectrum of triazole-linked DAG-benzophenone-
alkyne probe 2.2. 
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Spectrum 2.3. MALDI-TOF mass spectrum of triazole-linked bis(-cyanoethyl)-
protected PA-benzophenone-alkyne probe precursor 2.30. 
 
Spectrum 2.4. ESI-MS mass spectrum of triazole-linked PA-benzophenone-alkyne 
probe 2.3. 
 
Spectrum 2.5. MALDI-TOF mass spectrum of triazole-linked -cyanoethyl-protected 
N-Boc-lysine-t-butyl ester PS-benzophenone-alkyne probe precursor (2.37). 
99 
 
Spectrum 2.6. MALDI-TOF mass spectrum of triazole-linked DAG-alkyne-
tetrafluorophenyl azide probe 2.6. 
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3 CLICKABLE LIPID PHOTOAFFINITY PROBES WITH MORE CONSERVATIVE 
STRUCTURAL MODIFICATIONS 
3.1 Minimizing the Presence of Synthetic Structural Modifications on Probes 
Designs of biomimetic probe molecules for labeling studies must balance synthetic 
accessibility with congruence to the native biomolecular structure. Therefore, a modular 
approach such as the lysine linker strategy covered in the previous chapter makes sense 
as a solution to reducing the barrier to obtaining new probes. It is difficult to fairly judge 
the accuracy of a given probe’s representation as a lipid or lipid class when exploring 
largely uncharted biological territory, in this case the complete list of membrane lipid 
interactions with protein binding partners. A strategy for hedging against this uncertainty 
involves varying the phototag and conjugation handle components of probe sets, 
conducting parallel labeling experiments with each, and identifying labeling trends from 
the distinct-but-overlapping profiles that result.8 Including different phototags varies a 
non-biomimetic region of the probe structure and allows covalent protein attachment by 
different crosslinking mechanisms, and are thus expected to differentially label protein 
functional groups. 
Despite their synthetic facility and modular advantages, a major pitfall to the probe 
designs shown in Chapter 2 is that each bio-mimetic structure has synthetic additions in 
common that may introduce a potential bias for protein preference. The presence of 
groups such as a lysine linker, triazole bridge, or multiple peptide-like amide bonds may 
result in irrelevant protein labeling by probes. For instance, it is documented that triazole 
itself can imitate a phosphodiester bond in DNA in a manner compatable with polymerase 
activity.168 Common photoaffinity tags and their linkers also produce consistent proteomic 
background labeling, but by definition they must be included in order for a photoaffinity 
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probe to function.169-170 Considering an example from the probes presented in Chapter 
2, roughly half of the total molecular weight of DAG probe 2.2 is attributed to synthetic 
additions that enable labeling experiments. 
To investigate possible background labeling by y-shaped lysine photolabeling/click 
scaffolds used to synthesize probes 2.1, 2.3, and 2.6, a brief labeling study was 
performed, with help from Dr. Samuel Mattern-Schain of the Best Research Group, similar 
to an experiment done by by Dr. Rowland136 using previously synthesized scaffold methyl 
ester 2.17 (MeO-HG) or scaffold carboxylic acid 2.20 (HOOC-HG), with results displayed 
in Figures 3.1 and 3.2, respectively. In brief, probe was incubated with SKOV3 cell 
lysates in the presence of PA-containing PC liposomes (except for one trial in Figure 3.2) 
and compared to labeling with liposomes containing a generic probe (GP,171 6.2, shown 
in Figure 3.3, and also the its synthesis in Scheme 6.2 below).  
 
 
Figure 3.1: SKOV3 lysate labeling by lysine scaffold methyl ester 2.17. Generic 
probe 6.2, which bears triazole linkage to the same scaffold, included for 
comparison. 
Left: Fluorescence scan, excitation at 488 nm, emission at 526 nm. Right: Coomassie 
stained gel, visible light. “GP” refers to generic probe 6.2. 
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Figure 3.2: SKOV3 lysate labeling by lysine scaffold carboxylic acid 2.20. Generic 
probe 6.2, which bears a triazole linkage the same scaffold, included for 
comparison. 
Left: Fluorescence scan, excitation at 488 nm, emission at 526 nm. Right: Coomassie 
stained gel, visible light. “GP” refers to generic probe 6.2. 
 
The fluorescence results, which are similar to those found by Dr. Rowland, seem 
to indicate that these lysine scaffolds label proteins in a concentration dependent manner 
(Figure 3.1, comparing lane 2 to 3, or 7 to 8), either independently (2.17, 2.20) or 
anchored to a liposome membrane by a lipid scaffold (6.2). The strongest labeling 
appears to have occurred for carboxylic acid scaffold 2.20 in lipid-free solution (Figure 
3.2, lanes 1 and 6), as opposed to the presence of liposomes (lanes 2 and 7). However, 
it may also be possible that the organic probe molecules are non-specifically inserting 
into hydrophobic protein pockets to escape aqueous solvent. This possiblility is supported 
by the observation that non-specific labeling in these experiments appears to have been 
mitigated by the presence of liposomes which may have provided a hyrophobic 
environment for probe sequestration. 
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Figure 3.3: Structure of generic probe 6.2 used to compare proteomic labeling by 
lysine-benzophenone-alkyne scaffolds 2.17 and 2.20. 
 
With these observations in mind, we began to think about new ways to incorporate 
photolabeling and bioconjugation groups into probes that feature more conservative 
modifications to native lipid structures. Ideal probes would approach zero modification 
outside of adding the bare photoaffinity and click functional groups themselves, installed 
in positions to minimize interference with binding behavior we are attempting to study.172 
Click chemistry has already partially solved this problem by providing a way to delay the 
inclusion and choice of a bulky fluorophore or biotin group until after protein labeling has 
taken place. Additionally, we remained aware that any phototag must still be placed close 
to the headgroup, where binding by protein targets of interest is expected to occur. In this 
chapter, we describe the design and synthesis of DAG and PA probes (Compunds 3.1 
and 3.2 in Figure 3.4, and 3.3-3.8 in Figure 3.5) that maintain structures closer to the 
native biomolecules while still retaining click and photolabeling function. Then, we 
describe proteomic labeling experiments performed with these probes using HEK cell 
lysates and also in live cells, and the analysis of results by SDS-PAGE and LC-MS. 
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Figure 3.4: Structures of novel DAG lipid probes (3.1 and 3.2) that eliminate need 
for a lysine linker, and DAG (3.4 and 3.7) and PA (3.5 and 3.8) diazirine photoaffinity 
probes along with their “headless” generic probe counterparts (3.3 and 3.6). 
(*Syntheses of 3.2 and 3.6 were not finished) 
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3.2 Syntheses of Conservatively Modified DAG and PA Probes 
First, we formulated a long-term aim of switching to diazirine as our standard 
photocrosslinking unit. While benzophenone derivatives are convenient for their long-
term stability and ease of synthetic incorporation, we expected the low steric profile and 
relative non-polarity of diazirine to exhibit less steric interference with binding than 
benzophenone or Tfp-azide.173 Diazirine tags also utilize a carbene crosslinking 
mechanism unlike benzophenone or Tfp-azide, which could potentially diversify labeled 
protein profiles. We explored diazirine chemistry beginning with a well-known linker as a 
model system, shown in Scheme 3.1.174-175 Beginning with -keto acid 3.9, equilibration 
with ammonia in MeOH to the imine form followed by reaction with hydroxylamine-O-
sulfonic acid formed diaziridine 3.10. Oxidation with elemental iodine to form diazirine 
3.11 performed better than using PCC, oxides of silver, or Swern conditions. 
 
 
Scheme 3.1: Synthesis of common diazirine linker 3.11. 
i) 7N NH3/MeOH, 0C, then HOSA; ii) I2, TEA, MeOH, 11% (2 steps). 
 
Diazirine linker 3.11 was not featured in any completed lipid probes presented in 
this work but is readily available for incorporation by amide coupling if desired. In an 
exploratory effort toward simplified lipid probes omitting a lysine linker, intermediates to 
novel amide-linked diazirine probes were made, as presented in Scheme 3.2. Previously 
synthesized azide backbone 2.12 was subjected to catalytic hydrogenation under basic 
conditions to yield amino diol 3.12, which was then coupled with 3.9 using 2-(1H-
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benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) in the 
presence of diisopropylethylamine to make amide-linked ketone 3.13. A triazole-linked 
analog 3.15 was also synthesized by first coupling 3.9 to propargylamine using HBTU to 
make alkynyl amide 3.14, which was joined with azide 2.12 by Cu(I)-catalyzed azide 
alkyne cycloaddition (CuAAC) using sodium ascorbate to oxidize Cu(II) sulfate to its 
catalytic Cu(I) state. Molecules 3.15 and 3.13 were handed off to Samuel Mattern-Schain 
of the Best Research Group for further development. 
 
 
Scheme 3.2: Synthesis of intermediates 3.13 and 3.15, bearing ketone precursor for 
later installation of diazirine photoaffinity tag. 
3.13 and 3.15 were handed off to Sam Mattern-Schain for further development. i) H2, 10% 
Pd/C, Na2CO3, EtOAc, 60%; ii) 3.9, HBTU, DIEA, CHCl3, 59%; iii) propargylamine, HBTU, 
DIEA, CHCl3, 53%; iv) 2.12, CuSO4, sodium ascorbate, (1:3) H2O/THF, 15%.  
 
While direct coupling of the photoaffinity tag linker to the lipid backbone shown 
above excludes the lysine linker and several amide bonds seen in probes from Chapter 
2, it also eliminates the usual attachment point for the conjugation handle. Some 
published probe designs elegantly include an alkyne group on the same short chain as a 
diazirine linker,129, 172 and this concept is important to syntheses featured later in this 
chapter. However, we first chose to move the click handle on the ends of lipid tails, as 
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shown in Scheme 3.3, following the example of previously reported lipid probes.176 When 
located at the ends of the lipid tails, azide or alkyne handles have minimal chance of 
interfering with interfacial and surface protein interactions with probes.177 Finally, 
including a click handle on both tails creates two opportunities for fluorescent dye or biotin 
attachment to crosslinked protein-lipid complexes, increasing the likelihood of detection. 
Beginning with bromo alcohol 3.16, nucleophilic substitution with sodium azide 
(NaN3) to azide 3.17, followed by activation of the alcohol using methanesulfonyl chloride 
(MsCl) yielded azido mesylate 3.18. While this mesylate was a workable electrophile for 
ether coupling to a probe backbone, better results were achieved with azido bromide 3.19, 
which was obtained from substitution of mesylate 3.18 with potassium bromide (KBr) 
using phase transfer catalyst 18-crown-6. Compound 3.19 was also obtained directly from 
alcohol 3.16 by Mitsunobu reaction with hydrazoic acid (HN3) in the presence of 
diisopropylazidodicarboxylate (DIAD) and 1,2-bis(diphenylphosphino)ethane (DPPE), but 
this reaction required fresh preparation and titration of the nucleophile and provided 3.19 
in half the yield of the multistep process. 
 
 
Scheme 3.3: Synthesis of azide tail unit 3.19. 
i) NaN3, DMSO, 99%; ii) MsCl, TEA, CH2Cl2, -15C to 20C, 99%; iii) KBr, 18-crown-6, 
(1:2) DMF/THF, 80C, 98%; iv) HN3, DIAD, DPPE, THF, 0C to 20C, 43%. 
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DAG probe 3.1 was obtained through the synthesis outlined in Scheme 3.4, which 
overlaps with a published pathway reported by Dr. Smith.98 A stock of useful 
cyclopentylidine diol 3.20 was obtained from storage in the Best Lab freezer rather than 
re-synthesizing comparable acetonide diol 2.8. Monoactivation of diol 3.20 using p-
toluenesulfonyl chloride (TsCl) to tosylate 3.21 enabled nucleophilic substitution with 
NaN3 to form azide alcohol 3.22, which was then protected with p-methoxybenzyl chloride 
(PMBCl) in a Williamson ether synthesis to provide PMB-protected azide 3.23. Catalytic 
hydrogenation with palladium on carbon (Pd/C) under basic conditions gave PMB-
protected amine 3.24, which was subjected to coupling with 4-benzoylbenzoic acid using 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and hydroxybenzotriazole (HOBt) 
to yield benzophenone amide 3.25. Azide reduction at the backbone was necessary at 
this step since more azides were due to be added with attachment of the lipid tails. 
Cyclopentylidine deprotection under acidic conditions unveiled diol 3.26, which was 
coupled to two azido-lipid tail units (3.19) by Williamson ether synthesis to make PMB-  
 
 
Scheme 3.4: Synthesis of benzophenone DAG probe 3.1, eliminating the lysine 
linker by moving azide click tags to the ends of the lipid tails. 
i) TsCl, Ag2O, KI, CH2Cl2; ii) NaN3, DMF, 80C, 22% (2 steps); iii) NaH, DMF, 0C to 
20C; iv) PMBCl, 0C to 20C, 32% (2 steps); v) H2, 10% Pd/C, Na2CO3, EtOAc, 97%; 
vi) 4-benzoylbenzoic acid, EDCI, HOBt, DIEA, DMF, 0C to 20C, 81%; vii) 1N HCl, THF, 
86%; vii) 3.19, TBAI, DMF, 0C to 20C, 24%; ix) DDQ, (1:18) H2O/CH2Cl2, 99%. 
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protected lipid probe 3.27. Oxidative deprotection with 2,3-dichloro-5,6-dicyano-1,4-
benzoqunione (DDQ) to remove PMB from the remaining primary alcohol provided DAG 
probe 3.1, featuring lipid tail azide handles, three fewer amide bonds, and the omission 
of lysine compared to probes featured in Chapter 2.  
To build towards a toolbox of analogs representing this new lipid probe class, we 
sought to swap the benzophenone phototag of 3.1 with Tfp-azide, an effort outlined in 
Scheme 3.5. This time, previously synthesized intermediate PMB acetonide azide 2.11 
was available to provide easy access to amine 3.28 by catalytic hydrogenation with Pd/C 
in the presence of base.140 EDCI/HOBt-mediated coupling to previously synthesized Tfp-
azide carboxylic acid 2.44 yielded Tfp-azide amide 3.29, which was deprotected under 
acidic conditions to generate diol 3.30. However, the strongly basic conditions of 
attempted diether coupling with 3.19 caused decomposition, as indicated by TLC analysis 
during the reaction. If desired in the future, synthesis of the DAG probe targeted from 
intermediate 3.31 would have to be accomplished by Boc protection of amine 3.28 in 
order to postpone Tfp-azide linkage until after diether coupling. 
 
 
Scheme 3.5: Attempted synthesis of a tetrafluorophenylazide DAG probe, but failed 
to obtain PMB-protected lipid intermediate 3.31. 
i) H2, 10% Pd/C, Na2CO3, EtOAc, 82%; ii) 2.44, EDCI, HOBt, DIEA, DMF, 0C to 20C, 
50%; iii) 60% AcOH (aq) 50C, 65%; iv) NaH, DMF, 0C to 20C; v) 3.19, TBAI, DMF, 
0C to 20C. 
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In spite of the failure to obtain 3.31, the acquisition of DAG probe 3.1 provided a 
new class of lipid photoaffinity probe for labeling studies. However, this updated design 
still contained an amide linkage to phototags, which we sought to eliminate. One solution, 
pursued by Samuel Mattern-Schain of the Best Research Group, used a less polar ether 
linkage to phototags made from building blocks such as 4-hydroxylbenzoylbenzoic 
acid.178 Here, we draw inspiration from published syntheses of photoaffinity lipid probes 
utilizing diazirine,44, 119 and similar lines of thinking for improving drug design,179 to realize 
that amide linkage can be replaced with a simple alkyl chain extension in order to exclude 
unnecessary functionality.  
With this new aim in mind, we pivoted to a new round of lipid probe optimization 
beginning with a simple glycerol-based model system, shown in Scheme 3.6. Since a 
ketone precursor is required for implantation of the diazirine group, a problem emerged 
concerning where and how to place this ketone in a lipid probe since this chemistry was 
not featured in our lab’s established synthetic channels. We decided to attempt a “zero-
linkage” design that transforms an existing primary alcohol into a ketone for diazirine 
synthesis directly on the lipid backbone.  
In doing so, we were mindful of the following considerations: 1) alkyldiazirines with 
an -oxygen are vulnerable to a self-quenching photodecomposition pathway that could 
detract from effective protein capture;105 2) The reactive carbene intermediates formed 
by photolysis of alkyl diazirines are more vulnerable to quenching by protic solvent than 
their 3-phenyl-3-(trifluoromethyl)180 counterparts; 3) Imposing a phototag on a position so 
close to the headgroup and backbone could interfere with protein recognition of the probe 
as a representation of its native lipid. Addressing the first of these concerns, this 
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photodecomposition pathway is more of a risk at non-neutral pH than under the buffered 
conditions of planned experiments. Quenching by solvent likely will have an adverse 
effect on sensitivity compared to previously published probes,44, 127 which embed alkyl 
diazirine within hydrophobic membrane regions for labeling integral protein residues. 
However, it is also possible that enhanced selectivity will accompany our design, which 
targets peripheral protein binding at the membrane surface, correlating likelihood of 
protein capture with proximity to probes by rewarding tight binding and exclusion of water 
from PLI.12 Finally, while the diazirine group does have a more proximally intrusive 
location than phototags in past designs, it closely maps onto the same position as the 
replaced amide (or triazole) linkage and occupies much less space than benzophenone 
or Tfp-azide in general, so this is still considered a net reduction of synthetic presence. 
Moving ahead to solve the placement of a ketone at the primary alcohol of racemic 
glycerol acetonide 3.32 as shown in Scheme 3.6, oxidation with potassium 
permanganate (KMnO4) produced potassium carboxylate 3.33, which was converted to 
Weinreb amide 3.34 through an acid chloride intermediate using oxalyl chloride (COCl2). 
We overestimated the sensitivity of diazirine to synthetic conditions at this stage of 
pathway development and attempted to preserve the Weinreb amide in order to delay 
diaziridine installation. While acid-catalyzed deprotection of 3.34 to 3.35 proceded 
smoothly, subsequent diether formation with azide tail 3.19 gave a messy mix of diether 
3.36 and monoethers 3.37 and 3.38. N,O-dimethyl hydroxylamine byproducts were also 
detected, indicating a competing pathway of Weinreb amide decomposition.  
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Scheme 3.6: Initial model/generic probe pathway for installing diazirine onto 
glycerol backbone via Weinreb amide lipid 3.36. 
i) KMnO4, KOH, H2O, 0C to 20C, 90%; ii) (COCl)2, pyridine, Et2O, 0C to 20C; iii) 
CH3NHOCH3HCl, TEA, DMAP, CH2Cl2, 0C to 20C, 57% (2 steps); iv) 40% AcOH 
(aq), 35C, 99%; v) NaH, DMF, 0C to 20C; vi) 3.19, TBAI, DMF, 0C to 20C (3.36 = 
26%; 3.37 + 3.38 = 16%). 
 
To increase supply of compound 3.36, byproducts 3.37 and 3.38 were salvaged 
for 1,8-bis(dimethylamino)naphthalene (proton sponge)-mediated coupling with triflate 
3.41, obtained from previously synthesized 3.17, all shown in Scheme 3.7. Compound 
3.36 was then reacted with methyl Grignard (MeMgBr) and quenched with mild acid 
ammonium chloride (NH4Cl) to produce ketone lipid 3.39. Applying the diazirine formation 
method practiced in Scheme 3.1, “minimal” diazirine azide model lipid probe 3.3 was 
synthesized. Additionally, 3.3 would serve as a generic, headless analog for specific lipid 
probes of this class that would prove useful for measuring background labeling future 
experiments. 
We attempted to map this synthesis onto previously synthesized intermediate 2.61, 
as illustrated in Scheme 3.8. Due to existing protecting groups, neither permanganate 
nor Jones oxidations were appropriate for obtaining carboxylic acid 3.42. 
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Scheme 3.7: Endgame to obtaining generic diazirine azide lipid 3.3, drawing upon 
single-tailed byproduct isomers from preceding Scheme 3.6. 
i) 3.41, proton sponge, CH2Cl2, reflux, (9% from 3.37; 5% from 3.38); ii) MeMgBr, THF, 
-15C; iii) NH4Cl (aq), -15C to 0C, 73% (2 steps); iv) 7N NH3/MeOH, 0C, then HOSA; 
v) I2, TEA, MeOH, 23% (2 steps); vi) Tf2O, pyridine, CH2Cl2, 0C to 20C, 84%. 
 
We explored alternative pathways to generating an electrophilic carbon at the 
desired position including aldehyde formation by PCC, Parikh-Doering, and Swern 
oxidations, without success. A 2,2,6,6-tetramethylpiperidinlyloxy radical (TEMPO)-
mediated, sodium hypochlorite (NaClO, bleach)-catalyzed oxidation using sodium chlorite 
(NaClO2) as the stoichiometric oxidant provided 3.42, which was converted to its Weinreb 
amide 3.43 by EDCI/HBOt-mediated coupling. After acid catalyzed deprotection to diol 
3.44, attempted diether formation to install azide tails by either Williamson synthesis or 
triflate coupling provided disappointing yields, and the route was abandoned. 
Returning to intermediate 3.43, we decided to invert diazirine and ether tail 
installation steps, as shown in Scheme 3.9. Reaction with methyl Grignard to ketone 3.48 
and conversion to diazirine 3.49 proceeded smoothly, appearing to avoid significant 
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Scheme 3.8: Early synthetic route to specific diazirine probes, attempting to 
postpone Grignard addition until after installation of azide tails. 
i) TEMPO, NaClO2, NaOCl, NaH2PO4 buffer (aq), MeCN, pH = 6.7, 35C, 77%; ii) 
CH3NHOCH3HCl, EDCI, DIEA, DMAP, DMF, 0C to 20C, 96%; iii) 1N HCl, THF, 64%; 
iv) 3.41, proton sponge, CH2Cl2, reflux, (3.45, 3.46, 3.47 each <10%). 
 
racemization at the chiral -carbon according to TLC and NMR analysis. Acid 
deprotection to diol 3.50 set up diether formation under Williamson conditions with 3.19 
to give PMB-protected lipid 3.51. Oxidative deprotection with DDQ gave novel DAG probe 
3.4, featuring diazirine and azide functional groups on a conservatively-modified lipid 
scaffold. 
Looking ahead to a potential future aim of creating specific lipid probes capable of 
accommodating variation in ether or ester tails, we considered relocation of the 
conjugation handle. Again, we drew from previously published examples,119 this time 
combining ketone synthesis with installation of an alkyne handle connected by a short 
hydrocarbon chain, as shown in Scheme 3.10. Previously synthesized Weinreb amide 
3.43 was reacted with trimethylsilyl (TMS)-protected alkyne Grignard 3.57, generated 
fresh from chloride 3.56 following a procedure present in several sources that were 
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influential to this body of work,119, 127, 129 to give ketone 3.52. Following the same synthetic 
track as before, we converted to diazirine 3.53, then carried out acid-catalyzed 
 
 
Scheme 3.9: Synthesis of diazirine azide tail DAG probe 3.4. 
i) MeMgBr, THF, -15C; ii) NH4Cl (aq), -15C to 0C, 65% (2 steps); iii) 7N NH3/MeOH, 
0C, then HOSA; iv) I2, TEA, MeOH, 36% (2 steps); v) 1N HCl, THF, 88%; vi) NaH, DMF, 
0C to 20C; vii) 3.19, TBAI, DMF, 0C to 20C, 83% (2 steps); viii) DDQ, (1:18) 
H2O/CH2Cl2, 91%. 
 
deprotection to obtain 3.54. If desired, 3.54 could serve as a nodal intermediate for 
synthesizing dozens of probes with varied fatty ester or ether tails, although controlling 
regiochemistry of mixed-tail products may require more synthetic exploration. 
Experiments performed by Dr. Smith indicated that PMB-deprotection in a comparable 
lipid probe system resulted in minor acyl chain migration compared to other alcohol 
protecting groups.137 Here, we installed hexadecyl ether tails to form PMB-protected lipid 
3.55, which was subjected to oxidative deprotection with DDQ to give novel DAG probe 
3.7, featuring an alkyne click handle linked as a sidechain to the diazirine phototag group. 
Backtracking to make a generic equivalent to novel alkyne diazirine lipid probe 3.7, 
we returned to previously synthesized intermediate 3.35, as shown in Scheme 3.11. 
Ether tail coupling with 1-bromohexadecane yielded Weinreb amide lipid 3.58, which was 
subjected to coupling with TMS-alkyne Grignard 3.57 from the previous scheme to obtain 
ketone 3.59. While diazirine 3.60 was detected following the usual diaziridination protocol, 
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Scheme 3.10: Synthesis of diazirine alkyne DAG probe 3.7. 
i) 3.57, THF, -10C to 20C; ii) NH4Cl (aq), 0C to 20C, 28%; iii) 7N NH3/MeOH, 0C, 
then HOSA; iv) I2, TEA, MeOH, 21% (2 steps); v) 50% AcOH (aq), 50C, 86%; vi) NaH, 
DMF, 0C to 20C; vii) 1-bromohexadecane, TBAI, DMF, 0C to 20C, 57% (2 steps); 
viii) DDQ, (1:18) H2O/CH2Cl2, 99%. 
 
repeated low yields of this product its prevented isolation in pure form. 
With DAG probes 3.4 and 3.7 in hand, we drew upon chemistry developed in the 
synthesis of PA probe 2.31, covered in Chapter 2, to make novel PA probes 3.5 and 3.8. 
Illustrated in Scheme 3.12, DAG probe 3.4 was coupled with previously synthesized bis-
-CE protected phosphoramidite 2.29 in the presence of acid catalyst 4,5-
Dicyanoimidazole (4,5-DCI), followed by m-chloroperoxybenzoic acid (m-CPBA) 
oxidation,146-147 which provided protected PA probe precursor 3.61. Sialyl-assisted 
deprotection of the phosphate headgroup with N,O-bis(trimethylsilyl) trifluoroacetamide 
(BSTFA),148 followed by successive citric acid and ammonium acetate (NH4OAc) washes 
gave 2H+ form PA azide probe 3.5. A subsequent NaHCO3 (aq) wash gave novel diazirine 
azide disodium PA probe 3.62 in a salt form more suitable for storage. This series of 
reactions was then applied to DAG probe 3.7 to provide novel diazirine alkyne PA probe 
3.8 and 2Na+ form 3.64 proceeding through protected intermediate 3.63.  
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Scheme 3.11: Attempted synthesis of diazirine alkyne generic probe 3.6. 
i) NaH, DMF, 0C to 20C ; ii) 1-bromohexadecane, TBAI, DMF, 0C to 20C, 26% (2 
steps); iii) 3.57, THF, -10C to 20C; iv) NH4Cl (aq), 0C to 20C, 14% (2 steps); v) 7N 





Scheme 3.12: Synthesis of diazirine azide PA probes 3.5 and 3.8 and their 2Na+ 
salts 3.62 and 3.64, obtained from their respective DAG probe precursors. 
i) 2.29, 4,5-dicyanoimidazole, CH2Cl2; ii) mCPBA, CH2Cl2, -78C to 20C, (2 steps: 3.61 
= 87%; 3.63 = 99%); iii) BSTFA, DBU, CH2Cl2; iv) MeOH; citric acid (aq), then NH4OAc 




3.3 Labeling Experiments with Lipid Photoaffinity Probes 
In Vitro Proteomic Labeling with Lipid Probes in Liposomes 
Before testing lipid probes in live cells, we explored their application using 
liposomes as a way to imitate the bilayer environment of a cell membrane. A defined 
amount of DAG or PA lipid probe was mixed with other lipids in small unilamellar vesicles 
(SUVs, or liposomes). This system allowed us to assess probe performance ahead of 
more complex live cell experiments and is compatible with protein extracts from any cell. 
Samuel Mattern-Schain of the Best Research Group was primarily responsible for 
liposome experiments with lipid photoaffinity probes, and the results of this research are 
covered in his doctoral dissertation.181 These experiments are not discussed in any further 
detail herein. 
Proteomic Labeling of HEK Cell Lysates with Lipid Photoaffinity Probes 
Experiments with Human Embryonic Kidney 293T (HEK) cell lysates and live HEK 
cells were performed in the research lab of Dr. Benjamin Cravatt at the Scripps Research 
Institute in La Jolla, CA, in cooperation with Dr. Kenneth Lum, a former graduate student 
of the Cravatt Research Group. First, we incubated DAG (3.1, 3.4, 3.7), PA (3.62, 3.64), 
and generic (3.3) solution-phase lipid probes with whole HEK cell lysates to assess their 
usefulness for proteomic labeling. We performed these experiments alongside oleamide 
diazirine alkyne probe (O-DA, structure shown in Figure 3.5) as a positive control for well-
characterized proteomic labeling. O-DA was synthesized by Micah Niphakis, a former 
graduate student of the Cravatt Lab.119 In Figure 3.5, results are shown for incubation of 
lysates with 10 M of each probe before UV photocrosslinking, including corresponding 
no-UV (negative) controls for each experiment. Crosslinked samples were click- 
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Figure 3.5: 10 M probe labeling using whole HEK cell lysates in 1X PBS. 
Cravatt Lab Oleamide Diazirine Alkyne (O-DA) probe used as a comparator. *PA probes 
3.64 and 3.62 had poor solubility in DMSO stock; **DAG probe 3.7 precipitated out when 




conjugated with Alexafluor-alkyne (AF) or Rhodamine-azide (RA) as appropriate for their 
click handle, and analyzed by SDS-PAGE before imaging for flourescence. The first round 
of results showed clear labeling for O-DA and for DAG probes 3.1 and 3.4, as well as a 
few visible bands for DAG probe 3.7. Labeling patterns between 3.1 and 3.4 appear to be 
partially overlapping but each with their own distinct patterns of bright and unique bands. 
The few bands visible for 3.7 at ~70 kDa appear to match ones seen in 3.1 and 3.4. PA 
probes 3.62 and 3.64 did not label proteins. However, at the beginning of this experiment, 
we observed that both 3.62 and 3.64 were not very soluble in DMSO stock solution and 
stuck to the inner glass walls of their repective vials, and 3.7 formed a cloudy precipitate 
upon addition to the labeling media.  
Lipid Probe Photoaffinity Labeling in Live HEK Cells 
Next, we attempted labeling in live HEK cells by spiking DAG (3.1, 3.4, 3.7) or PA 
(3.62, 3.64) probes to 10 M in fresh, serum-free media (Dulbecco’s Modified Eagle 
Media, DMEM), and incubating the cells for 30 min before photocrosslinking and click-
conjugation with fluorescent dye, as shown in Figure 3.6. This time, proteomic labeling 
was minimal for all probes except for O-DA. Considering the limited solubility of lipid 
probes in aqueous media, we determined that the method required adjustment to bring 
the probes into solution and allow them to enter cells.  
For the next live HEK cell experiment shown in Figure 3.7, we included 10% FCS 
in labeling media, and increased concentration to 100 M probe. We hypothesized that 
hydrophobic lipid probes might adsorb onto bovine serum albumin (BSA), which could 
carry them into cells for further distribution. Again, we observed that probes 3.62 
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Figure 3.6: 10 M probe labeling using live HEK cells in FCS-free media. 
*PA probes 3.64 and 3.62 had poor solubility in DMSO stock; **DAG probe 3.7 




Figure 3.7: 100 M probe labeling in live HEK cells in 10% FCS media. 
*PA probes 3.64 and 3.62 had poor solubility in DMSO stock; **DAG probe 3.7 
precipitated out when added to labeling media. 
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and 3.63 were difficult to suspend and solubilize in DMSO stocks. DAG probe 3.7 
precipitated out of the labeling media, making the culture cloudy while. We re-solubilized 
probe 3.7 by adding ~10 L of absolute ethanol, but this killed most of the cells instantly. 
This culture was crosslinked and worked up with the rest in spite of cell death. 
 The resulting in-gel fluorescence images show improved live cell proteomic 
labeling mainly for DAG probe 3.4, and faintly for DAG probe 3.1 and PA probe 3.62. 
However, our lipid probes still did not qualitatively match performance of the more 
aqueous-soluble O-DA probe. DAG probe 3.7 also produced a fluorescent band at ~25 
kDa, while the lane for PA prove 3.64 was completely dark.  
Probe Tranport Complex Experiments with Live HEK Cells 
In order to better solubilize lipid probes and enhance their delivery to live cells, 
probes were complexed into a delivery system, using polyethylenimide (PEI) for PA 
probes or  -methylcyclodextrin (-MCD) for DAG and generic probes. For PA probes, 
the aim of doing so was to pair the anionic charges of the PA headgroup to cationic 
polymer-supported amine groups to bring the otherwise sparingly soluble probes into 
solution, following a technique used for DNA delivery.182 This ion pairing was expected to 
facilitate transport into the cell plasma membrane by mediating negative charge repulsion 
between PA probe and the cell surface.183 -MCD was chosen to transport DAG probes 
due to its known capacity for bringing small nonpolar molecules into aqueous solution by 
host-guest complexation.184-185 The expected mechanism of probe delivery to cells was 
that complexed lipid probes would exchange with cholesterol from the plasma cell 
membrane when mixed in with growth media. DAG probe 3.7 never fully dissolved in 
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solution containing 5x excess -MCD, despite warming and sonication. In future studies, 
a greater excess of -MCD or a differed CD altogether may be required. 
Pre-complexing DAG probes 3.1 and 3.4 with -MCD before incubating with HEK 
cells resulted in improved proteomic labeling, with probe 3.1 exhibiting surprisingly stong 
general labeling and probe 3.4 showing specific stong labeling in two bands at ~35 kDa, 
as shown in Figure 3.8. Including 5% FCS also seemed to strengthen labeling. PA probe 
3.62 showed some labeling, but this was not readily distinguished from no-UV 
background. Generic diazirine probe 3.3, which was not included in previous experiments, 
also produced faint labeling, which is encouraging for probe selectivity since the diazirine-
only headless scaffold is non-biomimetic and therefore should not have any meaningful 
interaction capacity with proteins. Gel lanes for PA probe 3.64 and DAG probe 3.7 were 
completely dark, which could have happened because probe content never dissolved in 
labeling media. 
The in-gel fluorescence results from lysate and live cell experiments indicate the 
potential for these lipid probes, particularly DAG mimics 3.1 and 3.4, to label proteins and 
to possibly provide useful insight into global protein-lipid interaction profiles. At the same 
time, challenges of compound solubility in labeling media and transport into live cells were 
apparent, limiting meaningful results to probes that mixed adequately with water. Future 
studies would likely include more experimentation with DAG probe--MCD complexes, 




Figure 3.8: Labeling in live HEK cells using 50 M probes complexed with delivery 
agents: -methylcyclodextrin (-MCD) or polyethylenimide (PEI). 
Labeling performed with or without 5% FCS. *Alkyne probes in general had poor solubility 
in DMSO stock and aqueous media. 
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3.4 MudPIT-SEQUEST Proteomic MS Analysis of HEK Cell Labeling  
Kenneth Lum of the Cravatt Research Group performed lipid photoaffinity probe 
labeling using SILAC light or heavy HEK293T cell lysates, with (heavy media-fed cells) or 
without (light media-fed cells) photocrosslinking, followed by biotin click and pulldown 
pulldown assay for MudPIT118 characterization. SEQUEST data treatment was applied to 
obtain the proteomic data presented below for probes 3.3, 3.4, 3.7, and 3.1. Tables for 
each probe are separated for 2-5x and >5x excess labeling from UV-crosslinked samples 
versus no-UV controls. Complete data lists are included in Appendix 2. 
First, headless generic diazirine N3-tailed probe 3.3 was tested as a “no-headgroup 
control” and indicator of potential background labeling by any specific probes such as 3.4 
and 3.7 that feature a diazirine group on the backbone. Very few protein hits registered 
2-5x, as shown in Table 3.1, or greater than 5x, as shown in Table 3.2, for probe 3.3 
compared to specific probes of the same class.  
 
Table 3.1: Proteomic hits (2-5x) for headless generic diazirine N3-tailed probe 3.3. 
uniprotID Protein description Symbol 
P21796 VDAC1 Voltage-dependent anion-selective channel protein  VDAC1 
 
Next, we tested labeling by DAG-diazirine N3-tailed probe 3.4, which produced a 
much longer list of 2-5x hits, as shown in Table 3.3, and >5x hits, as shown in Table 3.4, 
overall than the generic diazirine probe 3.3, indicating that the presence of the hydroxyl 
headgroup has a high impact on protein binding and labeling by these probes,. 
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Table 3.2: Proteomic hits (>5x) for headless generic diazirine N3-tailed probe 3.3. 
uniprotI
D 
Protein description Symbol 
P34947 GRK5 G protein-coupled receptor kinase 5  GRK5 
Q6ZS81 WDFY4 WD repeat- and FYVE domain-containing protein 4  WDFY4 
Q9NZI7 UBP1 Upstream-binding protein 1  UBP1 




Table 3.3: Proteomic hits (2-5x) for DAG-diazirine N3-tailed probe 3.4. 
uniprotID Protein description Symbol 
P24390 KDELR1 ER lumen protein retaining receptor 1  KDELR1 
P03886 MT-ND1 NADH-ubiquinone oxidoreductase chain 1  MT-ND1 
B4DLN1 
SLC25A10 cDNA FLJ60124, highly similar to Mitochondrial 
dic 
SLC25A10 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta  SRPRB 
Q9HD45 TM9SF3 Transmembrane 9 superfamily member 3  TM9SF3 
P46782 RPS5 40S ribosomal protein S5  RPS5 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M  HNRNPM 
P35610 SOAT1 Sterol O-acyltransferase 1  SOAT1 
Q9NVV0 TMEM38B Trimeric intracellular cation channel type B  TMEM38B 
P62829 RPL23 60S ribosomal protein L23  RPL23 
Q6P4A7 SFXN4 Sideroflexin-4  SFXN4 
P67812 SEC11A Signal peptidase complex catalytic subunit SEC11A  SEC11A 
Q9BTX1 TMEM48 Nucleoporin NDC1  TMEM48 
P61011 SRP54 Signal recognition particle 54 kDa protein  SRP54 
P55061 TMBIM6 Bax inhibitor 1  TMBIM6 
P49790 NUP153 Nuclear pore complex protein Nup153  NUP153 
O95197 RTN3 Reticulon-3  RTN3 
O95470 SGPL1 Sphingosine-1-phosphate lyase 1  SGPL1 
Q9UKN8 GTF3C4 General transcription factor 3C polypeptide 4  GTF3C4 
O75964 ATP5L ATP synthase subunit g, mitochondrial  ATP5L 
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Table 3.3 continued. 
uniprotID Protein description Symbol 
Q96KA5 CLPTM1L Cleft lip and palate transmembrane protein 1-like  CLPTM1L 
Q3SXM5 HSDL1 Inactive hydroxysteroid dehydrogenase-like protein HSDL1 
Q8TCT9 HM13 Minor histocompatibility antigen H13  HM13 
O43399 TPD52L2 Tumor protein D54  TPD52L2 
O60664 PLIN3 Perilipin-3  PLIN3 
Q96A26 FAM162A Protein FAM162A  FAM162A 
Q9NS69 
TOMM22 Mitochondrial import receptor subunit TOM22 
homolo 
TOMM22 




Table 3.4: Proteomic hits (>5x) for DAG-diazirine N3-tailed probe 3.4. 
uniprotID Protein description Symbol 
O95202 LETM1 LETM1 and EF-hand domain-containing protein 1, mit LETM1 
Q7Z449 CYP2U1 Cytochrome P450 2U1  CYP2U1 
Q96KC8 DNAJC1 DnaJ homolog subfamily C member 1  DNAJC1 
P38435 GGCX Vitamin K-dependent gamma-carboxylase  GGCX 
P49585 PCYT1A Choline-phosphate cytidylyltransferase A  PCYT1A 
Q53HC5 KLHL26 Kelch-like protein 26  KLHL26 
O15162 PLSCR1 Phospholipid scramblase 1  PLSCR1 
O43615 TIMM44 Mitochondrial import inner membrane translocase su TIMM44 
Q03135 CAV1 Caveolin-1  CAV1 
Q6PI78 TMEM65 Transmembrane protein 65  TMEM65 
Q8NEW0 SLC30A7 Zinc transporter 7  SLC30A7 
Q9H8H3 METTL7A Methyltransferase-like protein 7A  METTL7A 
Q9BSD7 NTPCR Cancer-related nucleoside-triphosphatase  NTPCR 
P21796 VDAC1 Voltage-dependent anion-selective channel protein  VDAC1 
Q9UBX3 SLC25A10 Mitochondrial dicarboxylate carrier  SLC25A10 
P45880 VDAC2 Voltage-dependent anion-selective channel protein  VDAC2 




Another DAG diazirine probe 3.7 produced an overall list of 2-5x hits, as shown in 
Table 3.5, and >5x hits, as shown in Table 3.6, that is well beyond the generic diazirine 
probe 3.3. While the backbone, photoaffinity groups, and ether linkages are the same 
between these two lipid probes, they differ in tail chain length, and in the placement and 
type of click handle. Probe 3.7’s closest generic probe analog, probe 3.6, was never 
synthesized, so this was the closest no-headgroup control available. 
Finally, amide-linked benzophenone N3-tailed DAG probe 3.1 was tested, with 2-
5x hits shown in Table 3.7 and >5x hits shown in Table 3.8. A generic probe equivalent 
to this molecule was not available as a no-headgroup control. Probe 3.1 labeled the most 
proteins in this round of experiments, which also appeared to be the case looking 
qualitatively at the SDS-PAGE results in Figures 3.5 through 3.8 above.  
 
Table 3.5: Proteomic hits (2-5x) for DAG-diazirine alkyne probe 3.7. 
uniprotID Protein description Symbol 
P52272 HNRNPM Heterogeneous nuclear ribonucleoprotein M  HNRNPM 
P21796 VDAC1 Voltage-dependent anion-selective channel protein  VDAC1 
Q969Z0 TBRG4 Protein TBRG4  TBRG4 
Q5VT52 RPRD2 Regulation of nuclear pre-mRNA domain-containing p RPRD2 
P24390 KDELR1 ER lumen protein retaining receptor 1  KDELR1 
O95202 LETM1 LETM1 and EF-hand domain-containing protein 1, mit LETM1 
P25705 ATP5A1 ATP synthase subunit alpha, mitochondrial  ATP5A1 
Q92616 GCN1L1 Translational activator GCN1  GCN1L1 
P45880 VDAC2 Voltage-dependent anion-selective channel protein  VDAC2 
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Table 3.5 continued. 
uniprotID Protein description Symbol 
P46782 RPS5 40S ribosomal protein S5  RPS5 
Q9BZZ5 API5 Apoptosis inhibitor 5  API5 
Q9NVI1 FANCI Fanconi anemia group I protein  FANCI 
P51648 ALDH3A2 Fatty aldehyde dehydrogenase  ALDH3A2 
Q9BWF3 RBM4 RNA-binding protein 4  RBM4 
P55060 CSE1L Exportin-2  CSE1L 
P24539 ATP5F1 ATP synthase subunit b, mitochondrial  ATP5F1 
Q13573 SNW1 SNW domain-containing protein 1  SNW1 
O43837 IDH3B Isocitrate dehydrogenase  IDH3B 
Q9BSD7 NTPCR Cancer-related nucleoside-triphosphatase  NTPCR 




Table 3.6: Proteomic hits (>5x) for DAG-diazirine alkyne probe 3.7. 
uniprotID Protein description Symbol 
O43615 TIMM44 Mitochondrial import inner membrane translocase su TIMM44 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta  SRPRB 
Q9NW68 BSDC1 BSD domain-containing protein 1  BSDC1 
P61011 SRP54 Signal recognition particle 54 kDa protein  SRP54 
Q9Y371 SH3GLB1 Endophilin-B1  SH3GLB1 
Q7L1Q6 BZW1 Basic leucine zipper and W2 domain-containing prot BZW1 
P48047 ATP5O ATP synthase subunit O, mitochondrial  ATP5O 
P78344 EIF4G2 Eukaryotic translation initiation factor 4 gamma 2 EIF4G2 
Q9UBX3 SLC25A10 Mitochondrial dicarboxylate carrier  SLC25A10 
O60664 PLIN3 Perilipin-3  PLIN3 
P62851 RPS25 40S ribosomal protein S25  RPS25 
B4DLN1 SLC25A10 cDNA FLJ60124, highly similar to Mitochondrial dic SLC25A10 
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Table 3.7: Proteomic hits (2-5x) for amide-linked benzophenone-DAG N3-tailed 
probe 3.1. 
uniprotID Protein description Symbol 
Q9BT22 ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransfer ALG1 
Q9NVV5 AIG1 Androgen-induced gene 1 protein  AIG1 
Q6P2E9 EDC4 Enhancer of mRNA-decapping protein 4  EDC4 
Q6UX53 METTL7B Methyltransferase-like protein 7B  METTL7B 
O95864 FADS2 Fatty acid desaturase 2  FADS2 
Q92797 SYMPK Symplekin  SYMPK 
Q96GQ5 C16orf58 UPF0420 protein C16orf58  C16orf58 
Q9H7Z7 PTGES2 Prostaglandin E synthase 2  PTGES2 
Q8WUY1 THEM6 UPF0670 protein THEM6  THEM6 
P51648 ALDH3A2 Fatty aldehyde dehydrogenase  ALDH3A2 
Q9Y672 ALG6 Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-gluco ALG6 
Q8IXI2 RHOT1 Mitochondrial Rho GTPase 1  RHOT1 
Q9NRZ5 AGPAT4 1-acyl-sn-glycerol-3-phosphate acyltransferase del AGPAT4 
P30519 HMOX2 Heme oxygenase 2  HMOX2 
Q9H1E5 TMX4 Thioredoxin-related transmembrane protein 4  TMX4 
O14524 TMEM194A Transmembrane protein 194A  TMEM194A 
Q9NW68 BSDC1 BSD domain-containing protein 1  BSDC1 
Q9NYV4 CDK12 Cyclin-dependent kinase 12  CDK12 
Q92616 GCN1L1 Translational activator GCN1  GCN1L1 
O95870 ABHD16A Abhydrolase domain-containing protein 16A  ABHD16A 
Q9BRR6 ADPGK ADP-dependent glucokinase  ADPGK 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q6P4A7 SFXN4 Sideroflexin-4  SFXN4 
Q9NX40 OCIAD1 OCIA domain-containing protein 1  OCIAD1 
A0FGR8 ESYT2 Extended synaptotagmin-2  ESYT2 
P53701 HCCS Cytochrome c-type heme lyase  HCCS 
Q9BVG9 PTDSS2 Phosphatidylserine synthase 2  PTDSS2 
Q9NXB9 ELOVL2 Elongation of very long chain fatty acids protein  ELOVL2 
O95674 CDS2 Phosphatidate cytidylyltransferase 2  CDS2 
Q9Y6A1 POMT1 Protein O-mannosyl-transferase 1  POMT1 
Q9Y6K0 CEPT1 Choline/ethanolaminephosphotransferase 1  CEPT1 
O14983 ATP2A1 Sarcoplasmic/endoplasmic reticulum calcium ATPase  ATP2A1 
Q5XKP0 QIL1 Protein QIL1  QIL1 
Q8IX01 SUGP2 SURP and G-patch domain-containing protein 2  SUGP2 
P42765 ACAA2 3-ketoacyl-CoA thiolase, mitochondrial  ACAA2 
O15121 DEGS1 Sphingolipid delta(4)-desaturase DES1  DEGS1 
Q9NYP7 ELOVL5 Elongation of very long chain fatty acids protein  ELOVL5 
Q6NUM9 RETSAT All-trans-retinol 13,14-reductase  RETSAT 
P63173 RPL38 60S ribosomal protein L38  RPL38 
Q99943 AGPAT1 1-acyl-sn-glycerol-3-phosphate acyltransferase alp AGPAT1 
Q9BZF1 OSBPL8 Oxysterol-binding protein-related protein 8  OSBPL8 
P16615 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase  ATP2A2 
Q6Y1H2 PTPLB 3-hydroxyacyl-CoA dehydratase 2  PTPLB 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q96AA3 RFT1 Protein RFT1 homolog  RFT1 
O43772 SLC25A20 Mitochondrial carnitine/acylcarnitine carrier prot SLC25A20 
Q53GQ0 HSD17B12 Estradiol 17-beta-dehydrogenase 12  HSD17B12 
O00567 NOP56 Nucleolar protein 56  NOP56 
Q9BXW9 FANCD2 Fanconi anemia group D2 protein  FANCD2 
Q86YH6 PDSS2 Decaprenyl-diphosphate synthase subunit 2  PDSS2 
P62851 RPS25 40S ribosomal protein S25  RPS25 
Q8IZL8 PELP1 Proline-, glutamic acid- and leucine-rich protein  PELP1 
Q6P1M0 SLC27A4 Long-chain fatty acid transport protein 4  SLC27A4 
Q5TFE4 NT5DC1 5-nucleotidase domain-containing protein 1  NT5DC1 
Q14728 MFSD10 Major facilitator superfamily domain-containing pr MFSD10 
Q9Y673 ALG5 Dolichyl-phosphate beta-glucosyltransferase  ALG5 
Q96KA5 CLPTM1L Cleft lip and palate transmembrane protein 1-like  CLPTM1L 
Q9NXF1 TEX10 Testis-expressed sequence 10 protein  TEX10 
P40939 HADHA Trifunctional enzyme subunit alpha, mitochondrial  HADHA 
O60725 ICMT Protein-S-isoprenylcysteine O-methyltransferase  ICMT 
P68366 TUBA4A Tubulin alpha-4A chain  TUBA4A 
Q9UHG3 PCYOX1 Prenylcysteine oxidase 1  PCYOX1 
Q9NY65 TUBA8 Tubulin alpha-8 chain  TUBA8 
Q71U36 TUBA1A Tubulin alpha-1A chain  TUBA1A 
Q9Y6I9 TEX264 Testis-expressed sequence 264 protein  TEX264 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q13748 TUBA3D Tubulin alpha-3C/D chain  TUBA3D 
Q8WWV3 RTN4IP1 Reticulon-4-interacting protein 1, mitochondrial  RTN4IP1 
P46977 STT3A Dolichyl-diphosphooligosaccharide--protein glycosy STT3A 
Q99643 SDHC Succinate dehydrogenase cytochrome b560 subunit, m SDHC 
Q99720 SIGMAR1 Sigma non-opioid intracellular receptor 1  SIGMAR1 
P57678 GEMIN4 Gem-associated protein 4  GEMIN4 
P23786 CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial  CPT2 
Q9BQG0 MYBBP1A Myb-binding protein 1A  MYBBP1A 
Q8TC12 RDH11 Retinol dehydrogenase 11  RDH11 
P50416 CPT1A Carnitine O-palmitoyltransferase 1, liver isoform  CPT1A 
Q9C0D9 EPT1 Ethanolaminephosphotransferase 1  EPT1 
Q8NBI6 XXYLT1 Xyloside xylosyltransferase 1  XXYLT1 
Q5UIP0 RIF1 Telomere-associated protein RIF1  RIF1 
Q6KC79 NIPBL Nipped-B-like protein  NIPBL 
Q9P0S9 TMEM14C Transmembrane protein 14C  TMEM14C 
Q9Y289 SLC5A6 Sodium-dependent multivitamin transporter  SLC5A6 
Q8N2K0 ABHD12 Monoacylglycerol lipase ABHD12  ABHD12 
Q96G23 CERS2 Ceramide synthase 2  CERS2 
Q9Y6X3 MAU2 MAU2 chromatid cohesion factor homolog  MAU2 
P0CG08 GPR89B Golgi pH regulator B  GPR89B 
Q9HBH5 RDH14 Retinol dehydrogenase 14  RDH14 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q96DG6 CMBL Carboxymethylenebutenolidase homolog  CMBL 
Q9NZ01 TECR Trans-2,3-enoyl-CoA reductase  TECR 
Q9Y4W2 LAS1L Ribosomal biogenesis protein LAS1L  LAS1L 
Q5C9Z4 NOM1 Nucleolar MIF4G domain-containing protein 1  NOM1 
P61619 SEC61A1 Protein transport protein Sec61 subunit alpha isof SEC61A1 
O75691 UTP20 Small subunit processome component 20 homolog  UTP20 
Q53R41 FASTKD1 FAST kinase domain-containing protein 1  FASTKD1 
Q9NU22 MDN1 Midasin  MDN1 
Q9Y679 AUP1 Ancient ubiquitous protein 1  AUP1 
O94919 ENDOD1 Endonuclease domain-containing 1 protein  ENDOD1 
Q9Y282 ERGIC3 Endoplasmic reticulum-Golgi intermediate compartme ERGIC3 
Q9H9S3 SEC61A2 Protein transport protein Sec61 subunit alpha isof SEC61A2 
F8VZB9 HLA-C HLA class I histocompatibility antigen, Cw-14 alph HLA-C 
P10321 HLA-C HLA class I histocompatibility antigen, Cw-7 alpha HLA-C 
Q9NXE4 SMPD4 Sphingomyelin phosphodiesterase 4  SMPD4 
Q7Z2K6 ERMP1 Endoplasmic reticulum metallopeptidase 1  ERMP1 
Q9H0U3 MAGT1 Magnesium transporter protein 1  MAGT1 
Q8N9F7 
GDPD1 Glycerophosphodiester phosphodiesterase domain-
con 
GDPD1 
Q9Y6Y8 SEC23IP SEC23-interacting protein  SEC23IP 
Q9UK61 FAM208A Protein FAM208A  FAM208A 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q9NRG7 SDR39U1 Epimerase family protein SDR39U1  SDR39U1 
Q29RF7 PDS5A Sister chromatid cohesion protein PDS5 homolog A  PDS5A 
Q16850 CYP51A1 Lanosterol 14-alpha demethylase  CYP51A1 
P48651 PTDSS1 Phosphatidylserine synthase 1  PTDSS1 
P35251 RFC1 Replication factor C subunit 1  RFC1 
Q96AB3 ISOC2 Isochorismatase domain-containing protein 2, mitoc ISOC2 
O75251 NDUFS7 NADH dehydrogenase  NDUFS7 
Q14004 CDK13 Cyclin-dependent kinase 13  CDK13 
O43251 RBFOX2 RNA binding protein fox-1 homolog 2  RBFOX2 
Q9HBM0 VEZT Vezatin  VEZT 
Q9Y3E5 PTRH2 Peptidyl-tRNA hydrolase 2, mitochondrial  PTRH2 
P57088 TMEM33 Transmembrane protein 33  TMEM33 
Q9NUT2 ABCB8 ATP-binding cassette sub-family B member 8, mitoch ABCB8 
O14681 EI24 Etoposide-induced protein 2.4 homolog  EI24 
Q9NTJ3 SMC4 Structural maintenance of chromosomes protein 4  SMC4 
Q8WYP5 AHCTF1 Protein ELYS  AHCTF1 
P35613 BSG Basigin  BSG 
Q9UPT9 USP22 Ubiquitin carboxyl-terminal hydrolase 22  USP22 
Q02978 SLC25A11 Mitochondrial 2-oxoglutarate/malate carrier protei SLC25A11 
O43681 ASNA1 ATPase ASNA1  ASNA1 
O60488 ACSL4 Long-chain-fatty-acid--CoA ligase 4  ACSL4 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q96C36 PYCR2 Pyrroline-5-carboxylate reductase 2  PYCR2 
Q9NTI5 PDS5B Sister chromatid cohesion protein PDS5 homolog B  PDS5B 
Q15800 MSMO1 Methylsterol monooxygenase 1  MSMO1 
O14880 MGST3 Microsomal glutathione S-transferase 3  MGST3 
Q99623 PHB2 Prohibitin-2  PHB2 
Q9Y2X3 NOP58 Nucleolar protein 58  NOP58 
Q8NF37 LPCAT1 Lysophosphatidylcholine acyltransferase 1  LPCAT1 
O60318 MCM3AP 80 kDa MCM3-associated protein  MCM3AP 
Q9Y3L5 RAP2C Ras-related protein Rap-2c  RAP2C 
O00159 MYO1C Unconventional myosin-Ic  MYO1C 
O60216 RAD21 Double-strand-break repair protein rad21 homolog  RAD21 
P21796 VDAC1 Voltage-dependent anion-selective channel protein  VDAC1 
O60664 PLIN3 Perilipin-3  PLIN3 
O75533 SF3B1 Splicing factor 3B subunit 1  SF3B1 
Q9Y6N1 COX11 Cytochrome c oxidase assembly protein COX11, mitoc COX11 
Q86TM6 SYVN1 E3 ubiquitin-protein ligase synoviolin  SYVN1 
O95573 ACSL3 Long-chain-fatty-acid--CoA ligase 3  ACSL3 
P35998 PSMC2 26S protease regulatory subunit 7  PSMC2 
Q9HD20 ATP13A1 Probable cation-transporting ATPase 13A1  ATP13A1 
Q6ZXV5 TMTC3 Transmembrane and TPR repeat-containing protein 3  TMTC3 
Q9BTV4 TMEM43 Transmembrane protein 43  TMEM43 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
P62273 RPS29 40S ribosomal protein S29  RPS29 
O75915 ARL6IP5 PRA1 family protein 3  ARL6IP5 
O43264 ZW10 Centromere/kinetochore protein zw10 homolog  ZW10 
Q8TCJ2 STT3B Dolichyl-diphosphooligosaccharide--protein glycosy STT3B 
Q5JTH9 RRP12 RRP12-like protein  RRP12 
P62269 RPS18 40S ribosomal protein S18  RPS18 
P51532 SMARCA4 Transcription activator BRG1  SMARCA4 
P55061 TMBIM6 Bax inhibitor 1  TMBIM6 
Q15629 TRAM1 Translocating chain-associated membrane protein 1  TRAM1 
Q6NUQ4 TMEM214 Transmembrane protein 214  TMEM214 
Q5T9A4 ATAD3B ATPase family AAA domain-containing protein 3B  ATAD3B 
Q68CP9 ARID2 AT-rich interactive domain-containing protein 2  ARID2 
Q7KZN9 
COX15 Cytochrome c oxidase assembly protein COX15 
homolo 
COX15 
O43826 SLC37A4 Glucose-6-phosphate translocase  SLC37A4 
Q14008 CKAP5 Cytoskeleton-associated protein 5  CKAP5 
Q86VR2 FAM134C Protein FAM134C  FAM134C 
P51153 RAB13 Ras-related protein Rab-13  RAB13 
Q9Y276 BCS1L Mitochondrial chaperone BCS1  BCS1L 
Q9BSJ8 ESYT1 Extended synaptotagmin-1  ESYT1 
Q5I7T1 ALG10B Putative Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol al ALG10B 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q5BKT4 ALG10 Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-g ALG10 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit al GNAI3 
Q969V3 NCLN Nicalin  NCLN 
O14735 CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransfe CDIPT 
P05091 ALDH2 Aldehyde dehydrogenase, mitochondrial  ALDH2 
Q9Y2R4 DDX52 Probable ATP-dependent RNA helicase DDX52  DDX52 
Q00325 SLC25A3 Phosphate carrier protein, mitochondrial  SLC25A3 
Q969N2 PIGT GPI transamidase component PIG-T  PIGT 
O94906 PRPF6 Pre-mRNA-processing factor 6  PRPF6 
Q6NUQ1 RINT1 RAD50-interacting protein 1  RINT1 
P39210 MPV17 Protein Mpv17  MPV17 
Q9BTT6 LRRC1 Leucine-rich repeat-containing protein 1  LRRC1 
Q9P003 CNIH4 Protein cornichon homolog 4  CNIH4 
Q9NRP0 OSTC Oligosaccharyltransferase complex subunit OSTC  OSTC 
P50402 EMD Emerin  EMD 
Q96HR9 REEP6 Receptor expression-enhancing protein 6  REEP6 
P38435 GGCX Vitamin K-dependent gamma-carboxylase  GGCX 
P63096 GNAI1 Guanine nucleotide-binding protein G(i) subunit al GNAI1 
Q14160 SCRIB Protein scribble homolog  SCRIB 
O15260 SURF4 Surfeit locus protein 4  SURF4 
Q69YN4 KIAA1429 Protein virilizer homolog  KIAA1429 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
P05141 SLC25A5 ADP/ATP translocase 2  SLC25A5 
P03905 MT-ND4 NADH-ubiquinone oxidoreductase chain 4  MT-ND4 
P51151 RAB9A Ras-related protein Rab-9A  RAB9A 
Q9P035 PTPLAD1 3-hydroxyacyl-CoA dehydratase 3  PTPLAD1 
P32322 PYCR1 Pyrroline-5-carboxylate reductase 1, mitochondrial PYCR1 
Q6NUK1 
SLC25A24 Calcium-binding mitochondrial carrier protein 
SCaM 
SLC25A24 
Q9HCC0 MCCC2 Methylcrotonoyl-CoA carboxylase beta chain, mitoch MCCC2 
O14654 IRS4 Insulin receptor substrate 4  IRS4 
P24390 KDELR1 ER lumen protein retaining receptor 1  KDELR1 
P33947 KDELR2 ER lumen protein retaining receptor 2  KDELR2 
P46782 RPS5 40S ribosomal protein S5  RPS5 
P12236 SLC25A6 ADP/ATP translocase 3  SLC25A6 
Q5T2N8 ATAD3C ATPase family AAA domain-containing protein 3C  ATAD3C 
O96008 
TOMM40 Mitochondrial import receptor subunit TOM40 
homolo 
TOMM40 
Q02880 TOP2B DNA topoisomerase 2-beta  TOP2B 
Q9NVI7 ATAD3A ATPase family AAA domain-containing protein 3A  ATAD3A 
Q9NVH1 DNAJC11 DnaJ homolog subfamily C member 11  DNAJC11 
Q9NTJ5 SACM1L Phosphatidylinositide phosphatase SAC1  SACM1L 
P07437 TUBB Tubulin beta chain  TUBB 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
Q14152 EIF3A Eukaryotic translation initiation factor 3 subunit EIF3A 
O75844 ZMPSTE24 CAAX prenyl protease 1 homolog  ZMPSTE24 
P04899 GNAI2 Guanine nucleotide-binding protein G(i) subunit al GNAI2 
Q14684 RRP1B Ribosomal RNA processing protein 1 homolog B  RRP1B 
Q13445 TMED1 Transmembrane emp24 domain-containing protein 1  TMED1 
H3BN98 Uncharacterized protein  Unch 
E7ERL9 VARS2 Valine--tRNA ligase, mitochondrial  VARS2 
P28288 ABCD3 ATP-binding cassette sub-family D member 3  ABCD3 
Q969Z0 TBRG4 Protein TBRG4  TBRG4 
Q9NVI1 FANCI Fanconi anemia group I protein  FANCI 
Q96CS3 FAF2 FAS-associated factor 2  FAF2 
P50336 PPOX Protoporphyrinogen oxidase  PPOX 
P61020 RAB5B Ras-related protein Rab-5B  RAB5B 
Q01844 EWSR1 RNA-binding protein EWS  EWSR1 
P12235 SLC25A4 ADP/ATP translocase 1  SLC25A4 
Q9NRZ9 HELLS Lymphoid-specific helicase  HELLS 
Q6UWP7 LCLAT1 Lysocardiolipin acyltransferase 1  LCLAT1 
O14828 SCAMP3 Secretory carrier-associated membrane protein 3  SCAMP3 
P42677 RPS27 40S ribosomal protein S27  RPS27 
Q96BW9 TAMM41 Mitochondrial translocator assembly and maintenanc TAMM41 
A1L0T0 ILVBL Acetolactate synthase-like protein  ILVBL 
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Table 3.7 continued. 
uniprotID Protein description Symbol 
P51148 RAB5C Ras-related protein Rab-5C  RAB5C 
Q92544 TM9SF4 Transmembrane 9 superfamily member 4  TM9SF4 
O94874 UFL1 E3 UFM1-protein ligase 1  UFL1 
Q13509 TUBB3 Tubulin beta-3 chain  TUBB3 
Q9UGU5 HMGXB4 HMG domain-containing protein 4  HMGXB4 
Q92667 AKAP1 A-kinase anchor protein 1, mitochondrial  AKAP1 
P53985 SLC16A1 Monocarboxylate transporter 1  SLC16A1 
P42167 TMPO Lamina-associated polypeptide 2, isoforms beta/gam TMPO 
  
146 
Table 3.8: Proteomic hits (>5x) for amide-linked benzophenone-DAG N3-tailed 
probe 3.1. 
uniprotID Protein description Symbol 
P07099 EPHX1 Epoxide hydrolase 1  EPHX1 
Q3SXM5 HSDL1 Inactive hydroxysteroid dehydrogenase-like protein HSDL1 
O15270 SPTLC2 Serine palmitoyltransferase 2  SPTLC2 
Q9Y4P3 TBL2 Transducin beta-like protein 2  TBL2 
Q9UPN3 MACF1 Microtubule-actin cross-linking factor 1, isoforms MACF1 
Q16880 UGT8 2-hydroxyacylsphingosine 1-beta-galactosyltransfer UGT8 
Q9H0V1 TMEM168 Transmembrane protein 168  TMEM168 
Q9Y4R8 TELO2 Telomere length regulation protein TEL2 homolog  TELO2 
Q96AD5 PNPLA2 Patatin-like phospholipase domain-containing prote PNPLA2 
Q96K37 SLC35E1 Solute carrier family 35 member E1  SLC35E1 
Q9H6R6 ZDHHC6 Palmitoyltransferase ZDHHC6  ZDHHC6 
Q86VU5 
COMTD1 Catechol O-methyltransferase domain-containing 
pro 
COMTD1 
Q9BSJ5 C17orf80 Uncharacterized protein C17orf80  C17orf80 
Q9BRB3 PIGQ Phosphatidylinositol N-acetylglucosaminyltransfera PIGQ 
Q99541 PLIN2 Perilipin-2  PLIN2 
Q9H4G4 GLIPR2 Golgi-associated plant pathogenesis-related protei GLIPR2 
Q15043 SLC39A14 Zinc transporter ZIP14  SLC39A14 
Q16611 BAK1 Bcl-2 homologous antagonist/killer  BAK1 
P50443 SLC26A2 Sulfate transporter  SLC26A2 
P46379 BAG6 Large proline-rich protein BAG6  BAG6 
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Table 3.8 continued. 
uniprotID Protein description Symbol 
O96011 PEX11B Peroxisomal membrane protein 11B  PEX11B 
O14925 TIMM23 Mitochondrial import inner membrane translocase su TIMM23 
A6NIH7 UNC119B Protein unc-119 homolog B  UNC119B 
Q8N8Q8 COX18 Mitochondrial inner membrane protein COX18  COX18 
Q96LJ7 DHRS1 Dehydrogenase/reductase SDR family member 1  DHRS1 
Q6P1S2 C3orf33 Uncharacterized protein C3orf33  C3orf33 
Q9Y5Q9 GTF3C3 General transcription factor 3C polypeptide 3  GTF3C3 
Q9HDC9 APMAP Adipocyte plasma membrane-associated protein  APMAP 
Q8NBX0 SCCPDH Saccharopine dehydrogenase-like oxidoreductase  SCCPDH 
Q6DD88 ATL3 Atlastin-3  ATL3 
Q9BU23 LMF2 Lipase maturation factor 2  LMF2 
Q8NEW0 SLC30A7 Zinc transporter 7  SLC30A7 
Q96H55 MYO19 Unconventional myosin-XIX  MYO19 
Q7Z449 CYP2U1 Cytochrome P450 2U1  CYP2U1 
O14521 SDHD Succinate dehydrogenase  SDHD 
Q96JJ7 TMX3 Protein disulfide-isomerase TMX3  TMX3 
Q14108 SCARB2 Lysosome membrane protein 2  SCARB2 
Q96N66 MBOAT7 Lysophospholipid acyltransferase 7  MBOAT7 
P41440 SLC19A1 Folate transporter 1  SLC19A1 
Q7L5N7 LPCAT2 Lysophosphatidylcholine acyltransferase 2  LPCAT2 
Q5BJF2 TMEM97 Transmembrane protein 97  TMEM97 
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Table 3.8 continued. 
uniprotID Protein description Symbol 
Q03518 TAP1 Antigen peptide transporter 1  TAP1 
Q9H936 SLC25A22 Mitochondrial glutamate carrier 1  SLC25A22 
Q13232 NME3 Nucleoside diphosphate kinase 3  NME3 
Q9BVK2 ALG8 Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 al ALG8 
Q03164 MLL Histone-lysine N-methyltransferase MLL  MLL 
Q8TBR7 FAM57A Protein FAM57A  FAM57A 
Q8N201 INTS1 Integrator complex subunit 1  INTS1 
Q8TCT9 HM13 Minor histocompatibility antigen H13  HM13 
Q9H6H4 REEP4 Receptor expression-enhancing protein 4  REEP4 
P15151 PVR Poliovirus receptor  PVR 
Q96E22 NUS1 Nogo-B receptor  NUS1 
Q8IXH7 TH1L Negative elongation factor C/D  TH1L 
O00767 SCD Acyl-CoA desaturase  SCD 
Q14318 FKBP8 Peptidyl-prolyl cis-trans isomerase FKBP8  FKBP8 
Q6UXV4 APOOL Apolipoprotein O-like  APOOL 
P55084 HADHB Trifunctional enzyme subunit beta, mitochondrial  HADHB 
P35610 SOAT1 Sterol O-acyltransferase 1  SOAT1 
O60831 PRAF2 PRA1 family protein 2  PRAF2 
Q00765 REEP5 Receptor expression-enhancing protein 5  REEP5 
Q8WUY8 NAT14 N-acetyltransferase 14  NAT14 
P21964 COMT Catechol O-methyltransferase  COMT 
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Table 3.8 continued. 
uniprotID Protein description Symbol 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein  VDAC3 
Q8IZV5 RDH10 Retinol dehydrogenase 10  RDH10 
P07237 P4HB Protein disulfide-isomerase  P4HB 
Q9NVV0 TMEM38B Trimeric intracellular cation channel type B  TMEM38B 
Q9HC21 SLC25A19 Mitochondrial thiamine pyrophosphate carrier  SLC25A19 
Q9BWD1 ACAT2 Acetyl-CoA acetyltransferase, cytosolic  ACAT2 
Q8TBP6 SLC25A40 Solute carrier family 25 member 40  SLC25A40 
Q96D53 ADCK4 Uncharacterized aarF domain-containing protein kin ADCK4 
O95197 RTN3 Reticulon-3  RTN3 
Q13286 CLN3 Battenin  CLN3 
Q9NQC3 RTN4 Reticulon-4  RTN4 
Q96MH6 TMEM68 Transmembrane protein 68  TMEM68 
P43007 SLC1A4 Neutral amino acid transporter A  SLC1A4 
Q9NRV9 HEBP1 Heme-binding protein 1  HEBP1 
P14174 MIF Macrophage migration inhibitory factor  MIF 
Q9NWW5 CLN6 Ceroid-lipofuscinosis neuronal protein 6  CLN6 
O94901 SUN1 SUN domain-containing protein 1  SUN1 
O43169 CYB5B Cytochrome b5 type B  CYB5B 
Q9NZJ7 MTCH1 Mitochondrial carrier homolog 1  MTCH1 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1  TMX1 
Q5K4L6 SLC27A3 Long-chain fatty acid transport protein 3  SLC27A3 
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Table 3.8 continued. 
uniprotID Protein description Symbol 
O15228 GNPAT Dihydroxyacetone phosphate acyltransferase  GNPAT 
Q9NQE9 HINT3 Histidine triad nucleotide-binding protein 3  HINT3 
P24752 ACAT1 Acetyl-CoA acetyltransferase, mitochondrial  ACAT1 
Q9BTX1 TMEM48 Nucleoporin NDC1  TMEM48 
Q8TED1 GPX8 Probable glutathione peroxidase 8  GPX8 
P45880 VDAC2 Voltage-dependent anion-selective channel protein  VDAC2 
P49069 CAMLG Calcium signal-modulating cyclophilin ligand  CAMLG 
Q9BUN8 DERL1 Derlin-1  DERL1 
P22307 SCP2 Non-specific lipid-transfer protein  SCP2 





Q07065 CKAP4 Cytoskeleton-associated protein 4  CKAP4 
Q86UL3 AGPAT6 Glycerol-3-phosphate acyltransferase 4  AGPAT6 
Q13126 MTAP S-methyl-5-thioadenosine phosphorylase  MTAP 
Q5VV42 
CDKAL1 Threonylcarbamoyladenosine tRNA 
methylthiotransfer 
CDKAL1 
Q92538 GBF1 Golgi-specific brefeldin A-resistance guanine nucl GBF1 
Q9Y6C9 MTCH2 Mitochondrial carrier homolog 2  MTCH2 
Q6UW68 TMEM205 Transmembrane protein 205  TMEM205 
Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta  SRPRB 
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At this time, these proteomic data in Tables 3.1-3.4 are still being evaluated for 
protein hits known to bind lipids, and that may be relevant to signaling and other 
membrane-related activities. 
In summary, we redisigned bifunctional lipid probes to eliminate the need for a 
lysine scaffold by relocating the click tag to the tail ends, and the photoaffinity tag directly 
onto the lipid backbone. We successfully completed syntheses of probes designed to 
mimic DAG (3.1, 3.4, and 3.7) and PA (3.5 and 3.8), and also completed a headless 
generic probe (3.3) useful for investigating background labeling for froms that utilize a 
diazirine-based scaffold. We successfully labeled HEK lysate and live cell proteomes and 
visualized results with SDS-PAGE. We also identified dozens of protein hits from HEK 
lysate solutions labeled by DAG probes 3.1, 3.4, and 3.7 using proteomic LC-MS 
methods. These results demonstrate the ability of these probes to photocrosslink proteins 
within complex biological mixtures and live cells and undergo click derivatization for 
analysis to yield distinct labeling profiles for each probe structure. In the future, we hope 
to optimize labeling protocols and continue similar studies with these probes. 
3.5 General Experimental 
Reagents and catalysts were purchased from Fisher Scientific or Sigma Aldrich 
and used as received, or purified according to standard methods as needed.157 Dry 
solvents were obtained from either a Pure Solv delivery system from Innovative 
Technologies, Inc, or distilled according to standard methods158 When required, solvents 
were degassed by repeated cycles of freezing with liquid N2, pumping under high vacuum, 
and thawing before backfilling with Ar. Column chromatography was performed using 230 
to 400 mesh silica gel purchased from Sorbent Technologies, or activated alumina from 
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Fisher Scientific. Thin layer chromatography was performed on aluminum or glass-
supported silica plates with UV-254 fluorescent indicator, and visualized using a 254 nm 
lamp, potassium permanganate (KMnO4), cerium molybdate (CeMo), ninhydrin, 
bromocresol green (BCG), 2,4-dinitrophenylhydrazine (2,4-DNP), or phospray stains. 
NMR spectra were recorded using Mercury 300 MHz and Varian 500 MHz instruments. 
Mass spectra were obtained using JEOL DART-AccuTOF, ABI Voyager DE Pro MALDI, 
ESI-Orbitrap Quadrupole, or ESI-QSTAR spectrometers.  
3.6 Detailed Syntheses 
 
 
4-(3-Methyl-3H-diazirin-3-yl)butanoic acid (3.11). A previously published 
procedure was followed.174 In a 10 mL test tube, commercially available 5-oxo-hexanoic 
acid (3.9, 100 mg, 0.768 mmol) was dissolved in 2 mL 7N ammonia (saturated) in 
methanol (NH3(MeOH)), and the solution was cooled to 0C and stirred for 75 min before 
adding in 5 portions hydroxylamine-O-sulfonic acid (HOSA, 87 mg, 0.768) over ~10 min. 
The opaque white suspension was stirred at 0C for 2.5 h, and then allowed to warm to 
rt and stir overnight. The resulting suspension was filtered through celite, rinsed with 
methanol, concentrated by rotary evaporation, and dried under high vacuum to give crude 
compound 3.10 as a white foam. This residue was then treated with 0.5 mL triethylamine 
(TEA) and then concentrated again by rotary evaporation. The residue was dissolved in 
1 mL methanol, 0.2 mL of TEA was added, and then, with stirring at rt, iodine (I2) was 
added in 10 mg portions until the brown color persisted in solution for >5 min. The solution 
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was concentrated by rotary evaporation, and the crude residue was purified on a silica 
gel column using a gradient elution of 20-40% acetone in hexanes to give a compound 
3.11 as a clear oil (12 mg, 11%). Rf = 0.63 (50% acetone-hexanes, BCG: yellow). NMR 
and MS characterization data matched previous reports.174 
 
 
5-oxo-N-(prop-2-yn-1-yl)hexanamide (3.14). In a flame dried 3 mL test tube, 
commercially available 5-oxo-hexanoic acid (3.9, 65 mg, 0.5 mmol) was dissolved in 2 
mL chloroform under argon, and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU, 190 mg, 0.5 mmol) was added to the stirring solution at rt, 
followed by diisopropylethylamine (DIEA, 165 L, 1.0 mmol). The solution was stirred for 
5 min before adding propargylamine (32 L, 0.5 mmol), and was then stirred for 4.5 h at 
rt. The orange solution was concentrated by rotary evaporation, dissolved in 15 mL 
methylene chloride, washed with 15 mL water and then 15 mL brine (saturated sodium 
chloride (aq)), and the organic layer was dried over magnesium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum. The crude residue was 
purified on a silica gel column using a gradient elution of 0-8% methanol in methylene 
chloride, and then recrystallized in ethyl ether to remove a colored impurity to give 
compound 3.14 as white crystals (44 mg, 53%). Rf = 0.37 (5% MeOH-CH2Cl2, KMnO4). 
1H NMR (500 MHz, CDCl3) δ 5.77 (s, 1H), 4.04 (ddd, J = 5.2, 2.6, 0.9 Hz, 2H), 2.52 (t, J 
= 7.0 Hz, 2H), 2.27 – 2.16 (m, 3H), 2.14 (s, 3H), 1.90 (pd, J = 7.2, 0.9 Hz, 2H). 13C NMR 
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(126 MHz, CDCl3) δ 208.46 , 171.93 , 79.50 , 71.55 (d, J = 1.6 Hz), 42.29 , 35.00 , 29.95 




triazol-4-yl)methyl)-5-oxohexanamide (3.15). This synthesis followed a modified 
published procedure.136 In a 3 mL test tube under argon, compound 3.14 (19 mg, 0.112 
mmol) and previously synthesized compound 2.12 (30mg, 0.112 mmol) were dissolved 
in 1.5 mL tetrahydrofuran. With stirring, copper(II) sulfate pentahydrate (CuSO4•5H2O, 
224 mg, 0.898 mmol) and sodium ascorbate (222 mg, 1.12 mmol) were added, followed 
by 0.5 mL water. The resulting black suspension was covered with foil and stirred at rt for 
2 h. The resulting purple suspension was concentrated by rotary evaporation, dissolved 
in 15 mL ethyl acetate, washed (3x) with 3 mL water and then 3 mL brine (saturated 
sodium chloride (aq)), dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The white ring-like crystalline crude was 
purified on a silica gel column using a gradient elution of 0-10% methanol in methylene 
chloride to give a compound 3.15 as a white solid (7 mg, 15%). Rf = 0.37 (10% MeOH-
CH2Cl2, UV). (NMR) This molecule was given to Samuel Mattern Schain for further 




(2S,3S)-1-Amino-4-((4-methoxybenzyl)oxy)butane-2,3-diol (3.12. In a 3 mL test 
tube, compound 2.12 (20 mg, 0.075 mmol), 10% palladium adsorbed on carbon (Pd/C, 3 
mg, 15% w/w of 2.12), and crushed sodium carbonate (Na2CO3, 21 mg, 0.202 mmol) 
were added, and the tube was flushed with argon. Ethyl acetate 0.3 mL was added, 
vigorous stirring begun, and the atmosphere was replaced with H2. After 50 min, the 
mixture was filtered through celite, concentrated by rotary evaporation, and dried under 
high vacuum to give 3.12 as a white solid (11 mg, 60% yield). TLC analysis with ninhydrin 
stain produced a purple spot. 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.22 (m, 2H), 6.92 – 
6.84 (m, 2H), 4.54 – 4.45 (m, 2H), 3.83 – 3.77 (m, 1H), 3.80 (s, 3H), 3.68 – 3.64 (m, 1H), 
3.59 (qd, J = 9.8, 4.8 Hz, 2H), 3.00 (dd, J = 12.7, 3.9 Hz, 1H), 2.82 (dd, J = 12.7, 5.5 Hz, 
1H), 2.58 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 159.34 , 129.79 , 129.44 , 113.86 , 73.34 





(3.13). In a flame dried 3 mL test tube under argon, commercially available compound 3.9 
(6 mg, 0.046 mmol) was dissolved in 2 mL chloroform, and (2-(1H-benzotriazol-1-yl)-
156 
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 17 mg, 0.046 mmol) was added 
to the stirring solution at rt, followed by diisopropylethylamine (DIEA, 15 L, 0.091 mmol). 
The cloudy suspension was stirred for 10 min before adding compound 3.12 (11 mg, 
0.046 mmol), and was then stirred for 4.5 h at rt. The resulting clear solution was 
concentrated by rotary evaporation, dissolved in 1.2 mL methylene chloride, washed with 
0.8 mL water and then 0.8 mL brine (saturated sodium chloride (aq)), and the organic 
layer was dried over magnesium sulfate, filtered, concentrated by rotary evaporation, and 
dried under high vacuum. The crude residue was purified on a silica gel column using a 
gradient elution of 0-12% methanol in methylene chloride, and the recovered residue, 
contaminated with DIEA/HOBt, was dissolved in 3 mL chloroform, washed with 3 mL 
water then 3 mL brine, dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, triturated with hexanes to remove grease impurity, and finally dried under 
high vacuum to give compound 3.13 as faintly yellow oil (9.5 mg, 59%). Rf = 0.53 (10% 
MeOH-CH2Cl2, UV). 1H NMR (500 MHz, CDCl3) δ 7.27 – 7.20 (m, 2H), 6.91 – 6.84 (m, 
2H), 6.05 (s, 1H), 4.52 – 4.44 (m, 2H), 3.80 (s, 3H), 3.75 – 3.66 (m, 1H), 3.69 – 3.62 (m, 
1H), 3.63 – 3.51 (m, 3H), 3.24 (ddd, J = 14.1, 7.0, 4.9 Hz, 1H), 3.01 (s, 1H), 2.50 (t, J = 
7.0 Hz, 2H), 2.20 (t, J = 7.3 Hz, 2H), 2.13 (s, 3H), 1.89 (p, J = 7.1 Hz, 2H), 1.71 (d, J = 
44.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 208.54 , 173.62 , 159.41 , 129.62 , 129.47 , 
113.91 , 73.34 , 71.59 , 71.27 , 70.50 , 55.26 , 42.61 , 42.40 , 35.24 , 29.92 , 19.57 . 
DART-MS: [M+H]+ for C18H27NO6 calcd, 354.1911; detected, 354.1914. (NMR) This 





methanamine (3.28). In a 100 mL round bottom flask, previously synthesized compound 
2.11 (85 mg, 0.277 mmol), 10% palladium adsorbed on carbon (Pd/C, 17 mg, 20% w/w 
of 2.11), and crushed sodium carbonate (Na2CO3, 79 mg, 0.747 mmol) were added, and 
the tube was flushed with argon. 5 mL ethyl acetate was added, vigorous stirring begun, 
and the atmosphere was replaced with H2. After 2 h, the mixture was filtered through 
celite, concentrated by rotary evaporation, and purified on a silica gel column using a 
gradient elution of 5-15% methanol in methylene chloride to give 3.28 as a clear oil (64 
mg, 82% yield). Rf = 0.31 (10% MeOH-CH2Cl2, UV, Ninhydrin: purple). 1H NMR (500 MHz, 
CDCl3) δ 7.29 – 7.22 (m, 2H), 6.91 – 6.84 (m, 2H), 4.55 – 4.46 (m, 2H), 3.97 – 3.89 (m, 
1H), 3.87 – 3.78 (m, 4H), 3.64 – 3.56 (m, 1H), 3.52 (dddd, J = 10.2, 5.1, 2.2, 1.2 Hz, 1H), 
2.92 (s, 1H), 2.83 (s, 1H), 1.44 – 1.38 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 159.25 , 
129.92 , 129.32 , 113.78 , 109.08 , 77.35 , 77.19 , 73.24 , 70.47 , 55.25 , 44.08 , 27.19 , 
27.00 . DART-MS: [M+H]+ for C15H23NO4 calcd, 282.1700; detected, 282.1758. 
 
4-Azido-2,3,5,6-tetrafluoro-N-(((4S,5S)-5-(((4-methoxybenzyl)oxy)methyl)-
2,2-dimethyl-1,3-dioxolan-4-yl)methyl)benzamide (3.29). In an oven dried 100 mL 
round bottom flask under argon, previously synthesized compound 2.44 (80 mg, 0.341 
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mmol), compound 3.28 (64 mg, 0.227), and hydroxybenzotriazole (HOBt, 52 mg, 0.341 
mmol) were dissolved in 5 mL N,N-dimethylformamide. After stirring and cooling to 0C, 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 59 mg, 0.341 mmol) 
was added in one portion, followed by diisopropylethylamine (DIEA, 56 L, 0.341 mmol). 
The mixture was allowed to warm to rt and was stirred for 2 h. The resulting solution was 
poured into 30 mL water, and the aqueous layer was extracted with (3x) 12 mL ethyl 
acetate. The combined organic layers were washed with (5x) 4 mL water, 6 mL brine 
(saturated sodium chloride (aq)), then dried over sodium sulfate, filtered, concentrated by 
rotary evaporation, and dried under high vacuum while protected from light. The crude 
yellow oil was purified on a silica gel column using a gradient elution of 20-50% ethyl 
acetate in hexanes to give 3.29 as a yellow oil (57 mg, 50% yield), which was handled 
and stored with care to avoid light. Rf = 0.46 (35% EtOAc-hexanes, UV). 1H NMR (500 
MHz, CDCl3) δ 7.21 – 7.12 (m, 2H), 6.81 – 6.77 (m, 2H), 6.75 (s, 1H), 4.53 – 4.43 (m, 
2H), 3.99 (dddd, J = 22.5, 7.8, 6.6, 4.6 Hz, 2H), 3.88 (ddd, J = 13.8, 6.7, 4.6 Hz, 1H), 3.80 
(s, 3H), 3.84 – 3.74 (m, 1H), 3.57 (dd, J = 9.6, 6.8 Hz, 1H), 3.49 (ddd, J = 13.8, 6.3, 4.0 
Hz, 1H), 1.44 – 1.37 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 159.26 , 157.67 , 129.20 , 
129.04 , 113.65 , 109.48 , 78.00 , 77.93 , 73.52 , 70.40 , 55.18 , 41.87 , 28.68 , 26.87 , 
26.76 , 21.03 , 14.18. 19F NMR (470 MHz, CDCl3) δ -141.06 – -141.34 (m), -150.44 – -






2,2-dimethyl-1,3-dioxolan-4-yl)methyl)benzamide (3.30). In a 6 dram vial, compound 
3.29 (57 mg, 0.114 mmol) was dissolved in 3 mL 60% acetic acid in water (AcOH (aq)) 
and heated to 55C overnight. The resulting solution was concentrated by rotary 
evaporation with azeotropic removal of AcOH using (3x) 1 mL benzene to give a crude 
yellow oil, which was purified on a silica gel column using a gradient elution of 20-50% 
acetone in hexanes to give compound 3.30 as a white solid (34 mg, 65%). Rf = 0.51 (50% 
acetone-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.20 (m, 2H), 6.92 – 6.85 (m, 
2H), 6.53 (s, 1H), 4.49 (d, J = 2.4 Hz, 2H), 3.89 – 3.77 (m, 2H), 3.81 (s, 3H), 3.74 (s, 1H), 
3.67 – 3.59 (m, 2H), 3.45 (ddd, J = 14.0, 7.0, 4.5 Hz, 1H), 2.96 (s, 1H), 2.75 (s, 1H). 13C 
NMR (126 MHz, CDCl3) δ 159.50 , 158.31 , 145.10 (d, J = 16.2 Hz), 143.06 (d, J = 18.1 
Hz), 141.42 (d, J = 21.3 Hz), 139.41 (d, J = 14.1 Hz), 129.51 , 129.32 , 122.02 , 113.95 , 
111.13 , 73.41 , 71.74 , 70.73 , 70.62 , 55.27 , 43.03. 19F NMR (470 MHz, CDCl3) δ -
140.55 – -141.12 (m), -150.25 – -150.80 (m). DART-MS: [M-H:]+ for C19H18F4N4O5 calcd, 







methylbenzene sulfonate (3.21). This synthesis followed a previously reported 
procedure.98 Compound 3.20 (From Best Lab freezer, 160 mg, 0.85 mmol), silver(I) oxide 
(Ag2O, 295 mg, 1.28 mmol), p-toluenesulfonyl chloride (p-TsCl, 178 mg, 0.94 mmol), and 
freshly crushed potassium iodide (KI, 28 mg, 0.17 mmol added to a 50 mL flame dried 
round bottom flask, dissolved in 5 mL methylene chloride under argon, and stirred at rt 
for 3h. The crude mixture was loaded onto a 3 cm plug of silica gel, eluted with ethyl 
acetate, concentrated by rotary evaporation, and dried under high vacuum to give crude 
compound 3.21 as a pale yellow oil, which was used in the next reaction (synthesis of 
compound 3.22) without further purification.  
 
 
((2S,3S)-3-(azidomethyl)-1,4-dioxaspiro[4.4]nonan-2-yl)methanol (3.22). This 
synthesis followed a previously reported procedure.98 In a flame dried 50 mL round 
bottom flask, 8 mL N,N-dimethylformamide were added to crude compound 3.21 
(theoretical yield from previous step, 0.85 mmol) and sodium azide (NaN3, 166 mg, 2.55 
mmol), and the mixture was stirred and heated to 85C overnight. The resulting orange 
suspension was concentrated by rotary evaporation, dissolved in 100 mL ethyl acetate, 
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washed with (5x) 10 mL water, 10mL brine (saturated sodium chloride (aq)), dried over 
magnesium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. The crude residue was purified on a silica gel column using a gradient elution of 
20-60% ethyl acetate in hexanes to give compound 3.22 as a clear oil (42 mg, 23% over 
2 steps from compound 3.20). Rf = 0.48 (50% EtOAc-hexanes, KMnO4). NMR and MS 




dioxaspiro[4.4] nonane (3.23). This synthesis is a modified version of a published 
procedure.137 In a flame dried 50 mL round bottom flask, compound 3.22 (200 mg, 0.938 
mmol) was vacuum dried, backfilled with argon, and dissolved in 3 mL of N,N-
dimethylformamide. After cooling the solution to 0C with stirring, sodium hydride (NaH, 
60% dispersion in mineral oil, 41 mg, 1.032 mmol) was added in one portion and the 
mixture was stirred for 10 min before warming to rt, then stirred for another 10 min. The 
pale yellow suspension was cooled again to 0C before adding 4-methoxybenzyl chloride 
(PMBCl, 140 L, 1.032 mmol) and stirred for 10 min before warming to rt and stirring 
overnight. The resulting red suspension was quenched with 0.3 mL methanol, poured into 
20 mL water, and extracted with (2x) 15 mL methylene chloride. The combined organic 
layers were washed with (x4) 6 mL water, and dried over sodium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum to produce a pale 
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orange oil. The crude mixture was purified on a silica gel column using a gradient elution 
of 10-50% ethyl acetate in hexanes to give 3.23 as a clear oil (100 mg, 32% yield) Rf = 
0.63 (25% EtOAc-Hexanes, UV and KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.21 
(m, 2H), 6.91 – 6.85 (m, 2H), 4.49 (d, J = 1.9 Hz, 2H), 4.02 – 3.88 (m, 2H), 3.81 (s, 3H), 
3.61 (dd, J = 10.0, 5.0 Hz, 1H), 3.53 – 3.45 (m, 2H), 3.31 (dd, J = 13.0, 5.4 Hz, 1H), 1.89 




methanamine (3.24). This synthesis applies reaction conditions from a published 
procedure.140 In a 100 mL round bottom flask, compound 3.23 (100 mg, 0.30 mmol), 10% 
palladium adsorbed on carbon (Pd/C, 20 mg, 20% w/w of 3.23), and crushed sodium 
carbonate (Na2CO3, 86 mg, 0.81 mmol) were added, and the tube was flushed with argon. 
Ethyl acetate (5 mL) was added, vigorous stirring begun, and the atmosphere was 
replaced with H2. After 2 h, the mixture was filtered through celite, concentrated by rotary 
evaporation, and purified on a silica gel column using a gradient elution of 5-15% 
methanol in methylene chloride to give 3.24 as a clear oil (89 mg, 97% yield). Rf = 0.31 
(10% MeOH-CH2Cl2, UV, Ninhydrin: purple). 1H NMR (500 MHz, CDCl3) δ 7.25 – 7.21 
(m, 2H), 6.91 – 6.84 (m, 2H), 4.55 – 4.46 (m, 2H), 3.88 (dt, J = 7.5, 5.5 Hz, 1H), 3.81 (s, 
3H), 3.83 – 3.73 (m, 1H), 3.60 (dd, J = 10.0, 5.6 Hz, 1H), 3.50 (dd, J = 10.0, 5.3 Hz, 1H), 
2.86 (d, J = 26.3 Hz, 2H), 1.93 – 1.60 (m, 8H). 13C NMR (126 MHz, CDCl3) δ 165.17 , 
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159.25 , 129.33 , 113.79 , 77.18 , 73.20 , 70.53 , 55.26 , 44.23 , 37.40 , 37.36 , 23.57 , 




[4.4]nonan-2-yl)methyl)benzamide (3.25). In an oven dried 100 mL round bottom flask 
under argon, compound 3.24 (89 mg, 0.290 mmol), 4-benzoylbenzoic acid (4-BBA, 98 
mg, 0.434), and hydroxybenzotriazole (HOBt, 66 mg, 0.434 mmol) were dissolved in 5 
mL N,N-dimethylformamide. After stirring and cooling to 0C, 1-ethyl-3-(3- EDCI (75 mg, 
0.434 mmol) was added in one portion, followed by DIEA (71 L, 0.434 mmol). The 
mixture was allowed to warm to rt and was stirred for 2 h. The resulting solution was 
poured into 30 mL water, and the aqueous layer was extracted with (3x) 12 mL ethyl 
acetate. The combined organic layers were washed with (5x) 4 mL water, 6 mL brine 
(saturated sodium chloride (aq)), then dried over sodium sulfate, filtered, concentrated by 
rotary evaporation, and dried under high vacuum while protected from light. The crude 
yellow oil was purified on a silica gel column using a gradient elution of 30-50% ethyl 
acetate in hexanes to give 3.25 as a clear oil (122 mg, 81% yield), which was handled 
and stored with care to avoid light. Rf = 0.48 (40% acetone-hexanes, UV). 1H NMR (500 
MHz, CDCl3) δ 7.85 – 7.74 (m, 6H), 7.65 – 7.57 (m, 1H), 7.53 – 7.46 (m, 2H), 7.26 – 7.20 
(m, 2H), 6.87 – 6.83 (m, 2H), 6.82 (s, 1H), 4.53 (q, J = 1.6 Hz, 2H), 4.04 – 3.91 (m, 2H), 
3.86 – 3.73 (m, 1H), 3.76 (s, 3H), 3.73 – 3.60 (m, 2H), 3.55 (dd, J = 9.9, 6.1 Hz, 1H), 1.92 
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– 1.73 (m, 4H), 1.76 – 1.61 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 195.89 , 166.67 , 
159.38 , 140.00 , 137.50 , 137.04 , 132.83 , 130.08 , 130.03 , 129.44 , 129.43 , 128.42 , 
126.90 , 119.45 , 113.88 , 77.77 , 77.68 , 73.48 , 70.05 , 55.22 , 41.89 , 37.26 , 37.21 , 




benzamide (3.26). In a 6 dram vial, compound 3.25 (120 mg, 0.232 mmol) was dissolved 
in 3 mL tetrahydrofuran, and with stirring 3 mL 1N hydrochloric acid was added (HCl (aq). 
The reaction was stirred for 22h, quenched with 8 mL saturated sodium bicarbonate 
(NaHCO3 (aq)), concentrated under rotary evaporation, diluted with 5 mL water, and 
extracted with (3x) 15 mL methylene chloride. The combined organic layers were dried 
over magnesium sulfate, filtered, concentrated by rotary evaporation, and the crude white 
powder was purified on a silica gel column using a gradient elution of 0-8% methanol in 
methylene chloride to give compound 3.26 as a white solid (91 mg, 86%). Rf = 0.38 (50% 
acetone-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.88 – 7.76 (m, 6H), 7.62 (ddt, J = 
7.9, 7.0, 1.3 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.29 – 7.21 (m, 2H), 6.92 – 6.86 (m, 2H), 6.79 
(d, J = 6.8 Hz, 1H), 4.50 (q, J = 2.8 Hz, 2H), 3.87 (s, 1H), 3.92 – 3.81 (m, 1H), 3.80 (s, 
3H), 3.84 – 3.74 (m, 1H), 3.65 (dd, J = 4.9, 1.4 Hz, 2H), 3.53 – 3.44 (m, 1H), 3.19 (d, J = 
4.8 Hz, 1H), 2.93 (d, J = 5.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 167.43 , 140.23 , 
137.23 , 137.00 , 132.87 , 130.11 , 130.06 , 129.55 , 128.43 , 126.95 , 113.97 , 73.46 , 
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71.77 , 71.36 , 70.73 , 59.00 , 55.28 , 43.21. DART-MS: [M+H]+ for C26H27NO6 calcd, 
450.1911; detected, 450.1928. 
 
 
PMB-protected DAG-benzophenone-azido tail probe precursor (3.27). In a 
flame dried 100 mL round bottom flask under argon, compound 3.26 (91 mg, 0.202 mmol) 
was dissolved in 5 mL N,N-dimethylformamide and cooled to 0C. Sodium hydride (NaH, 
60% dispersion in paraffin wax, 32 mg, 0.808 mmol) was added in one portion to the 
stirring solution, and the white suspension was stirred for 15 min, then warmed to rt and 
stirred for another 15 min. After cooling back to 0C, a solution of previously synthesized 
compound 3.19 (223 mg, 0.808 mmol) and tetrabutylammonium iodide (TBAI, 7 mg, 
0.020 mmol) in 1 mL N,N-dimethylformamide was added dropwise. The reaction was 
stirred for 5 min, the allowed to warm to rt and stirred overnight. The resulting white 
suspension was quenched with 1 mL methanol and stirred for 1 h, then poured into 30 
mL water, and the organic layer was extracted with (3x) 15 mL ethyl acetate. Hexanes (1 
mL) was added with intermittent swirling to break up an emulsion. The combined organic 
layers were washed (5x) with 5 mL water, then 5 mL brine (saturated sodium chloride 
(aq)), then dried over magnesium sulfate, filtered, concentrated by rotary evaporation, 
and dried under high vacuum to give a crude yellow oil, which was purified on a silica gel 
column using a gradient elution of 15-50% ethyl acetate in hexanes to give compound 
3.27 as a clear oil (40 mg, 24%). Rf = 0.52 (35% EtOAc-hexanes, UV). 1H NMR (300 
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MHz, CDCl3) δ 7.84 – 7.76 (m, 6H), 7.66 – 7.58 (m, 1H), 7.54 – 7.45 (m, 2H), 7.25 (d, J 
= 8.6 Hz, 2H), 7.15 (t, J = 5.4 Hz, 1H), 6.93 – 6.78 (m, 2H), 4.49 (t, 2H), 3.95 – 3.83 (m, 
1H), 3.78 (s, 3H), 3.77 – 3.38 (m, 5H), 3.24 (t, J = 6.9 Hz, 4H), 1.56 (h, J = 7.2 Hz, 4H), 
1.23 (d, J = 7.3 Hz, 36H). 13C NMR (75 MHz, CDCl3) δ 195.89 , 166.31 , 159.29 , 139.78 
, 138.01 , 137.11 , 132.78 , 130.04 , 130.01 , 129.98 , 129.37 , 128.40 , 126.82 , 113.80 
, 80.66 , 76.43 , 73.31 , 71.35 , 70.73 , 68.71 , 55.23 , 51.46 , 40.19 , 30.22 , 30.03 , 29.57 
, 29.52 , 29.48 , 29.46 , 29.13 , 28.81 , 26.69 , 26.21 , 26.12. DART-MS: [M+H]+ for 
C48H69N7O6 calcd, 840.5382; detected, 840.5005. 
 
 
DAG-benzophenone-azido tail probe (3.1) In a 6 dram vial, compound 3.27 (20 
mg, 0.024 mmol) was dissolved in 3 mL of methylene chloride, and 2,3-Dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ, 14 mg, 0.060 mmol) was added, followed by 170L 
water. The orange biphasic solution was stirred vigorously for 6 h at rt while protected 
from light. The resulting mixture was diluted with 8 mL methylene chloride, washed with 
(2x) 2 mL saturated sodium bicarbonate (NaHCO3 (aq)), (4x) 2 mL water, and then 2 mL 
brine (saturated sodium chloride (aq)). The organic layer was dried over sodium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to give a crude 
clear oil, which was purified on a silica gel column using a gradient elution of 30-50% 
ethyl acetate in hexanes to give compound 3.1 as a clear oil (17 mg, >99%). Rf = 0.43 
(50% EtOAc-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.86 (q, J = 8.3 Hz, 4H), 7.83 – 
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7.77 (m, 2H), 7.64 – 7.59 (m, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.15 (dd, J = 6.4, 4.5 Hz, 1H), 
3.97 (dt, J = 14.1, 6.0 Hz, 1H), 3.92 – 3.84 (m, 1H), 3.80 – 3.71 (m, 2H), 3.63 (ddt, J = 
11.4, 9.2, 6.7 Hz, 2H), 3.59 – 3.52 (m, 3H), 3.49 (dq, J = 14.0, 4.7 Hz, 1H), 3.24 (td, J = 
7.0, 1.2 Hz, 4H), 2.56 – 2.23 (m, 1H), 1.72 – 1.52 (m, 4H), 1.38 – 1.15 (m, 32H). 13C NMR 
(126 MHz, CDCl3) δ 195.85 , 166.36 , 139.97 , 137.85 , 137.06 , 132.82 , 130.09 , 130.04 
, 128.41 , 126.83 , 109.99 , 80.25 , 77.47 , 70.88 , 70.74 , 61.03 , 51.46 , 39.43 , 30.18 , 
30.04 , 29.51 , 29.50 , 29.43 , 29.41 , 29.10 , 28.80 , 26.67 , 26.18 , 26.14. DART-MS: 
[M+H]+ for C40H61N7O5 calcd, 720.4807; detected, 720.4719. 
 
 
Potassium 2,2-dimethyl-1,3-dioxolane-4-carboxylate (3.33). A previously 
published procedure was modified for this synthesis.186 In a 250 mL round bottom flask, 
commercially available compound 3.32 (solketal, 1.234 g, 9.34 mmol) was dissolved in 
20 mL water, and cooled to 0C. A 12 mL aqueous solution of potassium hydroxide (KOH, 
1.047 g, 18.6 mmol) was added, and then a 35 mL aqueous solution of potassium 
permanganate (KMnO4, 2.213 g, 14.0 mmol) was added portionwise, maintaining the 
reaction at <10C. The dark purple solution was allowed to slowly warm to rt and was 
stirred overnight, then cooled to 0C, quenched with 8 mL 10% sodium sulfite (Na2SO3 
(aq)) and stirred for 1.5 h, then filtered through a pad of celite. The filtrate was neutralized 
to pH = 7-8 with 1.5 mL of 10% sulfuric acid (H2SO4 (aq)), then concentrated by rotary 
evaporation to give a crude white crystalline solid, which was purified by resuspending in 
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boiling 99% ethanol, filtering off the solid K2SO4, concentrating by rotary evaporation, and 
drying under high vacuum to give compound 3.33 as white crystals (1.392 g, 90%). To 
confirm the product by MS and NMR, a sample of the product was dissolved in 0.8 mL 
4N HCl, extracted with 7 mL EtOAc, dried over Na2SO4, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. DART-MS: [M+H]+ for C6H10O4 
calcd,147.0652; detected, 147.0668. NMR characterization data for the corresponding 




Formation of the acid chloride intermediate was performed according to a previously 
published procedure.186 In an oven dried 50 mL round bottom flask under N2, compound 
3.33 (700 mg, 3.80 mmol) was suspended in 10 mL diethyl ether with stirring, cooled to 
0C, and pyridine (30 L, catalytic) was added, followed by oxalyl chloride ((COCl)2, 488 
L, 5.70 mmol), which was added dropwise. The solution was stirred for 5 min, then 
allowed to warm to rt and stir overnight. The resulting white suspension was filtered 
through an oven dried fritted glass funnel apparatus into a flame dried 50 mL round bottom 
flask under N2, concentrated under reduced pressure (<25C), and backfilled with N2. The 
crude yellow acid chloride oil was used in the next step without further purification. 
A modified version of a published procedure was used in the next step.188 In a 100 
mL oven dried round bottom flask under N2, N,O-dimethylhydroxylamine hydrochloride 
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(DMHA, 371 mg, 3.80 mmol) and N,N-dimethylaminopyridine (DMAP, 69 mg, 0.57 mmol) 
were dissolved in 10 mL methylene chloride. The clear solution was cooled to 0C, 
triethylamine (TEA, 1.05 mL, 7.60 mmol) was added in three portions, and the mixture 
was stirred for 15 min as a white precipitate formed. Then, the acid chloride intermediate 
from the first step was dissolved in 10 mL methylene chloride and added dropwise to the 
stirring white DMHA suspension. The mixture was stirred for 10 min at 0C, 30 min at rt, 
then filtered and 40 mL water were added. The organic layer was separated, the 
remaining aqueous layer was extracted with (2x) 20 mL methylene chloride, and the 
combined organic layers were dried with sodium sulfate, filtered, concentrated by rotary 
evaporation (<30C), and then purified on a silica gel column using a gradient elution of 
40-80% ethyl acetate in hexanes to give compound 3.34 as a clear oil (407 mg, 57% 
yield). Rf = 0.52 (70% EtOAc-hexanes, CeMo). NMR and MS characterization data  
matched previously reports.188 
 
 
2,3-Dihydroxy-N-methoxy-N-methylpropanamide (3.35). A modified published 
procedure was followed.189 In a 25 mL round bottom flask, compound 3.34 (407 mg, 2.15 
mmol) was dissolved in 40% acetic acid in water (AcOH (aq)). The mixture was stirred 
and warmed to 35C for 9.5 h, then concentrated by rotary evaporation using (3x) 1 mL 
toluene to azeotropically remove AcOH. The crude pale yellow oil was purified on a silica 
gel column using a gradient elution of 0-10% methanol in methylene chloride to give 
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compound 3.35 as a clear oi (318 mg, 99% yield). Rf = 0.33 (10% MeOH-CH2Cl2, KMnO4). 
DART-MS: [M+H]+ for C5H11NO4 calcd, 150.0761; detected, 150.0786. NMR 
characterization data matched previous reports.189 
 
 
2,3-Bis(hexadecyloxy)-N-methoxy-N-methylpropanamide (3.58). Reaction 
conditions from a published procedure were followed.136 In a 50 mL flame dried round 
bottom flask under argon, sodium hydride (NaH, 60% dispersion in paraffin wax, 171 mg, 
4.27 mmol) was suspended in 5 mL N,N-dimethylformamide, and cooled to 0C. A 
solution of compound 3.35 (106 mg, 0.711 mmol) in 5 mL N,N-dimethylformamide was 
added slowly, and the mixture was stirred for 30 min. Then, at 0C, tetrabutylammonium 
iodide (TBAI, 26 mg, 0.071 mmol) was added in one portion, followed by dropwise 
addition of 1-bromohexadecane (1-BHD, 870 L, 2.85 mmol). The mixture was allowed 
to warm to rt and stir overnight, and was then quenched with 2 mL methanol, diluted with 
150 mL ethyl acetate, washed with 150 mL brine (saturared sodium chloride (aq)), 150 
mL water, and 150 mL brine. The organic layer was dried over magnesium sulfate, 
filtered, concentrated by rotary evaportation, dried under high vacuum, and the oily white 
solid crude was purified on a silica gel column using a gradient elution of 0-7% methanol 
in methylene chloride to give compound 3.58 as a white solid (111 mg, 26% yield). Rf = 
0.56 (25% EtOAc-hexanes, CeMo). 1H NMR (500 MHz, CDCl3) δ 4.48 (s, 1H), 3.72 (s, 
3H), 3.65 (d, J = 5.8 Hz, 2H), 3.55 – 3.37 (m, 4H), 3.22 (s, 3H), 1.64 – 1.48 (m, 4H), 1.24 
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(s, 52H), 0.87 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 76.04 , 71.85 , 70.90 , 
70.53 , 63.06 , 61.48 , 32.80 , 31.91 , 29.72 , 29.69 , 29.67 , 29.64 , 29.62 , 29.60 , 29.58 
, 29.46 , 29.45 , 29.42 , 29.35 , 26.04 , 25.98 , 25.73 , 22.67 , 14.09. DART-MS: [M+H]+ 
for C37H75NO4 calcd, 598.5769; detected, 598.6045. 
 
 
(5-(Trimethylsilyl)pent-4-yn-1-yl)magnesium chloride (3.57). A published 
procedure was followed.129 In a flame dried 100 mL round bottom flask, freshly crushed 
magnesium turnings (Mg, 111 mg, 4.56 mmol) were dried by heating at 110C under high 
vacuum for 12 h, then backfilled with argon and covered with 4 mL tetrahydrofuran. The 
system was heated to 50C, then 2 drops of 1,2-dibromoethane were added. After 10 min 
to no effect, a single crystal of iodine was added, and after 15 min of stirring, a glass rod 
was used to crush the Mg and initiate an exothermic reaction. After 2 h, a solution of 
commercially available compound 3.56 (715 L, 4.0 mmol) and 1,2-dibromoethane (1 
drop, ~75 L) in 4 mL tetrahydrofuran was added dropwise, and the mixture was stirred 
vigorously at 50C overnight. The resulting yellow crude solution of compound 3.57 
(theoretically 0.44 M) was added to the next reaction (synthesis of compounds 3.52 and 




1,2-Bis(hexadecyloxy)-8-(trimethylsilyl)oct-7-yn-3-one (3.59). To a stirring 
solution of compound 3.58 (111 mg, 0.186 mmol) in 1.5 mL tetrahydrofuran in a 6 dram 
vial under argon at -10C, 0.8 mL of a compound 3.57 solution (theoretically 0.44 M, 0.352 
mmol from previous step) was added slowly. The cloudy suspension was stirred for 1 h 
at -15 C, then 45 min at rt before cooling ot 0C, adding 0.5 mL saturated ammonium 
chloride (NH4Cl (aq)), pouring into 5 mL water and extracting with (2x) 40 mL diethyl ether. 
The combined aqueous layers were washed with 10 mL brine (saturated sodium chloride 
(aq)), dried over sodium sulfate, filtered, concentrated by rotary evaporation, and dried 
under high vacuum to produce a crude white foam. This residue was purified on a silica 
gel column using 2.5-40% ethyl acetate in hexanes to recover starting material 3.58 (91 
mg, 82% RSM), and compound 3.59 as a clear oil (18 mg, 14% yield). Rf = 0.50 (10% 
EtOAc-hexanes, 2,4-DNP: red). 1H NMR (500 MHz, CDCl3) δ 3.83 (dd, J = 5.2, 4.0 Hz, 
1H), 3.69 – 3.59 (m, 2H), 3.49 (td, J = 6.7, 1.0 Hz, 2H), 3.46 – 3.35 (m, 2H), 2.70 (td, J = 
7.2, 2.9 Hz, 2H), 2.33 – 2.19 (m, 2H), 1.78 (p, J = 7.1 Hz, 2H), 1.60 (dt, J = 8.0, 6.5 Hz, 
2H), 1.57 – 1.48 (m, 2H), 1.25 (d, J = 2.4 Hz, 52H), 0.91 – 0.84 (m, 6H), 0.14 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 211.45 , 106.55 , 85.04 , 71.85 , 71.27 , 71.09 , 37.80 , 31.91 , 
30.30 , 29.82 , 29.69 , 29.67 , 29.65 , 29.62 , 29.59 , 29.47 , 29.45 , 29.44 , 29.35 , 26.05 




TMS-protected diazirine-alkyne-ether tails-generic probe precursor (3.60).  
Reaction conditions were followed from a published synthesis.174 In a 6 dram vial, 
compound 3.59 (18 mg, 0.027 mmol) was dissolved in 2 mL 7N ammonia (saturated) in 
methanol (NH3(MeOH)), and the solution was cooled to 0C and stirred for 75 min before 
adding in 1 portion hydroxylamine-O-sulfonic acid (HOSA, 4 mg, 0.035 mmol). The 
opaque white suspension was cooled to rt and stirred overnight. The resulting suspension 
was purged of NH3 with argon at 0C for 30 min, filtered through celite, rinsed with 
methanol, concentrated by rotary evaporation, and dried under high vacuum to give a 
clear crude oil. This residue was then treated with 0.5 mL triethylamine (TEA) and then 
concentrated again by rotary evaporation. The residue was dissolved in 2 mL methanol, 
5.6L of TEA were added, and then, with stirring at rt, iodine (I2) was added in 1 mg 
portions until the brown color persisted in solution for >5 min. The solution was 
concentrated by rotary evaporation, and the crude residue was purified on a silica gel 
column using a gradient elution of 0-1% acetone in chloroform to give a mixture of 3.60 
with starting material 3.59 as a yellow oil (2.5 mg). Rf = 0.95 (3% acetone-chloroform, 





11-Azidoundecan-1-ol (3.17). A published procedure was followed.190 In an oven 
dried 50 mL round bottom flask under argon, commercially available 11-bromoundecan-
1-ol (3.16, 1.00 g, 3.98 mmol) and sodium azide (NaN3, 388 mg, 5.98 mmol) were 
suspended in 15 mL dimethylsulfoxide (DMSO), and stirred for 24 h at rt. The white 
suspension was cooled to 0C, and quenched dropwise with 20 mL water, extracted with 
(3x) 15 mL hexanes, and then the combined organic layers were dried over magnesium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum to give 
compound 3.17 as a clear oil (838 mg, 99%). Rf = 0.50 (25% EtOAc-hexanes, KMnO4). 
DART-MS: [M-N2+H]+ for C11H23N3O calcd, 186.1852; detected, 186.1860. NMR data 
matched previous reports.191  
 
 
11-Azidoundecyl-1-methanesulfonate (3.18). In an oven dried 50 mL round 
bottom flask under N2, triethylamine (1.30 mL, 8.71 mmol) was added to a solution of 
compound 3.17 (1.69 g, 7.92 mmol) stirring in 20 mL methylene chloride at -15C. 
Methanesulfonyl chloride (MsCl, 674 L, 8.71 mmol) was added slowly, and the solution 
was stirred for 15 min before warming to rt and stirring for 100 min. The reaction was then 
quenched with 10 mL cold water, stirred for 10 min, and poured into 10 mL water. The 
organic layer was separated, and the remaining aqueous later was extracted with (2x) 20 
mL methylene chloride. The combined organic layers were dried over magnesium sulfate, 
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filtered, concentrated by rotary evaporation, and dried under high vacuum to give 3.18 as 
a pale yellow oil (2.31 g, >99% yield). Rf = 0.43 (25% EtOAc-hexanes, KMnO4). DART-
MS: [M-N2+H]+ for C12H25N3O3S calcd, 264.1628; detected, 264.1653. NMR data 
matches previous reports.192 
 
 
1-Azido-11-bromoundecane (3.19). In an oven dried 100 mL 3 neck flask under 
argon equipped with a condenser, potassium bromide (KBr, 902 mg, 7.58 mmol) and 18-
crown-6 (18-C-6, 1.00 g, 3.79 mmol) were dissolved in 15 mL tetrahydrofuran. A 5 mL 
solution of compound 3.18 (1.84 mL, 6.31 mmol) was added, and the mixture was heated 
to reflux with stirring. After 3 h, the gummy mixture was injected with 10 mL N,N-
dimethylformamide, and was heated at 80C for 3 h, then cooled to rt, diluted with 100 
mL ethyl acetate, washed with (4x) 20 mL water, then 20 mL brine (saturated sodium 
chloride (aq)), dried over sodium sulfate, filtered, concentrated by rotary evaporation, and 
dried under high vacuum to give a crude yellow oil, which was purified on a silica gel 
column using 10% ethyl acetate in hexanes to give compound 3.19 as a pale yellow oil 
(1.70 g, 97% yield). Rf = 0.70 (10% EtOAc-hexanes, KMnO4). DART-MS: [M-N2+H]+ for 






1-Azido-11-bromoundecane (3.19). Hydrazoic acid (HN3) solution was made 
according to a published procedure194 fresh with caution in a fume hood by the following 
method: In a 6 dram vial, sodium azide (NaN3, 500 mg, 2.624 mmol) was made into a 
paste using 0.5 mL warm (~60C) water, then 3.0 mL methylene chloride were added, 
and the biphasic suspension was cooled to 0C. Concentrated sulfuric acid (H2SO4, 205 
L) was added dropwise. The organic layer was pipetted onto a layer of crushed sodium 
sulfate prepared in an oven dried 5 mL round bottom flask under argon, and the solution 
was capped with a glass stopper until needed. Following a published analytical 
protocol,195 300 L of the HN3 solution were mixed with 100 L of 1% phenolphthalein in 
50% aqueous ethanol and were titrated with 0.1 N sodium hydroxide (NaOH (aq)), 
indicating a concentration of 1.69 N HN3 in methylene chloride. 
A modified published procedure was followed.196 In an oven dried 6 dram vial 
under N2, compound 3.16 (330 mg, 1.31 mmol) was dissolved in 0.7 mL tetrahydrofuran, 
followed by 1.07 mL of the HN3 solution (1.57 mmol). The mixture was cooled to 0C, and 
a 0.7 mL solution of diisopropylazidodicarboxylate (DIAD, 285 L, 1.45 mmol) in 
tetrahydrofuran were added, followed by dropwise addition of a 1.3 mL solution of 1,2-
bis(diphenylphosphino)ethane (DPPE, 314 mg, 0.79 mmol) in tetrahydrofuran. The 
bubbling orange solution was stirred for 10 min at 0C, and then the resulting white 
suspension was warmed to rt and stirred for 1 h. The reaction was filtered, rinsed with 
diethyl ether, concentrated by rotary evaporation, and dried under high vacuum, and then 
the crude reside was purified on a silica gel column using a gradient elution of 10-40% 
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ethyl acetate in hexanes to give compound 3.19 as a clear oil (155 mg, 43% yield). Rf = 
0.70 (10% EtOAc-hexanes, KMnO4). NMR data matched the same compound 3.19 made 
by the potassium bromide substitution method mentioned above. 
  
 
Azido tail-Weinreb amide generic probe precursor (3.36). Reaction conditions 
from a published procedure were used.136 In a flame dried 10 mL round bottom flask 
under N2, sodium hydride (NaH, 60% dispersion in paraffin wax, 22 mg, 0.561 mmol) was 
suspended in 2 mL N,N-dimethylformamide and cooled to 0C, then a 2 mL solution of 
compound 3.35 (33 mg, 0.224 mmol) was added slowly to the stirring suspension. The 
resulting opaque yellow suspension was stirred for 10 min, then warmed to rt and stirred 
for 15 min before cooling back to 0C, adding tetrabutylammonium iodide (TBAI, 8 mg, 
0.022 mmol) in a single portion, and finally a solution of previously synthesized compound 
3.19 (155 mg, 0.561 mmol) in 1 mL N,N-dimethylformamide was added dropwise. The 
reaction was stirred for 5 min, then allowed to warm to rt and stir for 6h. The resulting 
white suspension was quenched with 0.5 mL methanol, then poured into 7 mL water, and 
75 mL ethyl acetate was added. The organic layer was washed with (3x) 7 mL water, then 
7 mL brine, and then dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum to give a crude yellow oil, which was purified 
on a silica gel column using a gradient elution of 10-40% ethyl acetate in hexanes to give 
compound 3.36 as a clear oil (32 mg, 26%). Traces of single-tailed byproduct were also 
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detected spectroscopically but not isolated. Rf = 0.38 (25% EtOAc-hexanes, CeMo). 1H 
NMR (300 MHz, CDCl3) δ 4.47 (s, 1H), 3.72 (s, 3H), 3.65 (dd, J = 5.8, 0.6 Hz, 2H), 3.57 
– 3.36 (m, 4H), 3.29 – 3.19 (m, 7H), 1.68 – 1.46 (m, 4H), 1.40 – 1.19 (m, 32H). 13C NMR 
(126 MHz, CDCl3) δ 76.06 , 71.83 , 70.89 , 70.51 , 63.03 , 61.50 , 51.46 , 32.77 , 32.23 , 
29.71 , 29.56 , 29.54 , 29.49 , 29.46 , 29.44 , 29.41 , 29.41 , 29.12 , 29.11 , 28.81 , 26.69 
, 26.01 , 25.96 , 25.71. DART-MS: [M+H]+ for C27H53N7O4 calcd, 540.4232; detected, 
540.4210.     
 
 
Azido tail-ketone generic probe precursor (3.39). The reaction188 and quench197 
conditions used were from published procedures. In an oven dried 1 dram vial under 
argon, compound 3.36 (42 mg, 0.078 mmol) was dissolved in 1 mL tetrahydrofuran and 
cooled to -15C. Methyl magnesium bromide (156 L, 0.156 mmol, as a 1M solution in 
tetrahydrofuran) was added dropwise, and the solution was stirred at -15C for 4 h, then 
quenched with 0.5 mL saturated ammonium chloride (NH4Cl (aq)), diluted with 2 mL 
water, extracted with (2x) 4 mL diethyl ether, and the combined organic layers were dried 
over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. The crude residue was purified on a silica gel column using a gradient elution of 
5-15% ethyl acetate in hexanes to give compound 3.39 as a clear oil (28 mg, 73% yield). 
Rf = 0.76 (25% EtOAc-hexanes, KMnO4). 1H NMR (500 MHz, CDCl3) δ 3.80 (dd, J = 5.2, 
4.1 Hz, 1H), 3.68 – 3.60 (m, 2H), 3.53 – 3.46 (m, 2H), 3.49 – 3.35 (m, 2H), 3.25 (t, J = 7.0 
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Hz, 4H), 2.22 (s, 3H), 1.66 – 1.51 (m, 6H), 1.38 – 1.31 (m, 4H), 1.28 (h, J = 5.1, 4.7 Hz, 
26H). 13C NMR (126 MHz, CDCl3) δ 210.40 , 85.18 , 71.85 , 71.16 , 70.98 , 51.47 , 29.77 
, 29.51 , 29.45 , 29.44 , 29.39 , 29.38 , 29.13 , 28.82 , 26.90 , 26.70 , 26.04 , 26.02. DART-
MS: [M+H]+ for C26H50N6O3 calcd, 495.4017; detected, 495.4038. 
 
 
Diazirine-azido tail generic probe (3.3). Reaction conditions from a reported 
procedure were followed.174 In a 6 dram vial, compound 3.39 (28 mg, 0.057 mmol) was 
dissolved in 1 mL 7N ammonia (saturated) in methanol (NH3(MeOH)), and the solution 
was cooled to 0C and stirred vigorously for 1.5 h before adding in 5 portions of 
hydroxylamine-O-sulfonic acid (HOSA, 10 mg, 0.085 mmol). The opaque white 
suspension was stirred for 1 h at 0C, then warmed to rt and stirred for 2.5 h. The resulting 
white suspension was purged of NH3 with argon at 0C for 30 min, filtered through celite, 
concentrated by rotary evaporation, then treated with 0.5 mL triethylamine (TEA) and 
concentrated again by rotary evaporation. The residue was dissolved in 1 mL methanol, 
TEA (19 L, 0.133 mmol) was added, and then, with stirring at rt, iodine (I2) was added in 
2 mg portions until the brown color persisted in solution for >5 min. The solution was 
concentrated by rotary evaporation, mixed with 3 mL water, and extracted with (3x) 3 mL 
diethyl ether. The combined organic layers were washed with 2 mL sodium thiosulfate, 
then 1 mL water, and then dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude clear oil was purified on a silica gel 
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column using a gradient elution of 0-2% methanol in methylene chloride to give compound 
3.3 as a clear oil, which was handled and stored with care to protect from light (6.5 mg, 
23%). Rf = 0.67 (20% acetone-hexanes, KMnO4). 1H NMR (500 MHz, CDCl3) δ 3.69 (dt, 
J = 9.1, 6.7 Hz, 1H), 3.48 – 3.33 (m, 5H), 3.25 (t, J = 7.0 Hz, 4H), 2.99 (dd, J = 6.3, 5.5 
Hz, 1H), 1.64 – 1.51 (m, 6H), 1.40 – 1.21 (m, 30H), 1.03 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 79.42 , 71.78 , 70.34 , 69.63 , 51.47 , 29.76 , 29.60 , 29.53 , 29.46 , 29.45 , 
29.41 , 29.13 , 28.82 , 26.70 , 26.11 , 26.05 , 16.76. DART-MS: [M-N2+H]+ for C26H50N8O2 




carboxylic acid (3.42). Reaction conditions from a published method were applied.198 
This reaction is an explosion hazard at scales >1 mmol. Add sodium chlorite and bleach 
solutions slowly. In a 50 mL 3 neck flask equipped with a condenser, previously 
synthesized compound 2.61 (815 mg, 2.89 mmol) was dissolved in 14.5 mL acetonitrile, 
followed by 10.8 mL of phosphate buffer (0.67M, pH 6.7, 43.5 mol% Na2HPO4, 56.5 mol% 
NaH2PO4). 2,2,6,6-Tetramethylpiperidinyloxy (TEMPO, 45 mg, 0.289 mmol) was added, 
and the reaction was warmed to 35C. A solution of sodium chlorite (NaClO2, 936 mg, 
5.77 mmol) in 2.89 mL water was added in two portions with stirring, and then 1.45 mL of 
a sodium hypochlorite solution (NaClO, from a freshly made 2 mol% stock solution made 
by diluting 0.675 mL of 8.25% Clorox concentrated bleach to 20 mL with water) was added 
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dropwise. The resulting brown solution was carefully maintained at 35C with stirring, and 
additional NaClO stock solution was added dropwise whenever the brown color faded, 
totaling 7 mL over 4 h. After cooling to rt, 6 mL 1N sodium hydroxide (NaOH (aq)) were 
added to adjust the reaction to pH = 8. Then, 10 mL cold 10% sodium sulfite (Na2SO3 
(aq)) were added and the yellow solution was stirred until the color was eliminated (20 
min). The aqueous layer was washed with (3x) 12 mL methyl t-butyl ether (MTBE) to 
remove unreacted compound 2.61, and was then acidified to pH = 1-2 with 1N 
hydrochloric acid (HCl (aq)), indicated by litmus paper monitoring and by the formation of 
white precipitate. The resulting suspension was extracted with (3x) 30 mL with ethyl 
acetate, and the combined organic layers were dried over magnesium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum to give compound 3.42 
as a pale yellow oil (661 mg, 77%). TLC analysis with BCG stain gave a yellow spot. This 
compound is mentioned in a previous publication,199 but without characterization data. 1H 
NMR (500 MHz, CDCl3) δ 8.77 (s, 1H), 7.27 (d, J = 8.6 Hz, 2H), 6.91 – 6.85 (m, 2H), 4.57 
(s, 2H), 4.42 (d, J = 7.7 Hz, 1H), 4.35 (ddd, J = 8.0, 5.1, 3.8 Hz, 1H), 3.80 (d, J = 1.2 Hz, 
3H), 3.78 – 3.65 (m, 2H), 1.48 (d, J = 17.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 163.62 
, 159.36 , 131.81 , 129.43 , 113.86 , 112.04 , 77.98 , 77.95 , 77.88 , 75.45 , 73.41 , 69.34 







dioxolane-4-carboxamide (3.43). A modified published procedure was followed.200 In an 
oven dried 250 mL round bottom flask under argon, compound 3.42 (610 mg, 2.06 mmol), 
N,O-dimethylhydroxylamine hydrochloride (DMHA, 301 mg, 3.09 mmol) and 
hydroxybenzotriazole (HOBt, 473 mg, 3.09 mmol) were dissolved in 15 mL N,N-
dimethylformamide. After stirring and cooling to 0C, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 531 mg, 3.09 mmol) was added 
in one portion, followed by diisopropylethylamine (DIEA, 1.01 mL, 6.18 mmol). The 
mixture was allowed to warm to rt and was stirred for 2 h. The resulting solution was 
poured into 90 mL water, and the aqueous layer was extracted with (4x) 30 mL ethyl 
acetate. The combined organic layers were washed with 10 mL brine (saturated sodium 
chloride (aq)), then dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude yellow oil was purified on a silica 
gel column using a gradient elution of 30-50% ethyl acetate in hexanes to give 3.43 as a 
clear oil (672 mg, 96% yield). Rf = 0.48 (50% EtOAc-hexanes, UV, KMnO4) 
Characterization data was reported in a previous publication.199 However, the reported 
NMR data differs slightly from what was observed here. Also, the calculated and reported 
exact masses for [M+H]+ = 362.1580 and 362.1581, respectively, are not consistent with 
what was observed here due to a mass difference of ~13, even though the reported 
molecular formula of C17H25NO6 matches that used in this work.  
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For 3.43: 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.21 (m, 2H), 6.93 – 6.83 (m, 2H), 
4.69 (s, 1H), 4.59 (s, 1H), 4.53 (d, J = 3.5 Hz, 2H), 3.80 (s, 3H), 3.66 (s, 3H), 3.72 – 3.58 
(m, 2H), 3.20 (s, 3H), 1.51 – 1.43 (m, 6H). 13C NMR (126 MHz, Methanol-d4) δ 159.46 , 
131.28 , 129.93 , 129.15 , 113.49 , 113.31 , 111.07 , 78.09 , 74.16 , 72.71 , 69.23 , 60.78 





methylbutanamide (3.44). In a 50 mL round bottom flask, compound 3.44 (670 mg, 
1.974 mmol) was dissolved in 15 mL 40% acetic acid in water (AcOH (aq)), and heated 
to 50C with stirring for 4 h. The reaction was concentrated by rotary evaporation using 
azeotropic removal of AcOH with (3x) 3 mL toluene. The resulting crude was purified on 
a silica gel column using a gradient elution of 20-70% acetone in hexanes, giving 
compound 3.44 as an opaque oil (380 mg, 64% yield). Starting material 3.43 was also 
recovered (191 mg, 29% RSM). Rf(3.44) = 0.29 (50% acetone-hexanes, UV, KMnO4). 1H 
NMR (500 MHz, Methanol-d4) δ 7.29 – 7.23 (m, 2H), 6.91 – 6.85 (m, 2H), 4.55 (s, 1H), 
4.47 (s, 2H), 4.05 (dt, J = 6.6, 3.4 Hz, 1H), 3.77 (d, J = 1.0 Hz, 3H), 3.70 (d, J = 1.2 Hz, 
3H), 3.59 (dd, J = 9.7, 6.7 Hz, 1H), 3.49 (dd, J = 9.7, 6.1 Hz, 1H), 3.20 (s, 3H). 13C NMR 
(126 MHz, Methanol-d4) δ 168.99 , 159.39 , 130.14 , 129.07 , 113.31 , 72.60 , 70.28 , 
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PMB-protected-azido tail-Weinreb amide-DAG probe precursor (3.47). In an 
oven dried 1 dram vial under argon, compound 3.44 (110 mg, 0.367 mmol) and 1,8-
dimethylaminonaphthalene (proton sponge, 118 mg, 0.551 mmol), and previously 
synthesized compound 3.41 (190 mg, 0.551 mmol) were dissolved in 2 mL methylene 
chloride, and a microscale condenser was equipped. The mixture was stirred and heated 
to reflux overnight, and the resulting gold solution was concentrated by rotary 
evaporation, before adding 3 mL 1N hydrochloric acid (HCl (aq)) extracting with 4 mL 
ethyl acetate, washing the organic layer with (2x) 2mL water and then 2mL brine 
(saturated sodium chloride (aq)). The organic layer was dried over sodium sulfate, filtered, 
concentrated by rotary evaportation, and dried under high vacuum to give a crude clear 
oil, which was purified on a silica gel column using a gradient elution of 20-80% ethyl 
acetate-hexanes to give a mixture of products: Two single tailed regioisomer byproducts, 
3.45 and 3.46, which were not distinguishable spectroscopically but were isolated as clear 
oils (8 mg, 4% yield, and 42 mg, 23% yield); DART-MS (3.45, 3.46): [M-N2+H]+ for 
C25H42N4O6 calcd, 467.3115; detected, 467.3040. 
Double tail product 3.47 was isolated as a clear oil (8 mg, 3 % yield, Rf = 0.50, 35% 
EtOAc-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.27 – 7.20 (m, 2H), 6.87 – 6.82 (m, 
2H), 4.44 (s, 2H), 4.37 (d, J = 15.2 Hz, 1H), 3.80 (s, 3H), 3.67 (s, 3H), 3.66 – 3.55 (m, 
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5H), 3.52 (dd, J = 10.3, 5.4 Hz, 1H), 3.36 (dt, J = 9.1, 6.9 Hz, 1H), 3.25 (t, J = 7.0 Hz, 4H), 
3.16 (s, 3H), 1.56 (dd, J = 28.6, 14.4 Hz, 6H), 1.40 – 1.33 (m, 4H), 1.35 – 1.21 (m, 26H). 
13C NMR (126 MHz, CDCl3) δ 168.33 , 159.09 , 131.67 , 130.35 , 129.27 , 113.62 , 79.03 
, 72.96 , 71.99 , 71.09 , 69.35 , 55.24 , 51.47 , 30.07 , 29.74 , 29.57 , 29.54 , 29.50 , 29.49 
, 29.46 , 29.44 , 29.14 , 28.82 , 26.71 , 26.05 , 26.03. DART-MS: [M+H]+ for C36H63N7O6 
calcd, 690.4913; detected, 690.4843. 
 
 
PMB-protected-azido tail-ketone DAG probe precursor (3.65) In an oven dried 
1 dram vial under argon, compound 3.47 (13 mg, 0.019 mmol) was dissolved in 1 mL 
tetrahydrofuran and cooled to -15C. Methyl magnesium bromide (38 L, 0.038 mmol, as 
a 1M solution in tetrahydrofuran) was added dropwise, and the solution was stirred at -
15C for 2 h, then quenched with 0.3 mL saturated ammonium chloride (NH4Cl (aq)), 
diluted with 2 mL water, extracted with (2x) 4 mL diethyl ether, and the combined organic 
layers were dried over sodium sulfate, filtered, concentrated by rotary evaporation, and 
dried under high vacuum. The crude residue was purified on a silica gel column using a 
gradient elution of 5-20% ethyl acetate in hexanes to give compound 3.65 as a clear oil 
(5 mg, 41% yield). Rf = 0.63 (25% EtOAc-hexanes, UV, 2,4-DNP: red). 1H NMR (500 
MHz, CDCl3) δ 7.25 – 7.21 (m, 2H), 6.90 – 6.84 (m, 2H), 4.41 (dd, J = 11.6, 4.6 Hz, 2H), 
3.80 (s, 3H), 3.83 – 3.74 (m, 2H), 3.70 – 3.50 (m, 4H), 3.45 – 3.29 (m, 2H), 3.25 (t, J = 
7.0 Hz, 4H), 2.23 (s, 3H), 1.65 – 1.53 (m, 6H), 1.38 – 1.31 (m, 4H), 1.30 – 1.22 (m, 26H). 
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13C NMR (126 MHz, CDCl3) δ 212.23 , 159.21 , 131.61 , 129.27 , 113.74 , 85.82 , 79.67 
, 72.98 , 72.40 , 71.85 , 68.11 , 51.47 , 29.86 , 29.72 , 29.66 , 29.54 , 29.50 , 29.48 , 29.44 
, 29.43 , 29.36 , 29.13 , 28.82 , 27.78 , 26.70 , 26.08 , 25.92. DART-MS: [M-N2+H]+ for 




yl)ethan-1-one (3.48) The conditions for this synthesis were taken from previously 
reported procedures.188, 197 In an oven dried 6 dram vial under argon, compound 3.43 (32 
mg, 0.094 mmol) was dissolved in 2 mL tetrahydrofuran and cooled to -15C. Methyl 
magnesium bromide (189 L, 0.189 mmol, as a 1M solution in tetrahydrofuran) was 
added dropwise, and the solution was stirred at -15C for 1.5 h, then quenched with 0.5 
mL saturated ammonium chloride (NH4Cl (aq)), diluted with 2 mL water, extracted with 
(3x) 4 mL ethyl acetate, and the combined organic layers were washed with 2 mL brine 
(saturate sodium chloride (aq)) dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude residue was purified on a silica gel 
column using a gradient elution of 15-40% ethyl acetate in hexanes to give compound 
3.48 as a clear oil (18 mg, 65% yield). Rf = 0.50 (25% EtOAc-hexanes, UV, 2,4-DNP: 
red). The enantiomer of 3.48 is reported previously without characterization data.201 1H 
NMR (500 MHz, CDCl3) δ 7.26 (d, 2H), 6.87 (d, 2H), 4.53 (s, 2H), 4.21 – 4.14 (m, 2H), 
3.80 (s, 3H), 3.73 – 3.66 (m, 1H), 3.59 (ddd, J = 10.7, 4.5, 1.0 Hz, 1H), 2.27 (s, 3H), 1.45 
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(dd, J = 19.4, 0.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 208.30 , 159.23 , 129.91 , 129.33 
, 113.76 , 111.04 , 82.01 , 77.30 , 73.24 , 69.94 , 55.25 , 26.91 , 26.42 , 26.25. DART-MS: 




3-methyl-3H-diazirine (3.49). The reaction conditions for this synthesis were adapted 
from a published procedure.174 In a 50 mL round bottom flask under argon, compound 
3.48 was dissolved in 4 mL ammonia-saturated methanol (7N NH3(MeOH)), cooled to 
0C, and stirred for 4.5 h. A suspension of hydroxylamine-O-sulfonic acid (HOSA, 21 mg, 
0.188 mmol) in 1 mL methanol (anh) was added dropwise, and the resulting white 
suspension was allowed to warm to rt and stir overnight. The reaction was quenched at 
0C by gently purging with argon through a narrow-gauge needle for 30 min, then filtering 
through celite and concentrating by rotary evaporation, and drying under high vacuum. 
The crude oil was dissolved in 4 mL methanol, triethylamine (TEA, 34 L, 0.245 mmol) 
was added, and the solution was cooled to 0C. With stirring, iodine (I2) was added in two 
11 mg portions, and the brown color persisted as the mixture was stirred and warmed to 
rt over 2 h. The reaction was concentrated by rotary evaporation, dissolved in 2 mL diethyl 
ether, and 2 mL of water were added and the organic layer was separated. The aqueous 
later was extracted with (2x) 2 mL diethyl ether, and the combined organic layers were 
dried over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under 
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high vacuum to give a brown solid. The crude residue was purified on a silica gel column 
using a gradient elution of 15-30% ethyl acetate in hexanes to give 3.49 as a clear oil, 
which was handled and stored with care to protect from light (18 mg, 36% yield). Rf = 0.56 
(30% acetone-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 6.91 – 
6.86 (m, 2H), 4.53 (s, 2H), 4.00 (ddd, J = 8.2, 5.1, 4.4 Hz, 1H), 3.81 (s, 3H), 3.60 – 3.50 
(m, 2H), 3.47 (dd, J = 7.6, 5.8 Hz, 1H), 1.38 – 1.33 (m, 6H), 1.05 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 159.28 , 129.80 , 129.36 , 113.79 , 109.98 , 79.22 , 76.15 , 73.28 , 69.42 





diol (3.50). In a 6 dram vial, compound 3.49 (77 mg, 0.252 mmol) was dissolved in 4 mL 
tetrahydrofuran, then 4 mL 1 N hydrochloric acid (HCl (aq)) was added and the cloudy 
mixture was stirred at rt for 48 h while protected from light. The resulting clear solution 
was quenched with 8 mL saturated sodium bicarbonate (NaHCO3 (aq)) and stirred 
overnight at rt. The mixture was then poured into 25 mL water, extracted with (3x) 25 mL 
methylene chloride, and the combined organic layers were dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to give a clear 
oil. The crude residue was purified on a silica gel column using a gradient elution of 0-
30% acetone in chloroform to give compound 3.50 as a clear oil, which was handled and 
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stored with care to protect from light (59 mg, 88% yield). Rf = 0.44 (40% acetone-hexanes, 
UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.23 (d, 2H), 6.88 (d, 2H), 4.55 – 4.44 (m, 2H), 
3.81 (s, 3H), 3.70 – 3.62 (m, 2H), 3.62 – 3.52 (m, 1H), 3.34 (dd, J = 4.8, 3.7 Hz, 1H), 2.57 
(dd, J = 27.1, 5.2 Hz, 2H), 1.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.48 , 129.52 , 
129.35 , 113.93 , 73.38 , 72.93 , 71.46 , 69.38 , 55.27 , 26.74 , 16.53. DART-MS: [M-H:]+ 
for C13H18N2O4 calcd, 265.1194; detected, 265.1194. 
 
 
PMB-protected-azido tail-diazirine DAG probe precursor (3.51). Reaction 
conditions from a known procedure were adapted for this synthesis.136 In a 25 mL oven 
dried round bottom flask under argon, compound 3.50 (59 mg, 0.222 mmol) was dissolved 
in 5 mL N,N-dimethylformamide, stirred and cooled to 0C, and then sodium hydride 
(NaH, 60% dispersion in paraffin wax, 35 mg, 0.886 mmol) was added in one portion. The 
white suspension was stirred for 20 min, then warmed to rt and stirred for 10 min before 
cooling back to 0C. A solution of tetrabutylammonium iodide (TBAI, 8 mg, 0.022 mmol) 
and previously synthesized compound 3.19 (245 mg, 0.886 mmol) in 2 mL N,N-
dimethylformamide was added dropwise, and the resulting suspension was allowed to 
warm to rt and stir overnight while protected from light. The reaction was quenched with 
1 mL methanol and stirred for 1h, then diluted with 60 mL diethyl ether, washed with (5x) 
10 mL water, then 10 mL brine, then dried over magnesium sulfate, filtered, concentrated 
by rotary evaporation, and dried under high vacuum to give a yellow oil. The crude residue 
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was purified on a silica gel column using a gradient elution of 3-12% ethyl acetate in 
hexanes to give compound 3.51 as a clear oil, which was handled and stored with care 
to protect from light. (122 mg, 83% yield). Rf = 0.38 (10% EtOAc-hexanes, UV, KMnO4). 
1H NMR (500 MHz, CDCl3) δ 7.24 (d, 2H), 6.87 (d, 2H), 4.48 (q, 2H), 3.80 (s, 3H), 3.74 
(dt, J = 9.3, 6.6 Hz, 1H), 3.70 – 3.53 (m, 4H), 3.48 – 3.37 (m, 1H), 3.33 (dt, J = 9.4, 6.7 
Hz, 1H), 3.25 (t, J = 7.0 Hz, 4H), 2.76 (d, J = 4.7 Hz, 1H), 1.66 – 1.50 (m, 4H), 1.41 – 1.23 
(m, 32H), 1.04 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.17 , 130.24 , 129.29 , 113.71 , 
80.32 , 78.29 , 73.10 , 71.90 , 70.96 , 68.86 , 55.23 , 51.47 , 30.13 , 29.66 , 29.56 , 29.48 
, 29.46 , 29.43 , 29.14 , 28.83 , 26.70 , 26.11 , 26.07 , 25.85 , 17.13. DART-MS: [M-N2+H]+ 
for C35H60N8O4 calcd, 629.4749; detected, 629.4659. 
 
 
Azido tail-diazirine DAG probe (3.4). In a 6 dram vial under argon, compound 
3.51 (121 mg, 0.184 mmol) was dissolved in 2 mL methylene chloride, and 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ, 104 mg, 0.460 mmol) was added. The solution was 
protected from light, 112 L water (to make (18:1) CH2Cl2:H2O) was added, and the black 
biphasic mixture was stirred vigorously at rt for 4 h. The resulting orange reaction was 
diluted with 15 mL methylene chloride, washed with (2x) 4 mL saturated sodium 
bicarbonate (NaHCO3 (aq)), (3x) 4 mL water, and then dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to give a dark 
oil. The crude residue was purified on a silica gel column using a gradient elution of 10-
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30% ethyl acetate in hexanes, and then on a second silica gel column using a gradient 
elution of 0-2% methanol in methylene chloride to give compound 3.4 as a clear oil, which 
was handled and stored with care to protect from light (90 mg, 91% yield). Rf = 0.43 (2% 
MeOH-CH2Cl2, KMnO4). 1H NMR (500 MHz, CDCl3) δ 3.92 (ddd, J = 11.5, 7.2, 4.2 Hz, 
1H), 3.85 – 3.73 (m, 2H), 3.67 (dt, J = 9.2, 6.8 Hz, 1H), 3.58 (dt, J = 9.3, 6.7 Hz, 1H), 3.44 
– 3.31 (m, 2H), 3.25 (t, J = 7.0 Hz, 4H), 2.79 (d, J = 6.1 Hz, 1H), 2.13 (dd, J = 7.2, 5.2 Hz, 
1H), 1.64 – 1.53 (m, 4H), 1.39 – 1.25 (m, 32H), 1.06 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 81.76 , 79.59 , 71.87 , 70.79 , 61.75 , 51.47 , 30.14 , 29.74 , 29.53 , 29.52 , 29.46 , 
29.44 , 29.40 , 29.13 , 28.82 , 26.70 , 26.09 , 25.37 , 17.07. DART-MS: [M-N2+H]+ for 
C27H52N8O3 calcd, 509.4173; detected, 509.4178. 
 
 
Bis(-cyanoethyl) protected-Azido tail-diazirine PA probe precursor (3.61). A 
previously published procedure was followed.146 In a 1 dram oven dried vial under argon, 
compound 3.4 (20 mg, 0.037 mmol) was dissolved in 0.5 mL methylene chloride, and 4,5-
dicyanoimidazole (4,5-DCI, 5.5 mg, 0.045 mmol) was added to the stirring solution at rt, 
followed by a solution of previously synthesized phosphoramidite 2.29 (12 mg, 0.045 
mmol) in 0.5 mL methylene chloride. The solution was stirred for 3 h, then cooled to -
78C and a solution of m-chloroperoxybenzoic acid (m-CPBA, 70% dispersion with water, 
11 mg, 0.045 mmol) in 0.5 mL methylene chloride was added slowly. After stirring for 3 
min at -78C, the reaction was allowed to warm to rt and stir for 1.5 h, and was then 
192 
diluted with 8 mL methylene chloride, washed with 2 mL 10% sodium sulfite (Na2SO3 
(aq)), (2x) 2 mL saturated sodium bicarbonate (NaHCO3 (aq)), and 2 mL brine, then dried 
over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum to give a clear oil. The crude residue was purified on a silica gel column using a 
gradient elution of 30-40% acetone in hexanes to give compound 3.61 as a clear oil, 
which was handled and stored with care to protect from light (24 mg, 87% yield). Rf = 0.59 
(50% acetone-hexanes, KMnO4). 1H NMR (500 MHz, (1:1) Methanol-d/ CDCl3) δ 4.38 – 
4.26 (m, 6H), 3.77 (dt, J = 9.1, 6.7 Hz, 1H), 3.66 (td, J = 6.8, 1.4 Hz, 2H), 3.53 (tdd, J = 
5.3, 4.3, 0.8 Hz, 1H), 3.38 (dt, J = 9.1, 6.7 Hz, 1H), 3.26 (td, J = 6.9, 1.0 Hz, 4H), 2.82 
(ddd, J = 7.2, 6.2, 5.2 Hz, 5H), 1.65 – 1.54 (m, 4H), 1.43 – 1.26 (m, 32H), 1.08 (s, 3H). 
13C NMR (126 MHz, (1:1) Methanol-d/ CDCl3) δ 116.31 , 79.82 , 78.07 (d, J = 7.6 Hz), 
77.24 , 72.29 , 71.00 , 67.36 (d, J = 6.2 Hz), 62.36 (dd, J = 5.3, 3.5 Hz), 51.40 , 30.01 , 
29.59 , 29.48 , 29.46 , 29.40 , 29.38 , 29.37 , 29.34 , 29.05 , 28.73 , 26.61 , 25.98 , 25.92 
, 25.21 , 19.51 (dd, J = 7.3, 2.2 Hz), 16.85 . 31P NMR (202 MHz, (1:1) Methanol-d/ CDCl3) 
δ -2.53 . DART-MS: [M-N2+H]+ for C33H59N10O6P calcd, 695.4368; detected, 695.4305. 
 
 
Azido tail-diazirine PA probe, 2Na+ form (3.62) A previously published 
deprotection procedure was followed.148 In an oven dried 1 dram vial under argon, 
compound 3.61 (12 mg, 17 mol) was dissolved in 1 mL methylene chloride, and 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU, 12 L, 83 mol) was added to the stirring solution 
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at rt. Then, N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA, 22 L, 83 mol) was added, 
and the solution was stirred at rt for 15 min before adding 500 L methanol (anh). After 
15 min, the reaction was concentrated by rotary evaporation and dried under high vacuum 
to give a yellow oil, which was purified on a silica gel column using first a gradient elution 
of 5-15% methanol in methylene chloride to eliminate impurities, followed by a (65:25:4) 
mixture of chloroform/methanol/water to recover the product as its 2DBUH+ salt (identified 
as a blue baseline Phospray spot in 15% methanol-methylene chloride; confirmed on 
NMR and MS). The compound was converted to its 2H+ form (compound 3.5) by 
dissolving in 5 mL (1:4) methanol/chloroform and washing with (2x) 0.5 mL 10% citric acid 
(aq), which was confirmed by NMR, and then finally to its 2Na+ form by washing with 0.3 
mL 10% sodium carbonate, concentrating by rotary evaporation, and drying under high 
vacuum to give compound 3.62 as a white solid (8 mg, 71%). 1H NMR (500 MHz, (4:1) 
Methanol-d/ CDCl3, detected as 2H+ form 3.5) δ 3.93 (s, 2H), 3.54 (ddt, J = 14.1, 9.3, 6.8 
Hz, 2H), 3.45 (dt, J = 9.3, 7.0 Hz, 1H), 3.34 (q, J = 5.3 Hz, 1H), 3.22 – 3.14 (m, 2H), 3.11 
– 3.04 (m, 4H), 2.65 (d, J = 4.4 Hz, 1H), 1.46 – 1.34 (m, 4H), 1.23 – 1.03 (m, 32H), 0.89 
(s, 3H). 13C NMR (126 MHz, (4:1) Methanol-d/ CDCl3) δ 110.38 , 79.81 , 78.42 (d, J = 6.7 
Hz), 72.47 , 71.44 , 65.08 , 51.76 , 30.29 , 29.91 , 29.83 , 29.82 , 29.76 – 29.74 (m), 29.73 
, 29.72 , 29.41 , 29.09 , 26.98 , 26.33 , 26.26 , 25.83 , 17.28 . 31P NMR (202 MHz, (4:1) 
Methanol-d/ CDCl3) δ -0.02 . DART-MS (detected as 2H+ form 3.5): [M-H]- for 
C27H53N8O6P calcd, 615.3753; detected, 615.0103. [M-N2+H]+ for C27H53N8O6P calcd, 





6-(trimethylsilyl)hex-5-yn-1-one (3.52). In an oven dried 25 mL pear shaped flask under 
argon, compound 3.43 (610 mg, 1.80 mmol) was dissolved in 8 mL tetrahydrofuran, and 
the stirring solution was cooled to -10C. 8 mL of Grignard solution 3.57 (theoretically 
0.44 M, 3.60 mmol) was added slowly, and the reaction was stirred at -10C for 1 h, then 
at rt for 45 min. The gold solution was cooled to 0C, quenched with 3 mL saturated 
ammonium chloride (NH4Cl (aq)), poured into 7 mL water, and extracted with (2x) 50 mL 
diethyl ether. The combined organic layers were washed with 10 mL brine (saturated 
sodium chloride (aq)), dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum to give a gold oil. The crude residue was 
purified on a silica gel column using a gradient elution of 10-70% ethyl acetate in hexanes 
to recover starting material 3.43 (237 mg, 39% RSM), and an impure mixture containing 
compound 3.52, which was purified on a second silica gel column using a gradient elution 
of 2-10% ethyl acetate in hexanes to give pure compound 3.52 as a clear oil (213 mg, 
28% yield). Rf = 0.63 (25% EtOAc-hexanes, UV, 2,4-DNP: red). 1H NMR (500 MHz, 
CDCl3) δ 7.26 (d, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.54 (s, 2H), 4.21 – 4.16 (m, 2H), 3.80 (s, 
3H), 3.74 – 3.68 (m, 1H), 3.59 (ddd, J = 10.7, 3.7, 1.8 Hz, 1H), 2.89 – 2.67 (m, 2H), 2.29 
– 2.23 (m, 2H), 1.78 (t, J = 7.1 Hz, 2H), 1.49 – 1.42 (m, 6H), 0.14 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 209.69 , 159.25 , 129.95 , 129.35 , 113.78 , 111.04 , 106.19 , 85.47 , 81.78 
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, 77.48 , 73.26 , 69.95 , 55.27 , 37.27 , 26.94 , 26.33 , 21.60 , 19.08 , 0.13 .DART-MS: 




3-(5-(trimethylsilyl)pent-4-yn-1-yl)-3H-diazirine (3.53). A published procedure was 
followed.174 This compound was synthesized using the same protocol as was used in the 
synthesis of compound 3.49, using: compound 3.52 (213 mg, 0.509 mmol), 5 mL 
ammonia-saturated methanol (7N NH3(MeOH)), hydroxylamine-O-sulfonic acid (HOSA, 
55 mg, 0.585 mmol), triethylamine (TEA, 106 L, 0.764 mmol). The resulting crude yellow 
oil was purified on a silica gel column using a gradient elution of 10-20% ethyl acetate in 
hexanes to recover starting material 3.52 (66 mg, 31% RSM), and to give compound 3.53 
as a clear oil, which was handled and stored with care to protect from light (30 mg, 16% 
yield). Rf = 0.71 (25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.27 
(d, 2H), 6.89 (d, 2H), 4.52 (d, J = 1.8 Hz, 2H), 3.89 (dt, J = 8.3, 4.7 Hz, 1H), 3.81 (s, 3H), 
3.61 – 3.51 (m, 3H), 2.18 – 2.11 (m, 2H), 1.62 – 1.54 (m, 2H), 1.34 (d, J = 10.4 Hz, 6H), 
1.30 – 1.18 (m, 2H), 0.13 (d, J = 0.6 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 159.31 , 
129.81 , 129.40 , 113.81 , 109.87 , 106.03 , 78.71 , 75.86 , 73.29 , 69.26 , 55.28 , 28.43 
, 27.55 , 26.92 , 26.61 , 22.43 , 19.25 , 0.11 . DART-MS: [M+H]+ for C23H34N2O4Si calcd, 





diazirin-3-yl)propane-1,2-diol (3.54). In a 50 mL round bottom flask, compound 3.53 (39 
mg, 0.089 mmol) was dissolved in 8 mL 50% aqueous acetic acid (AcOH (aq)), and 
heated to 50C with stirring for 24 h. The reaction was concentrated under reduced 
pressure by azeotropic removal of AcOH with (5x) 3 mL toluene to give a clear oil. The 
crude reside was purified on a silica gel column using a gradient elution of 20-40% 
acetone in hexanes to give compound 3.54 as a clear oil, which was handled and stored 
with care to protect from light (30 mg, 86% yield). 1H NMR (500 MHz, CDCl3) δ 7.23 (d, 
2H), 6.88 (d, 2H), 4.46 (q, 2H), 3.80 (s, 3H), 3.66 – 3.53 (m, 3H), 3.52 – 3.46 (m, 1H), 
2.61 (d, J = 5.0 Hz, 1H), 2.55 (d, J = 5.0 Hz, 1H), 2.17 (t, J = 7.0 Hz, 2H), 1.68 – 1.55 (m, 
2H), 1.31 – 1.19 (m, 2H), 0.13 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 159.50 , 129.55 , 
129.37 , 113.95 , 106.14 , 85.34 , 73.38 , 72.07 , 71.42 , 69.17 , 55.29 , 29.38 , 28.43 , 







PMB protected-alkyne-diazirine DAG probe precursor (3.55). A previously 
published procedure was followed.136 In an oven dried 1 dram vial under argon, 
compound 3.54 (17 mg, 44 mol) was dissolved in 0.5 mL N,N-dimethylformamide, and 
the solution was cooled to 0C with stirring. Sodium hydride (NaH, 60% dispersion in 
paraffin wax, 6.1 mg, 0.152 mmol) was added in a single portion, and the white 
suspension was stirred for 20 min at 0C, then at rt for 8 min, and was then cooled again 
to 0C. A solution of tetrabutylammonium iodide (TBAI, 1.6 mg, 4.4 mol) and 1-
bromohexadecane (1-BHD, 47 L, 0.152 mmol) in 0.5 mL N,N-dimethylformamide was 
added dropwise, and the thick white suspension was stirred for 5 min at 0C, then warmed 
to rt and stirred overnight. The resulting solution was quenched with 0.2 mL methanol and 
stirred for 1 h before diluting with 12 mL diethyl ether, and the organic layer was washed 
with (5x) 2 mL water, then 2 mL brine (saturated sodium chloride (aq)), and then dried 
over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. The crude residue was purified on a silica gel column using a gradient elution of 
5-15% ethyl acetate in hexanes to give compound 3.55 as a clear oil, which was handled 
and stored with care to protect from light (19 mg, 57% yield). Rf = 0.54 (10% EtOAc-
hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.25 (d, 2H), 6.87 (d, 2H), 4.52 – 
4.43 (m, 2H), 3.80 (s, 3H), 3.75 – 3.53 (m, 5H), 3.41 – 3.28 (m, 2H), 2.97 (d, J = 5.1 Hz, 
1H), 2.08 (tdd, J = 7.0, 2.7, 1.9 Hz, 2H), 1.91 (t, J = 2.7 Hz, 1H), 1.75 (ddd, J = 15.0, 8.9, 
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7.4 Hz, 1H), 1.66 – 1.48 (m, 5H), 1.25 (s, 52H), 1.22 – 1.12 (m, 2H), 0.91 – 0.84 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 159.17 , 130.21 , 129.33 , 113.70 , 79.64 , 78.43 , 73.12 , 
71.90 , 71.17 , 68.83 , 55.22 , 31.91 , 30.15 , 29.70 , 29.66 , 29.65 , 29.54 , 29.49 , 29.35 
, 28.49 , 28.45 , 26.12 , 22.68 , 22.28 , 17.94 , 14.10. DART-MS: [M+H]+ for C49H86N2O4 
calcd, 767.6661; detected, 767.6456. 
 
 
Alkyne-diazirine DAG probe (3.7). In a 6 dram vial under argon, compound 3.55 
(5 mg, 6.5 mol) was dissolved in 1.35 mL methylene chloride, and 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ, 4 mg, 17.6 mol) was added. The solution was 
protected from light, 75 L water (to make (18:1) CH2Cl2:H2O) was added, and the black 
biphasic mixture was stirred vigorously at 35C for 2.5 h. The resulting orange reaction 
was diluted with 8 mL methylene chloride, washed with (2x) 2 mL saturated sodium 
bicarbonate (NaHCO3 (aq)), (4x) 2 mL water, then 2 mL brine (saturated sodium chloride 
(aq)), and then dried over sodium sulfate, filtered, concentrated by rotary evaporation, 
and dried under high vacuum to give a white solid. The crude residue was purified on a 
silica gel column using a gradient elution of 5-10% ethyl acetate in hexanes to give 
compound 3.7 as a white solid, which was handled and stored with care to protect from 
light (6 mg, 99% yield). Rf = 0.41 (15% EtOAc-hexanes, KMnO4). 1H NMR (500 MHz, 
CDCl3) δ 3.91 (ddd, J = 11.2, 6.8, 4.0 Hz, 1H), 3.82 – 3.73 (m, 2H), 3.65 (dt, J = 9.2, 6.8 
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Hz, 1H), 3.55 (dt, J = 9.2, 6.7 Hz, 1H), 3.37 (dt, J = 9.1, 6.6 Hz, 1H), 3.28 (ddd, J = 6.6, 
5.3, 4.0 Hz, 1H), 3.00 (d, J = 6.5 Hz, 1H), 2.17 – 2.04 (m, 3H), 1.93 (t, J = 2.6 Hz, 1H), 
1.84 – 1.74 (m, 1H), 1.66 – 1.51 (m, 5H), 1.25 (d, J = 1.4 Hz, 52H), 1.26 – 1.16 (m, 2H), 
0.88 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 83.18 , 80.92 , 79.62 , 71.96 , 70.99 
, 68.97 , 61.66 , 31.91 , 30.17 , 29.76 , 29.69 , 29.68 , 29.65 , 29.63 , 29.62 , 29.51 , 29.46 
, 29.35 , 28.56 , 28.05 , 26.12 , 22.68 , 22.18 , 17.91 , 14.10. DART-MS: [M+H]+ for 
C41H78N2O3 calcd, 647.6085; detected, 647.6278. 
 
 
Bis(-cyanoethyl) protected-alkyne-diazirine-PA probe precursor (3.63). This 
compound was synthesized using the same protocol as was used in the synthesis of 
compound 3.49, except with: compound 3.7 (7 mg, 10.8 mol), 2,4-dicyanoimidazole (2,4-
DCI, 1.5 mg, 13.0 mol), previously synthesized phosphoramidite compound 2.29 (3.5 
mg, 13 mol), m-chloroperoxybenzoic acid (3.2 mg, 13 mol). Following the same 
workup, the crude white solid was purified on a silica gel column using a gradient elution 
of 25-40% acetone in hexanes to give compound 3.63 as a white solid (9 mg, 99% yield). 
Rf = 0.58 (40% acetone-hexanes, KMnO4). 1H NMR (500 MHz, (1:9) Methanol-d/ CDCl3) 
δ 4.32 – 4.18 (m, 6H), 3.67 (dt, J = 9.0, 6.6 Hz, 1H), 3.58 (t, J = 6.8 Hz, 2H), 3.47 – 3.39 
(m, 1H), 3.37 – 3.26 (m, 1H), 2.94 (s, 1H), 2.76 (td, J = 6.1, 1.0 Hz, 4H), 2.11 – 2.01 (m, 
2H), 1.92 (t, J = 2.6 Hz, 1H), 1.78 – 1.57 (m, 2H), 1.56 – 1.45 (m, 4H), 1.20 (d, J = 1.5 
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Hz, 52H), 1.19 – 1.09 (m, 2H), 0.82 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz,  (1:9) 
Methanol-d/ CDCl3) δ 161.62 , 116.31 , 79.05 , 78.21 (d, J = 7.6 Hz), 72.30 , 71.21 , 69.03 
, 67.38 (d, J = 6.3 Hz), 62.45 – 62.27 (m), 31.84 , 30.03 , 29.62 , 29.59 , 29.57 , 29.46 , 
29.41 , 29.27 , 28.26 , 27.89 , 25.99 (d, J = 3.5 Hz), 22.60 , 22.08 , 19.52 (dd, J = 7.3, 2.2 
Hz), 17.76 , 13.98. 31P NMR (202 MHz, (1:9) Methanol-d/ CDCl3) δ -2.51. DART-MS: [M-
N2+H]+ for C47H85N4O6P calcd, 805.6218; detected, 805.7218.  
 
 
Alkyne-diazirine PA probe, 2Na+ form (3.64).  A known deprotection procedure 
was followed.148 In an oven dried 1 dram vial under argon, compound 3.63 (9 mg, 10.8 
mol) was dissolved in 0.5 mL methylene chloride, and 1,8-diazabicyclo(5.4.0)undec-7-
ene (DBU, 8.2 L, 54 mol) was added to the stirring solution at rt. Then, N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA, 14.5 L, 54 mol) was added, and the 
solution was stirred at rt for 30 min before adding 500 L methanol (anh). After 30 min, 
the reaction was concentrated under a stream of argon and dried under high vacuum to 
give a yellow oil, which was purified on a silica gel column using first a gradient elution of 
5-15% methanol in methylene chloride to eliminate impurities, followed by a 65:25:4 
chloroform:methanol:water eluant mixture to recover the product as its 2DBUH+ salt 
(identified as a blue Phospray spot at Rf = 0.60 in (65:25:4) CHCl3:MeOH:H2O). The 
compound was converted to its 2H+ form (compound 3.8) by dissolving in 5 mL of a 1:5 
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methanol:chloroform mixture and washing with (2x) 0.5 mL 10% citric acid (aq). Citric acid 
was removed by washing with 0.3 mL of 8 mM ammonium acetate, and the compound 
was characterized by NMR. Finally, 3.8 was converted to its 2Na+ form by washing with 
0.3 mL 10% sodium carbonate, concentrating by rotary evaporation, and drying under 
high vacuum to give compound 3.64 as a white solid (7 mg, 89% yield). 1H NMR (500 
MHz, (1:5) Methanol-d/ CDCl3; detected as 2H+ form 3.8) δ 4.06 (s, 2H), 3.70 – 3.58 (m, 
2H), 3.58 – 3.51 (m, 1H), 3.44 – 3.38 (m, 1H), 3.38 – 3.25 (m, 1H), 2.96 (d, J = 4.6 Hz, 
1H), 2.05 (td, J = 7.1, 2.6 Hz, 2H), 1.90 (t, J = 2.6 Hz, 1H), 1.78 – 1.69 (m, 1H), 1.64 – 
1.44 (m, 5H), 1.19 (s, 52H), 1.14 (s, 2H), 0.81 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, 
(1:5) Methanol-d/ CDCl3) δ 83.18 , 78.65 , 78.08 , 77.25 , 72.19 , 71.26 , 68.91 , 64.78 , 
31.84 , 29.91 , 29.62 , 29.58 , 29.57 , 29.56 , 29.44 (d, J = 4.7 Hz), 29.27 , 28.31 , 28.14 
, 25.95 (d, J = 8.2 Hz), 22.59 , 22.17 , 17.76 , 13.98. 31P NMR (202 MHz, (1:5) Methanol-
d/ CDCl3) δ 0.27. DART-MS (detected as 2H+ form 3.8): [M-N2+H]+ for C41H79N2O6P calcd, 




3.7 List of Mass Spectra for Final Compounds 
 
Spectrum 3.1. ACCUTOF-DART mass spectrum of compound 3.1. 
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Spectrum 3.2. ACCUTOF-DART mass spectrum of compound 3.60. 
204 
 
Spectrum 3.3. ACCUTOF-DART mass spectrum of compound 3.3. 
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Spectrum 3.4. ACCUTOF-DART mass spectrum of compound 3.4. 
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Spectrum 3.5. ACCUTOF-DART mass spectrum of compound 3.7. 
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Spectrum 3.6. ACCUTOF-DART mass spectrum of compound 3.61. 
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Spectrum 3.7. ACCUTOF-DART mass spectrum of compound 3.63. 
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Spectrum 3.8. ACCUTOF-DART mass spectrum of compound 3.5. 
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Spectrum 3.9. ACCUTOF-DART mass spectrum of compound 3.8. 
 
3.8 Protocol for Labeling of HEK Cell Proteins 
The equipment and protocols within this section were carried out in the research 
lab of Dr. Benjamin Cravatt at the Scripps Research Institute in La Jolla, CA with the 
assistance of former graduate student Dr. Kenneth Lum. The general methods followed 
modified published procedures.117-119  
HEK Cell Lysate Preparation 
HEK cells were thawed from a -80C frozen stock. Cells and lysates were kept at 
4C from this point until photocrosslinking was complete, unless otherwise noted. HEK 
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cells were suspended in 2 mL 1X PBS in an Eppendorf tube and lysed by probe sonication 
using a Branson Sonifier 250. Protein content of the whole cell lysate was determined 
using a Bradford assay as follows: (3x) each of 0, 2, 4, 6, 8, and 10 L aliquots of a 2 
mg/mL bovine serum albumin standard were transferred to a 96 well microplate along 
with (2x) 2 L aliquots of the HEK cell lysate. Buffer solutions proprietary to the Cravatt 
Lab, 25L buffer A followed by 200L buffer B, were added to each plate. Alternatively, a 
standard Bradford assay could be conducted if these buffers are not available. The 
microwell plate was incubated at rt for 10 min, and then absorbance was measured on a 
microplate reader. Following these results, the stock lysate was diluted with 1X PBS to 
adjust the protein concentration to 2 mg/mL. 
Lipid Probe Stock Solutions and Transport Complex Formation 
Unless otherwise noted, all 500 M probe stock solutions were made by 
transferring a 25 L aliquot from a 10 mM probe stock solution in DMSO to a fresh 1 dram 
vial, and diluting with 475 L of DMSO. Probe stock solutions were stored at -20 to -80C 
and thawed as needed, handling with care to protect from light. Probes with limited 
solubility in this stock medium were homogenized by gentle warming (< 40C) and/or 
sonication prior to spiking into labeling media. The addition of ethanol resulted in instant 
cell death during one HEK cell experiment and should be avoided for sensitive cell 
cultures or applied with caution in small amounts to aid solubilization. 
Probe transport complexes for PA probes were made following a modified 
published procedure.183 A 1 mg/mL stock solution of polyethylenimine (PEI; MW = 40,000; 
450 amine groups per monomer) was made using ultrapure water. 20 L PA probe was 
transferred from 10 mM DMSO stock to a clean 1 dram vial (to make 200 M PA probe 
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upon dilution to 1 mL), followed by 17.4 L PEI stock solution (equivalent to two amine 
groups per PA probe molecule). The mixture was diluted with 960 L serum-free DMEM 
to make 200 M probe, vortexed, and sonicated for 10-20 min at 33C until the 
suspensions were clear.   
Probe transport complexes for DAG probes were made following modified 
published procedures.184-185 A 13.1 mg/mL (10 mM) stock solution of -methylcyclodextrin 
(-MCD; MW = 1310) was made using ultrapure water. 20 L DAG probe was transferred 
from 10 mM DMSO stock to a clean 1 dram vial, followed by 100 L -MCD stock solution 
(5x mol excess of -MCD to DAG probe). The mixture was diluted with 880 L serum-
free DMEM to make 200 M probe, vortexed, and warmed and/or sonicated to a clear 
solution if needed. Allowing 12 h total for equilibration at rt is optimal. 
Labeling of Proteins using HEK Cell Lysates 
50 L of HEK whole cell lysate, standardized to 2 mg/mL, were transferred to a 96 
well plate. Each well was spiked with 1 L from the appropriate 500 M lipid probe stock 
solution in DMSO, and then the plate was shaken gently for 10 sec before being left to 
incubate at rt for 30 min in the dark. The lysates were then cooled to 4C and 
photoirradiated at 365 nm for 10 min using a Stratagene UV Stratalinker 1800, leaving no 
barrier between the samples and the light source, or kept in the dark at 4C for no-UV 
control samples. At this point, the samples were either frozen at -80C overnight or 




Labeling of Proteins in Live HEK Cells 
HEK cells were grown to ~80% confluence in 6 cm dishes in DMEM with 10% FCS 
at 37C in a 5% CO2 atmosphere. The growth medium was aspirated, the cells were 
washed with 1 mL 1X PBS, aspirated again, then covered with 1 mL DMEM spiked with 
a lipid probe or probe transport complex at the desired concentration, with or without FCS, 
and incubated for 30 min at 37C in the dark. Media was aspirated, and the cells were 
photoirradiated with 365 nm light for 10 min at 4C, or kept in the dark at 4C for no-UV 
control samples. Cells were then loosened from growth dishes by repeatedly rinsing down 
with 1 mL 1X PBS, and the resulting cell suspensions was transferred to 2 mL Eppendorf 
tubes, centrifuged at 3000 g for 3 min at 4C, and aspirated. At this point, the cell pellets 
were either frozen at -80C overnight or subjected immediately to protein determination 
and click reaction.  
Ideally, cell pellets for this experiment have a cell count of 2.5 to 3.0 x 106. To lyse 
crosslinked cells, pellets were resuspended in 200 L 1X PBS, probe sonicated to 
homogeneity, and subjected to protein determination as described above. 1X PBS was 
added to adjust lysate suspensions to 2 mg/mL, or as close to this as possible if less. 
Click Mix Preparation 
A click mix stock solution was prepared fresh and used within 12 h. For n labeled 
lysate samples, the following were pre-mixed in order, vortexing after each addition: 
3(n+3) L (1.7 mM TBTA in 4:1 t-BuOH/DMSO. Solution stored in dark at rt); (n+3) L 
(50 mM CuSO4•5H2O in ultrapure water. Solution stored at rt); (n+3) L (Alexa488-alkyne, 
Rhodamine-azide, or biotin-azide/alkyne, 1.25 mM in DMSO. Solution stored at -20 to -
80C). (n+3) L (14 mg/mL TCEP•HCl, made fresh in 1X PBS). To check reagent viability, 
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the same mix can be combined in a separate Eppendorf tube for n = 1, omitting dye or 
biotin, and should produce a bright green solution. For this click reaction, detergents 
should be avoided in lysate preparation or thoroughly washed out with PBS before adding 
click reagents.  
Click Dye Conjugation and SDS-PAGE of Labeled Proteins 
6 L of click mix were added to clean Eppendorf tubes, one per crosslinked lysate 
sample. For lysate labeling experiments in microwell plates, 6 L of click mix were added 
to each microwell directly. 50 L of cold, freshly vortexed lysate were added to each 
respective tube, and then each tube was gently vortexed for 10 sec before being left to 
incubate for 1 h at rt in the dark. If storing overnight, click reactions were quenched by 
moving the samples to -80C. Otherwise, click reactions were quenched by adding 25 L 
of 4x SDS-PAGE loading buffer to each tube, or 22 L to each microwell.  
Without boiling, 25 L each of the resulting samples were loaded onto 30 x 30 cm 
10% acrylamide SDS-PAGE gels, including a fluorescence-labeled proteome ladder. 
Gels were run at 4C for 3 h at constant 300 V to a distance of 12-15 cm, and then imaged 
using a Biorad ChemiDoc MP station with ImageLab Software (v. 5.2.1). 
MudPIT Protocol for Proteomics Experiments 
The content of this section reflects work that was done solely by Kenneth Lum to 
generate proteomic labeling data for our lipid probes following the MudPIT concept 
originally described by Yates,202 and optimized for proteomic affinity labeling by 
Cravatt.203 For experiments with our lipid probes, 500L whole lysates from HEK293T 
cells fed with SILAC media were subjected to the lysate labeling protocol described 
above. “Heavy” media-fed cell lysates included the irradiation step while “Light” media-
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fed cells were not irradiated (no-UV control). Following protein determination and 
standardization, a published protocol was followed,118 and the steps completed by 
Kenneth are briefly summarized as follows: click with biotin azide or biotin alkyne; protein 
precipitation, denaturing, reduction, and alkylation; avidin enrichment; trypsin digestion; 
peptide recovery; 2D-LC-MS/MS analysis on an LTQ-Orbitrap Velos mass spectrometer 
using two-dimensional separation column packed with C18 and strong cation exchange 
resin; data conversion using RAW convertor 1.0.0.0; data search using the ProLuCID 
algorithm against the human proteome (from Uniprot); data filtration using DTASelect 2.0 
within the Integrated Proteomics Pipeline software; peptide SILAC ratio quantification by 




4 AZIDE-BEARING GLYCEROL AND ACYLGLYCEROL ANALOGS FOR 
METABOLIC INFILTRATION OF THE YEAST LIPIDOME 
4.1 Metabolic Labeling of Lipids  
Metabolic labeling experiments seek to incorporate a chemically tagged group into 
biomolecules in vivo using a cell’s own enzymatic machinery. These experiments provide 
valuable insight into the opteration of metabolic pathways, ideally producing well-defined 
trails of labeled metabolites that are indicative of carbon movement and transformation 
within cells. They can also be included in media to probe effects of inhibitors on enzyme 
activity.204 
Historically, these experiments are carried out with radiolabeled (14C or 3H) 
analogs of natural metabolic precursors, the biosynthetic products of which can be traced 
with scintillation counting after chromatographic separation of labeled lysates.204-206 
However, radioactive lipids require special handling and licencing requirements for use, 
must be disposed of carefully, provide limited sensitivity, and cannot be directly imaged 
to observe localization in cells.30, 207 Relevant to our work, they also do not provide 
bionconjugation opportunities or generate unique new biomolecules. 
Metabolic labeling of lipids with bio-orthogonal conjugation tags emerged following 
metabolic labeling experiments by Bertozzi that utilized ketone,208 and then azide-
linked209 sialic acid precursors to label glycoproteins. Metabolic engineering with click-
capable glycans is now a well characterized area that has pushed novel strategies for 
bioconjugation and targeted delivery methods.210-212 
Lipid metabolic labeling with click chemistry tags has emerged in the last decade 
as a popular area of exploration. Synthetic fatty acids with alkyne or azide termini have 
been used for general lipidomic labeling30 and lipidated protein labeling213 with success 
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due to their minimal synthetic presence and distal tag placement from the ester linkage 
where enzymayic conjugation takes place. Diazirine derivatives of FA-alkynes have also 
been used for metabolic and photoaffinity labeling.129 Delgato synthesized azido-
sphingolipids and applied them to live cells to trace their metabolism, then characterized 
biosynthetic products by mass spectrometry. Salic successfully labeled PC with 
derivatives of choline that include a bio-orthogonal alkyne or azide group, confirming by 
live cell fluorescence labeling with click dyes.214-215 Hoffman synthesized a metabolically 
active alkyne cholesterol analog to label cholesterol derivatives in multiple species.216 
Baskin developed a method for monitoring PLD cleavage of PC to PA by taking advantage 
of enzymatic tolerance of a short primary azido alcohol, resulting in an azide-labed PA 
phosphodiester derivative.217 Guo successfully labeled glycosylphosphatidylinositol (GPI) 
anchors using an azido inositol derivative.218 Wang combined metabolic labeling with 
propargyl alkyne from and a diazirine-FA in order to generate bifunctional photoaffinity 
PC  probes in vivo for characterizing protein-lipid interactions.219 Thiele has achieved 
metabolic labeling using live cells and isolated enzymes with a variety of FA, sphingolipid, 
lysophospholipid, MAG, and DAG probes, most of which feature a FA with a synthetically-
installed terminal alkyne.177 
4.2 Glycerol-based Lipid Metabolic Probes in this Work 
Here, we present a series of azide-based glycerol probes for metabolic labeling of 
lipid backbones. The glycerol-N3 (4.1), monoacylglycerol-N3 (4.2-4.7), and 
monoetherglyerol-N3 (4.8-4.19) probes targeted for synthesis are summarized in Figure 
4.1, accompanied by structural details in Table 4.1. The unnatural azide group, joined to 
the analogous-sn-1 carbon (denoted sn-1’, and the same applies for sn-2’ and sn-3’) by  
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Figure 4.1: Structures of glycerol-based metabolic labeling probes, defining probe 
backbone positions as sn-3’, sn-2’, and sn-1’ with respect to native glycerol sn-3, 
sn-2, and sn-1 positions. 
 
a methylene linker, is intended to have a low synthetic profile while enabling click-
conjugation. This approach is unique in this placement of a bioconjugation tag compared 
to fatty acid chain or headgroup-derivatives mentioned previously. In addition to synthetic 
novelty, these probes could theoretically achieve global glycerolipid and phospholipid 
labeling since the glycerol backbone is a common metabolic feature that is propogated 
thorugh lipid biosynthesis. 
With these probes we followed the metabolic labeling protocol illustrated in Figure 
4.2. Glycerol-N3 or any of its monoacyl or monoether derivatives were spiked into cell 
cultures and incubated to allow uptake and labeling. After harvesting and washing the 
cells, one of two choices were made: whole cell click with a fluorescent dye was 
conducted to visualize probe metabolism and subcellular location by fluorescence 
microscopy; or, cells were lysed for lipid extraction, click derivatization with a fluorescent 
219 




dye, separation by TLC, and visualization under UV light. Success of labeling for TLC 
was judged by the presence of new spots that do not appear in probe-free or 
unmetabolized-probe control lanes. 
We chose yeast, mainly S. cerevisiae and occasionally C. albicans, as our 
experimental organisms for metabolic labeling, due to its ease of handling, rapid growth 
in fermentable or non-fermentable carbon sources, and overlap of biochemical systems 
with other eukaryotic organisms including mammals.220 Yeast lipid biosynthetic pathways 
are summarized in Figure 4.3 Ideally, 4.1 is designed to be taken up by a cell and enter 
lipid biosynthesis by phosphorylation, followed by acyl transfer to form labeled LPA, and 
then a second acyl transfer to form labeled PA. From there, all lipid classes could be 
accessible. While the proposed synthetic modification to glycerol creates an unnatural 2 
alcohol at the sn-1’ position, the 1 sn-3’ position is maintained to increase the likelihood 
of kinase and other enzymatic activity at the headgroup. Following this line of thinking, 
we recognize that the pathway tolerance for these probes will be indicated by final  
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Figure 4.2: General workflow for lipid metabolic labeling using azide-tagged 
probes. 
After probe incubation with yeast, labeled biomolecules are click-conjugated to an alkyne-
bearing fluorescent dye, either in whole cells for visualization by microscopy, or in lysates 
for visualization by TLC. 
 
analyses of metabolically labelled products.  
To explore ways to enhance probe uptake and increase chances of finding a well- 
tolerated metabolic probe, we synthesized probes with different acyl and ether patterns 
on the glycerol-N3 backbone within the boundaries of common fatty acid units found in 
yeasts.29 This strategy was pursued in response to past literature suggesting limited 
metabolic tolerance by yeast glycerol kinase for short hydrocarbon chains on the same 
backbone position where glycerol-N3 bears its methylene azide conjugation unit.221 
Ideally, this would create new points of metabolic infiltration into the yeast lipidome, and 
possibly result in unique labeling patterns between homologous probes bearing 
hydrocarbon chains of different lengths and degrees of unsaturation.  
4.3 Known roles of 1- and 2-MAG  
In general MAG have well-known antimicrobial, preservative, and emulsification 
properties that make them useful additives in the food industry, counteracting fungal,222 
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Figure 4.3: Overview of yeast lipid metabolism,48 highlighting lipids of interest for 
detection of metabolic labeling (yellow). 
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listerial,223 and general bacterial contamination,224 particularly in human milk fortifier for 
infants.225 Monocapryl and monolauryl esters of glycerol are the most well known as anti-
microbials, exhibiting broad activity by disrupting cell membrane structure and phase 
behavior226-227  to kill gram negative bacteria,228-230 gram positive bacteria, 231-234 Candida 
albicans,235-236 and also disrupt viral envelopes by changing the membrane properties,237   
Monocapryl and monolauryl ester of glycerol have both been explored as 
ingredients in topical antimicrobial hydrogel formulation,238-240 due to their known activity 
against HSV-1 and HSV-2,241-242  Neisseria gonorrhoeae,243 SIV,244 Chlamydia 
trachomatis,228 and other mucosal pathogens while sparing commensal organisms such 
as lactobacilli.236, 245 Studies have shown that organisms do not easily develop resistance 
to these potential treatments, since they act through membrane disruption rather than 
protein targeting.246 
In mammals, MAG are included as part of a system of lipids for innate defense 
against infection, particularly on the skin247-248 and within the intestinal tract and mucousal 
membranes. Saturated acyl chains of 8-12 carbons and unsaturated chains of greater 
than 14 carbons have been observed to be most effective in preventing infection. 238, 249-
250 
At the molecular level MAG destroys membranes by an incompletely understood 
mechanism, although monolauryl and monocapryl esters, are suspected to alter 
membrane morphology251 and destabilize bacterial and fungal235 plasma membranes.238  
Recent studies also suggest that in sub-bacteriostatic concentrations, monolauryl esters 
may disrupt signaling pathways to inhibit the production of bacterial lipase enzymes252 
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and virulence factors,253 as well as -lactamase, toxic shock toxin-1, and other 
expoproteins.254  
MAGs have several known signaling roles in mammals as well. They are 
byproducts of energy management pathways related to TAG degradation, and the 1- or 
2-acylglycerol intermediates are hydrolyzed by MAG lipase255 into glycerol and FA.256 2-
monoglycerides are known to participate in endocannabinoid pathways,257-258 and MAG 
lipase activity is important for the regulation of these systems, particularly for the signaling 
molecule 2-arachidonoylglycerol,259 which targets the CB1 and CB2 cannabinoid 
receptors.260-261 Mammalian lipid phosphate phosphatases (LPP) form 1-MAG by 
cleaving phosphate from lyso-PA, thought to reduce the amount of lyso-PA in the cell to 
dampen its signaling activity. Overexpression of this enzyme class in vivo in mammalian 
cells has been observed to suppress malignant growth.41 
In S. cerevisiae, DAG/TAG lipase,262-263 DAG acyltransferase,264 DAG kinase,265 
PL:DAG acyltransferase,266 and glycerol kinase221 pathways are well-characterized. LPA 
phosphatase267 activity has also been identified as a phosphate-releasing mechanism, 
generating 2-MAG as a byproduct. However, acyltransferase and kinase enzymes that 
utilize 1- and 2-MAG as a metabolic substrate are less clear,268-269 while MAG lipase 
enzymes have only recently been discovered in yeast. While the toxicity of some medium 
chain MAGs in fungi has been documented,235, 270 the elucidation of endogenous 
biological roles of MAGs in yeast has been limited, and only in the last decade have 
potential metabolic and signaling functions been suggested.  
In 2007,266 Ghosal demonstrated that phospholipid:diacylglycerol acyl transferase 
(PDAT) in S. cerevisiae can also mediate acyl transfer from PC to sn-1-oleylglycerol and 
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sn-2-monooleylglycerol, albeit at a much slower rate (~10-1) slower compared to when 
DAG is the acyl chain acceptor. 
A pivotal study was published in 2010271 when Heier identified Yju3p,272 located in 
lipid droplets and ER in S. cerevisiae,273-274 as having genetic similarity to mammalian 
MAG lipase. Peptide analysis of Yju3p indicated serine hydrolase resemblance275 and 
revealed typical lipolytic features including a G-X-S-X-G sequence and  hydrolase 
fold.276 In vitro experiments with isolated Yju3p and in vivo knockout (yju3) experiments 
with TLC analysis of radiolabeled 2-oleylglycerol confirmed high MAG lipase specificity 
and activity of this protein, pinpointed by fractionation studies to occur almost exclusively 
in lipid droplets. A later study by the same author also demonstrated Yju3p activity for 1-
palmitoylglycerol.277 Finally, Heier demonstrated that Dga1p and Lro1p,264 DAG 
acyltransferase enzymes crucial for TAG synthesis in lipid droplets, are capable of 
esterifying MAG as well, specifically 2-oleylglycerol. Relevant work by Thiele concerning 
metabolic labeling of lipid droplets in mammals pertaining to acyltransferase enzymes 
has also been performed using radiolabeled and intrinsically fluorescesnt lipid probes.278 
The work performed by Heier characterized a major mechanism for MAG 
degradation to glycerol and FA in the context of DAG/TAG energy storage pathways in 
S. cerevisiae. However, the data at the time also suggested the presence of other 
unknown sn-2-acylglycerol lipase enzymes.271 A more recent investigation by 
Selvaraju279 identified another highly specific MAG lipase in S. cerevisiae given the name 
Mgl2p, observing highest activity for C16, C18, and C(18:1), moderate activity for C14, 
and negligible activity for C8, C10, and C12 1-MAGs using TLC analysis of radiolabeled 
lipids. Unlike Yju3p, Mgl2p is localized to the plasma membrane and cytosol.280 Other 
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work by the same research group found Rog1p, a protein localized in the cytosol and 
nucleus.281 This protein also exhibited high specificity for MAGs, and greatly favored 
C(18:1) 1- and 2-MAGs over saturated acyl chains with even numbers of carbon C8-C18, 
also demonstrated by TLC of radiolabeled lipids. cRog1p and Mgl2p contain lipolytic 
domain characteristic of alpha/beta and serine hydrolase enzymes, respectively. 
Here, we synthesize novel MAG and monoetherglycerol (MEG) derivatives 
equipped with an azide bioconjugation tag and explore their application as metabolic 
labeling probes by feeding them to S. cerevisiae. Several fatty acid and alkyl ether chain 
permutations with even carbon numbers were selected to cover the spread of most 
common lipids found in yeast. 
4.4  Synthesis of Glycerol Azide and Acylated Derivatives 
Routes to glycerol azide probe 4.1 and various acylated derivatives are shown in 
Scheme 4.1. First, 4.1 was made by following a published procedure of refluxing 
previously synthesized acetonide-protected azido alcohol 2.10 in aqueous acetic acid.132 
4.1 is also reported in earlier work by others.282 Exhaustive acetylation of 4.1 using an 
excess of acetic anhydride in pyridine provided triacetyl glycerol azide 4.20, which is also 
a previously reported compound.282  
To obtain 4.23 with a lone acylated 1 alcohol, acetonide-protected azido tosylate 
4.21, which was pulled from a frozen stock previously synthesized by Dr. Smith, was 
subjected to nucleophilic substitution with sodium acetate to make acetonide-protected 
azido acetate 4.22. Subsequent warming in aqueous acetic acid produced homo-sn-3-
acetylated glycerol azide 4.23. 
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We then pursued 2,3-diacyl probe 4.25 beginning with 4-methoxybenzyl-protected 
acetonide azido compound 2.11, which was mentioned in Chapter 2. Warming in aqueous 
acetic acid gave free diol 2.12, also obtained in a synthesis in Chapter 2 under a different 
set of conditions. Acetylation with excess acetic anhydride in pyridine yielded diacetate 
4.24, which was then subjected to oxidative deprotection with dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) to provide 2,3-diacetylated glycerol azide 4.25. However, acyl 
group rearrangement under these conditions could not be controlled as predicted by 
previous reports,132 and these results guided the decision to install single longer chain 
(C10-C18) tails at the 2- and 3- positions with more stable ether linkages in later syntheses. 
 
 
Scheme 4.1: Synthesis of glycerol azide probe 4.1, and acylated derivatives 4.20, 
4.23, and 4.25. 
i) 90% AcOH (aq), reflux, 87%; ii) Ac2O, pyridine, 97%; iii) Sodium acetate, DMF, 75C, 
25%; iv) 80% AcOH (aq), 40C, 52%; v) 60% AcOH (aq), 50C, 75%; vi) DDQ, (1:18) 
H2O/CH2Cl2, 22%. 
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Next, we sought to optimize a route to 3’-monoacylglycerol (3’-MAG) azide 
derivatives that allowed fatty acid chains to be chosen and installed later in the synthesis 
for rapid creation of a diverse probe set, as shown in Scheme 4.2. The first attempt at 
doing so followed an ideal route of a single step from 4.1, the synthesis of which could be 
easily scaled up for this purpose. However, coupling hexanoyl, decanoyl, and 
tetradecanoyl chorides to 4.1 in the presence of N,N-dimethylaminopyridine (DMAP) 
following a published procedure produced corresponding 3’-MAG azide probes 4.26, 4.2, 
and 4.4 with significant impurities that were difficult to separate.283 An alternate route was 
attempted beginning from previously mentioned compounds 2.10 and 3.22 which had 
similar diol ketal protecting groups and were coupled to decanoic acid using N,N’-
dicyclohexylcarbodiimide (DCC) with DMAP to give the corresponding decanoate esters 
4.27 and 4.28. These two compounds were pooled for deprotection by warming in 
aqueous acetic acid to give common product 3’-monodecanoylglycerol azide 4.2. The 
gained control over regioselectivity at this step was worth the added cost of an extra 
deprotection step for each probe. 
The route to 3’-MAG azide probes was again adjusted as shown in Scheme 4.3, 
this time to overlap via intermediate 4.29 with a future route illustrated in Scheme 4.5 
later in this chapter. Following conditions from a previously published route,137 
Commercially available diethyl-L-tartrate (2.7) was reacted with 4-methoxybenzylidine 
dimethylacetal in the presence of p-toluenesulfonic acid (p-TsOH), then reduced with 
lithium aluminum hydride to give 4-methoxybenzylidene acetal (MPM)-protected diol 
4.29. A sodium alkoxide salt was formed using sodium hydride (NaH), and then reacted 
with one equivalent of t-butyldiphenylchlorosilane (TBDPSCl) to produce TBDPS- 
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Scheme 4.2: Systems explored for obtaining glycerol azide monoester probes 
bearing fatty acids on the primary (sn-3’) alcohol. 
i) Fatty acid chloride, DMAP, (1:3) DMF/CH2Cl2; ii) Decanoic acid, DCC, DMAP, Benzene, 
0C to 20C, (4.27 = 54%, 4.28 = 71%); iii) 75% AcOH (aq), 45C, 88%. 
 
protected alcohol 4.30 as a pair of diastereomers, which were kept as a mixture for the 
next reaction under Mistsunobu conditions with diphenylphosphoryl azide (DPPA), 
triphenylphosphine (PPh3), and diisopropyl azidodicarboxylate (DIAD) to yield azide 4.31 
as a pair of diastereomers. 4.31 was silyl deprotected with tetrabutylammonium fluoride 
(TBAF)284 to provide free alcohol 4.32 as a pair of diastereomers, which was analogous 
to the 2.10/3.22 synthetic starting point presented in Scheme 4.2. The supply of 4.32 was 
split and reacted with different fatty acids using DCC and DMAP285 to give a set of 
protected fatty ester products, each as pairs of diastereomers: decanoic acid to give 4.33; 
dodecanoic acid to give 4.34; tetradecanoic acid to give 4.35; hexadecenoic acid to give 
4.36; octadecanoic acid to give 4.37; oleic acid to give 4.38. Finally, 4.33-4.38 were 
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deprotected with a mixture of acetic acid, tetrahydrofuran, and water,286 warming slightly 
to solubilize longer chain unsaturated esters as needed, to give the corresponding set of 
3’-MAG azide probes 4.2-4.7. 
 
 
Scheme 4.3: Completed syntheses of 3’-monoacylglycerol azide probes 4.2 
through 4.7, featuring a diversity-creating step from intermediate 4.32. 
i) 4-methoxybenzaldehyde dimethyl acetal, p-TsOH, benzene, 85C; ii) LiAlH4, THF, 0C 
to 20C, 68% (2 step); iii) NaH, DMF, 0C; iv) TBDPSCl, 0C to 20C, 74% (2 steps); v) 
DIAD, PPh3, THF; vi) DPPA 96%* (2 steps, unreacted DPPA impurity); vii) TBAF, THF, 
0C to 20C, 65%; viii) Fatty acid, DCC, DMAP, benzene, 0C to 20C; ix) (3:2:1) 
AcOH/THF/H2O, 20-30C.  
 
Next, illustrated in Scheme 4.4, we sought to synthesize 1’- and 2’-MAG azide 
probes that would complement the 3’-MAG azide probes already in hand. First, we 
pursued  a route to allow 2’-monoacyl derivatives using reaction conditions from a 
published protocol287 for  installing 1,3-benzylidine protection on 1,2,3-triol groups. 
Gylcerol azide 4.1 was reacted with benzaldehyde and trimethylorthoformate in the 
presence of ()-10-camphorsulfonic acid (CSA) to give 1,3-protected alcohol 4.72, which 
was acylated with acetic anhydride in pyridine to make acetate 4.39. However, 
deprotection by heating in aqueous acetic acid produced three separate monoacyl 
products 4.40, 4.23, and 4.41 upon purification by column chromatography, again 
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demonstrating the sensitivity of internally acylated alcohols to acyl migration in this 
system. 3’-MAG 4.23 was identified by matching spectra with the same molecule made 
intentionally by alternate means in Scheme 1, but the small amounts of desired 2’-MAG 
4.40 and 1’-MAG byproduct 4.41 were not worth characterizing since low yields and lack 
of synthetic control terminated further interest in this route. 
Then, to pursue 1’-monoacyl derivatives a previously published synthesis288 was 
tested using ascorbic acid (4.42) as a commercially available starting material by first 
reacting with acetone and copper(II) sulfate (CuSO4) to make acetonide-protected 
derivative 4.43.  Oxidative cleavage using aqueous hydrogen peroxide (H2O2) with 
potassium carbonate (K2CO3) to form potassium carboxylate intermediate 4.44, followed 
by reaction with methyl iodide (MeI) gave methyl ester 4.45 with low yield that discouraged 
further work on this route. 
 
 
Scheme 4.4: Systems explored for obtaining glycerol azide monoether probes 
bearing hydrocarbon chains on individual secondary alcohols. 
Top route: 2’-MEG-N3 compounds; bottom route: 1’-MEG-N3 compounds. i) 
Benzaldehyde, trimethylorthoformate, ()-10-CSA, CH2Cl2, 0C to 20C; ii) TEA, 24% (2 
steps); iii) Ac2O, pyridine, 99%; iv) 75% AcOH (aq) 50C (4.40, 4.41 = trace detected; 
4.23 = 27%. v) CuSO4, acetone, 85%; vi) K2CO3, 30% H2O2 (aq), 4C to 20C,; vii) MeI, 
MeCN, reflux, 7% (2 steps); viii) LiAlH4, THF, 0C to 20C; ix) TBDPSCl, TEA, CH2Cl2.  
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Finally, we pivoted back to the 1’,2’-protection system demonstrated earlier to 
pursue a new route shown in Scheme 4.5.  Common intermediate diol 4.29 was 
converted to its alkoxide salt with NaH and reacted with one equivalent of p-
methoxybenzychloride (PMBCl)137 to generate PMB-protected alcohol 4.48 as a pair of 
diastereomers. Activation of the free alcohol of 4.48 using methanesulfonyl chloride 
(MsCl) with triethylamine (TEA) formed mesylate 4.49 as a pair of diastereomers, which 
was subjected to nucleophilic substitution with sodium azide (NaN3) to give fully-protected 
azide 4.50 as a pair of diastereomers. Alternatively, activation of 4.48 with p-
toluenesulfonyl chloride and substitution with sodium azide gave a similar yield of 4.50 
(route not shown). 
At this point, the utility of the MPM protecting group proved essential in obtaining 
exclusively free alcohols at either the 1’- or 2’-position. According to previous work, 
attenuated reducing agents such as diisobutylaluminum hydride (DIBALH)289-292 or 
sodium cyanoborohydride (NaBH3CN)293-295 asymmetrically transform MPM-protected 
diols to a free alcohol and a PMB-protected alcohol. The regioselectivity of this reaction 
depends on steric crowding during the deprotective transition state and can be influenced 
by the presence of an acid by stabilizing and favoring full deprotection of the more 
electron-rich alcohol.292-293 When we applied these reactions to 4.50, we observed some 
condition dependent regioselectivity. However, both free 1’-alcohol 4.51 and 2’-alcohol 
4.52 were desired target molecules, so a lack of selectivity is beneficial to our synthetic 
aims. Reaction of 4.50 with DIBALH was regioselective for 4.52 over 4.51 by a ratio of 
(3.5 to 1), while reaction with NaBH3CN in the presence of 4Å molecular sieves and 
trifluoroacetic acid (TFA) was regioselective for 4.51 over 4.52 by a ratio of (1.6 to 1) and 
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also produced diol byproduct 2.12. Regioisomers 4.51 and 4.52 were separable by 
column chromatography.  
With appropriately protected alcohols 4.51 and 4.52 in hand, we entered into the 
diversity-creating phase of the synthesis. While ester linkages to make 1’- and 2’- MAG 
azide probes would have been more appropriate for mimicking biology, especially for 
comparing to previously reported radiolabeled lipid TLC experiments characterizing MAG 
lipase activity,271 we elected to install hydrocarbon tails with ether linkages to avoid acyl 
chain migration that could occur during synthesis or storage. To form 1’-monoether 
glycerol (1’-MEG) azides, 4.51 was converted to its alkoxide salt with NaH, and then used 
in Williamson ether synthesis with a tetrabutylammonium iodide (TBAI) catalyst to give 
each protected 1’-monoether product: reaction with 1-bromodecane gave 4.53; 1-
bromododecane gave 4.54; 1-bromotetradecane gave 4.55; 1-bromohexadecane gave 
4.56; 1-bromooctoadecane gave 4.57; and (Z)-1-bromooctadec-9-ene gave 4.58. 
Deprotection with TFA gave the desired 1’-MEG azide probes 4.14-4.19. To make the 
analogous 2’-MEG azides, identical conditions were applied beginning with compound 
4.52 to give protected intermediates 4.59-4.64, and finally probes 4.8-4.13. 
To aid in detection of labeled products, two molecules were synthesized as shown 
in Scheme 4.6. First, commercially available carboxylic acid 4.65 was coupled to 
propargylamine using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) in the presence of diisopropylethylamine (DIEA) to give 
alkyne 4.66, which was also reported by Dr. Tanei Ricks of the Best Research Group.296 
This molecule was intended for use as an isotope tag (bromide doublet) that could be  
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Scheme 4.5: Current route to obtaining 1’-MEG-N3 (4.14-4.19) and 2’-MEG-N3 (4.8-
4.13) glycerol azide monoethers. 
i) 1) NaH, DMF, 0C to 20C; ii) PMBCl, 0C to 20C, 64% (2 steps); iii) MsCl, TEA, 
CH2Cl2, -15C to 0C, 78%; iv) NaN3, DMF, 80C, 86%; v) DIBALH, CH2Cl2, -78C; (4.51 
= 10%; 4.52 = 35%) vi) NaBH3CN, 4Å-MS, CH2Cl2; vii) TFA, THF (2 steps: 4.51 = 39%; 
4.52 = 25%, 2.12 = 29%; viii) NaH, DMF, 0C to 20C; ix) 1-bromoalkane or 1-
bromoalkene, TBAI, 0C to 20C (Yields range 34 – 69%); x) (1:4) TFA/CH2Cl2 (Yields 
range 51 – 99%). 
 
clicked onto labeled molecules and enhance their detectability among complex mass 
spectra.  
Next, a commercially available clickable alkyne dye 4.70 was synthesized in house 
according to previous protocols due to its expensive price (Tocris Bioscience #5712).297-
299 Commercially available precursor 4.67 was reacted with ethylamine to give 
naphthalimide 4.68, and then subjected to Sonogashira coupling300 with trimethylsilyl 
(TMS)-protected ethyne to give protected alkyne 4.69. Deprotection under basic 
conditions with potassium carbonate (K2CO3) gave 4.70. This click dye is a modified UV-
active fluorophore,301 and was useful in the experiments presented due to its shift in 
fluorescence upon click reaction,210 enhancing detection of azide-labeled products and 
reducing background fluorescence. It is also neutral and much less polar compared to 
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other clickable dyes such as TAMRA alkyne296 and Cy3 alkyne, reducing perturbation of 
lipid Rf on TLC compared to native structures.  
 
Scheme 4.6: Synthesis of lipid labeling detection aids for mass spectrometry (4.66) 
and fluorescence TLC (4.70). 
i) Propargylamine, HBTU, DIEA, CHCl3, 65%; ii) Ethylamine, (1:1) 1,4-dioxane/H2O, 
100C, 75%; iii) Ethynyltrimethylsilane, Pd(Ph3)4, CuI, TEA, THF, 50%; iv) K2CO3, (1:3) 
H2O/MeOH, 80%. 
  
4.5 Metabolic Labeling Experiments in Yeast 
Labeling with Glycerol Azide 4.1 
All metabolic labeling experiments were performed in S. cerevisiae using 2% 
glycerol synthetic media unless noted otherwise. The TLC results of our first complete 
labeling experiment with probe 4.1 are displayed in Figure 4.4. After labeling yeast 
cultures with 100 M 4.1 overnight, lipid extracts were clicked with commercially available 
Cyanine 3-alkyne (Cy3) and loaded onto a TLC plate in 0.125-8.0 L quantities. After 
separating with a two-phase elution solvent mixtures (First elute to Rf of 0.6 with a 
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Figure 4.4: 100 M labeling experiment, screening or optimal TLC plate loading. 
Cy3 alkyne used as fluorescent dye. 
 
65:25:4:1 chloroform:methanol:water:acetic acid mixture. Then, after drying, elute to Rf of 
1.0 with a 1:1 ethyl acetate:cyclohexane mixture),30 we observed high sensitivity for Cy3. 
However, a no-probe control was not included on this TLC plate, so background from 
unclicked dye is not distinguishable. 
Next, we performed another overnight labeling experiment at concentrations 0-100 
M, as shown in Figure 4.5. This time, it was clear that Cy3 has a high background in 
dye-only (lane E) and no-probe (lane I) controls, which makes it difficult to distinguish any 
metabolic labeling. However, it does appear that new TLC spots emerge as probe 
concentration is increased (lane F, above brightest backgtound spot).  
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Figure 4.5: Metabolic labeling for different probe (4.1) concentrations. Click with 
Cy3 alkyne. 
 
Followng the previous result, we decided to try a new click dye, 
ethynylnaphthalimide 4.70, since it became apparent that the high polarity and 
background labeling with Cy3 was not suitable for tracing labeled lipid products in this 
system. Compound 4.70 is fluorogenic, exhibiting an emission shift upon click with an 
alkyne unit, so we selected this dye as a way to reduce TLC background from unclicked 
dye. Also, 4.70 is relatively nonpolar compared to polysulfonated Cy3, so we considered 
that it would have less of a perturbing effect on lipid retention factors on TLC compared 
to their native lipid forms.  
Pivoting on this new click dye system, we ran TLC analysis shown in Figure 4.6 
of lipid standards using our standard elution solvents, including PC, PA, PE, PG, DAG, 
and PS, as well as unmetabolized probe 4.1. Background from 4.1 was imaged by UV 
fluorescence, demonsrating the effectiveness of click dye 4.70. Lipid standards were  
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Figure 4.6: Standard TLC plate, giving Rf values for 4.1, and for PC, PA, PE, PG, 
DAG. And PS. 
Left: Click product fluorescence with alkyne 4.70 under 365 nm light. Right: Primuline 
stain under 365 nm light. 
 
imaged using primulin stain with UV visualization, showing spots with Rf values that match 
previously published expreiments using the same elution system.30 
Next, we incubated yeast with 2 mM 4.1 for 8 h, and clicked lipid extracts with 4.70 
to give the TLC results shown in Figure 4.7. Lanes that included clicked metabolic 
extracts of 4.1 (G-H) appeared to have unique fluorescent spots compared to dye-only 
(A-C) and probe-free lipid extract (D-F) lanes. Lanes G-I appear to show uptake of probe 
4.1 with spots at mid-plate, and also a polar spot that does not appear to match the probe 
background pattern (lane denoted with * on the right), and seems to match R f of a 
phospholipid standard, possible PC or PS. 
Encouraged by this result, we repeated labeling with 2 mM probe 4.1, this time 
comparing 2 h and 8 h incubation times. The click fluorescene results, displayed on the 
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Figure 4.7: 2 mM incubation of probe 4.1 for 8 h. 
Lane marked with * is probe 4.1 subjected to click method 1 with dye 4.70 in absence of 
any lipid content.  
 
left in Figure 4.8, seem to replicate what was observed in Figure 4.7, showing evidence 
of cellular uptake of 4.1 with fluorescent spots near mid-plate in lanes D-I, and unique 
spots that appear closed to the origin in lanes F-G that match phospholipid standards. 
Primuline stain results, shown on the right of Figure 4.8, indicate that the low spot 
overlaps with phospholipid content from the yeast lipidome. Stronger spots are apparent 
in the 8 h lanes (G-I) versus the 2 h lanes (D-F), although lane F anomalously shows 
stronger fluorescence. 
After these initial successes, the original yeast culture used for these experiments 
was was lost and repeatability and sensitivity was not good, even at higher concentrations 
(~10 mM). At this point, we discontinued metabolic labeling experiments featuring 4.1. 
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Figure 4.8: 2 mM incubation of probe 4.1 for 2 or 8 h. 
Left: Click product fluorescence under 365 nm light. Right: Primuline stain under 365 nm 
light. 
 
Labeling with Glycerol-N3-Acetate Derivatives 4.23, 4.25, and 4.20 
In order to explore new strategies for enhancing uptake and metabolism of 
glycerol-N3-based probes, we modified probe 4.1 with different acylation patterns to give 
glycerol-N3-3’-acetate 4.23, glyecerol-N3-1’,2’-diacetate 4.25, and triacetin glycerol-N3 
4.20. The TLC results of labeling at 1 mM of each probe in C. albicans for 4.5 h are shown 
in Figure 4.9. Candida was tried for this experiment due to ready availability, and to see 
if results wer noticeably different from Saccharomyces experiments. After click with dye 
4.70 Both lipid (left image) and polar/aqueous (right image) extracts from the cell lysates 
appeared to show enhanced labeling for the 3’-acetate probe 4.23. No metabolism of 
probes was observed other than acetate cleavage back to 4.1. 
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Figure 4.9: TLC results for labeling with acetate esters of 4.1, comparing uptake of 
acylated glycerol-N3 derivatives (4.23, 4.25, 4.20) to the original glycerol-N3 probe 
(4.1). 
 
Metabolic Labeling Experiments in Yeast With 3’-MAG-N3 Probes 
Noticing the impact of alcohol esterification on uptake in these experiments, a new 
approach was followed to investigate the effects of longer acyl chains at the 3’-position. 
Incubation at 3.5 mM for 10 h in Candida using 3’-hexanoate, decanoate, and 
tetradecanoate esters (4.26, 4.2 and 4.4) of glycerol-N3 gave the TLC result shown in 
Figure 4.10. Here, strong metabolic labeling appears to be happening for 4.2 (lanes E-F, 
G is unmetabolized probe control), producing new fluorescent spots at an Rf characteristic 
of diacyl and tiracylglycreols, indicating that acyltransferase activity may be esterifying 
this probe with one or more fatty acid chains. Compounds 4.26 and 4.4 produced some 
faint spots in patterns distinct from 4.2.  
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Figure 4.10: TLC results from 3.5 mM screening experiment exploring lipid labeling 
using 3’-monoacylated glycerol-N3 probes (4.26, 4.2, and 4.4). 
(*Probe-only, yeast-free click control). 
 
Probe 4.2 was used again in a time and concentration-dependent experiment, this 
time back in S. cerevisiae and this time in 2% galactose media, both of which produced 
similar results in trial labeling runs. Using galactose media also has the advantage of 
faster culture growth over glycerol media. The TLC results shown in Figure 4.11 seem to 
indicate that labeling with 4.2 increases with higher labeling concentrations and longer 
incubation times, with the cutoff for detecting uptake appearing to be at 250 M (lane E, 
5.5 h plate). Labeling patterns also appear to be similar to those seen in Figure 4.10. 
However, probe 4.2 inhibited yeast growth at concentrations above 50 M, as 
demonstrated in the growth chart in Figure 4.12. 
Growth suppression of yeast by probe 4.2 should not be suprising due to the known 
antifungal effects of its natural analog, 1-monocaprylglycerol, mentioned in the 
background section in this Chapter. However, this created a dilemma of requiring toxic 
242 
 








levels of 4.2 in order to see clear metabolic labeling using this system. At this point, we 
synthesized the series of 3’-MAG homologs shown below in Figure 4.13 to screen for a 
probe that gives high levels of metabolic labeling with minimal toxicity in yeast. Again 
using 2% galactose media and Saccharomyces, we incubate probes 4.2-4.7 at 50, 250, 
and 1000 M, for 4h and click the resulting lipid extracts with dye 4.70. Again, we see the 
same labeling patterns for 4.2 in lane D, while other probes do not exhibit strong labeling. 
Some faint acyltransferase activity is present for probes 4.5 (lane P) and 4.6 (lane U), 
while lipase activity seems to produce spots in lanes C and F that match the glycerol-N3 
control (lane J). Growth curves for this experiment, shown in Figure 4.14, show growth 
suppression for probes 4.2 and 4.3 that increases with concentration.  
 
 
Figure 4.13: TLC results of 50, 250, or 1000 M labeling with 3’-MAG-N3 probes 4.2 
– 4.7 in 2% galactose media. 




Figure 4.14: Growth charts for labeling experiments in galactose media with 3’-
MAG-N3 probes. 
All data points are for single culture replicates. 
 
Finally, a similar 3’-MAG-N3 labeling experiment was conducted using 2% glycerol 
media for 6.5 h, which appeared to have an affect on metabolic labeling. The TLC results, 
shown in Figure 4.15, show strong metabolic labeling for probes 4.2 (lane D), 4.3 (lane 
H), 4.4 (lanes L-M), 4.6 (lane V), and 4.7 (lane Z), and no discernable activity for 4.5. 
Labeling patterns all seem to reflect acyltransferase activity to form DAG or TAG 
molecules, but further analysis with mass spectrometry, or with clicked synthetic DAG 
and TAG probe analogs as TLC standards would be beneficial. Growth curves in Figure 
4.16 show that toxicity of all probes typically increases with higher probe concentrations 
and with decreasing acyl chain lengths. Fortunately, we find that Probe 4.4 appears to 
produce strong, concentration-depndent metabolic labeling in this system, while 
exhibiting minimal growth suppression to the host organism. In future experiments, we 
will explore whole cell click fluorescence experiments in yeast using probe 4.4. Also, we 




Figure 4.15: TLC results 50, 250, or 1000 M incubation of 3’-MAG-N3 probes 4.2 – 




Figure 4.16: Growth charts for labeling experiments in glycreol media with 3’-MAG-
N3 probes. 
All data points are for single culture replicates. 
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4.6  General Synthetic Experimental  
General synthetic methods and equipment are the same as those mentioned in 
Chapter 1.  
4.7  Detailed Syntheses 
 
 
(2S,3S)-4-Azidobutane-1,2,3-triol (4.1). A previously reported procedure was 
followed.132 In a 50 mL round bottom flask, previously synthesized compound 2.10 (84 
mg, 0.41 mmol) was dissolved in 5 mL 90% aqueous acetic acid (AcOH (aq)), and the 
mixture was stirred while heated to reflux for 15 min. The resulting solution was 
concentrated by rotary evaporation with azeotropic removal of AcOH using (3x) 3 mL 
benzene. The resulting crude reside was purified on a silica gel column using a gradient 
elution of 0-2% methanol in ethyl acetate to give compound 4.1 as a clear oil (53 mg, 87% 
yield) Rf = 0.35 (10% MeOH-CH2Cl2, KMnO4). NMR and MS characterization data  
matched previous reports.132 
 
 
(2S,3S)-4-Azidobutane-1,2,3-triyl triacetate (4.20). In a 50 mL flame dried round 
bottom flask, compound 4.1 (10 mg, 0.068 mmol) was dissolved in 7 mL pyridine, and 
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acetic anhydride (64 L, 0.680 mmol) was added dropwise, and the solution was stirred 
overnight at rt. The resulting mixture was concentrated by rotary evaporation, dried under 
high vacuum, and purified on a silica gel column using a gradient elution of 15-35% ethyl 
acetate in hexanes to give compound 4.20 as a clear oil (18 mg, 97% yield). Rf = 0.60 
(35% EtOAc-hexanes, KMnO4). DART-MS: [M+H]+ for C10H15N3O6 calcd, 274.1034; 




(4.22). In an oven-dried 6 dram vial under argon, compound 4.21 (from frozen stock made 
by previous Best Research Group member Dr. Matt Smith, 121mg, 0.354 mmol)132 was 
dissolved in 2 mL N,N-dimethylformamide, and sodium acetate (NaOAc, 44 mg, 0.532 
mmol) was added in one portion. The suspension was heated to 75C with stirring for 24 
h, then a second portion of NaOAc (44 mg, 0.532 mmol) was added and the suspension 
was heated at 75C for another 12 hours. After cooling to rt, the resulting mixture was 
diluted with 15 mL water and extracted with (2x) 8 mL methylene chloride. The combined 
organic layers were washed with (5x) 2 mL water, then 2 mL brine (saturated sodium 
chloride (aq)), dried over sodium sulfate, filtered, concentrated by rotary evaporation, and 
dried under high vacuum to obtain a yellow oil. The crude residue was purified on a silica 
gel column using a gradient elution of 10-30% ethyl acetate in hexanes to give 4.22 as a 
clear oil. (20 mg, 25% yield). Rf = 0.30 (20% EtOAc-hexanes, KMnO4). 1H NMR (300 
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MHz, CDCl3) δ 4.31 – 4.20 (m, 1H), 4.20 – 4.05 (m, 2H), 4.05 – 3.92 (m, 1H), 3.61 – 3.27 
(m, 2H), 2.10 (s, 3H), 1.45 (dd, J = 12.4, 0.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 170.60 
, 110.38 , 76.91 , 75.92 , 63.82 , 51.68 , 26.91 , 26.84 , 20.75. DART-MS: [M-N2+H]+ for 
C9H15N3O4 calcd, 202.1074; detected, 202.1079. 
 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl acetate (4.23). In a 6 dram vial, compound 
4.22 (20 mg, 0.087 mmol) was dissolved in 5 mL 80% aqueous acetic acid (AcOH (aq)). 
The vial was stoppered and the solution was warmed to 40C with stirring for 16 h, and 
then concentrated by rotary evaporation with azeotropic removal of AcOH using (5x) 1 
mL toluene. The crude residue was purified on a silica gel column using a gradient elution 
of 50-75% ethyl acetate in hexanes to give compound 4.23 as a clear oil (8.5 mg, 52% 
yield). Rf = 0.55 (70% EtOAc-hexanes, KMnO4). 1H NMR (500 MHz, CDCl3) δ 4.26 – 4.13 
(m, 2H), 3.83 (ddd, J = 6.6, 5.0, 3.3 Hz, 1H), 3.76 (ddd, J = 6.7, 4.9, 3.3 Hz, 1H), 3.53 – 
3.40 (m, 2H), 2.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.41 , 70.14 , 69.89 , 65.51 , 







dioxolane (2.11) This compound was also synthesized in Chapter 2 by a different route. 
In a 100 mL oven dried round bottom flask under argon, compound 2.62 (641 mg, 1.778 
g) and sodium azide (NaN3, 347 mg, 5.335 mmol) were suspended in 15 mL N,N-
dimethylformamide, and the mixture was heated with stirring to 85C overnight. In light of 
a leaky rotary evaporator seal, the resulting mixture was concentrated by equipping a 
distillation head with a condenser and distilling off the solvents under vacuum at 85C. 
The residue was mixed with 75 mL water and extracted with (2x) 50 mL methylene 
chloride, and then the combined organic layers were washed with 35 mL brine (saturated 
sodium chloride (aq)), dried over magnesium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum to give a yellow oil. The crude residue was 
purified on a silica gel column using a gradient elution of 10-30% ethyl acetate in hexanes 
to give compound 2.11 as a clear oil (491 mg, 90% yield). Rf = 0.60 (25% EtOAc-hexanes, 
UV, KMnO4). NMR and MS characterization data  matched previous reports.132 
 
 
(2S,3S)-1-Azido-4-((4-methoxybenzyl)oxy)butane-2,3-diol (2.12). This 
compound was also synthesized in Chapter 2 by a different procedure. In a 6 dram vial, 
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compound 2.11 (90 mg, 0.293 mmol) was dissolved in 3 mL 60% aqueous acetic acid 
(AcOH (aq)). The vial was stoppered, and the mixture was warmed to 50C with stirring 
for 16 h, then was concentrated by rotary evaporation with azeotropic removal of AcOH 
using (5x) 1 mL toluene. The resulting crude residue was purified on a silica gel column 
using a gradient elution of 50-75% ethyl acetate in hexanes to give compound 2.12 as a 
clear oil (57 mg, 73% yield) Rf = 0.38 (50% EtOAc-hexanes, UV, KMnO4). NMR and MS 
characterization data  matched previous reports.132 
 
 
(2S,3S)-1-Azido-4-((4-methoxybenzyl)oxy)butane-2,3-diyl diacetate (4.24). In 
an oven dried 6 dram vial under argon, compound 2.12 (57 mg, 0.213 mmol) was 
dissolved in 2 mL pyridine, and acetic anhydride (Ac2O, 121 L, 1.28 mmol) was added, 
and the solution was stirred at rt overnight. The resulting brown solution was concentrated 
by rotary evaporation to give a brown oil. The crude residue was purified on a silica gel 
column using a gradient elution of 20-40% ethyl acetate in hexanes to give compound 
4.24 as a clear oil (Rf = 0.50 (35% EtOAc-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 
7.22 (d, 2H), 6.88 (d, 2H), 5.30 (ddd, J = 6.2, 5.4, 4.1 Hz, 1H), 5.21 (dt, J = 5.4, 4.9 Hz, 
1H), 4.43 (q, 2H), 3.81 (s, 3H), 3.52 (d, J = 4.9 Hz, 2H), 3.46 (dd, J = 13.2, 4.1 Hz, 1H), 
3.36 (dd, J = 13.2, 6.3 Hz, 1H), 2.08 (d, J = 4.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
170.09 , 169.95 , 159.39 , 129.48 , 129.41 , 113.85 , 73.00 , 70.75 , 70.71 , 67.33 , 55.27 
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(2S,3S)-1-Azido-4-hydroxybutane-2,3-diyl diacetate (4.25). In a 6 dram vial 
under argon, compound 4.24 (45 mg, 0.128 mmol) was dissolved in 3.0 mL methylene 
chloride, and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 73 mg, 0.320 mmol) was 
added. The solution was protected from light, 170 L water (to make (18:1) CH2Cl2/H2O) 
was added, and the black biphasic mixture was stirred vigorously at rt for 3 h. The 
resulting orange reaction was diluted with 8 mL methylene chloride, washed with (2x) 2 
mL saturated sodium bicarbonate (NaHCO3 (aq)), (4x) 2 mL water, then 2 mL brine 
(saturated sodium chloride (aq)), and then dried over sodium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum. The crude residue was 
purified on a silica gel column using a gradient elution of 30-55% ethyl acetate in hexanes 
to give an inseparable mixture of rearranged diacetate regioisomers (15 mg, 51% yield), 
and compound 4.25 as a clear oil (7 mg, 22% yield). Rf = 0.41 (50% EtOAc-hexanes, 
KMnO4). 1H NMR (500 MHz, CDCl3) δ 5.12 (ddd, J = 6.2, 4.9, 3.8 Hz, 1H), 4.41 (dd, J = 
11.9, 4.9 Hz, 1H), 4.15 (dd, J = 11.9, 6.2 Hz, 1H), 3.94 (td, J = 5.6, 3.8 Hz, 1H), 3.44 – 
3.38 (m, 2H), 2.44 (s, 1H), 2.13 (s, 3H), 2.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.69 
, 170.25 , 71.43 , 69.52 , 62.15 , 53.41 , 20.83 , 20.72.  DART-MS: [M-OH]+ for C8H13N3O5 




The following general method was used as an exploratory synthesis for 
compounds 4.26, 4.2, and 4.4: A modified version of a published procedure was 
followed.283 In an oven dried 6 dram vial under argon, compound 4.1 was dissolved in 2.5 
mL of a 1:4 N,N-dimethylformamide:methylene chloride mixture, and fatty acid chloride 
was added, followed by N,N-dimethylaminopyridine (DMAP). The reaction was stirred for 
3 h at rt, then concentrated by rotary evaporation, diluted and vortexed with 1 mL 
saturated sodium bicarbonate (NaHCO3 (aq)), diluted with 4 mL water, and extracted with 
(2x) 4 mL ethyl acetate. The combined organic layers were washed with (5x) 1 mL water, 
then 1 mL brine (saturated sodium chloride (aq)), dried over magnesium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum. The crude residue was 
purified on a silica gel column using a gradient elution of 20-50% ethyl acetate in hexanes 
to give the target compound, 
(2S,3S)-4-Azido-2,3-dihydroxybutyl hexanoate (4.26, n = 4). Compound 4.1 (23 
mg, 0.156 mmol), hexanoyl chloride (48 L, 0.244 mmol), DMAP (3 mg, 0.023 mmol), 
giving compound 4.26 as a clear oil (8 mg, 21% yield). Rf = 0.52 (50% EtOAc-hexanes, 
KMnO4). 1H NMR (500 MHz, CDCl3) δ 4.27 – 4.12 (m, 2H), 3.85 – 3.77 (m, 1H), 3.77 – 
3.70 (m, 1H), 3.51 – 3.38 (m, 2H), 2.37 – 2.30 (m, 2H), 1.68 – 1.57 (m, 2H), 1.38 – 1.22 
(m, 4H), 0.94 – 0.83 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 174.28 , 70.17 , 69.96 , 65.31 
, 53.60 , 34.07 , 31.22 , 24.53 , 22.25 , 13.85. DART-MS: [M+H]+ for C10H19N3O4 calcd, 
246.1449; detected, 246.1351. 
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(2S,3S)-4-Azido-2,3-dihydroxybutyl decanoate (4.2, n = 8). Compound 4.1 (29 
mg, 0.197 mmol), decanoyl chloride (90 L, 0.434 mmol), DMAP (3 mg, 0.023 mmol), 
giving compound 4.2 as a clear oil (23 mg, 39% yield). Rf = 0.45 (40% EtOAc-hexanes, 
KMnO4). NMR and MS data are consistent with results from a different synthesis 
presented later in this chapter. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl tetradecanoate (4.4, n = 12) Compound 
4.1 (31 mg, 0.211 mmol), decanoyl chloride (126 L, 0.464 mmol), DMAP (3 mg, 0.023 
mmol), giving compound 4.4 as a white powder (14 mg, 18% yield). Rf = 0.50 (40% 
EtOAc-hexanes, KMnO4). NMR and MS data are consistent with results from a different 




(4.27). A previously published protocol was followed.285 In an oven dried 6 dram vial, 
previously synthesized compound 2.10 (25 mg, 0.134 mmol), decanoic acid (28 mg, 
0.160) and N,N-dimethylaminopyridine (DMAP, 2 mg, 0.015 mmol) were dissolved in 3 
mL benzene, and cooled to 0C. To the stirring white suspension, N,N-
dicyclohexylcarbodiimide (DCC, 33 mg, 0.160) was added in a single portion, and the 
reaction was allowed to warm to rt and stir for 105 min. The cloudy suspension was diluted 
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in diethyl ether, filtered through celite, and concentrated by rotary evaporation to give a 
white solid. The crude residue was purified on a silica gel column using an elution gradient 
of 0-10% ethyl acetate in hexanes to give compound 4.27 as a clear oil (25 mg, 54% 
yield). Rf = 0.42 (10% EtOAc-hexanes, KMnO4). 1H NMR (500 MHz, CDCl3) δ 4.28 – 4.13 
(m, 1H), 4.09 (ddd, J = 8.1, 5.3, 4.3 Hz, 2H), 3.98 (ddd, J = 8.2, 4.8, 3.8 Hz, 1H), 3.56 (dd, 
J = 13.1, 3.9 Hz, 1H), 3.33 (dd, J = 13.2, 4.9 Hz, 1H), 2.34 (t, J = 7.6 Hz, 2H), 1.63 (q, J 
= 7.4 Hz, 2H), 1.46 (s, 3H), 1.42 (s, 3H), 1.35 – 1.21 (m, 12H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.44 , 110.30 , 75.92 , 63.49 , 51.68 , 34.04 , 31.82 , 
29.37 , 29.21 , 29.09 , 26.92 , 26.84 , 24.83 , 22.63 , 14.07. DART-MS: [M-N2+H]+ for 




(4.28). A previously published protocol was followed.285 The same procedure was 
followed as was used in the synthesis of compound 4.27, using: compound 3.22 (10 mg, 
0.045 mmol), decanoic acid (9 mg, 0.053 mmol), N,N-dimethylaminopyridine (DMAP, 0.5 
mg, 0.0045 mmol), N,N-dicyclohexylcarbodiimide (DCC, 11 mg, 0.053 mmol). The same 
workup was followed, and the crude residue was purified on a silica gel column using a 
gradient elution of 0-12% ethyl acetate in hexanes to give compound 4.28 as a clear oil 
(12 mg, 71% yield). Rf = 0.42 (10% EtOAc-hexanes, CeMo). 1H NMR (500 MHz, CDCl3) 
δ 4.24 – 4.13 (m, 2H), 4.04 (dt, J = 7.3, 5.1 Hz, 1H), 3.94 (ddd, J = 7.3, 5.3, 4.1 Hz, 1H), 
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3.51 (dd, J = 13.0, 4.1 Hz, 1H), 3.35 (dd, J = 13.1, 5.3 Hz, 1H), 2.33 (t, J = 7.6 Hz, 2H), 
1.92 – 1.76 (m, 4H), 1.77 – 1.58 (m, 6H), 1.34 – 1.23 (m, 12H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.46 , 120.21 , 76.89 , 75.93 , 63.61 , 51.90 , 37.31 , 
37.15 , 34.06 , 31.83 , 29.37 , 29.22 , 29.09 , 24.84 , 23.47 , 23.40 , 22.63 , 14.07 . DART-
MS: [M-N2+H]+ for C19H33N3O4 calcd, 340.2482; detected, 340.2486. 
 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl decanoate (4.2). In a 50 mL round bottom 
flask, compound 4.27 (25 mg, 0.073 mmol) and compound 4.28 (12 mg, 0.033 mmol) 
were combined and dissolved in 10 mL 75% aqueous acetic acid (AcOH (aq)). The 
solution was capped with a stopper, stirred, and warmed to 45C for 9 days, although 12 
h should have been sufficient. The solvents were removed by rotary evaporation with 
azeotropic removal of AcOH with (5x) 2 mL toluene, and the crude residue was purified 
on a silica gel column using 15-50% ethyl acetate in hexanes to give compound 4.2 as a 
clear oil (28 mg, 88% yield). Rf = 0.45 (40% EtOAc-hexanes, KMnO4). NMR and MS data 






(4S,5S)-4-(Azidomethyl)-2-phenyl-1,3-dioxan-5-ol (4.72). A published reaction 
protocol was applied to this synthesis.287 In an oven dried 6 dram vial under argon, 
compound 4.1 was dissolved in 2 mL methylene chloride, the solution was cooled to 0C, 
and benzaldehyde (22 L, 0.212 mmol), trimethylorthoformate (23 L, 0.212 mmol), and 
(+/-)-10-camphorsufonic acid ((+/-)-10-CSA, 14 mg, 0.062 mmol) were added. The 
reaction was allowed to warm to rt, and was stirred for 24 h before quenching with 
triethylamine (TEA, 13 L, 0.092 mmol). The resulting solution was concentrated by rotary 
evaporation to give a crude yellow syrup, which was purified on a silica gel column using 
a gradient elution of 4-12% acetone in chloroform to give compound 4.72 as a clear oil 
(10 mg, 24% yield). Rf = 0.48 (40% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, 
CDCl3) δ 7.53 – 7.42 (m, 2H), 7.44 – 7.32 (m, 3H), 5.63 (s, 1H), 4.34 – 4.19 (m, 1H), 4.16 
– 4.05 (m, 2H), 3.66 (dd, J = 12.9, 7.7 Hz, 1H), 3.62 – 3.55 (m, 1H), 3.42 – 3.35 (m, 1H), 
2.64 (d, J = 11.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 137.17 , 129.13 , 128.31 , 125.78 
, 101.34 , 78.77 , 72.44 , 64.17 , 51.52 . DART-MS: [M-H:]+ for C11H13N3O3 calcd, 






(4S,5S)-4-(Azidomethyl)-2-phenyl-1,3-dioxan-5-yl acetate (4.39) A published 
reaction protocol was applied to this synthesis.302 In an oven dried 1 dram vial under N2, 
compound 4.72 (10 mg, 0.043 mmol) and N.N-dimethylaminopyridine (DMAP, ~0.2 mg, 
catalytic) were dissolved in 0.5 mL methylene chloride at rt. Pyridine was added (3.5 L, 
0.043 mmol), followed by acetic anhydride (Ac2O, 8 L, 0.086 mmol), and the solution 
was stirred for 4 h. The reaction was concentrated by rotary evaporation and dried under 
high vacuum to give an opaque solid, and the crude residue was purified on a silica gel 
column using a gradient elution of 15-45% ethyl acetate in hexanes to give compound 
4.39 as a clear film (12 mg, >99% yield). Rf = 0.60 (35% EtOAc-hexanes, UV, KMnO4). 
1H NMR (500 MHz, CDCl3) δ 7.55 – 7.47 (m, 2H), 7.41 – 7.31 (m, 3H), 5.64 (s, 1H), 4.78 
(q, J = 1.7 Hz, 1H), 4.35 (dd, J = 13.1, 1.6 Hz, 1H), 4.21 (ddd, J = 7.9, 5.1, 1.8 Hz, 1H), 
4.12 (dd, J = 13.1, 1.7 Hz, 1H), 3.62 (dd, J = 12.9, 7.8 Hz, 1H), 3.28 (dd, J = 12.9, 5.0 Hz, 
1H), 2.16 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.74 , 137.18 , 129.09 , 128.28 , 125.92 
, 101.06 , 69.33 , 65.59 , 51.16 , 21.01. DART-MS: [M-H:]+ for C13H15N3O4 calcd, 






(2S,3S)-4-Azido-1,3-dihydroxybutan-2-yl acetate (4.40). In a 50 mL round 
bottom flask, compound 4.39 (12 mg, 0.043 mmol) was dissolved in 5 mL 75% aqueous 
acetic acid (AcOH (aq)), and the flask was capped with a stopper before warming to 50C 
with stirring for 6 h. The reaction was concentrated by rotary evaporation with azeotropic 
removal of AcOH using (5x) 1 ml toluene to give an opaque white solid. The crude residue 
was purified on a silica gel column using a gradient elution of 50-75% ethyl acetate in 
hexanes to give three monoacyl products, with the major regioisomer being compound 
4.23 (2.5 mg, 31% byproduct), which matched the NMR of a previous intentional 
synthesis of 4.23, and the other two being desired product 4.40 and regioisomer 
byproduct 4.41, which were detected by MS. DART-MS (all three isomers): [M+H]+ for 




(4.43). A previously published protocol was followed.288 In an oven dried 6 dram vial under 
argon, commercially available L-ascorbic acid (100 mg, 0.578 mmol) and copper (II) 
sulfate (CuSO4, 136 mg, 0.852 mmol) were suspended in acetone (anh). The mixture was 
stirred for 28 h at rt, filtered, and concentrated by rotary evaporation to give 4.43 as white 
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crystals (106 mg, 85% yield). Rf = 0.33 (20% MeOH-CH2Cl2). 1H NMR (500 MHz, 
Acetone-d6) δ 8.78 (s, 1H), 6.16 (s, 1H), 3.40 (d, J = 3.4 Hz, 1H), 3.06 (tt, J = 6.7, 3.4 Hz, 
1H), 2.88 (dd, J = 8.5, 6.8 Hz, 1H), 2.75 – 2.68 (m, 1H), 1.65 (d, J = 18.2 Hz, 6H). DART-
MS: [M+H]+ for C9H12O6 calcd, 217.0707; detected, 217.0720. 
 
 
Potassium (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetate (4.44). 
A published protocol was followed.288 In a 6 dram vial, compound 4.44 (106 mg, 0.490 
mmol) and potassium carbonate (K2CO3, 136 mg, 0.980) were suspended in 2 mL water 
and cooled to 4C. A solution of 38% aqueous hydrogen peroxide (H2O2 (aq), 107 L) 
was added slowly, and the reaction clarified as it was stirred at 4C for 10 min, then 
allowed to warm to rt and stir for 18 h. The solution was concentrated by rotary 
evaporation and dried under high vacuum to give a white solid, which was filtered (5x) 5 
mL boiling 99% ethanol, and the filtrated was concentrated by rotary evaporation to give 







Methyl (R)-2-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyacetate (4.45). A 
published protocol was followed.288 In a 6 dram vial under argon, compound 4.44 (85 mg, 
theoretical yield from previous step of 0.397 mmol) was suspended in 2 mL acetonitrile 
at rt, and methyl iodide (MeI, 132 L, 0.516 mmol) was added slowly. A condenser was 
equipped, and the reaction was refluxed overnight. The mixture was concentrated by 
rotary evaporation, diluted with 3 mL water, and extracted with (3x) 3 mL ethyl acetate. 
The combined organic layers were washed with 2 mL brine (saturated sodium chloride 
(aq)), dried over sodium sulfate, filtered, and concentrated by rotary evaporation to give 
a yellow oil. The crude residue was purified on a silica gel column using a gradient elution 
of 10-40% ethyl acetate in hexanes to give compound 4.45 as a clear oil (6 mg, 7% yield). 
Rf = 0.37 (40% EtOAc-hexanes, KMnO4). 1H NMR (500 MHz, CDCl3) δ 4.38 (td, J = 6.7, 
2.8 Hz, 1H), 4.12 (d, J = 2.8 Hz, 1H), 4.05 (ddd, J = 38.8, 8.3, 6.8 Hz, 2H), 3.82 (s, 3H), 
2.90 (s, 1H), 1.42 (d, J = 0.8 Hz, 3H), 1.35 (d, J = 0.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 172.50 , 110.02 , 76.24 , 70.30 , 65.59 , 52.75 , 26.07 , 25.28. DART-MS: [M+H]+ for 
C8H14O5 calcd, 191.0914; detected, 191.0903. NMR data agreed with previous reports,288 





((4S,5S)-2-(4-Methoxyphenyl)-1,3-dioxolane-4,5-diyl)dimethanol (4.29). A 
published procedure was followed.289 In a 250 mL flame dried 3 neck flask equipped with 
a Dean-Stark trap, commercially available diethyl-L-tartrate (2.7, 8.14 g, 39.5 mmol), 4-
methoxybenzaldehyde dimethylacetal (8.86 g, 48.6 mmol), and p-tolunenesulfonic acid 
monohydrate (p-TsOH•H2O, 128 mg, 0.672 mmol) were dissolved in 80 mL benzene. The 
solution was heated to 85C for 4 h, then the rose colored solution was cooled to rt, and 
200 mg sodium carbonate (Na2CO3, freshly crushed) was added. The suspension was 
stirred for 2 h, filtered, concentrated by rotary evaporation, and dried thoroughly under 
high vacuum to give a yellow syrup. The crude residue was dissolved in 20 mL 
tetrahydrofuran and added to a dropping funnel. In a flame dried 250 mL 3 neck flask, 
lithium aluminum hydride (LiAlH4, 3.0 g, 79.0 mmol) was suspended in 70 ml 
tetrahydrofuran and cooled to 0C. The crude solution was added dropwise to the stirring 
LiAlH4 suspension over 30 min, stirred for 45 min at 0C, then warmed to rt and stirred 
for 45 min. The reaction was then cooled to 0C and carefully quenched with 3 mL water, 
3 mL 10% sodium hydroxide (NaOH (aq)), and 9 mL water before warming to rt and 
stirring vigorously for 1 h. Magnesium sulfate (anh) was added to dry, and the suspension 
was stirred for 30 min at rt, filtered, concentrated by rotary evaporation, and dried under 
high vacuum to give a dark yellow oil. The crude residue was purified on a silica gel 
column using a gradient elution of 3-12% methanol in methylene chloride to give 
compound 4.29 as a white solid (6.475 g, 68% yield over 2 steps from compound 2.7). Rf 
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= 0.50 (10% MeOH-CH2Cl2, UV). DART-MS: [M+H]+ for C13H18O5 calcd, 241.1071; 




dioxolan-4-yl)methanol (4.30). In an oven dried 125 mL round bottom flask under N2, 
sodium hydride (NaH, 60% dispersion in paraffin wax, 266 mg, 6.659 mmol) was 
dissolved in 10 mL tetrahydrofuran, and cooled to 0C. To the stirring suspension was 
added dropwise a solution of compound 4.29 (1.60 g, 6.659 mmol) in 5 mL 
tetrahydrofuran, and the white suspension was stirred for 40 min at 0C before adding 
dropwise t-butyldiphenylchlorosilane (TBDPSCl, 1.732 mL, 6.659 mmol). The reaction 
was stirred at 0C for 20 min, then at rt for 35 min, then cooled to 0C and quenched with 
60 mL water. The aqueous layer was extracted with (3x) 35 ml ethyl acetate and the 
combined organic layers were dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum to give a yellow oil. The crude residue was 
purified on a silica gel column using a gradient elution of 10-45% ethyl acetate in hexanes 
to give compound 4.30 as a clear oil (mixture of diastereomers, 2.345 g, 74% yield). Rf = 
0.54 + 0.44 (35% EtOAc-hexanes, UV, KMnO4). DART-MS: [M+H]+ for C28H34O5Si calcd, 
479.2249; detected, 479.2247. NMR data matched a previous report for the enantiomer 





(tert-butyl)diphenylsilane (4.31). Reaction conditions from a previously published 
procedure were adapted for this synthesis.132 In an oven dried 250 mL round bottom flask 
under N2, compound 4.30 (2.345 g, 4.899 mmol), was dissolved in 40 mL of 
tetrahydrofuran at rt, and triphenylphosphine (PPh3, 2.570 g, 9.798 mmol) was added, 
followed by diisopropylazidodicarboxylate (DIAD, 1.929 mL, 9,798 mmol). A solution of 
diphenylphosphoryl azide (DPPA, 2.112 mL, 9.798 mmol) in 14 mL tetrahydrofuran was 
added, and the dark yellow solution left to stir overnight at rt. The reaction was 
concentrated by rotary evaporation to give a yellow oil, which was purified on a silica gel 
column using a gradient elution of 3-12% ethyl acetate in hexanes to give compound 
4.31* as a clear oil (mixture of diastereomers, 2.375 g, 96%* with DPPA impurity visible 
in 1H NMR spectra ~ = ) Rf = 0.43 (two overlapping spots, 10% EtOAc-hexanes, UV). 
1H NMR (300 MHz, CDCl3) δ 7.74 – 7.57 (m, 3H), 7.51 – 7.35 (m, 10H), 6.98 – 6.77 (m, 
2H), 5.94 (d, J = 3.3 Hz, 1H), 4.43 – 4.04 (m, 1H), 3.96 – 3.82 (m, 1H), 3.82 – 3.78 (m, 
4H), 3.57 (dd, J = 7.4, 3.9 Hz, 1H), 3.43 (td, J = 12.8, 12.4, 5.4 Hz, 1H), 1.08 (dt, J = 5.3, 
0.6 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 160.04 , 135.63 , 135.56 , 133.32 , 133.10 , 
130.28 , 129.70 , 127.66 , 127.26 , 113.57 , 101.34 , 79.69 , 77.18 , 72.64 , 63.85 , 63.21 






(4.32). Reaction conditions from a previously published procedure were adapted for this 
synthesis.284 In a 100 mL round bottom flask under N2, compound 4.31 (2.00 g, 3.971 
mmol) was dissolved in 40 mL tetrahydrofuran and cooled to 0C. Tetrabutylammonium 
fluoride (TBAF, 1M solution in tetrahydrofuran, 4.765 mL, 4.765 mmol) was added slowly, 
and the solution was stirred at 0C for 5 min, then allowed to warm to rt and stir for 105 
min. The reaction was poured into 120 mL water, extracted with (3x) 50 mL ethyl acetate, 
and the combined organic layers were washed with 40 mL water, then 30 mL brine 
(saturated sodium chloride (aq)), and dried over magnesium sulfate, filtered, concentrated 
by rotary evaporation, and dried under high vacuum to give a purple oil. The crude residue 
was purified on a silica gel column using a gradient elution of 25-65% ethyl acetate in 
hexanes to give compound 4.32 as a clear oil (mixture of diastereomers, 619 mg, 59% 
yield). Rf = 0.55 + 0.48 (40% EtOAc-hexanes, UV). Diastereomers were separated for 
NMR characterization: 4.32, first diastereomer:  1H NMR (500 MHz, CDCl3) δ 7.45 – 7.38 
(m, 2H), 6.95 – 6.88 (m, 2H), 5.97 (s, 1H), 4.28 (dt, J = 6.9, 4.8 Hz, 1H), 4.18 – 4.11 (m, 
1H), 3.95 – 3.87 (m, 1H), 3.81 (s, 3H), 3.74 (ddd, J = 12.0, 7.5, 4.4 Hz, 1H), 3.61 (dd, J = 
13.0, 4.5 Hz, 1H), 3.48 (dd, J = 13.0, 4.9 Hz, 1H), 1.88 (s, 1H). 13C NMR (126 MHz, CDCl3) 
δ 160.68 , 129.00 , 127.95 , 113.88 , 103.97 , 79.79 , 76.24 , 62.02 , 55.32 , 53.39 , 52.09; 
4.32, second diastereomer 1H NMR (500 MHz, CDCl3) δ 7.43 (d, 2H), 6.92 (d, 2H), 5.94 
(s, 1H), 4.26 – 4.19 (m, 1H), 4.12 (ddd, J = 6.6, 4.9, 4.0 Hz, 1H), 3.90 – 3.72 (m, 3H), 
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3.61 (dd, J = 13.0, 4.4 Hz, 1H), 3.54 – 3.46 (m, 3H), 1.90 (t, J = 6.2 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 160.64 , 129.01 , 128.01 , 113.84 , 104.11 , 78.90 , 77.14 , 62.27 , 
55.30 , 53.39 , 52.07. DART-MS (4.32 mixture of diastereomers): [M+H]+ for C12H15N3O4 
calcd, 266.1136; detected, 266.1073.  
 
 
The following general method was used to synthesize compounds 4.33-4.38: In 
an oven dried 100 mL round bottom flask under N2, compound 4.32 (122 mg, 0.460 
mmol), the required fatty acid (0.552 mmol), and N,N-dimethylaminopyridine (DMAP, 6 
mg, 0.046 mmol) were dissolved in 15 mL benzene and cooled to 0C. N,N-
dicyclohexylcarbodiimide (DCC, 114 mg, 0.552 mmol) was added in a single portion, the 
solution was stirred for 5 min at 0C, and then the resulting cloudy white suspension was 
allowed to warm to rt and stir for 3 h. 50 mL of diethyl ether were added, and the mixture 
was allowed to stand at 0C overnight, filtered to remove N,N-dicyclohexylurea (DCU) 
byproduct, and the filtrate was concentrated by rotary evaporation and dried under high 
vacuum. The crude residue was purified on a silica gel column using a gradient elution of 
5-15% ethyl acetate in hexanes to give the target compound. Due to persistent DCU 
impurity (visible in 4.33-4.38 1H NMR spectra ~ = 2.5, 1.7-2.0; 13C ~ = 160), final yields 




decanoate (4.33, n = 8). Decanoic acid (95 mg, 0.552 mmol) was used, giving compound 
4.33 as a clear oil (mixture of diastereomers, 208 mg). Rf = 0.52 (two overlapping spots, 
25% EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.41 (t, 2H), 6.91 (dd, 2H), 5.94 
(d, J = 25.5 Hz, 1H), 4.36 – 4.20 (m, 3H), 4.14 (dtd, J = 6.2, 4.7, 1.9 Hz, 1H), 3.81 (d, J = 
0.6 Hz, 3H), 3.59 (ddd, J = 13.1, 4.4, 1.4 Hz, 1H), 3.48 (ddd, J = 12.9, 7.5, 5.1 Hz, 1H), 
2.35 (dt, J = 12.1, 7.5 Hz, 2H), 1.63 (q, J = 7.3 Hz, 2H), 1.32 – 1.23 (m, 12H), 0.87 (t, J = 
6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.46 (d, J = 5.8 Hz), 128.89 , 128.58 , 128.08 
, 128.03 , 113.80 , 104.22 , 104.17 , 77.67 , 77.16 , 77.08 , 76.29 , 63.42 , 63.38 , 55.29 
, 52.16 , 51.93 , 34.10 , 34.05 , 31.83 , 30.91 , 29.38 , 29.26 , 29.23 , 29.11 , 26.41 , 24.86 




dodecanoate (4.34, n = 10). Dodecanoic acid (111 mg, 0.552 mmol) was used, giving 
compound 4.34 as a clear oil (mixture of diastereomers, 210 mg). Rf = 0.48 (two 
overlapping spots, 25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.42 
(t, 2H), 6.91 (d, 2H), 5.94 (d, J = 25.5 Hz, 1H), 4.36 – 4.19 (m, 3H), 4.14 (dtd, J = 6.1, 4.6, 
1.8 Hz, 1H), 3.81 (d, J = 0.6 Hz, 3H), 3.59 (ddd, J = 13.1, 4.4, 1.5 Hz, 1H), 3.48 (ddd, J = 
12.9, 7.6, 5.2 Hz, 1H), 2.35 (dt, J = 12.1, 7.6 Hz, 2H), 1.67 – 1.57 (m, 2H), 1.27 (d, J = 
20.1 Hz, 16H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.48 , 128.89 , 
128.58 , 128.09 , 128.03 , 113.81 , 113.80 , 104.22 , 104.17 , 77.67 , 77.16 , 77.08 , 76.29 
, 63.42 , 63.38 , 55.30 , 52.16 , 51.93 , 34.11 , 34.05 , 31.88 , 29.58 , 29.43 , 29.31 , 29.26 
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, 29.24 , 29.12 , 24.86 , 24.84 , 22.66 , 14.09. DART-MS: [M+H]+ for C24H37N3O5 calcd, 
448.2806; detected, 448.2795.  
 
((4S,5S)-5-(Azidomethyl)-2-(4-methoxybenzyl)-1,3-dioxolan-4-yl)methyl 
tetradecanoate (4.35, n = 12). Tetradecanoic acid (126 mg, 0.552 mmol) was used, 
giving compound 4.35 as a clear oil (mixture of diastereomers, 236 mg). Rf = 0.50 (two 
overlapping spots, 25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.42 
(t, 2H), 6.91 (d, 2H), 5.94 (d, J = 25.6 Hz, 1H), 4.36 – 4.19 (m, 3H), 4.14 (dtd, J = 6.0, 4.6, 
1.9 Hz, 1H), 3.81 (s, 3H), 3.59 (ddd, J = 13.0, 4.4, 1.5 Hz, 1H), 3.48 (ddd, J = 12.8, 7.5, 
5.1 Hz, 1H), 2.35 (dt, J = 12.1, 7.6 Hz, 2H), 1.66 – 1.59 (m, 2H), 1.25 (s, 20H), 0.88 (t, J 
= 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.48 , 128.89 , 128.58 , 128.09 , 128.03 , 
113.81 , 113.80 , 104.22 , 104.17 , 77.67 , 77.19 , 77.16 , 77.08 , 76.29 , 63.42 , 63.38 , 
55.30 , 52.16 , 51.93 , 34.11 , 34.05 , 31.90 , 29.65 , 29.62 , 29.58 , 29.43 , 29.33 , 29.24 
, 29.12 , 24.86 , 22.67 , 14.10 . DART-MS: [M+H]+ for C26H41N3O5 calcd, 476.3119; 
detected, 476.3105.  
 
((4S,5S)-5-(Azidomethyl)-2-(4-methoxybenzyl)-1,3-dioxolan-4-yl)methyl 
hexadecanoate (4.36, n = 14). Hexadecanoic acid (141 mg, 0.552 mmol) was used, 
giving compound 4.36 as a colorless solid (mixture of diastereomers, 250 mg). Rf = 0.55 
+ 0.48 (25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.41 (t, J = 8.5 
Hz, 2H), 6.91 (dd, 2H), 5.94 (d, J = 25.6 Hz, 1H), 4.35 – 4.20 (m, 3H), 4.18 – 4.08 (m, 
1H), 3.81 (s, 3H), 3.63 – 3.55 (m, 1H), 3.48 (ddd, J = 12.9, 7.6, 5.1 Hz, 1H), 2.35 (dt, J = 
11.9, 7.7 Hz, 2H), 1.63 (q, J = 7.3 Hz, 2H), 1.33 – 1.17 (m, 24H), 0.91 – 0.84 (m, 3H). 13C 
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NMR (126 MHz, CDCl3) δ 173.43 , 128.89 , 128.58 , 128.08 , 128.02 , 113.81 , 113.80 , 
104.22 , 104.17 , 77.67 , 77.16 , 77.08 , 76.29 , 63.42 , 63.38 , 55.29 , 52.16 , 51.93 , 
34.10 , 34.05 , 31.90 , 29.67 , 29.66 , 29.63 , 29.58 , 29.44 , 29.34 , 29.24 , 29.12 , 24.86 
, 24.84 , 24.70 , 22.67 , 14.10. DART-MS: [M+H]+ for C28H45N3O5 calcd, 504.3432; 
detected, 504.3457.  
 
((4S,5S)-5-(Azidomethyl)-2-(4-methoxybenzyl)-1,3-dioxolan-4-yl)methyl 
octadecanoate (4.37, n = 16). Octadecanoic acid (157 mg, 0.552 mmol) was used, giving 
compound 4.37 as a white solid (mixture of diastereomers, 265 mg). Rf = 0.60 + 0.50 
(25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.41 (t, J = 8.5 Hz, 2H), 
6.91 (dd, J = 8.6, 3.1 Hz, 2H), 5.94 (d, J = 25.6 Hz, 1H), 4.35 – 4.21 (m, 3H), 4.20 – 4.10 
(m, 1H), 3.81 (d, J = 0.7 Hz, 3H), 3.63 – 3.56 (m, 1H), 3.48 (ddd, J = 13.0, 7.6, 5.2 Hz, 
1H), 2.35 (dt, J = 12.2, 7.5 Hz, 2H), 1.63 (h, J = 7.6 Hz, 2H), 1.33 – 1.23 (m, 28H), 0.91 
– 0.84 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 173.43 , 128.89 , 128.58 , 128.08 , 128.03 
, 113.80 , 104.22 , 104.17 , 77.67 , 77.16 , 77.09 , 76.29 , 63.42 , 63.38 , 55.29 , 52.16 , 
51.93 , 34.10 , 34.05 , 31.91 , 29.68 , 29.67 , 29.64 , 29.59 , 29.44 , 29.34 , 29.24 , 29.12 
, 24.86 , 24.84 , 22.67 , 14.10. DART-MS: [M+H]+ for C30H49N3O5 calcd, 532.3745; 
detected, 532.3761.  
 
((4S,5S)-5-(Azidomethyl)-2-(4-methoxybenzyl)-1,3-dioxolan-4-yl)methyl 
oleate (4.38, n = 16:1). (Z)-Octadec-9-enoic acid (Oleic acid, 156 mg, 0.552 mmol) was 
used, giving compound 4.38 as a clear oil (mixture of diastereomers, 256 mg). Rf = 0.47 
(two overlapping spots, 25% EtOAc-hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 
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7.41 (t, J = 8.5 Hz, 2H), 6.91 (dd, 2H), 5.94 (d, J = 25.8 Hz, 1H), 5.34 (tt, J = 5.8, 2.9 Hz, 
2H), 4.35 – 4.20 (m, 3H), 4.14 (qd, J = 5.7, 5.2, 1.9 Hz, 1H), 3.81 (s, 3H), 3.59 (ddd, J = 
13.1, 4.4, 1.3 Hz, 1H), 3.48 (ddd, J = 14.6, 7.5, 5.1 Hz, 1H), 2.35 (dt, J = 12.1, 7.6 Hz, 
2H), 2.04 – 1.96 (m, 4H), 1.63 (h, J = 7.9 Hz, 2H), 1.40 – 1.17 (m, 20H), 0.89 – 0.84 (m, 
3H). 13C NMR (126 MHz, CDCl3) δ 173.45 , 130.00 , 129.68 , 128.89 , 128.57 , 128.08 , 
128.03 , 113.81 , 113.80 , 104.23 , 104.16 , 77.67 , 77.16 , 77.09 , 76.29 , 63.43 , 63.41 
, 55.30 , 52.16 , 51.93 , 34.08 , 34.03 , 31.88 , 30.91 , 29.75 , 29.67 , 29.50 , 29.33 , 29.30 
, 29.24 , 29.15 , 29.11 , 29.09 , 29.08 , 27.20 , 27.18 , 27.17 , 27.15 , 24.85 , 24.82 , 22.66 
, 14.10. DART-MS: [M+H]+ for C30H47N3O5 calcd, 530.3589; detected, 530.3575.  
 
 
The following general method was used to synthesize compounds 4.2-4.7 adapting 
conditions from a previously published procedure:286 In a 50 mL round bottom flask, 
compound 4.33-4.38 (theoretically 0.552 mmol from the previous step) was suspended 
in 6 mL of (3:2:1) Acetic acid/tetrahydrofuran/water (AcOH/THF/H2O), and the mixture 
was stirred at 20-30C, depending on solubility. After the disappearance of starting 
material on TLC (Rf ~ 0.5 (25% EtOAc-hexanes, UV), the reaction was concentrated by 
rotary evaporation with azeotropic removal of AcOH using (5x) 2 mL toluene. The crude 
residue was purified on a silica gel column using a gradient elution of 5-15% acetone in 
chloroform to give the target compound.  
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(2S,3S)-4-Azido-2,3-dihydroxybutyl decanoate (4.2, n = 8). Compound 4.33 
was reacted at rt for 22 h, giving compound 4.2 as a yellow oil (114 mg, 82% yield over 2 
steps). Rf = 0.32 (10% acetone-CHCl3, KMnO4). 1H NMR (300 MHz, CDCl3) δ 4.30 – 4.09 
(m, 2H), 3.86 – 3.67 (m, 2H), 3.55 – 3.37 (m, 2H), 2.59 (t, J = 6.1 Hz, 2H), 2.34 (t, J = 7.6 
Hz, 2H), 1.62 (t, J = 7.3 Hz, 2H), 1.33 – 1.21 (m, 12H), 0.93 – 0.81 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 174.29 , 70.18 , 69.97 , 65.32 , 53.60 , 34.12 , 31.82 , 29.37 , 29.22 , 29.20 
, 29.09 , 24.86 , 22.63 , 14.07. DART-MS: [M+H]+ for C14H27N3O4 calcd, 302.2075; 
detected, 302.2124. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl dodecanoate (4.3, n = 10). Compound 4.34 
was reacted at 30C for 8 h, giving compound 4.3 as a white solid (118 mg, 78% yield 
over 2 steps). Rf = 0.35 (10% acetone-CHCl3, KMnO4). 1H NMR (500 MHz, CDCl3) δ 4.24 
(dd, J = 11.7, 4.9 Hz, 1H), 4.16 (dd, J = 11.7, 6.5 Hz, 1H), 3.83 (ddd, J = 6.5, 4.9, 3.2 Hz, 
1H), 3.74 (ddd, J = 6.7, 4.9, 3.2 Hz, 1H), 3.52 – 3.40 (m, 2H), 2.59 (s, 2H), 2.34 (t, J = 7.5 
Hz, 2H), 1.62 (p, J = 7.5 Hz, 2H), 1.27 (d, J = 17.4 Hz, 16H), 0.87 (t, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 174.30 , 70.18 , 69.98 , 65.32 , 53.60 , 34.12 , 31.88 , 29.57 , 
29.41 , 29.30 , 29.21 , 29.09 , 24.86 , 22.66 , 14.09. DART-MS: [M+H]+ for C16H31N3O4 
calcd, 330.2388; detected, 330.2397. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl tetradecanoate (4.4, n = 12). Compound 
4.35 was reacted at 30C for 8 h, giving compound 4.4 as white crystals (113 mg, 69% 
yield over 2 steps). Rf = 0.32 (10% acetone-CHCl3, KMnO4). 1H NMR (500 MHz, CDCl3) 
δ 4.24 (dd, J = 11.7, 4.9 Hz, 1H), 4.16 (dd, J = 11.7, 6.5 Hz, 1H), 3.83 (ddd, J = 6.5, 4.8, 
271 
3.2 Hz, 1H), 3.78 – 3.71 (m, 1H), 3.52 – 3.40 (m, 2H), 2.54 (s, 2H), 2.35 (t, J = 7.6 Hz, 
2H), 1.67 – 1.59 (m, 2H), 1.25 (s, 20H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 174.33 , 70.19 , 69.96 , 65.29 , 53.59 , 34.12 , 31.89 , 29.65 , 29.62 , 29.57 , 
29.42 , 29.33 , 29.21 , 29.10 , 24.86 , 22.66 , 14.09. DART-MS: [M+H]+ for C18H35N3O4 
calcd, 358.2701; detected, 358.2714. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl hexadecanoate (4.5, n = 14). Compound 
4.36 was reacted at at rt for 22 h, then 35C for 8 h, giving compound 4.5 as white solid 
(142 mg, 80% yield over 2 steps). Rf = 0.33 (10% acetone-CHCl3, KMnO4). 1H NMR (300 
MHz, CDCl3) δ 4.29 – 4.07 (m, 2H), 3.78 (dddd, J = 24.4, 6.5, 5.1, 3.2 Hz, 2H), 3.55 – 
3.36 (m, 2H), 2.68 (s, 2H), 2.34 (dd, J = 8.4, 6.7 Hz, 2H), 1.62 (s, 2H), 1.25 (s, 24H), 0.92 
– 0.81 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 174.33 , 70.19 , 69.97 , 65.29 , 53.58 , 
34.12 , 31.90 , 29.67 , 29.65 , 29.63 , 29.62 , 29.57 , 29.42 , 29.33 , 29.21 , 29.10 , 29.06 
, 24.85 , 22.67 , 14.09. DART-MS: [M+H]+ for C20H39N3O4 calcd, 386.3014; detected, 
386.1554. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl octadecanoate (4.6, n = 16). Compound 
4.37 was reacted at rt for 22 h, then 35C for 8 h, giving compound 4.6 as white solid (143 
mg, 75% yield over 2 steps). Rf = 0.34 (10% acetone-CHCl3, KMnO4). 1H NMR (300 MHz, 
CDCl3) δ 4.29 – 4.09 (m, 2H), 3.78 (dddd, J = 23.6, 6.4, 5.1, 3.2 Hz, 2H), 3.54 – 3.36 (m, 
2H), 2.72 (s, 2H), 2.33 (t, J = 7.5 Hz, 2H), 1.61 (s, 2H), 1.24 (s, 28H), 0.92 – 0.82 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ 174.34 , 70.20 , 69.96 , 65.28 , 53.58 , 34.12 , 31.90 , 29.67 
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, 29.63 , 29.62 , 29.58 , 29.43 , 29.34 , 29.22 , 29.10 , 24.85 , 22.67 , 14.09. DART-MS: 
[M+H]+ for C22H43N3O4 calcd, 414.3327; detected, 413.9884. 
 
(2S,3S)-4-Azido-2,3-dihydroxybutyl oleate (4.7, n = 16:1). Compound 4.38 was 
reacted at 25C for 8 h, giving compound 4.7 as clear oil (95 mg, 50% yield over 2 steps). 
Rf = 0.36 (10% acetone-CHCl3, KMnO4). 1H NMR (500 MHz, CDCl3) δ 5.40 – 5.28 (m, 
2H), 4.27 – 4.12 (m, 2H), 3.83 (ddd, J = 6.5, 4.9, 3.3 Hz, 1H), 3.74 (ddd, J = 6.7, 4.9, 3.2 
Hz, 1H), 3.52 – 3.40 (m, 2H), 2.57 (s, 2H), 2.35 (t, J = 7.6 Hz, 2H), 2.09 – 1.96 (m, 4H), 
1.66 – 1.59 (m, 2H), 1.30 (tdd, J = 22.6, 9.4, 6.3 Hz, 20H), 0.92 – 0.84 (m, 3H). 13C NMR 
(126 MHz, CDCl3) δ 174.26 , 130.02 , 129.67 , 70.17 , 69.98 , 65.34 , 53.61 , 34.10 , 31.88 
, 29.74 , 29.66 , 29.56 , 29.50 , 29.30 , 29.12 , 29.06 , 27.20 , 27.14 , 24.84 , 22.66 , 14.09. 




dioxolan-4-yl)methanol (4.48). Reaction conditions from a published procedure were 
adapted for this synthesis.132 In an oven dried 250 mL round bottom flask under N2, 
sodium hydride (NaH, 60% dispersion in paraffin wax, 316 mg, 7.908 mmol) was 
suspended in 50 mL N,N-dimethylformamide and cooled to 0C. A solution of compound 
4.29 (1.90 g, 7.908 mmol) in 30 mL N,N-dimethylformamide was added dropwise, and 
the reaction was stirred at 0C for 10 min, then warmed to rt and stirred for 40 min. The 
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gray suspension was then cooled back to 0C, 4-methoxybenzylchloride (PMBCl, 1.178 
mL, 8.699 mmol) was added slowly, and the reaction was allowed to slowly warm to rt 
and stir overnight. After cooling to 0C, the white suspension was quenched with 100 mL 
cold water, extracted with (x3) 50 mL methylene chloride, and the combined organic 
layers were dried over magnesium sulfate, filtered, concentrated by rotary evaporation, 
and dried under high vacuum to give a yellow oil. The crude residue was purified on a 
silica gel column using a gradient elution of 40-65% ethyl acetate in hexanes to give 
compound 4.48 as a clear oil (mixture of diastereomers, 1.825 g, 64% yield). Starting 
material could be recovered by gradient elution of 0-5% methanol in ethyl acetate. Rf 
(4.48) = 0.32 + 0.27 (50% EtOAc-hexanes, UV). Diastereomers were separated for NMR 
characterization: 4.48, first diastereomer: 1H NMR (300 MHz, CDCl3) δ 7.40 (d, 2H), 7.26 
(d, 2H), 6.89 (dd, 4H), 5.91 (s, 1H), 4.54 (s, 2H), 4.26 – 4.06 (m, 2H), 3.91 – 3.73 (m, 2H), 
3.80 (d, J = 1.0 Hz, 6H), 3.73 – 3.53 (m, 2H), 2.09 (d, J = 6.3 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 160.54 , 159.34 , 129.70 , 129.43 , 129.41 , 129.36 , 128.00 , 113.85 , 
113.79 , 103.84 , 80.40 , 73.30 , 69.76 , 62.69 , 55.29 , 55.26; 4.48, first diastereomer: 1H 
NMR (300 MHz, CDCl3) δ 7.39 (d, 2H), 7.25 (d, 2H), 6.88 (dd, 4H), 5.91 (s, 1H), 4.53 (s, 
2H), 4.23 – 4.01 (m, 2H), 3.80 (s, 6H), 3.85 – 3.72 (m, 3H), 3.72 – 3.52 (m, 1H), 2.19 – 
2.04 (m, 1H). DART-MS (4.48, mixture of diastereomers): [M-H:]+ for C20H24O6 calcd, 





dioxolan-4-yl)methyl methanesulfonate (4.49). In an oven dried 250 mL round bottom 
flask under N2, compound 4.48 (770 mg, 2.136 mmol) was dissolved in 15 mL methylene 
chloride. Triethylamine (TEA, 335 L, 2.243 mmol) was added to the stirring solution, 
which was then cooled to -15C and methanesulfonyl chloride (MsCl, 174 L, 2.243 
mmol) was added dropwise. The reaction was allowed to stir and warm slowly to rt over 
1.5 h, and was then cooled back to 0C and quenched with 35 mL water. The organic 
layer was separated, and the remaining aqueous layer was extracted with (2x) 25 mL 
methylene chloride. The combined organic layers were washed with 30 mL brine 
(saturated sodium chloride (aq)), dried over sodium sulfate, filtered, concentrated by 
rotary evaporation and dried under high vacuum to give an opaque resin. The crude 
residue was purified on a silica gel column using a gradient elution of 0-10% acetone in 
chloroform to give compound 4.49 as a clear oil (mixture of diastereomers, 730 mg, 78% 
yield). Rf = 0.72 (two overlapping spots, 10% acetone-CHCl3, UV, KMnO4). 1H NMR (500 
MHz, CDCl3) δ 7.39 (dd, 2H), 7.26 (d, 2H), 6.93 – 6.84 (m, 4H), 5.92 (d, J = 16.9 Hz, 1H), 
4.55 – 4.51 (m, 2H), 4.49 – 4.11 (m, 4H), 3.84 – 3.79 (m, 6H), 3.77 – 3.58 (m, 2H), 3.01 
(d, J = 40.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.61 , 159.37 , 129.64 , 129.62 , 
129.42 , 129.36 , 128.11 , 128.03 , 113.89 , 113.87 , 113.77 , 109.99 , 104.46 , 104.16 , 
77.19 , 77.13 , 76.91 , 76.26 , 73.35 , 73.31 , 69.49 , 69.46 , 68.96 , 68.82 , 55.30 , 55.27 





dioxolan-4-yl)methyl 4-methylbenzenesulfonate (4.71). Reaction conditions from a 
previously reported procedure were adapted to this synthesis, which was used to replace 
mesylate formation due to reagent shortage.304 In an oven dried 100 mL round bottom 
flask under N2, compound 4.48 (2.20 mg, 6.104 mmol) was dissolved in 30 mL methylene 
chloride and cooled to 0C. p-Toluenesulfonylchloride (p-TsCl, 1.280 g, 6.715 mmol) and 
N,N-dimethylaminopyridine (DMAP, 150 mg, 1.220 mmol) were added in single portions, 
and the white suspension was allowed to stir and warm to rt for 6 h. The clarified solution 
was then cooled to 0C and quenched with 10 mL water, followed by 15 mL diethyl ether, 
and the layers were separated. The remaining organic layer was washed with (2x) 15 mL 
diethyl ether, and the combined organic layers were washed with 20 mL brine, dried over 
sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high 
vacuum. The crude residue was purified on a silica gel column using a gradient elution of 
0-5% acetone in chloroform to give unreacted starting material 4.48 (465 mg, 21% RSM) 
and product compound 4.71 as a clear oil (Mixture of diastereomers, 2.55 g, 81% yield). 
Rf = 0.60 (5% acetone-CHCl3, UV). 1H NMR (500 MHz, CDCl3) δ 7.78 (dd, 2H), 7.36 – 
7.19 (m, 6H), 6.92 – 6.81 (m, 4H), 5.81 (d, J = 66.1 Hz, 1H), 4.56 – 4.46 (m, 2H), 4.31 – 
4.09 (m, 4H), 3.81 (dd, J = 7.4, 2.4 Hz, 6H), 3.71 – 3.54 (m, 2H), 2.42 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 160.54 (d, J = 5.2 Hz), 159.31 , 144.98 , 132.67 (d, J = 11.4 Hz), 
129.86 , 129.82 , 129.72 , 129.33 , 129.28 , 128.08 , 128.06 , 128.00 , 113.86 , 113.83 , 
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113.67 , 113.65 , 104.33 , 104.14 , 77.19 , 77.16 , 76.78 , 76.46 , 76.31 , 73.24 , 73.22 , 
69.56 , 69.54 , 69.24 , 69.13 , 55.29 , 55.28 , 21.63. DART-MS: [M+H]+ for C27H30O8S 




methyl)-1,3-dioxolane (4.50). Reaction conditions from a previously published 
procedure were adapted for this synthesis.98 In an oven dried 250 mL round bottom flask 
under N2, compound 4.49 (1.43 g, 3.261 mmol) and sodium azide (NaN3, 636 mg, 9.783 
mmol) were suspended in 40 mL N,N-dimethylformamide, then heated to 80C with 
stirring overnight. The resulting cloudy mixture was concentrated by rotary evaporation, 
diluted with 100 mL water, extracted with (3x) 65 mL methylene chloride, and the 
combined organic layers were washed with 35 mL brine, dried over sodium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to give a gold 
oil. The crude residue was purified on a silica gel column using a gradient elution of 15-
40% ethyl acetate in hexanes to give compound 4.50 as a clear oil (mixture of 
diastereomers, 1.085 mg, 86% yield). Rf = 0.54 (two overlapping spots, 35% EtOAc-
hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.41 (t, 2H), 7.24 (t, 2H), 6.93 – 6.84 (m, 4H), 
5.92 (d, J = 17.9 Hz, 1H), 4.52 (d, J = 7.0 Hz, 2H), 4.26 – 4.12 (m, 2H), 3.83 – 3.78 (m, 
6H), 3.75 – 3.53 (m, 3H), 3.43 (ddd, J = 13.2, 6.7, 5.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 160.54 , 159.33 , 129.78 , 129.74 , 129.37 , 129.30 , 129.10 , 128.07 , 128.05 , 113.85 
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, 113.83 , 113.74 , 113.73 , 104.13 , 103.95 , 78.43 , 78.12 , 77.96 , 77.04 , 73.30 , 73.27 
, 69.68 , 69.63 , 55.29 , 55.27 , 52.41 , 52.26. DART-MS: [M-H:]+ for C20H23N3O5 calcd, 
384.1565; detected, 384.1605. 
 
 
(2S,3S)-1-Azido-3,4-bis((4-methoxybenzyl)oxy)butan-2-ol (4.51) and (2S,3S)-
1-azido-2,4-bis((4-methoxybenzyl)oxy)butan-3-ol (4.52). Reaction conditions from a 
previously published procedure were adapted for this synthesis.292 In an oven dried 50 
mL round bottom flask under N2, compound 4.50 (400 mg, 1.038 mmol) was dissolved in 
20 mL methylene chloride and cooled to -78C. Diisobutylaluminum hydride (DIBALH, 1M 
solution in hexanes, 6.23 mL, 6.23 mmol) was added in small portions over 30 min. The 
solution was stirred for 2 h at -78C, then quenched slowly with 12 mL cold 10% sodium 
potassium tartrate, and allowed to stir and warm to rt after placing in a bath of rt water. 
10 mL methylene chloride were added, the layers were separated, and the remaining 
aqueous layer was extracted with (2x) 20 mL methylene chloride. The combined organic 
layers were dried over sodium sulfate, filtered, concentrated by rotary evaporation, and 
dried under high vacuum to give a clear oil. The crude residue was purified on a silica gel 
column to give unreacted starting material 4.50 (68 mg, 17% RSM), compound 4.51 as a 
clear oil (40 mg, 10% yield), and compound 4.52 as a clear oil (141 mg, 35% yield).  
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Characterization data for 4.51: Rf = 0.60 (40% EtOAc-hexanes, UV). 1H NMR (500 
MHz, CDCl3) δ 7.23 (t, 4H), 6.92 – 6.84 (m, 4H), 4.65 (d, J = 11.3 Hz, 1H), 4.53 – 4.42 
(m, 3H), 3.85 (q, J = 5.0 Hz, 1H), 3.81 (d, J = 2.3 Hz, 6H), 3.67 – 3.54 (m, 3H), 3.36 – 
3.24 (m, 2H), 2.68 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 159.46 , 159.36 , 129.76 , 129.70 
, 129.68 , 129.40 , 113.89 , 113.87 , 73.24 , 72.36 , 71.34 , 68.92 , 55.27 , 53.24  DART-
MS: [M-N2+H]+ for C20H25N3O5 calcd, 360.1805; detected, 360.1801. 
 
Characterization data for 4.52: Rf = 0.48 (40% EtOAc-hexanes, UV). 1H NMR (500 
MHz, CDCl3) δ 7.24 (d, 4H), 6.92 – 6.84 (m, 4H), 4.69 – 4.59 (m, 1H), 4.48 (d, J = 11.0 
Hz, 1H), 4.44 (s, 2H), 3.80 (d, J = 1.1 Hz, 7H), 3.68 (dt, J = 6.5, 4.3 Hz, 1H), 3.47 (d, J = 
5.6 Hz, 2H), 3.46 – 3.33 (m, 2H), 2.24 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 159.49 , 
159.36 , 129.82 , 129.79 , 129.67 , 129.52 , 113.90 , 113.85 , 77.70 , 73.19 , 73.11 , 70.29 




(2S,3S)-1-Azido-3,4-bis((4-methoxybenzyl)oxy)butan-2-ol (4.51) and (2S,3S)-
1-azido-2,4-bis((4-methoxybenzyl)oxy)butan-3-ol (4.52). Caution was used in 
handling all content containing any cyanoborohydride material. In an oven dried 6 dram 
vial under N2, compound 4.50 (56 mg, 0.145 mmol) and 190 mg 4-Å molecular sieves 
were gently mixed for 20 min at rt with 5.8 mL methylene chloride. To the gently stirring 
mixture, sodium cyanoborohydride (NaBH3CN, 91 mg, 1.45 mmol) was added in a single 
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portion, followed by 4.4 mL of tetrahydrofuran which clarified the cloudy suspension, and 
then trifluoroacetic acid (TFA, 217 L, 2.78 mmol), which caused bubbling, probably due 
to drying action by the molecular sieves. The reaction was mixed for 20 h at rt, then 
filtered, concentrated by rotary evaporation, diluted with 4 mL methylene chloride, washed 
with 2 mL saturated sodium bicarbonate (NaHCO3 (aq)), 2 mL brine (saturated sodium 
chloride (aq)), and 2 mL water, dried over sodium sulfate, filtered concentrated by rotary 
evaporation, and dried under high vacuum to give a clear oil. The crude reside was 
purified on a silica gel column using a gradient elution of 25-65% ethyl acetate in hexanes 
to give compound 4.51 as a clear oil (22 mg, 39% yield), compound 4.52 as a clear oil 
(14 mg, 25% yield), and another byproduct 2.12 as a clear oil (16 mg, 29% byproduct). 
Characterization data for 4.51 and 4.52 matched that obtained from the DIBALH version 




The following general method was used to synthesize compounds 4.53-4.58: In a 
6 dram vial under N2, compound 4.51 (78 mg, 0.20 mmol) was dissolved in 3 mL N,N-
dimethylformamide, cooled to 0C. Then, sodium hydride (NaH, 10 mg, 0.24 mmol* as a 
60% dispersion in paraffin wax) was added in one portion, and the mixture was stirred at 
0C for 30 min. (*A separate reaction indicated that 1.5 eq of NaH is optimal). A solution 
of alkyl bromide (0.24 mmol) and tetrabutylammonium iodide (TBAI, 4 mg, 0.01 mmol) in 
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2 mL N,N-dimethylformamide was added dropwise to the reaction, and the mixture was 
allowed to warm to rt and stir overnight. The reaction was cooled to 0C, quenched with 
10 mL H2O, poured into 15 mL brine (saturated sodium chloride (aq)), and extracted with 
(2x) 20 mL CH2Cl2. The combined organic layers were dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum to give the 
crude compound mixture, which was purified on a silica gel column using a gradient 
elution of 5-15% ethyl acetate in hexanes. 
 
4,4'-((((2S,3S)-4-Azido-3-(decyloxy)butane-1,2-diyl)bis(oxy))bis(methylene)) 
bis(methoxybenzene) (4.53, n = 8). 1-Bromodecane (53 mg, 0.24 mmol) was used, 
giving compound 4.53 as a clear oil (69 mg, 65% yield). Rf = 0.3 (10% EtOAc-hexanes, 
UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.7, 2.1 Hz, 4H), 6.90 – 6.83 (m, 4H), 4.67 
– 4.49 (m, 2H), 4.45 (d, J = 1.8 Hz, 2H), 3.81 (d, J = 3.7 Hz, 6H), 3.69 – 3.60 (m, 2H), 
3.60 – 3.44 (m, 4H), 3.34 – 3.22 (m, 2H), 1.55 (d, J = 14.2 Hz, 2H), 1.26 (s, 14H), 0.91 – 
0.84 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 159.25 , 159.21 , 130.39 , 130.14 , 129.62 , 
129.27 , 113.76 , 113.71 , 79.00 , 77.10 , 73.07 , 72.54 , 71.82 , 68.90 , 55.25 , 51.37 , 
31.89 , 30.08 , 29.60 , 29.58 , 29.48 , 29.32 , 26.05 , 22.67 , 14.10 . DART-MS: [M-N2+H]+ 
for C30H45N3O5 calcd, 500.3370; detected, 500.3368. 
 
4,4'-((((2S,3S)-4-Azido-3-(dodecyloxy)butane-1,2-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.54, n = 10). 1-Bromododecane (60 mg, 0.24 
mmol) was used, giving compound 4.54 as a clear oil (76 mg, 69% yield). Rf = 0.3 (10% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.6, 2.1 Hz, 4H), 6.90 – 
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6.83 (m, 4H), 4.57 (dd, J = 62.7, 11.5 Hz, 2H), 4.45 (d, J = 1.8 Hz, 2H), 3.81 (d, J = 3.8 
Hz, 6H), 3.69 – 3.60 (m, 2H), 3.60 – 3.44 (m, 4H), 3.34 – 3.22 (m, 2H), 1.53 (s, 2H), 1.25 
(s, 18H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.25 , 159.21 , 130.39 
, 130.14 , 129.63 , 129.27 , 113.76 , 113.71 , 79.00 , 77.10 , 73.07 , 72.54 , 71.82 , 68.90 
, 55.25 , 51.37 , 31.91 , 30.08 , 29.67 , 29.63 , 29.60 , 29.48 , 29.34 , 26.05 , 22.67 , 14.10 
. DART-MS: [M-N2+H]+ for C32H49N3O5 calcd, 528.3683; detected, 528.3764. 
 
4,4'-((((2S,3S)-4-Azido-3-(tetradecyloxy)butane-1,2-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.55, n = 12). 1-Bromotetradecane (67 mg, 0.24 
mmol) was used, giving compound 4.55 as a clear oil (48 mg, 41% yield). Rf = 0.3 (10% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.6, 2.1 Hz, 4H), 6.87 (q, 
4H), 4.67 – 4.49 (m, 2H), 4.45 (d, J = 1.7 Hz, 2H), 3.80 (d, J = 3.7 Hz, 6H), 3.69 – 3.60 
(m, 2H), 3.60 – 3.44 (m, 4H), 3.34 – 3.22 (m, 2H), 1.55 (p, J = 14.3 Hz, 2H), 1.25 (s, 22H), 
0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.25 , 159.21 , 130.38 , 129.63 
, 129.27 , 113.76 , 113.71 , 79.00 , 77.10 , 73.07 , 72.55 , 71.83 , 68.90 , 55.25 , 51.36 , 
31.91 , 30.08 , 29.69 , 29.68 , 29.67 , 29.65 , 29.63 , 29.61 , 29.48 , 29.35 , 26.06 , 22.68 
, 14.10 . DART-MS: [M-N2+H]+ for C34H53N3O5 calcd, 556.3996; detected, 556.4035. 
 
4,4'-((((2S,3S)-4-Azido-3-(hexadecyloxy)butane-1,2-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.56, n = 14). 1-Bromohexadecane (73 mg, 0.24 
mmol) was used, giving compound 4.56 as a clear oil (68 mg, 56% yield). Rf = 0.3 (10% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.7, 2.1 Hz, 4H), 6.87 (t, 
J = 8.7 Hz, 4H), 4.57 (q, 2H), 4.48 – 4.40 (m, 2H), 3.80 (d, J = 3.8 Hz, 6H), 3.69 – 3.60 
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(m, 2H), 3.60 – 3.44 (m, 4H), 3.34 – 3.22 (m, 2H), 1.54 (d, J = 7.5 Hz, 2H), 1.25 (d, J = 
2.1 Hz, 26H), 0.88 (t, J = 6.9 Hz, 3H). 13C  NMR (126 MHz, CDCl3) δ 159.25 , 159.21 , 
130.39 , 130.14 , 129.62 , 129.27 , 113.76 , 113.71 , 79.00 , 77.10 , 73.07 , 72.54 , 71.82 
, 68.90 , 55.25 , 51.37 , 31.91 , 30.08 , 29.69 , 29.67 , 29.65 , 29.64 , 29.61 , 29.48 , 29.35 




(methylene))bis(methoxybenzene) (4.57, n = 16). 1-Bromooctadecane (80 mg, 0.24 
mmol) was used, giving compound 4.57 as a clear oil (43 mg, 34% yield). Rf = 0.3 (10% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.87 (t, 4H), 4.57 (q, J 
= 62.7, 11.6 Hz, 2H), 4.45 (t, J = 1.8 Hz, 2H), 3.80 (d, J = 3.7 Hz, 6H), 3.69 – 3.60 (m, 
2H), 3.60 – 3.44 (m, 4H), 3.34 – 3.22 (m, 2H), 1.60 – 1.50 (m, 2H), 1.25 (s, 30H), 0.88 (t, 
J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.25 , 159.21 , 130.39 , 130.14 , 129.62 
, 129.27 , 113.76 , 113.71 , 79.00 , 77.10 , 73.07 , 72.54 , 71.83 , 68.90 , 55.25 , 51.37 , 
31.91 , 30.08 , 29.69 , 29.68 , 29.64 , 29.61 , 29.48 , 29.35 , 26.06 , 22.68 , 14.10 . DART-
MS: [M-N2+H]+ for C38H61N3O5 calcd, 612.4622; detected, 612.4510.  
 
4,4'-((((2S,3S)-4-azido-3-(((Z)-octadec-9-en-1-yl)oxy)butane-1,2-diyl)bis(oxy)) 
bis(methylene))bis(methoxybenzene) (4.58, n = (16:1)). Oleyl-1-bromide (80 mg, 0.24 
mmol) was used, giving compound 4.58 as a clear oil (47 mg, 37% yield). Rf = 0.3 (10% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.6, 2.1 Hz, 4H), 6.87 (t, 
4H), 5.41 – 5.31 (m, 1H), 5.34 (s, 1H), 4.68 – 4.49 (m, 2H), 4.46 (q, 2H), 3.80 (d, J = 3.7 
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Hz, 6H), 3.68 – 3.60 (m, 2H), 3.61 – 3.45 (m, 4H), 3.34 – 3.22 (m, 2H), 2.06 – 1.94 (m, 
4H), 1.55 (s, 2H), 1.36 – 1.20 (m, 22H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 159.25 , 159.21 , 130.39 , 130.14 , 129.91 , 129.81 , 129.62 , 129.27 , 113.76 , 
113.71 , 79.01 , 77.10 , 73.07 , 72.54 , 71.82 , 68.90 , 55.25 , 51.37 , 32.59 , 31.89 , 30.08 
, 29.76 , 29.69 , 29.65 , 29.51 , 29.46 , 29.35 , 29.31 , 29.30 , 29.28 , 27.20 , 26.06 , 22.67 
, 14.10 . DART-MS: [M-N2+H]+ for C38H59N3O5 calcd, 610.4466; detected, 610.4593. 
 
 
The following general method was used to synthesize compounds 4.14-4.19: In a 
6 dram vial, the bis-PMB-protected 1’-MEG precursor (compounds 4.53-4.58) was 
dissolved in 2 mL methylene chloride, and then trifluoroacetic acid (TFA, 0.5 mL, “wet” 
from storage bottle without prior distillation) was added. The reaction was stirred for 10 
min at rt as it turned light pink and then dark purple, and was then concentrated by rotary 
evaportation. Traces of TFA were removed by repeated (4x) rotary evaporation with 2 mL 
of a 1:1 benzene:methylene chloride mixture, and the resulting crude brown solid was 
dried under high vacuum and then purified on a silica gel column using a gradient elution 
of 8-15% acetone in chloroform. 
 
(2S,3S)-4-Azido-3-(decyloxy)butane-1,2-diol (4.14, n = 8). Starting with 
compound 4.53 (69 mg, 0.131 mmol), compound 4.14 was obtained as a clear oil (22 mg, 
58% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.77 
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– 3.61 (m, 4H), 3.55 – 3.44 (m, 3H), 3.40 – 3.32 (m, 1H), 2.19 (s, 2H), 1.65 – 1.53 (m, 
2H), 1.39 – 1.18 (m, 14H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 78.99 , 
71.54 , 71.37 , 63.41 , 50.66 , 31.86 , 30.01 , 29.53 , 29.52 , 29.40 , 29.28 , 26.00 , 22.65 
, 14.09 . DART-MS: [M-N2+H]+ for C14H29N3O3 calcd, 260.2220; detected, 260.2250. 
 
(2S,3S)-4-Azido-3-(dodecyloxy)butane-1,2-diol (4.15, n = 10). Starting with 
compound 4.54 (76 mg, 0.137 mmol), compound 4.15 was obtained as a clear oil (36 mg, 
84% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.77 
– 3.62 (m, 4H), 3.55 – 3.44 (m, 3H), 3.40 – 3.31 (m, 1H), 2.27 (s, 2H), 1.66 – 1.53 (m, 
2H), 1.37 – 1.22 (m, 18H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 78.99 , 
71.53 , 71.35 , 63.42 , 50.65 , 31.89 , 30.01 , 29.62 , 29.60 , 29.57 , 29.53 , 29.40 , 29.32 
, 26.01 , 22.66 , 14.09 . DART-MS: [M-N2+H]+ for C16H33N3O3 calcd, 288.2533; detected, 
288.2683. 
 
(2S,3S)-4-Azido-3-(tetradecyloxy)butane-1,2-diol (4.16, n = 12). Starting with 
compound 4.55 (48 mg, 0.082 mmol), compound 4.16 was obtained as a clear oil (17 mg, 
61% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.79 
– 3.62 (m, 4H), 3.55 – 3.44 (m, 3H), 3.41 – 3.31 (m, 1H), 2.55 (s, 1H), 2.14 (s, 1H), 1.63 
– 1.55 (m, 2H), 1.25 (s, 22H), 0.87 (t, J = 7.0 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 78.99 
, 71.54 , 71.35 , 63.41 , 50.65 , 31.90 , 30.01 , 29.67 , 29.65 , 29.63 , 29.57 , 29.54 , 29.41 




(2S,3S)-4-Azido-3-(hexadecyloxy)butane-1,2-diol (4.17, n = 14). Starting with 
compound 4.56 (68 mg, 0.111 mmol), compound 4.17 was obtained as a white solid (26 
mg, 63% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) 
δ 3.80 – 3.62 (m, 4H), 3.56 – 3.44 (m, 3H), 3.41 – 3.31 (m, 1H), 2.56 (s, 1H), 2.05 (s, 1H), 
1.64 – 1.55 (m, 2H), 1.25 (s, 26H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
78.99 , 71.53 , 71.33 , 63.42 , 50.65 , 31.90 , 30.01 , 29.67 , 29.65 , 29.64 , 29.58 , 29.54 
, 29.41 , 29.34 , 26.01 , 22.67 , 14.10 . DART-MS: [M-N2+H]+ for C20H41N3O3 calcd, 
344.3159; detected, 344.3387. 
 
(2S,3S)-4-Azido-3-(octadecyloxy)butane-1,2-diol (4.18, n = 16). Starting with 
compound 4.57 (43 mg, 0.067 mmol), compound 4.18 was obtained as a white solid (29 
mg, 99% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) 
δ 3.79 – 3.62 (m, 4H), 3.56 – 3.44 (m, 3H), 3.41 – 3.31 (m, 1H), 2.55 (s, 1H), 2.04 (s, 1H), 
1.65 – 1.54 (m, 2H), 1.25 (s, 30H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
78.99 , 71.53 , 71.34 , 63.42 , 50.65 , 31.91 , 30.01 , 29.68 , 29.65 , 29.64 , 29.58 , 29.54 
, 29.41 , 29.34 , 26.01 , 22.67 , 14.10 . DART-MS: [M-N2+H]+ for C22H45N3O3 calcd, 
372.3472; detected, 372.3797. 
 
(2S,3S)-4-Azido-3-(((Z)-octadec-9-en-1-yl)oxy)butane-1,2-diol (4.19, n = 
(16:1)). Starting with compound 4.58 (47 mg, 0.074 mmol), compound 4.19 was obtained 
as a clear oil (16 mg, 55 % yield) and was confirmed by mass spectrometry, but analysis 
by NMR indicated a significant aromatic impurity. Rf = 0.6 (20% Acetone-chloroform, UV 




The following general method was used to synthesize compounds 4.59-4.64: In a 
6 dram vial under N2, compound 4.52 (78 mg, 0.20 mmol) was dissolved in 3 mL N,N-
dimethylformamide, cooled to 0C. Then, sodium hydride (NaH, 12 mg, 0.30 mmol as a 
60% dispersion in paraffin wax) was added in one portion, and the mixture was stirred at 
0C for 30 min. A solution of alkyl bromide (0.24 mmol) and tetrabutylammonium iodide 
(TBAI, 4 mg, 0.01 mmol) in 2 mL N,N-dimethylformamide was added dropwise to the 
reaction, and the mixture was allowed to warm to rt and stir overnight. The reaction was 
cooled to 0C, quenched with 10 mL H2O, poured into 20 mL brine (saturated sodium 
chloride (aq)), and extracted with (2x) 15 mL CH2Cl2. The combined organic layers were 
dried over magnesium sulfate, filtered, concentrated by rotary evaporation, and dried 
under high vacuum to give the crude compound mixture, which was purified on a silica 
gel column using a gradient elution of 5-15% ethyl acetate in hexanes. 
 
4,4'-((((2S,3S)-4-Azido-2-(decyloxy)butane-1,3-diyl)bis(oxy))bis(methylene)) 
bis(methoxybenzene) (4.59, n = 8). 1-Bromodecane (53 mg, 0.24 mmol) was used, 
giving compound 4.59 as a clear oil (50 mg, 47% yield). Rf = 0.6 (25% EtOAc-hexanes, 
UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.91 – 6.83 (m, 4H), 4.65 – 4.50 (m, 2H), 
4.42 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, J = 7.0, 4.4 Hz, 1H), 3.65 – 3.56 (m, 2H), 
3.53 (q, J = 4.6 Hz, 1H), 3.51 – 3.40 (m, 2H), 3.42 – 3.25 (m, 2H), 1.59 – 1.48 (m, 2H), 
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1.26 (s, 14H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.31 , 159.20 , 
130.13 , 129.73 , 129.28 , 113.75 , 113.75 , 78.52 , 77.79 , 73.03 , 71.43 , 68.67 , 55.24 
, 51.39 , 31.89 , 30.07 , 29.61 , 29.58 , 29.47 , 29.32 , 26.10 , 22.67 , 14.10 . DART-MS: 
[M-N2+H]+ for C30H45N3O5 calcd, 500.3370; detected, 500.3368. 
 
4,4'-((((2S,3S)-4-Azido-2-(dodecyloxy)butane-1,3-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.60, n = 10). 1-Bromododecane (60 mg, 0.24 
mmol) was used, giving compound 4.60 as a clear oil (66 mg, 60% yield). Rf = 0.6 (25% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.90 – 6.82 (m, 4H), 
4.65 – 4.50 (m, 2H), 4.42 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, J = 7.1, 4.5 Hz, 1H), 
3.67 – 3.57 (m, 2H), 3.53 (q, J = 4.6 Hz, 1H), 3.51 – 3.40 (m, 2H), 3.41 – 3.26 (m, 2H), 
1.59 – 1.49 (m, 2H), 1.25 (s, 18H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
159.31 , 159.20 , 130.14 , 129.73 , 129.28 , 113.75 , 113.75 , 78.52 , 77.79 , 73.03 , 71.43 
, 68.67 , 55.24 , 51.39 , 31.91 , 30.07 , 29.67 , 29.63 , 29.48 , 29.34 , 26.11 , 22.68 , 14.10 
. DART-MS: [M-N2+H]+ for C32H49N3O5 calcd, 528.3683; detected, 528.3764. 
 
4,4'-((((2S,3S)-4-Azido-2-(tetradecyloxy)butane-1,3-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.61, n = 12). 1-Bromotetradecane (67 mg, 0.24 
mmol) was used, giving compound 4.61 as a clear oil 63 mg, 54% yield). Rf = 0.6 (25% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.90 – 6.83 (m, 4H), 
4.67 – 4.48 (m, 2H), 4.42 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, J = 7.1, 4.5 Hz, 1H), 
3.66 – 3.56 (m, 2H), 3.53 (q, J = 4.6 Hz, 1H), 3.50 – 3.41 (m, 2H), 3.41 – 3.27 (m, 2H), 
1.54 (h, J = 7.0 Hz, 2H), 1.25 (s, 22H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
288 
CDCl3) δ 159.31 , 159.20 , 130.13 , 129.73 , 129.28 , 113.75 , 78.52 , 77.78 , 77.19 , 
73.03 , 71.43 , 68.67 , 55.24 , 51.39 , 31.91 , 30.07 , 29.69 , 29.68 , 29.67 , 29.65 , 29.63 
, 29.61 , 29.47 , 29.35 , 26.11 , 22.68 , 14.10 . DART-MS: [M-N2+H]+ for C34H53N3O5 calcd, 
556.3996; detected, 556.4035. 
 
4,4'-((((2S,3S)-4-Azido-2-(hexadecyloxy)butane-1,3-diyl)bis(oxy))bis 
(methylene))bis(methoxybenzene) (4.62, n = 14). 1-Bromohexadecane (73 mg, 0.24 
mmol) was used, giving compound 4.62 as a clear oil (69 mg, 57% yield). Rf = 0.6 (25% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.90 – 6.82 (m, 4H), 
4.65 – 4.50 (m, 2H), 4.42 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, J = 7.1, 4.5 Hz, 1H), 
3.67 – 3.56 (m, 2H), 3.53 (q, J = 4.6 Hz, 1H), 3.51 – 3.40 (m, 2H), 3.41 – 3.23 (m, 2H), 
1.59 – 1.48 (m, 2H), 1.25 (d, J = 2.1 Hz, 26H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 159.31 , 159.20 , 130.13 , 129.73 , 129.28 , 113.75 , 78.52 , 77.78 , 73.03 
, 71.43 , 68.67 , 55.24 , 51.39 , 31.91 , 30.07 , 29.69 , 29.67 , 29.64 , 29.62 , 29.48 , 29.35 




(methylene))bis(methoxybenzene) (4.63, n = 16). 1-Bromooctadecane (80 mg, 0.24 
mmol) was used, giving compound 4.63 as a clear oil (80 mg, 63% yield). Rf = 0.6 (25% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.90 – 6.82 (m, 4H), 
4.67 – 4.48 (m, 2H), 4.42 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, J = 7.0, 4.4 Hz, 1H), 
3.67 – 3.56 (m, 2H), 3.53 (q, J = 4.6 Hz, 1H), 3.51 – 3.41 (m, 2H), 3.41 – 3.26 (m, 2H), 
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1.54 (s, 2H), 1.25 (s, 30H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.31 
, 159.20 , 130.13 , 129.74 , 129.28 , 113.75 , 78.52 , 77.78 , 73.03 , 71.43 , 68.67 , 55.24 
, 51.39 , 31.91 , 30.07 , 29.69 , 29.68 , 29.64 , 29.62 , 29.48 , 29.35 , 26.11 , 22.68 , 14.10 
. DART-MS: [M-N2+H]+ for C38H61N3O5 calcd, 612.4622; detected, 612.4510. 
 
4,4'-((((2S,3S)-4-azido-2-(((Z)-octadec-9-en-1-yl)oxy)butane-1,3-diyl)bis(oxy)) 
bis(methylene))bis(methoxybenzene) (4.64, n = (16:1)). Oleyl-1-bromide (80 mg, 0.24 
mmol) was used, giving compound 4.64 as a clear oil (58 mg, 45% yield). Rf = 0.6 (25% 
EtOAc-hexanes, UV) 1H NMR (500 MHz, CDCl3) δ 7.24 (dd, 4H), 6.90 – 6.83 (m, 4H), 
5.39 – 5.33 (m, 2H), 4.65 – 4.53 (m, 2H), 4.41 (s, 2H), 3.80 (d, J = 4.1 Hz, 6H), 3.70 (dt, 
J = 7.0, 4.4 Hz, 1H), 3.66 – 3.56 (m, 2H), 3.53 (q, J = 4.7 Hz, 1H), 3.51 – 3.41 (m, 2H), 
3.41 – 3.26 (m, 2H), 2.06 – 1.92 (m, 4H), 1.55 (s, 2H), 1.36 – 1.22 (m, 22H), 0.88 (t, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.31 , 159.20 , 130.13 , 129.92 , 129.81 , 
129.73 , 129.28 , 113.75 , 113.75 , 78.52 , 77.77 , 73.03 , 71.42 , 68.67 , 55.24 , 51.38 , 
31.89 , 30.07 , 29.76 , 29.69 , 29.65 , 29.51 , 29.47 , 29.45 , 29.31 , 29.30 , 29.28 , 27.20 




The following general method was used to synthesize compounds 4.8-4.13: In a 6 
dram vial, the bis-PMB-protected 2’-MEG precursor (compounds 4.59-4.64) was 
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dissolved in 2 mL methylene chloride, and then trifluoroacetic acid (TFA, 0.5 mL, “wet” 
from storage bottle without prior distillation) was added. The reaction was stirred for 10 
min at rt as it turned light pink and then dark purple, and was then concentrated by rotary 
evaportation. Traces of TFA were removed by repeated (4x) rotary evaporation with 2 mL 
of a 1:1 benzene:methylene chloride mixture, and the resulting crude brown solid was 
dried under high vacuum and then purified on a silica gel column using a gradient elution 
of 8-15% acetone in chloroform. 
 
(2S,3S)-4-Azido-2-(decyloxy)butane-1,3-diol (4.8, n = 8). Starting with 
compound 4.59 (50 mg, 0.095 mmol), compound 4.8 was obtained as a clear oil (21 mg, 
78% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.91 
(dt, J = 6.4, 4.7 Hz, 1H), 3.85 (dd, J = 11.9, 4.7 Hz, 1H), 3.76 – 3.62 (m, 2H), 3.55 – 3.32 
(m, 4H), 2.70 (s, 1H), 2.00 (s, 1H), 1.64 – 1.55 (m, 2H), 1.38 – 1.21 (m, 14H), 0.88 (t, J = 
6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 79.08 , 71.15 , 71.09 , 61.21 , 53.19 , 31.86 , 
30.00 , 29.55 , 29.53 , 29.41 , 29.28 , 26.08 , 22.65 , 14.09 . DART-MS: [M-N2+H]+ for 
C14H29N3O3 calcd, 260.2220; detected, 260.2093. 
 
(2S,3S)-4-Azido-2-(dodecyloxy)butane-1,3-diol (4.9, n = 10). Starting with 
compound 4.60 (66 mg, 0.119 mmol), compound 4.9 was obtained as a clear oil (26 mg, 
70% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.91 
(dt, J = 6.4, 4.7 Hz, 1H), 3.85 (dd, J = 11.9, 4.7 Hz, 1H), 3.76 – 3.62 (m, 2H), 3.53 – 3.35 
(m, 4H), 2.57 (s, 1H), 2.00 (s, 1H), 1.66 – 1.53 (m, 2H), 1.37 – 1.17 (m, 18H), 0.91 – 0.84 
(m, 3H). 13C NMR (126 MHz, CDCl3) δ 79.08 , 71.15 , 71.10 , 61.22 , 53.19 , 31.89 , 30.00 
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, 29.63 , 29.60 , 29.57 , 29.55 , 29.41 , 29.32 , 26.08 , 22.66 , 14.09 . DART-MS: [M-
N2+H]+ for C16H33N3O3 calcd, 288.2533; detected, 288.2573. 
 
(2S,3S)-4-Azido-2-(tetradecyloxy)butane-1,3-diol (4.10, n = 12). Starting with 
compound 4.61 (63 mg, 0.108 mmol), compound 4.10 was obtained as a clear oil (19 mg, 
51% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) δ 3.92 
(dt, J = 6.4, 4.7 Hz, 1H), 3.86 (dd, J = 11.9, 4.6 Hz, 1H), 3.73 – 3.63 (m, 2H), 3.55 – 3.34 
(m, 4H), 2.60 (s, 1H), 1.81 (s, 1H), 1.66 – 1.53 (m, 2H), 1.26 (s, 22H), 0.88 (t, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 79.09 , 71.15 , 71.10 , 61.23 , 53.18 , 31.90 , 30.00 , 
29.67 , 29.65 , 29.63 , 29.58 , 29.55 , 29.42 , 29.34 , 26.09 , 22.67 , 14.10 . DART-MS: 
[M-N2+H]+ for C18H37N3O3 calcd, 316.2846; detected, 316.2709. 
 
(2S,3S)-4-Azido-2-(hexadecyloxy)butane-1,3-diol (4.11, n = 14). Starting with 
compound 4.62 (69 mg, 0.113 mmol), compound 4.11 was obtained as a white solid (22 
mg, 52% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) 
δ 3.92 (dt, J = 6.4, 4.7 Hz, 1H), 3.86 (dd, J = 11.9, 4.6 Hz, 1H), 3.73 – 3.62 (m, 2H), 3.55 
– 3.34 (m, 4H), 2.10 (s, 2H), 1.66 – 1.53 (m, 2H), 1.25 (s, 26H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 79.08 , 71.15 , 71.10 , 61.23 , 53.18 , 31.91 , 30.00 , 29.68 
, 29.65 , 29.64 , 29.59 , 29.55 , 29.42 , 29.34 , 26.09 , 22.67 , 14.10 . DART-MS: [M-
N2+H]+ for C20H41N3O3 calcd, 344.3159; detected, 344.3143. 
 
(2S,3S)-4-Azido-2-(octadecyloxy)butane-1,3-diol (4.12, n = 16). Starting with 
compound 4.63 (80 mg, 0.125 mmol), compound 4.12 was obtained as a white solid (31 
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mg, 62% yield). Rf = 0.6 (20% Acetone-chloroform, KMnO4) 1H NMR (500 MHz, CDCl3) 
δ 3.92 (dt, J = 6.3, 4.7 Hz, 1H), 3.86 (dd, J = 11.9, 4.7 Hz, 1H), 3.76 – 3.63 (m, 2H), 3.56 
– 3.34 (m, 4H), 1.93 (s, 2H), 1.66 – 1.53 (m, 2H), 1.25 (s, 30H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 79.09 , 71.15 , 71.10 , 61.23 , 53.18 , 31.91 , 30.00 , 29.68 
, 29.66 , 29.64 , 29.59 , 29.56 , 29.42 , 29.34 , 26.09 , 22.67 , 14.10 . DART-MS: [M-
N2+H]+ for C22H45N3O3 calcd, 372.3472; detected, 372.3367. 
 
(2S,3S)-4-Azido-2-(((Z)-octadec-9-en-1-yl)oxy)butane-1,3-diol (4.13, n = 
(16:1)). Starting with compound 4.64 (58 mg, 0.091 mmol), compound 4.19 was obtained 
as a clear oil (21 mg, 58% yield) and was confirmed by mass spectrometry, but analysis 
by NMR indicated a significant aromatic impurity. Rf = 0.6 (20% Acetone-chloroform, UV 
and KMnO4). DART-MS: [M-N2+H]+ for C22H43N3O3 calcd, 370.3315; detected, 370.3301. 
 
 
4-Bromo-N-(prop-2-yn-1-yl)benzamide (4.66). In an oven dried 25 mL round 
bottom flask under argon, commercially available 4-bromobenzoic acid (4.65, 143 mg, 
0.711 mmol) and propargylamine (46 L, 0.711) were dissolved in 5 mL chloroform. The 
brown suspension was cooled to 0C, and (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU, 270 mg, 0.711 mmol) was added in one 
portion, followed by diisopropylethylamine (DIEA, 184 L, 1.42 mmol). The reaction was 
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stirred for 20 min at 0C, then allowed to warm to rt and stirred for 11 h as a precipitate 
formed. The resulting brown suspension was diluted with 10 mL chloroform, washed with 
5 mL 1N hydrochloric acid (HCl (aq)), 5 mL water, 5 mL 2N sodium bicarbonate (NaHCO3 
(aq)), 5 mL water, then 5 mL brine (saturated sodium chloride (aq)), and then dried over 
sodium sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum 
to give a yellow powder. The crude residue was purified on a silica gel column using a 
gradient elution of 15-45 mL ethyl acetate in hexanes to give compound 4.66 as a white 
solid (110 mg, 65% yield). Rf = 0.56 (35% EtOAc-hexanes, UV). DART-MS: [M+H]+ for 
C10H8BrNO calcd, 237.9862; detected, 237.9867. NMR data matched previous reports.296 
 
 
6-Bromo-2-ethyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (4.68). A published 
protocol was followed.305 In a 100 ml 3 neck flask equipped with a condenser, 
commercially available compound 4.67 (515 mg, 1.86 mmol) was suspended in 40 mL 
(1:1) 1,4-dioxane/water. Heat was applied with stirring, and ethylamine (143 L, 2.23 
mmol) was added, turning the mixture from light brown to a dark brown suspension, and 
then gradually tan-red as heating continued. Upon reaching 100C, the reaction clarified 
to a red-brown solution, and then turned dark purple over 1.5 h. A second aliquot of 
ethylamine (97 L, 1.51 mmol) was added, causing the reaction to darken even more, 
and was stirred for 2 h at 100C. A third aliquot of ethylamine (30 L, 0.49 mmol) was 
294 
then added, and after 15 min the reaction was allowed to cool to rt and was poured into 
190 mL water. The suspension was filtered and the filtrand was rinsed with 120 mL water, 
transferred to a round bottom flask by rinsing the filter paper with methylene chloride, 
concentrated by rotary evaporation with azeotropic removal of water using (3x) 3 mL 
toluene to give 4.68 as a yellow solid (420 mg, 75% yield). Rf = 0.73 (40% acetone-
hexanes, UV). DART-MS: [M+H]+ for C14H10BrNO2 calcd, 303.9968; detected, 303.9951. 




(4.69). A published protocol was followed.297 In an oven dried 100 mL round bottom flask 
under argon, compound 4.68 (420 mg, 1.386 mmol), copper(I) iodide (CuI, 27 mg, 0.139 
mmol), and tetrakis(triphenylphosphine) palladium(0) (Pd(PPh3)4, 80 mg, 0.069 mmol) 
were suspended in a freshly degassed solution of triethylamine (386 L, 2.772 mmol) in 
10 mL tetrahydrofuran. The dark yellow-green mixture was stirred at rt for 23 h, then 
concentrated by rotary evaporation, diluted with 35 mL ethyl acetate, washed with 10 mL 
saturated ammonium chloride (NH4Cl (aq)), 10 mL water, then 10 mL brine (saturated 
sodium chloride (aq)), and then dried over magnesium sulfate, filtered, concentrated by 
rotary evaporation, and dried under high vacuum to give a red oil. The crude residue was 
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purified on a silica gel column using a gradient elution of 5-8% ethyl acetate in hexanes 
to give compound 4.69 as a pale yellow powder (224 mg, 50% yield) Rf = 0.80 (25% 
EtOAc-hexanes, long wave UV: blue). DART-MS: [M+H]+ for C19H19NO2Si calcd, 
322.1258; detected, 322.1271. NMR data matched previous reports.297 
 
 
2-Ethyl-6-ethynyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (4.70). A published 
procedure was followed.298 This compound is also known commercially as 4-ethynyl-N-
ethyl-1,8-napththalimide. In a 6 dram vial, compound 4.69 (19 mg, 0.059 mmol) was 
dissolved in 1.5 mL methanol. A solution of potassium carbonate (K2CO3, 8 mg, 0.059 
mmol) in 0.5 mL water was added, and the yellow-brown suspension was stirred at rt for 
2 h. 1.5 mL of water were added, the precipitate was filtered off and rinsed with water, 
and the filtrand was rinsed into a round bottom flask using ethyl acetate, concentrated by 
rotary evaporation, and dried under high vacuum to give a brown solid. The crude residue 
was purified on a silica gel column using a gradient elution of 10-50% ethyl acetate in 
hexanes, and then on a second column using chloroform to give compound 4.70 as a 
pale yellow solid (12 mg, 80% yield). Rf = 0.56 (25% EtOAc-hexanes, long wave UV). 
DART-MS: [M+H]+ for C16H11NO2 calcd, 250.0863; detected, 250.0869. NMR data 
matched previous reports.297 
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4.8  List of Mass Spectra for Final Compounds Used in Studies 
 
 
Spectrum 4.1. ACCUTOF-DART mass spectrum of compound 4.1. 
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Spectrum 4.2. ACCUTOF-DART mass spectrum of compound 4.20. 
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Spectrum 4.3. ACCUTOF-DART mass spectrum of compound 4.23. 
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Spectrum 4.4. ACCUTOF-DART mass spectrum of compound 4.25. 
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Spectrum 4.5. ACCUTOF-DART mass spectrum of compound 4.26. 
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Spectrum 4.6. ACCUTOF-DART mass spectrum of compound 4.2. 
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Spectrum 4.7. ACCUTOF-DART mass spectrum of compound 4.3. 
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Spectrum 4.8. ACCUTOF-DART mass spectrum of compound 4.4. 
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Spectrum 4.9. ACCUTOF-DART mass spectrum of compound 4.5. 
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Spectrum 4.10. ACCUTOF-DART mass spectrum of compound 4.6. 
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Spectrum 4.11. ACCUTOF-DART mass spectrum of compound 4.7. 
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Spectrum 4.12. ACCUTOF-DART mass spectrum of compound 4.14. 
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Spectrum 4.13. ACCUTOF-DART mass spectrum of compound 4.15. 
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Spectrum 4.14. ACCUTOF-DART mass spectrum of compound 4.16. 
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Spectrum 4.15. ACCUTOF-DART mass spectrum of compound 4.17. 
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Spectrum 4.16. ACCUTOF-DART mass spectrum of compound 4.18. 
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Spectrum 4.17. ACCUTOF-DART mass spectrum of compound 4.19. 
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Spectrum 4.18. ACCUTOF-DART mass spectrum of compound 4.8. 
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Spectrum 4.19. ACCUTOF-DART mass spectrum of compound 4.9. 
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Spectrum 4.20. ACCUTOF-DART mass spectrum of compound 4.10-. 
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Spectrum 4.21. ACCUTOF-DART mass spectrum of compound 4.11. 
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Spectrum 4.22. ACCUTOF-DART mass spectrum of compound 4.12. 
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Spectrum 4.23. ACCUTOF-DART mass spectrum of compound 4.13. 
 
4.9  General Experimental for Yeast Labeling Experiments 
All yeast growth, incubation, and harvesting procedures were performed in the 
laboratory of Todd Reynolds of the University of Tennessee, Knoxville. Yeast labeling 
experiments were performed with S. cerevisiae strain TRY181, or C. albicans wild type, 
beginning from cultures kept on YPD (yeast extract, peptone, dextrose) agar plates. 5mL 
liquid media starter cultures in glass tubes were inoculated from a plate and incubated at 
30C with shaking at 300 rpm. To acclimate yeast to growing in 2% glycerol media and 
prepared them for labeling experiments, cultures were re-innoculated into 5 mL fresh 
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media 1-2 times per week with ~0.2-0.5 OD count of cells until growth cycle time from 
inoculation to log phase was compressed to <24h.  
Synthetic complete liquid media was made with 1 L Millipore water, 20 g glycerol 
(for 2% glycerol medium) or 20 g galactose (for 2% galactose medium, added by 0.2 m 
filtration after autoclaving), 5 g ammonium sulfate, 1 g dibasic potassium phosphate 500 
mg magnesium sulfate, 1 g sodium chloride, 100 mg calcium chloride hexahydrate, 0.5 
mg boric acid, 40 g cupric sulfate, 0.1 mg potassium iodide, 0.2 mg ferric chloride, 0.4 
mg manganese sulfate, 0.2 mg sodium molybdate, 0.4 mg zinc sulfate, 2 g biotin, 400 
g calcium pantothenate, 2 g folic acid, 400 g niacin, 200 g p-aminobenzoic acid, 0.4 
mg pyridoxine hydrochloride, 0.2 mg riboflavin, 0.4 mg thiamine, 20 mg adenine sulfate, 
20 mg arginine, 20 mg histidine, 60 mg leucine, 230 mg lysine, 20 mg methionine, 300 
mg threonine, 20 mg tryptophan, and 40 mg uracil.296  
100 mM stock solutions of probe molecules were kept in 99% ethanol, with 
sonication to disperse insoluble content, and stored at rt in the dark. Thin layer 
chromatography was performed on 10 x 10 cm glass-supported silica plates with or 
without UV-254 fluorescent indicator, pre-treated by soaking in 2% boric acid in ethanol, 
then heating in an oven at 100C for 10 min. Fluoresence images of labeled lipids were 
visualized using a 365 nm lamp and captured using an iPhone 8 camera (true color 
images); alternatively, images were visualized using a UV-365 transilluminator and 
captured using a Geldoc with a SYBR Green emission filter (grayscale images). After 
imaging fluorescence from clicked samples, plates were stained with primulin (5 mg per 
100 mL (9:1) acetone/water), dried at rt, and imaged using either previously mentioned 
method.  ImageJ software was used for image processing. 
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4.10 Labeling of Yeast with Azide Glycerol-Based Probes 
From an existing pre-culture in log phase, an aliquot of yeast cells was taken and 
inoculated to 0.2 OD600/mL in 5 mL of fresh 2% galactose or 2% glycerol media in each 
glass culture tube and shaken overnight at 300 rpm and at 30C. Media with reduced 
carbon content (< 2% glycerol or galactose) was made by dilution with carbon-free 
synthetic media of identical mineral content to normal media. Probe stock solutions were 
spiked directly into media, avoiding touching the glass tube inner walls, to achieve desired 
final concentrations at the appropriate time, depending on experiment (spike upon initial 
inoculation at t = 0, or whenever cultures reach ~ 0.8 OD/mL), or with 50 L of 99% 
ethanol for probe-free control cultures. Labeling cultures were incubated with shaking for 
the appropriate time (2-24 h), then diluted to 10 mL with cold 1X PBS in 10 mL falcon 
tubes, centrifuged at 3500 rpm for 3 min, aspirated, resuspended by vortexing in 10 mL 
cold 1X PBS, centrifuging at 3500 rpm for 3 min, and aspirating again. Cell pellets were 
kept on on ice for transportation and were stored at -80C overnight if required.   
4.11 Lipid Extraction, Click, and TLC Procedure 
A modified published protocol was followed.127 Cell pellets on ice were 
resuspended in 1 mL cold 1X PBS, transferred to 2 mL Eppendorf tube, centrifuged at 
1000 g for 5 min, aspirated, and resuspended in 300 L cold 1X PBS, followed by 600 L 
methanol, and 150 L chloroform, vortexing for 10 sec after each addition. Then, ~1 mg 
glass beads were added, then vortexed at high intensity for 30 sec. The suspension was 
centrifuged at 14,000 g for 5 min, and the supernatant was transferred to a fresh 2 mL 
tube leaving behind the insoluble pellet, and 300 L chloroform, then 600 l 0.1% acetic 
acid in Millipore water was added, vortexing for 10 sec after each additon. The tube was 
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centrifuged at 14,000 g for 5 min, then the upper phase was aspirated (or saved for 
analysis as the “polar/aqueous fraction”), and the remaining lower organic phase was 
transferred to a fresh 2 mL tube, then dried under streaming N2. The lipid films were 
suspended in 8 L chloroform before adding 30 L of a freshly-prepared click mix (6.7L 
of 10 mM (1:1) dimethylsulfoxide/chloroform solution of compound 4.70; 200 L of 10 mM 
acetonitrile solution of tetrakis(acetonitrile)copper(I) tetrafluoroborate; 800 L 99% 
ethanol). The mixture was centrifuged for 10 sec, briefly spun down, and then incubated 
without agitation in the dark in a water bath at 43C for 3 h. As noted by the original 
authors of this method, evaporation of solvent from the mixture, as indicated by 
condensation of solvent on the inner lid, is essential for the click reaction to proceed.30 
After the reaction was complete, samples were spun down, vortexed gently, and then 
spotted on a 10 x 10 cm TLC plate (8 L, 0.5 cm wide, 9 spots per plate). Spots were 
dried in a fume hood at rt, then eluted once to Rf = 0.6 with (65:25:4:1) 
chloroform/methanol/water/acetic acid (CMWA), followed by elution to Rf = 1.0 with (1:1) 
cyclohexane/ethyl acetate (CyHEA). Plates with spots of polar/aqueous extracts were 
eluted in a single stage to Rf = 1.0 with CMWA. Plates were dried with a gentle stream of 
warm air before imaging and primulin staining. 
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5 CONTRIBUTIONS TOWARD SYNTHESIS OF A CALCIUM-CHELATING INDO-
1 LIPID 
The content of this chapter was included as part of the following publication: 
Lou, J.; Carr, A.J.; Watson, A.J.; Mattern-Schain, S.I.; Best, M.D. Calcium-Responsive 
Liposomes via a Synthetic Lipid Switch. Chem. Eur. J. 2018, 24 (14), 3599-360 
5.1 Calcium-Binding Lipid Concept 
Calcium ions (Ca++) are abundant, yet highly regulated in living systems. This ion 
influences cell functioning and signaling as well as disease status and is maintained at 
specific concentrations when a cell is healthy. Synthetic systems that are capable of 
recognizing and responding to Ca++ have potential diagnostic and drug delivery 
applications. Existing concepts that enable targeted delivery for liposomes involve inputs 
such as light or heat, or local changes in pH and enzyme expression to trigger cargo 
release near or within targeted cells and tissues.306-308 Contending with these approaches 
requires specific Ca++ recognition compared to other common biological cations, and 
integration of this feature into a system that translates the energy of chelation into 
liposome destruction to release encapsulated contents. 
This chapter covers progress made toward synthesizing a Ca++-responsive lipid 
5.1, which is designed after the previously reported Ca++ sensor molecule Indo-1 (5.2),309 
capable of selectively binding Ca++ to trigger a molecular conformation change. 
Compounds 5.1 and 5.2 are compared in Figure 5.1. Calcium-chelating lipid 5.1 is 
equipped with lipid tails to allow membrane incorporation and carboxylate headgroups 
that are anionic at physiological pH and exhibit a strong affinity for Ca++. Following Ca++ 
binding, a conformational switching action rearranges the spatial arrangement of the lipid 
tails causing membrane bilayer disruption. This action is demonstrated by fluorescence-  
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Figure 5.1: Structures of Ca++-binding synthetic target lipid 5.1, and Indo-1 (5.2), a 
Ca++-indicating probe that fluoresces upon metal chelation to the tetracarboxylate 
array. 
 
based release, DLS, and STEM experiments, while 5.1 preference for Ca++ was 
demonstrated by comparing binding across a panel of different cations. The ability of 5.1 
to disintegrate liposomes in response to Ca++ supports the concept of ion-triggered 
systems for drug release.310   
5.2 Synthetic work towards an Indo-1 Lipid 
The initial route to 5.1 shown in Scheme 5.1 was explored with help from with 
Alexa Watson of the Best Research Group. Following a known protocol,311 commercially 
available 3-amino-4-hydroxybenzoic acid (5.3) was protected using di-t-butyl 
decarbonate (Boc2O) to give N-Boc protected benzoic acid derivative 5.4, which was 
subjected to amide coupling to 1-dodecylamine using by 1-ethyl-3-
dimethylaminopropylcarbodiimide (EDCI), hydroxybenzotriazole (HOBt), and 
diisopropylethylaime (DIEA) to give amphiphilic phenol 5.5. Attempted bridging of two 5.5  
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Scheme 5.1: Early synthetic route in pursuit of Ca++-chelating lipid 5.1, leading to 
synthetic dead end in form of benzoxazine 5.6. 
i) (Boc)2O, (2:1) Dioxane/H2O, 84%; ii) 1-dodecylamine, EDCI, HOBt, DIEA, DMF, 0C to 
20C, 65%; iii) 1,2-dibromoethane, K2CO3, DMF, 120C, (5.6 = 31%; 5.7 = trace). 
 
molecules together by double nucleophilic substitution to 1,2-dibromoethane in the 
presence of potassium carbonate (K2CO3)312-313 yielded benzoxazine byproduct 5.6314 
and only a trace of desired bidentate lipid 5.7. 
The first attempt to bypass the undesired benzoxazine pathway involved a 
stepwise approach summarized in Scheme 5.2, first with nucleophilic substitution of 2-
bromoethanol with phenol 5.5 in the presence of K2CO3 to give glycol ether 5.8 in very 
low yield.315-316 Attempted Mistunobu coupling of the resulting free alcohol on 5.8 to the 
phenol group of another 5.5 unit using diisopropyl azidodicarboxylate (DIAD) and 
triphenylphosphine (PPh3) and did not give product 5.7. Similar Mitsunobu conditions317 
failed to bridge two units of phenol 5.5 in a single step using ethylene glycol. 
Considering the low yield of coupling 5.5 to 2-bromoethanol, we tried preemptively 
protecting the free ethyl chain alcohol, first by monobenzylation139 of ethylene glycol 
(5.10) using benzyl bromide (BnBr) with silver(I) oxide (Ag2O) to form protected alcohol 
5.11, which was converted to bromide 5.12 by Appel reaction with carbon tetrabromide 
(CBr4) and PPh3.318 5.12 was coupled to 5.5 using the same conditions mentioned 
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previously for similar reactions to give benzyl-protected intermediate 5.9, but at this point 
the synthesis was abandoned in favor of a simpler synthetic route to 5.1. 
 
 
Scheme 5.2: Summary of attempted solutions connecting two units of lipid 5.5 
without benzoxazine cyclization. 
i) 2-bromoethanol, K2CO3, DMSO, 7%; ii) DIAD, PPh3, THF, 0C to 20C; iii) Ethylene 
glycol, DIAD, PPh3, THF; iv) 5.12, K2CO3, DMF, 34%; 110C; v) BnBr, Ag2O, CH2Cl2, 
69%; vi) CBr4, PPh3, THF, 0C to 20C, 60%. 
 
As shown in Scheme 5.3, we restarted synthesis with commercially available 
compound 4-hydroxy-3-nitrobenzoic acid (5.13). Here, we follow a similar series of steps 
as presented in Scheme 501, but with a nitro (–NO2) group in place of a Boc-protected 
aniline (–NH2), avoiding the issue of cyclization to a benzoxazine byproduct. First, 1-
dodecylamine was coupled to the carboxylic acid of 5.13 using EDCI, HOBt, and DIEA to 
give amphiphilic phenol 5.14. This time, installation of the ethylene diether bridge between 
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two units of 5.14 using 1,2-dibromoethane in the presence of K2CO3 gave bidentate lipid 
5.15 as the major product. Dinitro lipid 5.15 was reduced to its dianiline counterpart 5.16 
by catalytic hydrogenation with 10% palladium on carbon (Pd/C), which was then 
subjected to tetrasubstitution, twice on each free nitrogen, with ethyl bromoacetate in the 
presence of sodium iodide (NaI) and 1,8-bisdimethylaminonaphthalene (proton sponge) 
to yield 5.17, which is the tetraethyl ester-protected precursor to final product 5.1. 
Responsibility for this synthesis was transferred to Jinchao Lou of the Best Research 
Group for completion of the final step, and for the metal binding and triggered liposome 
release experiments covered in the resulting publication.310 
 
 
Scheme 5.3:  Installation of the ethane bridge, leading to tetraethyl ester-protected 
lipid 5.17. 
i) 1-dodecylamine, EDCI, HOBt, DIEA, DMF, 0C to 20C, 87%; ii) 1,2-dibromoethane, 
K2CO3, DMF, 120C, 69%; iii) H2, 10% Pd/C, EtOAc, 66%; iv) ethyl bromoacetate, NaI, 
proton sponge, (1:10) THF/MeCN, reflux, 10%. 
 
5.3  General Experimental 






5.4  Detailed Syntheses 
 
 
3-((tert-Butoxycarbonyl)amino)-4-hydroxybenzoic acid (5.4). A published 
protocol was followed.311 In a 50 mL round bottom flask, commercially available 
compound 3-amino-4-hydroxybenzoic acid (5.3, 500 mg, 3.265 mmol) was dissolved in 
10 mL (2:1) 2,4-dioxane/water, and di-tert-butyl dicarbonate (Boc2O, 790 mg, 3.620 
mmol) was added in a single portion to the stirring solution at rt. The reaction turned from 
opaque brown to clear orange, and was stirred for 22 h before adding an additional 80 
mg Boc2O, then 50 mg Boc2O (130 mg, 0.596 mmol total), and stirring for an additional 
24 hours. 5 mL of water were added, then the aqueous layer was extracted with (3x) 8 
mL ethyl acetate, and the combined organic layers were washed with 5 mL brine 
(saturated sodium chloride (aq)), dried over magnesium sulfate, filtered, concentrated by 
rotary evaporation, and dried under high vacuum to give compound 5.4 as a red-brown 
powder (695 mg, 84% yield). Rf = 0.70 (15% MeOH-CH2Cl2, UV, BCG: yellow).  DART-





tert-Butyl (2-hydroxy-5-(dodecylcarbamoyl)phenyl)carbamate (5.5). In an 
oven dried 50 mL round bottom flask under argon, compound 5.4 (348 mg, 1.374 mmol), 
hydroxybenzotriazole (HOBt, 316 mg, 2.061 mmol), and 1-dodecylamine (382 mg, 2.061 
mmol) were dissolved in 7 mL N,N-dimethylformamide, and the mixture was cooled to 
0C. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI•HCl, 395 mg, 
2.061 mmol) was added to the stirring suspension in one portion, followed by 
diisopropylethylamine (DIEA, 454 L, 2.748 mmol), and the reaction clarified to a dark 
solution as it was warmed to rt and stirred for overnight. The resulting mixture was cooled 
to 0C and quenched with 10 mL water, stirred for 10 min, poured into 40 mL water, 
extracted with (2x) 30 mL ethyl acetate, and the combined organic layers were washed 
with (2x) 20 mL water, 13 mL brine (saturated sodium chloride (aq)), dried over sodium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum to give 
a red oil. The crude residue was purified on a silica gel column using a gradient elution of 
20-40% acetone in hexanes to give compound 5.5 as a red oil (374 mg, 65% yield) Rf = 
0.71 (50% acetone-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H), 7.35 (d, J = 
8.4 Hz, 1H), 7.13 (s, 1H), 6.85 (d, 1H), 6.26 (s, 1H), 3.40 (q, J = 6.8 Hz, 2H), 2.78 – 2.70 
(m, 1H), 1.59 (q, J = 7.3 Hz, 2H), 1.52 (s, 9H), 1.25 (s, 18H), 0.91 – 0.84 (m, 3H). 13C 
NMR (126 MHz, CDCl3) δ 167.79 , 154.14 , 149.80 , 126.48 , 125.84 , 123.33 , 117.96 , 
116.61 , 81.48 , 40.24 , 31.90 , 29.65 , 29.63 , 29.60 , 29.57 , 29.53 , 29.33 , 29.32 , 28.28 
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carboxylate (5.6). Publsihed protocols were modified for this synthesis.313, 317 This 
synthesis was intended to produce compound 5.7, but consistently yielded compound 5.6 
instead. In an oven dried 1 dram vial under argon, compound 5.5 (22 mg, 0.052 mmol), 
potassium carbonate (K2CO3, 8.7 mg, 0.063; Cesium carbonate gave similar results), and 
potassium iodide (KI, 0.9 mg, 5.2 mol) was suspended in 0.3 mL dimethylsulfoxide. 1,2-
dibromoethane (5.4 L, 0.063 mmol) was added slowly to the stirring mixture at rt, and 
the resulting orange solution was stirred for 38 h. The reaction was cooled to 0C, 
quenched with 0.5 mL saturated ammonium chloride (NH4Cl (aq)), poured into 10 mL 
water, extracted with 5 mL ethyl ether, dried over magnesium sulfate, filtered, 
concentrated by rotary evaporation, and dried under high vacuum to give and orange oil. 
The crude residue was purified on a silica gel column using an gradient elution of 20 to 
60% ethyl acetate in hexanes to give compound 5.6 (6 mg, 31% byproduct). Traces of 
desired product 5.7 were detected by mass spectroscopy. Rf (5.6) = 0.61 (40% EtOAc-
hexanes, UV). NMR (5.6) 1H NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.42 (d, J = 8.1 Hz, 
1H), 6.89 (d, J = 8.5 Hz, 1H), 6.01 (s, 1H), 4.27 (t, 2H), 3.87 (t, 2H), 3.42 (q, J = 7.3, 5.8 
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Hz, 2H), 1.59 (s, 2H), 1.57 (s, 9H), 1.26 (s, 18H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 166.92 , 152.37 , 148.29 , 126.99 , 125.90 , 123.22 , 117.04 , 82.13 , 65.78 
, 40.06 , 31.90 , 29.76 , 29.63 , 29.61 , 29.57 , 29.55 , 29.33 , 28.33 , 27.01 , 22.67 , 14.10. 
DART-MS (5.6): [M+H]+ for C26H42N2O4 calcd, 447.3218; detected, 447.3188. DART-MS 




(5.8). Published protocols were adapted for this synthesis.315-316 In an oven dried 1 dram 
vial under argon, compound 5.5 (33 mg, 0.079 mmol) and potassium carbonate (K2CO3, 
11 mg, 0.082 mmol) were suspended in 1 mL dimethylsulfoxide at rt. Ethylene 
bromohydrin (5.8 L, 0.082 mmol) was added, and the red-orange reaction was stirred at 
rt for 3 days before adding a second equivalent of ethylene bromohydrin (5.8 L, 0.082), 
and stirred overnight. The resulting mixture was poured into 8 mL cold water, extracted 
with (2x) 4 mL diethyl ether, and the combined organic layers were washed with (2x) 1 
mL water, then 1 mL brine (saturated sodium chloride (aq)), and then dried over sodium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum to give 
a red oil. The crude residue was purified on a silica gel column using a gradient elution of 
30-50% ethyl acetate in hexanes to give compound 5.8 as a yellow oil (3 mg, 7% yield). 
Rf = 0.40 (70% EtOAc-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 8.38 (s, 1H), 7.64 – 
331 
7.55 (m, 1H), 7.45 (dd, J = 8.3, 1.7 Hz, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.11 (s, 1H), 6.91 
(d, J = 8.6 Hz, 1H), 6.14 (d, J = 36.9 Hz, 1H), 4.20 (dd, J = 5.2, 3.9 Hz, 2H), 3.43 – 3.38 
(m, 2H), 2.10 (s, 1H), 1.65 – 1.50 (m, 2H), 1.55 (s, 9H), 1.26 (d, J = 1.9 Hz, 18H), 0.88 (t, 
J = 6.6 Hz, 3H). DART-MS: [M+H]+ for C26H44N2O5 calcd, 465.3323; detected, 465.3311. 
 
 
2-(Benzyloxy)ethan-1-ol (5.11). A published protocol was followed.139 In an oven 
dried 6 dram vial under argon, compound 5.10 (130 mg, 2.09 mmol) was dissolved in 3 
mL methylene chloride, and silver(I) oxide (Ag2O, 728 mg, 3.14 mmol) was added in a 
single portion to the stirring solution at rt, followed by benzyl bromide (BnBr, 273 L, 2.30 
mmol), and the black suspension was stirred overnight. The reaction was filtered through 
a short plug of silica, and the eluate was concentrated by rotary evaporation to give a 
yellow oil, which was purified on a silica gel column using a gradient elution of 15-45% 
ethyl acetate in hexanes to give compound 5.11 as a clear oil (220 mg, 69% yield). Rf = 
0.33 (35% EtOAc, UV, KMnO4). 5.11 is a commercially available compound, and NMR319 
data matched previous reports. 
 
 
((2-bromoethoxy)methyl)benzene (5.12). A previously published protocol was 
followed.318 In an oven dried 100 mL round bottom flask under argon, compound 5.11 (73 
mg, 0.480 mmol) was dissolved in 2 mL tetrahydrofuran, carbon tetrabromide was added 
(CBr4, 317 mg, 0.955 mmol), and the solution was stirred and cooled to 0C. A solution 
332 
of triphenylphosphine (PPh3, 253 mg, 0.965 mmol) in 1 mL tetrahydrofuran was added 
dropwise to the reaction, and a precipitate formed as the mixture was allowed to warm to 
rt and stir for 2 h. The opaque orange suspension was concentrated by rotary evaporation 
and dried under high vacuum to give an orange solid, which was purified on a silica gel 
column using a gradient elution of 0-50% chloroform in hexanes to give 5.12 as a clear 
oil (62 mg, 60% yield). Rf = 0.49 (10% EtOAc-hexanes, UV, KMnO4). DART-MS: [M+H]+ 





(5.9). In an oven dried 1 dram vial under argon, compound 5.5 (55 mg, 0.131 mmol) and 
potassium carbonate (K2CO3, 36 mg, 0.262 mmol) were suspended in 0.5 mL N,N-
dimethylformamide. A solution of compound 5.12 (31 mg, 0.144 mmol) in 0.2 mL 
tetrahydrofuran was added to the vigorously stirring reaction at rt, and the opaque orange 
solution was heated to 115C for 3 h. The resulting light brown suspension darkened upon 
cooling, and was poured into 5 mL water, extracted with (4x) 3 mL chloroform, and the 
combined organic layers were washed (x3) 2 mL water, then 1 mL brine (saturated 
sodium chloride (aq)), and was dried over sodium sulfate, filtered, concentrated by rotary 
evaporation, and dried under high vacuum. The crude reside was purified on a silica gel 
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column using a gradient elution of 0-4% methanol in methylene chloride, then on a second 
column using a gradient elution of 25-55% ethyl acetate in hexanes to give compound 5.9 
as a clear oil (25 mg, 34% yield). Rf = 0.45 (30% acetone-hexanes, UV). 1H NMR (500 
MHz, CDCl3) δ 8.42 (s, 1H), 7.61 – 7.48 (m, 1H), 7.36 (d, J = 4.5 Hz, 4H), 7.35 – 7.24 (m, 
1H), 7.20 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.17 (s, 1H), 4.27 – 4.21 (m, 2H), 
3.86 – 3.79 (m, 2H), 3.45 – 3.37 (m, 2H), 1.61 (s, 2H), 1.54 (s, 9H), 1.38 – 1.24 (m, 18H), 
0.88 (t, 3H). 13C NMR (126 MHz, CDCl3) δ 166.93 , 152.78 , 148.81 , 137.67 , 128.52 , 
128.42 , 128.10 , 127.87 , 127.69 , 127.60 , 122.77 , 121.31 , 111.98 , 109.47 , 108.69 , 
77.19 , 73.33 , 73.29 , 68.79 , 67.95 , 42.80 , 40.13 , 31.90 , 29.78 , 29.64 , 29.61 , 29.58 
, 29.54 , 29.33 , 28.36 , 27.02 , 22.67 , 14.10. DART-MS: [M+H]+ for C32H48N2O5 calcd, 
555.3793; detected, 555.3417. 
 
 
N-Dodecyl-4-hydroxy-3-nitrobenzamide (5.14). In an oven dried 1 dram vial, 
commercially available 4-hydroxy-3-nitrobenzoic acid (5.13, 50 mg, 0.273 mmol), 
hydroxybenzotriazole (HOBt, 63 mg, 0.410 mmol), and 1-dodecylamine (76 mg, 0.410 
mmol) were dissolved in 1 mL N,N-dimethylformamide, and the yellow opaque mixture 
was cooled to 0C. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDCI•HCl, 79 mg, 0.410 mmol) was added to the stirring suspension in one portion, 
followed by diisopropylethylamine (DIEA, 113 L, 0.683 mmol), and the suspension 
334 
turned orange as it was warmed to rt and stirred for 1 h. Then, 0.5 mL N,N-
dimethylformamide was added to remedy a stuck stirbar resulting from thick precipitate, 
and the yellow suspension was stirred for 3.5 h.  The resulting mixture was quenched 
with 1 mL water, and the dark orange suspension was poured into 12 mL 1N hydrochloric 
acid (HCl (aq)), extracted with (2x) 15 mL ethyl acetate, and the combined organic layers 
were washed with (4x) 5 mL water, then 5 mL brine (saturated sodium chloride (aq)), 
dried over sodium sulfate, filtered, concentrated by rotary evaporation, and dried under 
high vacuum to give a yellow solid. The crude residue was purified on a silica gel column 
using a gradient elution of 0-4% methanol in methylene chloride to give compound 5.14 
as a pale yellow powder (83 mg, 87% yield) Rf = 0.78 (50% acetone-hexanes, UV). NMR 
and MS data were included in the cited publication.310  
 
 
4,4'-(Ethane-1,2-diylbis(oxy))bis(N-dodecyl-3-nitrobenzamide) (5.15). In a 5 
mL oven dried round bottom flask, compound 5.14 (41 mg, 0.117 mmol) and potassium 
carbonate (K2CO3, 18 mg, 0.129 mmol) were suspended in 1 ml N,N-dimethylformamide. 
1,2-Dibromoethane (4.5 L, 0.053 mmol) was added, and the bright orange mixture was 
heated to 120C and stirred for 2 h, then an extra equivlent of 1,2-dibromoethane (9 L, 
0.106 mmol) was added and the reaction was stirred for 3 h. The yellow mixture was 
cooled to rt, poured into 4 mL water, filtered through celite*, eluted with (3x) water, then 
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(3x) 3 mL methylene chloride, and the collected biphasic liquid was washed with 1 mL 
0.1N sodium hydroxide (NaOH (aq)), 1 mL water, 1 ml brine, and dried over sodium 
sulfate, filtered, concentrated by rotary evaporation, and dried under high vacuum to give 
a yellow solid (*celite filtration should be omitted in future, go directly to wash/extraction 
instead). Additional compound was freed from the celite plug with a warm mixture of (1:9) 
methanol/chloroform and combined with the organic fraction. The crude residue was 
purified on a silica gel column using a gradient elution of 0-4% methanol in 
dichloromethane to give compound 5.15 as a white solid (30 mg, 69% yield) Rf = 0.50 
(5% MeOH-CH2Cl2, UV). NMR and MS data were included in the cited publication.310  
 
 
4,4'-(Ethane-1,2-diylbis(oxy))bis(3-amino-N-dodecylbenzamide) (5.16). In a 3 
mL test tube under argon, a solution of compound 5.15 (28 mg, 0.039 mmol) in 1 mL ethyl 
acetate was added to 10% palladium on carbon (Pd/C, 6 mg, 20% w/w% 5.15). High-
speed stirring was initiated, and the atmosphere was replaced with H2, and the light gray 
suspension was stirred at rt overnight. Then, the atmosphere was flushed with argon, and 
the black suspension was filtered through celite, rinsed with (1:1) methanol/chloroform, 
and the filtrate was concentrated by rotary evaporation to give a tan solid. The crude 
residue was purified on a silica gel column using a gradient elution of 0-8% ammonia-
saturated methanol (7N NH3(MeOH)) in chloroform to give compound 5.16 as a light tan 
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solid (17 mg, 66% yield). Rf = 0.55 (10% MeOH-CHCl3, UV, Ninhydrin). NMR and MS 
data were included in the cited publication.310  
 
 
Tetraethyl ester-protected Indo-1 lipid precursor (5.17). Reaction conditions 
from a previously published protocol were adapted for this synthesis.309 In an oven dried 
6 dram vial under argon, compound 5.16 (10 mg, 15 mol), sodium iodide (NaI, 12 mg, 
79 mol), and 1,8-dimethylaminonaphthalene (proton sponge, 17 mg, 80 mol) were 
suspended in 4 mL acetonitrile, 0.4 mL tetrahydrofuran was added, and the mixture was 
heated to reflux with stirring to dissolve reagents. Ethyl bromoacetate (8.8 L, 80 mol) 
was added, which turned the reaction cloudy purple, and was refluxed for 21 h. The 
reaction was cooled, concentrated by rotary evaporation, diluted with 3 mL water, 
extracted with (2x) 3 mL ethyl acetate, and the combined organic layers were washed 
with (3x) 2 mL 5% phosphoric acid (H3PO4 (aq)), then 2 mL brine (saturated sodium 
chloride (aq)), and concentrated by rotary evaporation, The crude residue was purified on 
a silica gel column using a gradient elution of 0-4% methanol in chloroform to give 
compound 5.17 as a brown solid (1.5 mg, 10%). Rf = 0.61, (10% MeOH-CHCl3, UV). NMR 
and MS data were included in the cited publication.310  
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6 MISCELLANEOUS PROJECT CONTRIBUTIONS 
6.1  Synthesis of Generic Lipid Photoprobes  
As mentioned in Chapter 1, global profiles of proteins that are recruited to a 
membrane surface can be labeled using a generic probe (GP) approach distinct from the 
specific probe strategy that underlies Chapters 2 and 3. Using a “headless” lipid as a 
membrane anchor, GPs fix a clickable photolabeling array to the surface of a membrane. 
Ideally, GPs are not recognized by peripheral proteins and therefore have no influence 
on recruitment and are capable of non-selective, or general, photocrosslinking at the 
membrane surface.  The syntheses of two such probes, ether-tailed GP 6.1 and ester-
tailed GP 6.2, are shown below in Scheme 6.1. 
Beginning with azido ether-tailed lipid anchor 6.3, provided by Best Research 
Group member Dr. Stuart Whitehead, a click reaction144 to previously mentioned lysine 
scaffold 2.25 using copper(I) iodide (CuI) and diisopropylethylamine (DIEA) yielded 
triazole-linked intermediate 6.4. Then, t-butyl carbamate (Boc) deprotection using 
trifluoroacetic acid (TFA) provided the free amine analog to 6.4 (not shown), which was 
subjected to amide coupling with previously mentioned alkyne linker 2.19 using 
diisopropylcarbodiimide (DIC) hydroxybenzotriazole (HOBt) in the presence of DIEA to 
give ether-tailed GP 6.1. 
An identical series of steps was followed beginning with ester-tailed azido lipid 
anchor 6.5, which was also provided by Dr. Whitehead. Click reaction with lysine scaffold 
2.25 gave precursor 6.6. Then, Boc deprotection followed by amide coupling to alkyne 
linker 2.20 produced ester-tailed GP 6.2. 6.1 and 6.2 were ultimately used by Best 
Research Group member Dr. Samuel Mattern-Schain for protein-membrane binding 
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Scheme 6.1: Synthesis of generic probes with ether (6.1) and ester (6.2) lipid tails, 
with lipid scaffolds provided by Stuart Whitehead. 
i) 2.25, CuI, DIEA, 2,6-lutidine, (1:1) MeCN/THF (6.4 = 89%; 6.6 = 86%); ii) TFA, CH2Cl2; 
iii) 2.19, DIC, HOBt, DIEA, CH2Cl2 (6.1 = 33% over 2 steps; 6.2 = 62% over 2 steps). 
 
6.2  Synthesis and Characterization of a Uniblue-conjugated PE Lipid 
This synthesis was carried out to provide previously known Uniblue-conjugated PE 
lipid 6.9,322 named LysoUB, to Haden Scott of the Barrera Research Group at the 
University of Tennessee, Knoxville. This molecule was originally designed as a probe for 
characterizing peptide topology in membranes as part of a Förster resonance energy 
transfer (FRET) method.323 Compound 6.9 can be incorporated into either one or both 
leaflets of a liposome bilayer, putting FRET-quenching unit Uniblue A in position to 
indicate the blilayer insertion properties of fluorescent FRET donor-tagged peptides.   
A published protocol was followed,322 but here we also provide NMR and MS 
characterization data not included in the original publication. As showin in Scheme 6.2, 
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vinyl sulfone324 Uniblue A was premixed with aqueous sodium carbonate (Na2CO3) buffer 
before adding 1-palmitoyl-lyso-phosphatidylethanolamine (lyso-PE) dissolved in N-
methylpyrrolidone and DIEA. The product LysoUB probe 6.9 was isolated by preparative 
thin-layer chromatography, with a representative example shown in Figure 6.1.  
 
 
Scheme 6.2: Synthesis of Uniblue A lyso-PE probe 6.9. 
i) 6.7. 0.2M Na2CO3 (aq, pH = 11); then 6.8, 2M DIEA (NMP), 4%. 
 
6.3 General Experimental 





Figure 6.1: Representative image of a preparative thin-layer chromatography plate 
to isolate LysoUB probe 6.9. 
Blue arrow indicates the band containing 6.9. 
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6.4 Detailed Syntheses 
To make ether and ester-tail generic probes, lysine scaffold 2.25 was click-coupled 
to lipid scaffolds 6.3 and 6.5, which were synthesized by Stuart Whitehead of the Best 
Research Group.  
 
Triazole-linked N-Boc-protected benzophenone-hexadecyl diether tail-
generic probe precursor (6.4). Reaction conditions from a published protocol were 
adapted for this synthesis.144 In a 100 mL oven dried round bottom flask under argon, 
previously synthesized compound 2.25 (52 mg, 0.105 mmol), compound 6.3 (60 mg, 
0.105 mmol, synthesized by Dr. Stuart Whitehead), and copper(I) iodide (CuI, 2 mg, 0.011 
mmol) were dissolved in 4 mL of freshly degassed (1:1) acetonitrile/tetrahydrofuran. Then 
2,6-lutidine (24 L, 0.211 mmol) and diisopropylethylamine (DIEA, 35 L, 0.211 mmol) 
were added, and the resulting clear yellow solution was stirred at rt for 2 h while protected 
from light. The resulting blue mixture was concentrated by rotary evaporation, and the 
crude residue was dissolved in 20 mL ethyl acetate, washed (2x) with 4 mL (9:1) saturated 
ammonium chloride/30% ammonium hydroxide (NH4Cl (aq)/ NH3 (aq)), then (2x) 4 mL 
0.5 N hydrochloric acid (HCl (aq)). The organic layer was dried over magnesium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum. The crude 
residue was purified on a silica gel column using a gradient elution of 25-40% acetone in 
hexanes to give 6.4 as an opaque tan resin (77 mg, 89% yield) Rf = 0.73 (50% Acetone-
Hexanes, UV, KMnO4). 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 8.3 Hz, 2H), 7.81 (dd, 
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4H), 7.70 (dd, J = 5.7, 3.3 Hz, 1H), 7.61 (t, 2H), 7.56 – 7.45 (m, 2H), 7.08 (d, J = 7.3 Hz, 
1H), 6.86 (s, 1H), 4.69 – 4.63 (m, 2H), 4.62 – 4.51 (m, 3H), 4.36 (dd, J = 14.1, 7.4 Hz, 
1H), 4.26 – 4.17 (m, 1H), 3.80 – 3.72 (m, 1H), 3.53 – 3.28 (m, 6H), 3.10 (s, 2H), 1.98 (ddt, 
J = 14.1, 9.8, 5.9 Hz, 1H), 1.81 (dt, J = 14.5, 7.3 Hz, 1H), 1.74 – 1.51 (m, 4H), 1.52 – 1.37 
(m, 2H), 1.40 (s, 9H), 1.35 – 1.20 (m, 52H), 0.96 – 0.81 (m, 6H). 13C NMR (126 MHz, 
CDCl3) δ 195.82 , 156.16 , 140.31 , 137.01 , 136.99 , 132.84 , 132.44 , 130.83 , 130.07 , 
130.05 , 128.77 , 128.41 , 127.15 , 123.40 , 71.92 , 70.61 , 69.56 , 68.14 , 53.44 , 51.76 
, 38.72 , 35.18 , 31.90 , 30.35 , 29.83 , 29.69 , 29.66 , 29.64 , 29.61 , 29.60 , 29.58 , 29.48 
, 29.38 , 29.34 , 28.91 , 28.38 , 23.73 , 22.96 , 22.67 , 22.56 , 14.09 , 14.02 , 10.94. DART-




Triazole-linked benzophenone-alkyne-hexadecyl diether tail-generic probe 
(6.1). In a 50 mL flame dried round bottom flask under argon, compound 6.4 (18 mg, 17 
mol) was dissolved in 1 mL methylene chloride, and then 0.7 mL trifluoroacetic acid 
(TFA) was added dropwise, and the pale brown solution was stirred at rt for 1.5 h. Boc 
deprotection was confirmed by TLC (Rf ~ 0.5 (50% acetone-hexanes, ninhydrin: purple), 
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and the reaction was concentrated by rotary evaporation with azeoptropic removal of TFA 
using (3x) 1 mL of a 1:1 benzene:methylene chloride mixture, and the crude reside was 
dissolved in 20 mL methylene chloride, washed with 2 mL 30% ammonium hydroxide 
(NH4OH (aq)), dried over sodium sulfate, filtered, concentrated by rotary evaporation, 
dried under high vacuum, and backfilled with argon to prepare compound 6.10 for the 
next step.  
In an oven dried 1 dram vial under argon, previously synthesized compound 2.19 
(2.9 mg, 19 mol) and hydroxybenzotriazole (HOBt, 2.5 mg, 19 mol) were dissolved in 
0.5 mL methylene chloride, N,N-diisopropylcarbodiimide (2.9 L, 19 mol) was added, 
and the solution was stirred for 30 min at rt. Then, a solution of compound 6.10 (theoretical 
yield of 17 mol from previous step) and diisopropylethylamine (DIEA, 8.4 L, 51 mol) 
in 0.6 mL methylene chloride was added slowly, and the reaction was stirred at rt 
overnight. The resulting mixture was concentrated by rotary evaporation and purified on 
a silica gel column using a gradient elution of 15-60% ethyl acetate in hexanes to give 
compound 6.1 as a tan solid (6 mg, 33% yield). Rf = 0.52 (50% acetone-hexanes, UV). 
1H NMR (500 MHz, CDCl3) δ 7.97 (d, 2H), 7.86 – 7.76 (m, 4H), 7.67 – 7.58 (m, 2H), 7.56 
– 7.46 (m, 4H), 7.38 (d, J = 7.2 Hz, 1H), 6.73 (t, J = 5.4 Hz, 1H), 6.64 (t, J = 6.2 Hz, 1H), 
4.69 – 4.55 (m, 3H), 4.43 (ddd, J = 69.8, 14.6, 6.4 Hz, 2H), 4.00 (dt, J = 5.2, 2.6 Hz, 2H), 
3.75 (d, J = 11.5 Hz, 1H), 3.54 – 3.37 (m, 6H), 3.35 – 3.26 (m, 2H), 3.21 (dt, J = 13.6, 6.3 
Hz, 1H), 2.57 – 2.46 (m, 4H), 2.21 (t, J = 2.5 Hz, 1H), 2.00 – 1.78 (m, 2H), 1.61 – 1.34 
(m, 6H), 1.24 (d, J = 6.8 Hz, 52H), 0.91 – 0.84 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 
195.98 , 172.61 , 172.05 , 171.71 , 166.47 , 140.27 , 137.13 , 136.97 , 132.88 , 130.09 , 
129.97 , 128.42 , 127.28 , 79.57 , 71.92 , 71.41 , 70.62 , 69.57 , 53.53 , 51.82 , 38.58 , 
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35.06 , 31.90 , 31.83 , 31.36 , 31.32 , 29.84 , 29.69 , 29.67 , 29.64 , 29.61 , 29.58 , 29.48 
, 29.39 , 29.34 , 29.19 , 28.54 , 26.09 , 25.98 , 22.67 , 22.18 , 14.09 . MALDI-MS: [M+Na]+ 
calcd for C65H103N7O7, 1116.7811; detected, 1116.7539. 
 
 
Triazole-linked N-Boc-protected benzophenone-octadecanoyl diester tail-
generic probe precursor (6.6). Reaction conditions from a published protocol were 
adapted for this synthesis.144 In a 50 mL oven dried round bottom flask under argon, 
previously synthesized compound 2.25 (38 mg, 0.077 mmol), compound 6.5 (46 mg, 
0.071 mmol, synthesized by Dr. Stuart Whitehead), and copper(I) iodide (CuI, 1.5 mg, 
0.008 mmol) were dissolved in 2 mL of freshly degassed (1:1) acetonitrile/tetrahydrofuran. 
Then 2,6-lutidine (18 L, 0.155 mmol) and diisopropylethylamine (DIEA, 26 L, 0.155 
mmol) were added, and the resulting clear yellow-green solution was stirred at rt for 2 hr 
while protected from light. The resulting blue mixture was concentrated by rotary 
evaporation, and the crude residue was dissolved in 20 mL ethyl acetate, washed (2x) 
with 4 mL (9:1) saturated ammonium chloride/30% ammonium hydroxide (NH4Cl (aq)/ 
NH3 (aq)), then (2x) 4 mL 0.5 N hydrochloric acid (HCl (aq)). The organic layer was dried 
over magnesium sulfate, filtered, concentrated by rotary evaporation, and dried under 
high vacuum. The crude residue was purified on a silica gel column using a gradient 
elution of 25-50% acetone in hexanes to give 6.6 as an opaque tan resin (69 mg, 86% 
yield) Rf = 0.74 (50% Acetone-Hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 
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8.1 Hz, 2H), 7.81 (d, 4H), 7.64 – 7.58 (m, 2H), 7.50 (t, 2H), 7.07 (s, 1H), 6.89 (s, 1H), 5.36 
(q, J = 5.2 Hz, 1H), 4.68 – 4.51 (m, 6H), 4.28 (dd, J = 12.1, 4.5 Hz, 1H), 4.04 (dd, J = 
12.2, 5.3 Hz, 1H), 3.10 (s, 2H), 2.36 – 2.25 (m, 4H), 2.04 – 1.92 (m, 1H), 1.80 (s, 1H), 
1.54 (d, J = 14.9 Hz, 4H), 1.39 (s, 9H), 1.31 – 1.22 (m, 60H), 0.87 (t, J = 6.9 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 195.61 , 132.86 , 130.06 , 128.42 , 127.19 , 109.99 , 34.01 , 
33.97 , 31.91 , 29.69 , 29.67 , 29.65 , 29.64 , 29.62 , 29.57 , 29.48 , 29.43 , 29.34 , 29.27 
, 29.25 , 29.23 , 29.12 , 29.07 , 28.37 , 24.83 , 24.74 , 22.67 , 22.57 , 14.09. DART-MS: 




Triazole-linked benzophenone-alkyne-octadecanoyl diester tail-generic 
probe (6.2). In a 50 mL flame dried round bottom flask under argon, compound 6.6 (23 
mg, 20 mol) was dissolved in 1 mL methylene chloride, and then 0.75 mL trifluoroacetic 
acid (TFA) was added dropwise, and the clear solution was stirred at rt for 75 min. Boc 
deprotection was confirmed by TLC (Rf ~ 0.45 (50% acetone-hexanes, ninhydrin: purple), 
and the reaction was concentrated by rotary evaporation with azeoptropic removal of TFA 
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using (3x) 1 mL of (1:1) benzene/methylene chloride, and the crude reside was dissolved 
in 20 mL methylene chloride, washed with (2x) 2 mL 30% ammonium hydroxide (NH4OH 
(aq)), dried over sodium sulfate, filtered, concentrated by rotary evaporation, dried under 
high vacuum, and backfilled with argon to prepare compound 6.11 for the next step.  
In an oven dried 1 dram vial under argon, previously synthesized compound 2.19 
(3.4 mg, 22 mol) and hydroxybenzotriazole (HOBt, 3.0 mg, 22 mol) were dissolved in 
0.5 mL methylene chloride at 0C, then N,N-diisopropylcarbodiimide (3.5 L, 22 mol) 
was added, and the solution was allowed to warm to rt and stir 30 min. Then, a solution 
of compound 6.11 (theoretical yield of 20 mol from previous step) and 
diisopropylethylamine (DIEA, 10 L, 60 mol) in 0.6 mL methylene chloride was added 
slowly, and the reaction was stirred at rt for 1 h. The resulting mixture was concentrated 
by rotary evaporation, diluted with 20 mL methylene chloride, washed with (2x) 3 mL 
water, then 3 mL brine (saturated sodium chloride (aq)), dried over sodium sulfate, 
filtered, concentrated by rotary evaporation, and dried under high vacuum. The crude 
residue was purified on a silica gel column using a gradient elution of 0-5% methanol 
dissolved in (1:1) acetone/chloroform to give compound 6.2 as a white solid (15 mg, 62% 
yield). Rf = 0.38 (50% acetone-hexanes, UV). 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 
8.0 Hz, 2H), 7.85 – 7.73 (m, 4H), 7.67 – 7.57 (m, 2H), 7.53 – 7.44 (m, 3H), 6.82 (t, J = 5.3 
Hz, 1H), 6.61 (t, J = 6.4 Hz, 1H), 5.38 (p, J = 5.0 Hz, 1H), 4.70 – 4.48 (m, 4H), 4.30 (dd, 
J = 12.1, 4.1 Hz, 1H), 4.04 (dt, J = 12.2, 4.8 Hz, 1H), 3.97 (dd, J = 5.3, 2.5 Hz, 2H), 3.22 
(dh, J = 20.0, 7.0, 6.4 Hz, 2H), 2.50 (s, 4H), 2.30 (dt, J = 17.9, 7.6 Hz, 4H), 2.19 (t, J = 
2.5 Hz, 1H), 1.99 – 1.74 (m, 4H), 1.65 – 1.46 (m, 4H), 1.38 (dt, J = 13.7, 7.3 Hz, 2H), 1.33 
– 1.22 (m, 58H), 0.87 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 195.97 , 173.15 , 
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172.62 , 172.61 , 172.07 , 171.92 , 166.59 , 140.29 , 137.07 , 136.93 , 132.90 , 130.09 , 
129.94 , 128.43 , 127.32 , 79.59 , 71.39 , 69.36 , 62.04 , 53.64 , 50.11 , 38.57 , 35.00 , 
34.03 , 33.98 , 31.90 , 31.79 , 31.23 , 29.68 , 29.66 , 29.64 , 29.62 , 29.48 , 29.34 , 29.27 
, 29.14 , 29.12 , 29.04 , 28.68 , 24.83 , 24.75 , 22.67 , 22.29 , 14.09 . MALDI-MS: [M+Na]+ 
calcd for C69H107N7O9, 1200.8022; detected, 1200.5439. 
 
 
Uniblue A lyso-PE probe (6.9). A published protocol was followed,322 and an 
alternative protocol is recommended for future syntheses.325 In a 1 dram vial, lyso-
phosphatidylethanolamine (6.8, 8 mg, 17.6 mol) was dissolved in 0.4 mL N-methyl-2-
pyrrolidone (NMP) with diisopropylethylamine (DIEA, 135 L, 0.800 mmol, 2 M in NMP). 
A solution of Uniblue A vinyl sulfone Na+ salt (6.7, 20 mg, 39.5 mol) in 0.2 mL of 0.2 M 
sodium carbonate (Na2CO3 (aq), pH = 11) was added, and the biphasic mixture was 
stirred vigorously overnight at rt. The resulting blue mixture was concentrated under a 
streaming N2, dried under high vacuum, dissolved in 3 mL chloroform, washed with (5x) 
15 mL water, and the organic layer was applied to a 10 x 10 cm glass-backed fluorophore-
free TLC plate and eluted with (65:30:2.5:2.5) chloroform/methanol/water/33% aqueous 
ammonium hydroxide* (*A later publication describes a superior elution mixture that uses 
triethylamine (TEA) in place of NH4OH (aq)).325 The band at Rr = 0.2 was scraped into a 
6 dram vial, sonicated in 2 mL of (2:1) chloroform methanol, centrifuged for 3 min at 3000 
rpm, decanted into a new vial, and dried under a stream of N2 to give compound 6.9 as a 
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blue solid (1.5 mg, 4%). 1H NMR (500 MHz, Methanol-d4) δ 8.32 – 8.23 (m, 2H), 8.18 (s, 
1H), 8.05 (d, J = 0.6 Hz, 2H), 7.80 (s, 2H), 7.74 (ddd, J = 10.9, 7.4, 1.6 Hz, 2H), 7.62 – 
7.59 (m, 2H), 7.45 (s, 0H), 7.47 – 7.43 (m, 1H), 7.44 (s, 0H), 4.32 – 4.26 (m, 2H), 4.25 – 
4.19 (m, 2H), 4.12 – 3.98 (m, 6H), 3.72 – 3.66 (m, 2H), 3.42 – 3.36 (m, 4H), 2.29 (t, J = 
7.6 Hz, 2H), 1.54 (d, J = 6.6 Hz, 4H), 1.47 – 1.40 (m, 2H), 1.40 (s, 0H), 1.40 – 1.34 (m, 
2H), 1.32 – 1.17 (m, 19H), 0.91 (t, J = 7.5 Hz, 3H). 31P NMR (202 MHz, Methanol-d4) δ -
1.23. ESI-MS: [M-H+]- calcd for C43H60N3O14PS2, 936.3182; detected, 936.2492. 
6.5  List of Mass Spectra 
 
 
Spectrum 6.1. MALDI-TOF mass spectrum of amide-linked Triazole-linked 
benzophenone-alkyne-hexadecyl diether tail-generic probe 6.1. 
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Spectrum 6.2. MALDI-TOF mass spectrum of amide-linked Triazole-linked 
benzophenone-alkyne-octadecyl diester tail-generic probe 6.2. 
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Spectrum 6.3. ESI mass spectrum of Uniblue A lyso-PE probe 6.9. 
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APPENDIX: NMR SPECTRA 
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Spectrum A.1: 1H NMR of compound 2.14. 
 
Spectrum A.2: 13C NMR of compound 2.14.  
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Spectrum A.3: 1H NMR of compound 2.21. 
 
Spectrum A.4: 13C NMR of compound 2.21.  
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Spectrum A.5: 1H NMR of compound 2.26. 
 
Spectrum A.6: 13C NMR of compound 2.26. 
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Spectrum A.7: 1H NMR of compound 2.69. 
 
Spectrum A.8: 13C NMR of compound 2.69. 
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Spectrum A.9: 1H NMR of compound 2.23. 
 
Spectrum A.10: 13C NMR of compound 2.23. 
380 
 
Spectrum A.11: 1H NMR of compound 2.30. 
 
Spectrum A.12: 13C NMR of compound 2.30. 
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Spectrum A.14 1H NMR of compound 2.3. 
 
Spectrum A.15: 31P NMR of compound 2.3. 
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Spectrum A.17: 1H NMR of compound 2.37. 
 
Spectrum A.18: 13C NMR of compound 2.37. 
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Spectrum A.20: 1H NMR of compound 2.40. 
 
Spectrum A.21: 13C NMR of compound 2.40. 
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Spectrum A.22: 1H NMR of compound 2.41. 
 
Spectrum A.23: 13C NMR of compound 2.41. 
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Spectrum A.25: 1H NMR of compound 2.6. 
 
Spectrum A.26: 19F NMR of compound 2.6. 
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Spectrum A.27: 1H NMR of compound 2.54. 
 
Spectrum A.28: 13C NMR of compound 2.54. 
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Spectrum A.30: 1H NMR of compound 2.57. 
 
Spectrum A.31: 19F NMR of compound 2.57. 
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Spectrum A.32: 1H NMR of compound 2.58. 
 
Spectrum A.33: 13C NMR of compound 2.58. 
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Spectrum A.34: 19F NMR of compound 2.58. 
 
Spectrum A.35: 31P NMR of compound 2.58. 
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Spectrum A.36: 1H NMR of compound 2.59. 
 
Spectrum A.37: 13C NMR of compound 2.59. 
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Spectrum A.38: 31P NMR of compound 2.59. 
 
Spectrum A.39: 19F NMR of compound 2.59. 
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Spectrum A.40: 1H NMR of compound 2.62. 
 
Spectrum A.41: 13C NMR of compound 2.62. 
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Spectrum A.42: 1H NMR of compound 2.63. 
 
Spectrum A.43: 13C NMR of compound 2.63. 
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Spectrum A.45: 1H NMR of compound 3.14. 
 
Spectrum A.46: 13C NMR of compound 3.14. 
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Spectrum A.47: 1H NMR of compound 3.12. 
 
Spectrum A.48: 13C NMR of compound 3.12. 
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Spectrum A.49: 1H NMR of compound 3.13. 
 
Spectrum A.50: 13C NMR of compound 3.13. 
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Spectrum A.52: 1H NMR of compound 3.29. 
 
Spectrum A.53: 13C NMR of compound 3.29. 
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Spectrum A.55: 1H NMR of compound 3.30. 
 
Spectrum A.56: 13C NMR of compound 3.30. 
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Spectrum A.59: 1H NMR of compound 3.24. 
 
Spectrum A.60: 13C NMR of compound 3.24. 
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Spectrum A.61: 1H NMR of compound 3.25. 
 
Spectrum A.62: 13C NMR of compound 3.25. 
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Spectrum A.63: 1H NMR of compound 3.26. 
 
Spectrum A.64: 13C NMR of compound 3.26. 
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Spectrum A.65: 1H NMR of compound 3.27. 
 
Spectrum A.66: 13C NMR of compound 3.27. 
413 
 
Spectrum A.67: 1H NMR of compound 3.1. 
 
Spectrum A.68: 13C NMR of compound 3.1. 
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Spectrum A.69: 1H NMR of compound 3.58. 
 
Spectrum A.70: 13C NMR of compound 3.58. 
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Spectrum A.71: 1H NMR of compound 3.59. 
 
Spectrum A.72: 13C NMR of compound 3.59. 
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Spectrum A.73: 1H NMR of compound 3.36. 
 
Spectrum A.74: 13C NMR of compound 3.36. 
417 
 
Spectrum A.75: 1H NMR of compound 3.39. 
 
Spectrum A.76: 13C NMR of compound 3.39. 
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Spectrum A.77: 1H NMR of compound 3.3. 
 
Spectrum A.78: 13C NMR of compound 3.3. 
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Spectrum A.79: 1H NMR of compound 3.42. 
 
Spectrum A.80: 13C NMR of compound 3.42. 
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Spectrum A.81: 1H NMR of compound 3.43. 
 
Spectrum A.82: 13C NMR of compound 3.43. 
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Spectrum A.83: 1H NMR of compound 3.44. 
 
Spectrum A.84: 13C NMR of compound 3.44. 
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Spectrum A.85: 1H NMR of compound 3.47. 
 
Spectrum A.86: 13C NMR of compound 3.47. 
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Spectrum A.87: 1H NMR of compound 3.65. 
 
Spectrum A.88: 13C NMR of compound 3.65. 
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Spectrum A.89: 1H NMR of compound 3.48. 
 
Spectrum A.90: 13C NMR of compound 3.48. 
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Spectrum A.91: 1H NMR of compound 3.49. 
 
Spectrum A.92: 13C NMR of compound 3.49. 
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Spectrum A.93: 1H NMR of compound 3.50. 
 
Spectrum A.94: 13C NMR of compound 3.50. 
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Spectrum A.95: 1H NMR of compound 3.51. 
 
Spectrum A.96: 13C NMR of compound 3.51. 
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Spectrum A.97: 1H NMR of compound 3.4. 
 
Spectrum A.98: 13C NMR of compound 3.4. 
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Spectrum A.99: 1H NMR of compound 3.61. 
 
Spectrum A.100: 13C NMR of compound 3.61. 
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Spectrum A.102: 1H NMR of compound 3.5. 
 
Spectrum A.103: 13C NMR of compound 3.5. 
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Spectrum A.105: 1H NMR of compound 3.52. 
 
Spectrum A.106: 13C NMR of compound 3.52. 
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Spectrum A.107: 1H NMR of compound 3.53. 
 
Spectrum A.108: 13C NMR of compound 3.53. 
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Spectrum A.109: 1H NMR of compound 3.54. 
 
Spectrum A.110: 13C NMR of compound 3.54. 
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Spectrum A.111: 1H NMR of compound 3.55. 
 
Spectrum A.112: 13C NMR of compound 3.55. 
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Spectrum A.113: 1H NMR of compound 3.7. 
 
Spectrum A.114: 13C NMR of compound 3.7. 
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Spectrum A.115: 1H NMR of compound 3.63. 
 
Spectrum A.116: 13C NMR of compound 3.63. 
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Spectrum A.118: 1H NMR of compound 3.8. 
 
Spectrum A.119: 13C NMR of compound 3.8. 
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Spectrum A.121: 1H NMR of compound 4.22. 
 
Spectrum A.122: 13C NMR of compound 4.22. 
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Spectrum A.123: 1H NMR of compound 4.23. 
 
Spectrum A.124: 13C NMR of compound 4.23. 
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Spectrum A.125: 1H NMR of compound 4.24. 
 
Spectrum A.126: 13C NMR of compound 4.24. 
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Spectrum A.127: 1H NMR of compound 4.25. 
 
Spectrum A.128: 13C NMR of compound 4.25. 
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Spectrum A.129: 1H NMR of compound 4.26. 
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Spectrum A.130: 13C NMR of compound 4.26. 
 
Spectrum A.131: 1H NMR of compound 4.27. 
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Spectrum A.132: 13C NMR of compound 4.27. 
 
Spectrum A.133: 1H NMR of compound 4.28. 
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Spectrum A.134: 13C NMR of compound 4.28. 
 
Spectrum A.135: 1H NMR of compound 4.72. 
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Spectrum A.136: 13C NMR of compound 4.72. 
 
Spectrum A.137: 1H NMR of compound 4.39. 
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Spectrum A.138: 13C NMR of compound 4.39. 
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Spectrum A.140: 1H NMR of compound 4.45. 
 
Spectrum A.141: 13C NMR of compound 4.45. 
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Spectrum A.142: 1H NMR of compound 4.31. 
 
Spectrum A.143: 13C NMR of compound 4.31. 
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Spectrum A.144: 1H NMR of compound 4.32, first diastereomer. 
 
Spectrum A.145: 13C NMR of compound 4.32, first diastereomer. 
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Spectrum A.146: 1H NMR of compound 4.32, second diastereomer. 
 
Spectrum A.147: 13C NMR of compound 4.32, second diastereomer. 
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Spectrum A.148: 1H NMR of compound 4.33. 
 
Spectrum A.149: 13C NMR of compound 4.33. 
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Spectrum A.150: 1H NMR of compound 4.34. 
 
Spectrum A.151: 13C NMR of compound 4.34. 
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Spectrum A.152: 1H NMR of compound 4.35. 
 
Spectrum A.153: 13C NMR of compound 4.35. 
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Spectrum A.154: 1H NMR of compound 4.36. 
 
Spectrum A.155: 13C NMR of compound 4.36. 
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Spectrum A.156: 1H NMR of compound 4.37. 
 
Spectrum A.157: 13C NMR of compound 4.37. 
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Spectrum A.158: 1H NMR of compound 4.38. 
 
Spectrum A.159: 13C NMR of compound 4.38. 
463 
 
Spectrum A.160: 1H NMR of compound 4.2. 
 
Spectrum A.161: 13C NMR of compound 4.2. 
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Spectrum A.162: 1H NMR of compound 4.3. 
 
Spectrum A.163: 13C NMR of compound 4.3. 
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Spectrum A.164: 1H NMR of compound 4.4. 
 
Spectrum A.165: 13C NMR of compound 4.4. 
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Spectrum A.166: 1H NMR of compound 4.5. 
 
Spectrum A.167: 13C NMR of compound 4.5. 
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Spectrum A.168: 1H NMR of compound 4.6. 
 
Spectrum A.169: 13C NMR of compound 4.6. 
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Spectrum A.170: 1H NMR of compound 4.7. 
 
Spectrum A.171: 13C NMR of compound 4.7. 
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Spectrum A.172: 1H NMR of compound 4.48, first diastereomer. 
 
Spectrum A.173: 13C NMR of compound 4.48, first diastereomer. 
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Spectrum A.175: 1H NMR of compound 4.49. 
 
Spectrum A.176: 13C NMR of compound 4.49. 
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Spectrum A.177: 1H NMR of compound 4.71. 
 
Spectrum A.178: 13C NMR of compound 4.71. 
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Spectrum A.179: 1H NMR of compound 4.50. 
 
Spectrum A.180: 13C NMR of compound 4.50. 
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Spectrum A.181: 1H NMR of compound 4.51. 
 
Spectrum A.182: 13C NMR of compound 4.51. 
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Spectrum A.183: 1H NMR of compound 4.52. 
 
Spectrum A.184: 13C NMR of compound 4.52. 
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Spectrum A.185: 1H NMR of compound 4.53. 
  
Spectrum A.186: 13C NMR of compound 4.53. 
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Spectrum A.187: 1H NMR of compound 4.54. 
  
Spectrum A.188: 13C NMR of compound 4.54. 
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Spectrum A.189: 1H NMR of compound 4.55. 
  
Spectrum A.190: 13C NMR of compound 4.55. 
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Spectrum A.191: 1H NMR of compound 4.56. 
 
Spectrum A.192: 13C NMR of compound 4.56. 
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Spectrum A.193: 1H NMR of compound 4.57. 
  
Spectrum A.194: 13C NMR of compound 4.57. 
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Spectrum A.195: 1H NMR of compound 4.58. 
  
Spectrum A.196: 13C NMR of compound 4.59. 
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Spectrum A.197: 1H NMR of compound 4.14. 
  
Spectrum A.198: 13C NMR of compound 4.14. 
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Spectrum A.199: 1H NMR of compound 4.15. 
  
Spectrum A.200: 13C NMR of compound 4.15. 
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Spectrum A.201: 1H NMR of compound 4.16. 
  
Spectrum A.202: 13C NMR of compound 4.16. 
485 
  
Spectrum A.203: 1H NMR of compound 4.17. 
  
Spectrum A.204: 13C NMR of compound 4.17. 
486 
  
Spectrum A.205: 1H NMR of compound 4.18. 
 
Spectrum A.206: 13C NMR of compound 4.18. 
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Spectrum A.207: 1H NMR of compound 4.59. 
  
Spectrum A.208: 13C NMR of compound 4.59. 
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Spectrum A.209: 1H NMR of compound 4.60. 
  
Spectrum A.210: 13C NMR of compound 4.60. 
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Spectrum A.211: 1H NMR of compound 4.61. 
  
Spectrum A.212: 13C NMR of compound 4.61. 
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Spectrum A.213: 1H NMR of compound 4.62. 
 
Spectrum A.214: 13C NMR of compound 4.62. 
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Spectrum A.215: 1H NMR of compound 4.63. 
  
Spectrum A.216: 13C NMR of compound 4.63. 
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Spectrum A.217: 1H NMR of compound 4.64. 
  
Spectrum A.218: 13C NMR of compound 4.64. 
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Spectrum A.219: 1H NMR of compound 4.8. 
  
Spectrum A.220: 13C NMR of compound 4.8. 
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Spectrum A.221: 1H NMR of compound 4.9. 
  
Spectrum A.222: 13C NMR of compound 4.9. 
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Spectrum A.223: 1H NMR of compound 4.10. 
  
Spectrum A.224: 13C NMR of compound 4.10. 
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Spectrum A.225: 1H NMR of compound 4.11. 
  
Spectrum A.226: 13C NMR of compound 4.11. 
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Spectrum A.227: 1H NMR of compound 4.12. 
 
Spectrum A.228: 13C NMR of compound 4.12. 
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Spectrum A.229: 1H NMR of compound 5.5. 
 
Spectrum A.230: 13C NMR of compound 5.5. 
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Spectrum A.231: 1H NMR of compound 5.6. 
 
Spectrum A.232: 13C NMR of compound 5.6. 
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Spectrum A.234: 1H NMR of compound 5.9. 
 
Spectrum A.235: 13C NMR of compound 5.9. 
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Spectrum A.236: 1H NMR of compound 6.4. 
 
Spectrum A.237: 13C NMR of compound 6.4. 
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Spectrum A.238: 1H NMR of compound 6.1. 
 
Spectrum A.239: 13C NMR of compound 6.1. 
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Spectrum A.240: 1H NMR of compound 6.6. 
 
Spectrum A.241: 13C NMR of compound 6.6. 
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Spectrum A.242: 1H NMR of compound 6.2. 
 
Spectrum A.243: 13C NMR of compound 6.2. 
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Spectrum A.244: 1H NMR of compound 6.9. 
 
Spectrum A.245: 31P NMR of compound 6.9.  
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